Lung function and structure in Cystic Fibrosis infants one year after diagnosis by newborn screening. by Thia, LP
1 
 
 
Lung Function and Structure in Cystic Fibrosis Infants One 
Year after Diagnosis by Newborn Screening 
 
 
Lena Priscilla Lee-Nah THIA 
 
University College London, UCL 
 
This thesis is submitted for the degree                                   
Doctor of Medicine MD (Res) 
 
 
 
 
DECLARATION 
I, Lena Priscilla Lee-Nah Thia, confirm that the work presented in this thesis is my 
own. Where information has been derived from other sources, I confirm that this has 
been indicated within the thesis.   
 
2 
 
ABSTRACT 
Title: Lung Function and Structure in Cystic Fibrosis Infants One Year after 
Diagnosis by Newborn Screening 
 
It is challenging to identify lung disease in asymptomatic infants with Cystic Fibrosis 
(CF) diagnosed by newborn screening (NBS). Since very little is known about the 
origin and progression of lung disease in these infants, there is uncertainty on how best 
to design intervention trials to protect these infants from pulmonary functional and 
structural decline. 
 
This London CF collaborative (LCFC) observational study aimed to assess lung 
function and structure in NBS CF infants. Infant lung function tests (ILFT) which 
measured airway calibre (forced expiratory manoeuvres), hyperinflation 
(plethysmographic lung volumes) and ventilation inhomogeneity (multiple breath 
washout) were performed in contemporaneous healthy controls and CF infants at 3 
months and 1 year of age. In addition, CF infants underwent chest computed 
tomography (CT) at 1 year under general anaesthesia (GA).  
 
At age 1-year, NBS CF infants (n=72) had impaired lung function compared to 
controls (n=44). There was significant improvement in forced expired flows and 
volumes and no deterioration with respect to hyperinflation or ventilation 
inhomogeneity since 3-months. Fewer NBS CF infants had abnormal lung function by 
a year. Observed impairment was much less than reported in previous studies.   
 
The challenges of performing multicentre standardised volume-controlled chest CTs 
under GA became evident. The lack of agreement between two experienced 
radiologists in scoring the CTs was unexpected, suggesting that the current established 
CT-CF scoring system may not be sensitive enough to describe mild CF lung disease. 
Contrary to published data, fewer and milder CT abnormalities were detected and 
there was poor correlation between lung function and CT changes in our NBS infant 
cohort. 
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This LCFC longitudinal study is the only study of NBS CF infants to include healthy 
controls that has shown no progressive decline in lung function during the first year of 
life and that structural changes are mild. Adequately powered intervention studies that 
use objective measures of lung function and structure during infancy will therefore 
need to be much larger than hitherto believed.   
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1 INTRODUCTION 
 
1.1 BACKGROUND ON CYSTIC FIBROSIS 
Cystic Fibrosis (CF) is the most common life shortening autosomal recessive 
condition in the white population; with an incidence of 1:2000-3000 live births.1 
Currently there are 9,000 CF patients in the UK (http://www.cftrust.org.uk/) and 
30,000 in the USA (http://www.cff.org/). Although it is a multi-system disease, lung 
disease leads to most of the increased morbidity and reduced lifespan.2,3 
 
CF may present at any time from antenatal period to extreme old age, although it 
usually presents within the first two years of life with recurrent respiratory symptoms 
(cough, wheeze or respiratory failure) and failure to thrive. Less common 
presentations are meconium ileus, rectal prolapse or electrolyte imbalance. 
Increasingly, CF has been diagnosed through newborn screening (NBS). 
 
CF is caused by mutations in a single gene on the long arm of chromosome 7, which 
encodes the cystic fibrosis transmembrane receptor (CFTR) protein. The absence or 
reduced function of CFTR protein is the fundamental defect in CF. The most common 
mutation is a three base pair deletion that codes for phenylalanine at position 508 of 
the CFTR protein which accounts for 70% of CF alleles in the white population.4 
Advances in genetic and molecular biology have provided increased understanding 
into the functions of the CFTR protein and the pathophysiology of CF. This has led to 
a paradigm shift in therapy for CF, from targeting the downstream consequences of 
CFTR dysfunction, such as bronchial infection, inflammation and mucus retention to 
the development of therapies correcting the basic defect, including gene therapy and 
genotype class-specific therapies, such as PTC124 to over-ride premature stop codons 
5,6 and VX-770 for the class 3 gating mutation G551D.7,8  It would seem likely that 
these novel therapies would be most effective in early stage disease, before irreversible 
airway damage has developed. 
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 Pathophysiology and natural history of CF lung disease 
CF primarily affects the airways and submucosal glands with sparing of the 
interstitium until late in the disease. CFTR is highly expressed in the serous epithelial 
cells of submucosal glands where it regulates chloride secretion and water transport 
across the cell membrane in all exocrine glands of the body. The precise mechanism 
by which CFTR dysfunction produces CF lung disease is unclear. 
 
In normal airway epithelia, there is an airway surface liquid layer (ASL) which 
consists of two layers above the epithelial surface - a mucus layer and a periciliary 
liquid layer (PCL); the latter has a thickness similar to the length of the cilium. The 
PCL is highly controlled by an adenosine-regulated pathway to provide a low viscosity 
solution for mucociliary clearance. The current hypothesis is that as a result of absent 
or dysfunctional CFTR protein, there is defective chloride and water transport due to 
over-activity of the sodium channel ENaC, leading to abnormally elevated isotonic 
fluid absorption.9,10 This depletes the adenosine regulated PCL, reduces mucociliary 
clearance and encourages mucus stasis and chronic infection due to reduced clearance 
of micro-organisms (low-volume hypothesis). The PCL is vulnerable to CF microbial 
insults especially viral infections such as respiratory syncytial virus which diminish 
motion-dependent ATP regulation of the CF PCL height and volume.11 Increased ASL 
salt concentrations have also been reported in CF which would inactivate salt-sensitive 
antimicrobial peptides (high-salt hypothesis) and predispose CF patients to bacterial 
infections; however, evidence for this hypothesis is less compelling. It has been 
suggested from the newborn CF porcine model that lack of CFTR results in lower pH 
in the ASL i,e a more acidic environment which impairs the antimicrobial activity of 
ASL. This group hypothesised that CFTR dysfunction also affects bicarbonate (HCO3
-
) transport leading to defective secretion of HCO3
-, lower ASL pH and hence inhibits 
antimicrobial function and impairs bacterial killing.12 Although the ‘low volume’ 
hypothesis is favoured, these hypothesised mechanisms on the ASL in CF could lead 
to defective airway clearance and defence, thus promoting endobronchial infection in 
young children with CF.13,14  
 
Pulmonary involvement is present early, with some CF infants having evidence of 
inflammation in the bronchoalveolar lavage fluid (BALF) as early as 4 weeks of 
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age.15,16    Two main components of CF airway disease are chronic infection and an 
exuberant host inflammatory response. The most characteristic feature of 
inflammation within the lung in CF is the infiltration of enormous numbers of 
neutrophils into the airway lumen.17 This massive excess of neutrophils is harmful to 
the lung and is at the centre of a vicious cycle of increased inflammation.18 
Neutrophils undergo necrosis in the airway lumen and these necrotic neutrophils are 
the major source of the DNA that makes CF sputum so tenacious.17 These neutrophils 
release an array of tissue damaging mediators, oxidants and proteases, including 
neutrophil elastase (NE). Free neutrophil elastase causes uncontrolled proteolysis and 
chondrolysis of airway support tissue, resulting in damaged airways which eventually 
become dilated and then bronchiectatic.19 
 
The relationship between infection and inflammation in the pathogenesis of CF lung 
disease is unclear, but the ultimate result of this cycle of infection and inflammation is 
damaged airways (bronchiectasis), progressive airway obstruction and impaired gas 
exchange. As airways disease worsens, there is an increased likelihood of serious 
respiratory complications, including pneumothorax, haemoptysis, and respiratory 
failure and death. 
 
 Life expectancy in CF  
CF was formerly known as a 'killer disease' of childhood. However, current increased 
life expectancy means that more than 50% of CF patients in the UK are adults. It has 
been estimated that those born in the current decade will have a median life 
expectancy at greater than 50 years.20 With increasing global uptake of NBS for CF 
and advanced CF therapies to optimise nutrition and pulmonary health, current CF 
babies may have an even longer life expectancy. Prognosis for those born with CF 
diagnosed through NBS has improved dramatically over the years.21 
 
 
1.2 NEONATAL SCREENING FOR CF  
 Worldwide and national experience 
The first European experience in CF NBS started in the early 1970s with screening 
programmes that examined the albumin content of meconium.22 Elevation of blood 
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immunoreactive trypsin (IRT) in the blood spots of neonates with CF was first 
described in 197922 which led to screening programmes being developed and 
introduced in Australasia and parts of Europe. Identification of CFTR gene mutations 
in the 1990s with subsequent incorporation of DNA testing into screening protocols 
led to further improvements in screening programmes, and an increase in the number 
of countries implementing neonatal screening. There are now eight countries in the 
European Union,23 the entire USA (www.cff.org), Australia24 and New Zealand 
(www.cfnz.org.nz) who have adopted universal NBS for CF. In Canada, there is 
currently regional NBS (five Canadian provinces and two territories) available 
(www.cysticfibrosis.ca). Since October 2007, universal NBS for CF has been 
implemented in the UK.   
 
There are several different screening protocols currently in use but in general they 
involve a combination of measurement of IRT and CFTR mutation analysis followed 
by confirmatory sweat testing. In the UK, screening for CF is incorporated into the 
routine neonatal screening using the blood spot obtained from a heel prick test on the 
Guthrie card taken 6-7 days after birth. The screening protocol used in the UK consists 
of IRT-DNA analysis. If measured IRT level is elevated to levels >60 ng/ml (>99% 
centile), the next step of the screening protocol will include CFTR gene mutation 
analysis for the 4 most common mutations on the same sample. Infants found to be 
homozygous (or compound heterozygous) for known disease producing CF mutations 
are immediately referred for a confirmatory sweat test. Those with only one CF 
disease producing gene undergo a second IRT 4 weeks later in addition to extended 
CFTR DNA analysis (29 or 31 mutations). If the second IRT is still raised, they have a 
sweat test.25 Currently, the median age of diagnosis in the UK through CF NBS is 1 
month2,26 while in the US, it is 2.3 weeks.27,28  
 
 Benefits versus disadvantages of newborn screening 
The effect of CF NBS has been extensively studied and debated. Evidence from the 
Wisconsin Cystic Fibrosis Neonatal Screening Project 29-32 (the only randomised 
controlled trial of NBS) and observational studies from other countries33-35 is overall 
strongly suggestive of benefits, especially in terms of nutritional status. With CF NBS, 
a normal growth pattern can be achieved and maintained. Better nutrition and fat 
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soluble vitamin levels were associated with better cognitive abilities in children with 
CF diagnosed through NBS. 31,32 
 
Evidence that NBS results in improvement with pulmonary health in CF is less clear. 
The Wisconsin group did not demonstrate better chest radiographic scores or lung 
function parameters likely due to confounding factors (see below). They showed that 
at the time of CF diagnosis for either screened or clinically diagnosed groups, 
quantitative radiographic scores were better for those who were diagnosed early 
through screening. However when a CXR was repeated later (mean age of 10 years), 
the mean Brasfield and Wisconsin CXR scores in the screened group were 
significantly worse than the clinically diagnosed group. Scores were worse in those 
who had Pseudomoas aeruginosa (PsA) infection, which accelerated radiographic 
deterioration.36 The result of this study was confounded by the fact that one of the 
older CF centres did not have robust infection control policies which resulted in cross 
infection within the NBS CF population attending routine outpatient clinics. A British 
study also failed to demonstrate any pulmonary benefits with screening, although 
patients in this study were not managed by specialist CF centres using standardised 
treatment protocols.37 In contrast, a French34 study compared a screened CF cohort in 
one city to that in a neighbouring city in which CF was only diagnosed clinically and 
found that Brasfield CXR scores in the screened cohort were better than the non- 
screened CF cohort at all ages to 10 years of age despite similar treatment protocols. In 
a cross sectional Dutch study, significantly better radiographic scores were seen in a 
screened CF cohort than non-screened at diagnosis and at 9 years of age. 38,39  Both 
these studies also showed stable lung function and less progressive decline in the NBS 
CF cohorts compared to the clinically diagnosed CF cohort.34,40  
 
Those with CF diagnosed through NBS have better quality of life, less morbidity and 
better survival.21,27,29,30,41 A recent long term longitudinal study in Australia provided 
the first evidence that spirometric outcomes were superior in NBS CF children at 
transfer to adult care compared to those who were diagnosed clinically. In the few 
years just prior to the introduction of screening, the NBS CF cohort also showed 
improved nutrition during childhood and improved survival at age 25 years.21 
Compared to diagnosis made clinically, NBS is associated with reduced treatment 
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costs due to the improved clinical status hence NBS for CF might have not only 
clinical and social benefits, but also economic benefits to society.42 
 
NBS for CF has potential disadvantages. In the Wisconsin study, prior to the 
enforcement of segregation, screened children who were cared for in a specialist centre 
acquired PsA at an earlier age which may explain why no pulmonary benefit was 
detected in the screened population.36  With strict infection control measures and 
segregation clinics, this should no longer be of concern. In fact, from US27 and UK2 
databases, screened CF children have less chronic infection with PsA than those 
diagnosed clinically. There were concerns that parental bonding may be affected by 
the early diagnosis through NBS of a child having a life-limiting condition. Breaking 
bad news to the parents must be handled sensitively to reduce the inevitable shock and 
anxiety. However some parents may gain consolation that the condition has been 
identified before any significant lung disease or poor nutrition had occurred. NBS 
could result in earlier diagnosis of mild and atypical CF at an age when they may 
never have been diagnosed clinically. It could also detect significant numbers of CF 
carriers which may increase parental anxiety and have wider implications for the 
extended family. As with all NBS screening, some cases will be missed (i.e. false 
negative cases).43,44 There are concerns that doctors might assume that a child cannot 
have CF if they have tested negative after the introduction of universal NBS, which 
could lead to a delay in diagnosis.45  
 
Nonetheless, on balance, the evidence in favour of CF NBS outweighs the potential 
disadvantages,26,46 such that universal CF NBS is increasingly implemented 
worldwide.  
 
1.3 EARLY DETECTION OF LUNG DISEASE AND OUTCOME 
MEASURES 
The first two years of postnatal life is a particularly important period for normal lung 
development when the lung is undergoing rapid alveolarisation.47 During this period 
the lung is particularly sensitive to noxious insults, which may have profound long-
term consequences.48,49 The airways of CF infants are probably virtually normal at 
birth and it is crucial to institute treatment early to try and prevent the onset of 
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pulmonary infection and inflammation. However, it is during this same period that the 
developing lungs are most susceptible to iatrogenic damage; and when objective 
monitoring of response to treatment is most difficult.  
 
In the past, clinical therapeutic trials in infants and young children with CF have been 
hindered by a lack of sensitive and reproducible outcome measures. However in the 
last decade, significant progress has led to physiologic, structural, bronchoscopic and 
clinical measures that may serve as reliable and feasible endpoints for future 
intervention trials in young children with CF.50 These techniques include infant lung 
function tests (ILFT)51 which provide physiological measures, structural markers of 
disease through various imaging techniques (primarily computed tomography (CT) of 
chest)52 and markers of infection and inflammation through BAL.53,54 For all these 
outcome measures, attempts have been made to standardise data collection and 
analysis which, in some cases such as ILFT, have been achieved. One of the main 
limiting factors for  either clinical or research applications of these outcome measures 
has been the lack of appropriate reference values or contemporaneous healthy control 
data,55 together with  limited information regarding short or long term repeatability 
and a paucity of longitudinal data using these tests. In addition, these tests are time 
consuming, expensive and highly specialised, usually requiring the expertise of 
tertiary respiratory centres.  
 
The research presented in this thesis addresses gaps in current knowledge regarding 
the evolution of early lung disease in NBS CF infants, using physiological and 
structural measures. In the remainder of this chapter, I summarise the background 
methodology for the various ILFT used for this thesis, together with that for chest CT 
and the rationale for their use in the early detection of CF lung disease. This will be 
followed by a literature review of current knowledge until December 2011 about ILFT 
and chest CT in infants with CF diagnosed clinically or through newborn screening.  
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1.4 INFANT LUNG FUNCTION TESTS  
 Background 
Preservation of lung function will likely reduce morbidity and mortality in infants and 
children with CF. Regular monitoring of lung function has long been considered an 
essential part of the clinical management of older children and adults, whereas in 
infants and pre-schoolers, this remains a challenge and ILFT is considered a 
specialised test conducted only in a few laboratories.  
 
During the past decade, commercial equipment for assessing a wide range of lung 
function tests in infants has become available together with international guidelines 
and improved reference equations with which to interpret results.56-61 Early 
physiologic abnormalities have been detected in infants with CF using a variety of 
ILFT techniques,60,62-67 including plethysmography, forced expiratory flow-volume 
manoeuvres and multiple breath washout/ gas dilution techniques. The commonest 
lung function abnormalities described in CF lung disease have been airway 
obstruction, 60 hyperinflation62 indicated by elevated resting lung volumes, increased 
ventilation inhomogeneity and gas trapping.63,64  
 
 Methodologies of different infant lung function tests 
For each of the different ILFT [plethysmography, raised volume rapid thoraco-
abdominal compression (RVRTC) and multiple breath washout (MBW)], a brief 
background into the physiology of the test and the rationale for conducting these tests 
in this research study will be described. A detailed account on how these lung function 
tests are performed will be reported in chapter 2. 
 
1.4.2.1  Plethysmography 
Plethysmography was one of the first techniques used to assess lung function 
abnormalities in sedated infants and young children with CF. 62,68-73 Historically, only 
custom-made equipment was available. There is now however commercial equipment 
available with appropriate reference equations59 based on healthy control infants 
measured using the same equipment (Jaeger MasterScreen Body Plethysmograph). 
International ATS/ERS guidelines are also available to ensure that plethysmographic 
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measurements of FRC are collected in a standardised manner and as accurately as 
possible.61,74 (section 2.3.2) 
 
Theoretical background 
Plethysmographic Functional Residual Capacity (FRCpleth), i.e. the resting lung 
volume at end expiration, is the only static lung volume that can be measured routinely 
in infants.  It measures the total thoracic gas volume, including areas of trapped gas 
during occluded breathing efforts against a closed shutter, based on Boyle’s law. 
Boyle’s law states that for any given mass of gas at a fixed temperature, pressure 
multiplied by volume remains constant. Assessments of FRCpleth are made while the 
sleeping infant lies within the closed plethysmograph and breathes through a facemask 
attached to a pneumotachometer (PNT) which records air flow (and hence volume). A 
shutter is used to occlude the airways for 6-8 seconds during tidal breathing, retaining 
a fixed mass of gas in the lungs.  During this period, the infant continues to breathe 
against the occlusion, which causes cyclic expansion and compression of this gas 
volume. Such changes in lung volume are measured as changes in box pressure while, 
in the absence of any airflow, the accompanying changes in alveolar pressure are 
assumed to be the same as pressure changes at the airway opening. By knowing the 
initial pressure in the lungs (which is atmospheric at end expiration) and the associated 
changes in alveolar pressure and volume, it is possible to calculate the only unknown 
variable i.e. the initial lung volume.  When performing this technique in infants, the 
occlusion is usually performed at the end of tidal inspiration, rather than at end 
expiration as in adults, since for infants this is less disturbing, causes less glottal 
closure and facilitates improved equilibrium of pressures throughout the respiratory 
system when compared with end expiratory occlusions.75 FRCpleth is then obtained by 
subtracting the tidal volume above the end-expiratory level from the measured thoracic 
gas volume.61  
There are several advantages of infant plethysmography which include the following:  
 Measurements of FRCpleth can be obtained rapidly and reproducibly.  
 Although subject to potential errors which will be discussed later, the 
difference between paired measurements of FRC obtained by plethysmography 
and gas dilution technique (see section 1.4.2.3) may be a useful reflection of 
gas trapping.76 
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The major limitations of infant plethysmography are: 
 Equipment is expensive and relatively bulky, and therefore cannot be used as a 
bedside test. 
 Overestimation of FRC may occur in the presence of severe airway 
obstruction, due to poor equilibration of alveolar pressure changes with those 
occurring at the airway opening during airway occlusions.  
 
Early CF lung disease manifests itself as airway obstruction in the smaller and distal 
peripheral airways during the initial stages of pulmonary involvement, followed later 
by obstruction and destruction of more proximal larger airways.77 An increase in 
FRCpleth may indicate either dynamic hyperinflation or gas trapping. In the presence of 
increased airways resistance due to reduced airway calibre, and hence a prolonged 
expiratory time constant, there may be insufficient time during expiration to empty the 
lungs to the relaxed elastic equilibrium volume that determines FRC in health. This is 
particularly likely to occur in the presence of a rapid respiratory rate and hence short 
expiratory time and results in dynamic hyperinflation.  This phenomenon can also 
occur in healthy infants during the first months of life due to the high compliance of 
the chest wall and rapid respiratory rates. By contrast, there may be true ‘gas trapping’ 
secondary to virtually complete obstruction of some of the smaller airways with 
secretions, leading to very poorly ventilated areas of the lung.  While either 
phenomenon will result in an increase in FRCpleth, when using gas washout methods, 
measured FRC is likely to be increased in the presence of dynamic hyperinflation, but 
decreased in the presence of gas trapped behind virtually closed airways, such that 
assessment of the difference between the two techniques (plethysmography−gas 
mixing) may be very informative. However, such data do require careful interpretation 
as if the obstruction is too severe, plethysmographic lung volumes will be erroneously 
over-estimated due to the poor equilibr ation of alveolar pressure with those at the 
airway opening.74 If both dynamic hyperinflation and gas trapping occur, FRC by gas 
washout may appear relatively normal, but ventilation will be very uneven, further 
complicating the interpretation of these tests.   Nevertheless, plethysmographic lung 
volumes have been recognised as a potentially sensitive marker of early CF lung 
disease62,71,72 and were therefore performed as part of this research protocol. 
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1.4.2.2 Raised Volume Rapid Thoraco-abdominal Compression Technique  
Spirometry is an accepted monitoring tool for school-age children and adults with CF. 
Modification of this technique for sedated infants has made it possible to obtain forced 
expiratory flow-volume measurements during either tidal breathing (tidal  (or partial) 
Rapid Thoraco-abdominal Compression (RTC) or ‘tidal squeeze’ technique), where 
the main outcome is maximal flow at FRC (V’maxFRC) or in the form of the Raised 
Volume Rapid Thoraco-abdominal Compression (RVRTC) technique which allows 
full expiratory manoeuvres to be obtained after inflating the infant’s lungs towards 
total lung capacity (TLC).78  
 
Theoretical background 
Since the introduction of the RVRTC technique, the ‘tidal squeeze’ method to detect 
airway obstruction has been largely superseded. This is due to limitations related to the 
variability of FRC in infants and potential overestimation of V’maxFRC in the presence 
of any gas trapping or hyperinflation which reduces the sensitivity of this outcome.79,80 
Flow limitation may also be more difficult to achieve in healthy controls when using 
the ‘tidal squeeze’ method.80 In contrast, the raised volume technique assesses flow 
from a reproducible lung volume and flow limitation can usually be achieved, 
resulting in more reliable and reproducible results 78  
When using the RVRTC technique to produce full forced expiratory manoeuvres 
(Section: 2.3.3), relaxation of the respiratory muscles and a respiratory pause is 
induced by inflating the lungs of sleeping infants several times towards TLC. Once 
relaxed, the infant’s lungs are inflated to 30 cmH2O pressure and a forced expiratory 
manoeuvre is then produced by applying rapid thoraco-abdominal compression with 
an inflatable jacket. The forced involuntary expiratory manoeuvres undertaken after 
the lungs have been inflated towards TLC during the RVRTC technique are similar to 
the voluntary expiratory manoeuvres undertaken by older children and adults in 
spirometry. Hence it is possible to obtain ‘adult-type’ flow-volume curves through this 
method which can be repeated and monitored long term.  
 
In contrast to the relative insensitivity of conventional spirometry in children with 
CF,63,64,81 the RVRTC has been found to discriminate clearly between infants with CF 
and healthy controls.60,62,82,83  RVRTC has shown that CF infants have airway 
obstruction, and this method was found to be as sensitive as the lung clearance index 
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(LCI), measured through MBW.83(see section 2.3.1).  Possible explanations for this 
age-related discrepancy in relative sensitivity include differences in measurement 
conditions and developmental changes. The chest wall is highly compliant during 
infancy which results in more airway closure and early flow limitation in the presence 
of milder airway disease than in older individuals.75,83 Infants have relatively large 
airways compared to lung volume at birth and therefore have a shorter expiratory time 
constant than older individuals, with relatively rapid lung emptying in less than a 
second during forced expiration. Consequently, it is not always possible to obtain 
forced expiratory volume in one second (FEV1) in very young children, which is 
commonly substituted by the measurement of forced expiratory volume in 0.5 second 
(FEV0.5) or forced expiratory volume in 0.75 second (FEV75) in infants and pre-
schoolers respectively. Further work is required to assess the relationship between 
these different outcomes during early life.84 
 
Potential advantages of RVRTC include: 
 Forced expiratory flow volume (FEFV) outcomes that can be measured from a 
reproducible lung volume. 
 Forced expiratory flows and volumes can be assessed over an extended volume 
range from near TLC to Residual Volume (RV). 
 Easier to obtain flow limitation with RVRTC. 
 Longitudinal assessments of similar outcomes are possible from infancy to 
adulthood. 
 
There are several limitations associated with RVRTC which include: 
 Although extensive training of specialised dedicated staff can ensure precision 
with respect to timing and inflation pressures, it is a more demanding 
technique compared to tidal flow-volume manoeuvres.  
 Leaks are more likely to occur around the face during positive pressure 
inflations. 
 Children with severe airway disease may not relax sufficiently or may 
consistently inhale before RV is reached. 
 Repeated inflations may result in the accumulation of gas in the stomach which 
may be uncomfortable for the infant and invalidate the results.  
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 Considerable caution is required in infants who are oxygen-dependent, in 
whom repeated lung inflations, with associated reductions in pCO2 might lead 
to prolonged apnoea and hypoxia. 
 
Commercial equipment is internationally available with which to perform the RVRTC 
in sedated infants. With recent publication of reference data57,59 and international 
guidelines56 it is now possible to ensure standardised performance of tests for data 
collection and analysis, provided adequate training is received. Forced expiratory 
volumes and flows can be obtained through these methods.  
 
1.4.2.3 Multiple Breath Inert Gas Washout Technique 
MBW is a tidal breathing test that is potentially beneficial in assessing early lung 
disease in infants and young children as it requires only passive cooperation.85 In 
children from 3 years of age, there has been increasing evidence that the MBW 
technique is more sensitive than conventional spirometry in detecting early pulmonary 
changes, and there has been considerable interest in the use of MBW to detect early 
CF lung disease in infants.83,86 
 
Conventional spirometry, the most commonly used lung function test (LFT) records 
forced expiratory flows and volumes which are primarily influenced by changes in 
airway resistance during linear gas flow in the conducting airways.  Gas transport and 
mixing by convection predominate in the conducting airway zone (defined as 
respiratory generation 0-16) where linear gas flow velocity is relatively high. When 
airways further divide into generations 17-23 (intra-acinar regions) there is a markedly 
increased total cross sectional area for gas exchange such that the linear gas flow 
velocity in the peripheral airways is very low. The resistance of the peripheral airways 
therefore makes a relatively small contribution to any expiratory flow limitation 
measured during spirometry. Despite representing 95% of the total airway volume, the 
peripheral or ‘small’ airways (arbitrarily defined as those with a luminal diameter of 
less than 2mm and corresponding to airway generations 8-23 which would include the 
gas exchanging units or ‘alveoli’) account for only 10–20% of the total airway flow-
resistance in healthy adult lungs.87 In addition, heterogeneous changes in distal airway 
function may be masked by increased flow through non-flow-limited distal airways. 
For these reasons, spirometry primarily reflects large rather than small airway 
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function, and is relatively insensitive to early small airway impairment which is where 
early CF lung disease generally starts. 
 
Theoretical Background 
Convective gas flow is the predominant transport mechanism in the conducting 
airways. Within the acinus, contribution of convective gas flow is minimal and the 
predominant transport mechanism is diffusion. A combination of these two 
mechanisms occurs in the region known as the convection-diffusion front located 
around the entry into the acini. Unevenness of ventilation distribution is present even 
in healthy lungs and is known as ventilation inhomogeneity. This is due to several 
mechanisms. Inhomogeneity in conducting airways arises due to differences in 
specific ventilation between large lung regions or between smaller lung units with 
differing mechanical properties such as decreased airway calibre leading to increased 
resistance and hence differences in time constants (lung filling and emptying). More 
distally within acinar airways, inhomogeneity may arise due to marked asymmetry of 
the lung with respect to the cross-sectional area at branch points and subtended lung 
volumes at branch points.88 With the MBW technique, it is possible to measure 
ventilation inhomogeneity89 including that occurring due to changes in small airway 
function when pathological processes affect the distribution of ventilation between 
different parallel pathways.  
 
Although inert gas washout techniques have been available for the last 60 years, their 
use has been restricted mainly to research due to lack of commercially available 
equipment. In recent years, development of fast responding gas analysers and 
advancing computer technology, have facilitated intensive scientific work in this field. 
The development of commercially available devices based on photoacoustic/ infrared 
gas analysers90,91 and ultrasonic transducer technology86,92-95 could facilitate both 
clinical applications of this technique and its use as an outcome measure in multicentre 
trials, although reference data are currently limited. 
 
Tracer gas 
MBW can be performed using an inert tracer gas such a sulphur hexafluoride (SF6), 
helium (He) or Argon (Ar) or by using 100% oxygen (O2) to washout the resident 
nitrogen (N2) within the lung. In infants due to the risk of apnoea or alteration in tidal 
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breathing by inhaling 100% oxygen for N2-MBW,
96 the inert gas MBW technique has 
been more commonly performed using a tracer gas mixture (4% SF6 and/or He, 21% 
O2 and balanced N2).
83,86,89 SF6 is a synthetic colourless, odourless and tasteless inert 
gas. At concentrations used in clinical settings, it is non-toxic and has no known side-
effects in humans. However it is a potential greenhouse gas and in several countries 
SF6 mixture is not licenced for medical use, thus preventing it from being used as a 
routine clinical test. The use of 100% O2 for N2-washout is therefore an attractive 
alternative to inert gas MBW. O2 is readily available for medical use, relatively cheap 
and reduces test duration as N2-MBW does not require a wash-in phase and O2 has no 
adverse effect on the environment.95 However the potential effect on breathing 
patterns in infants using 100% O2 is not clear. With young children beyond infancy, 
there is renewed interest in using N2-MBW technique using one of the commercially 
available systems. 
 
Equipment 
There are currently two commercial systems which use ultrasonic technology, which 
vary according to where the ultrasonic transducer is located to measure changes in 
molar mass of gases (N2, SF6 or He). Mainstream ultrasonic equipment (Exhalyzer D, 
Eco Medics AG, Switzerland) using SF6 has been validated in infants.
97,98 In this 
equipment, the sensor containing two transducers is mounted on opposite sides of the 
flow tube that transmit pulses crossing the subject’s airflow. The lack of validated 
correction algorithms for the temperature and humidity fluctuations that influence 
assessment of molar mass may limit its utility beyond infancy.95 The EasyOne Pro, 
ndd, Medical Technologies, Switzerland device has overcome some of these problems 
by limiting the use of the mainstream ultrasonic sensor to measuring flow, while using 
a side-stream ultrasonic transducer to measure molar mass, but this system has only 
been validated for use in older children94 due to the larger equipment deadspace that 
precludes its use in infants. Although both these devices can potentially be used with 
SF6 or N2 as a tracer gas, to date, work in infants has only involved use of SF6 with the 
mainstream Exhalyzer D, Ecomedics system, for reasons discussed previously. 
A modified photoacoustic gas analyser (Innocor, Innovision, Odense, Denmark) uses a 
PNT and a highly sensitive side-stream infra-red gas analyser that is very sensitive to 
SF6 and has been validated for use in adults and older children.
90 Due to a high gas 
sample flow of 120ml/min and a longer analyser response time, this device is not 
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currently suitable for measurements in infants and young children.90  This system can 
also be used for nitrogen washout using infrared nitrogen analysers. 
 
Measurement outcomes 
Although numerous indices can be calculated from MBW, the simplest and most 
commonly used outcome variable that is sensitive and robust to changes seen in early 
CF lung disease in children and adults is the LCI.  LCI reflects the ventilation or the 
number of FRC turnovers required to clear an inert tracer gas from the lungs, corrected 
for lung size. An increase in LCI would signify increased ventilation inhomogeneity 
(unevenness) or inefficient gas mixing which may occur even in the presence of mild 
peripheral lung disease.77,81,89,99,100  
 
Until recently, LCI (which is internally adjusted for lung volume) was considered to 
be constant across all age groups in health but with increasing availability of data from 
young children and infants, it became apparent that values of LCI are higher in the 
first few years of life even when adjusted for both airway and equipment 
deadspace.58,101 This is probably due to developmental physiological changes seen 
with rapid lung growth in this age group.58,94 Although variability of LCI in healthy 
children and adolescents is low over a wide age range,102 with  minimal within- and 
between-test variability,81,94 variability in infants may be greater. When using MBW 
procedures in studies of early lung disease or treatment effects, it is important that 
reported changes detected over time do not merely reflect alterations in respiratory 
pattern. Longitudinal data for ventilation inhomogeneity indices during normal lung 
development with age are needed.103 Therefore although a potentially useful and 
sensitive outcome measure for longitudinal studies, results of LCI in infants with lung 
disease will need to be interpreted in light of early lung development by testing 
contemporaneous healthy controls.     
 
Functional Residual Capacity (FRCMBW) can also be measured using MBW 
techniques. Lung volume that readily communicates with central airways during tidal 
breathing can be measured through this method. MBW is unable to assess any volume 
of thoracic gas that is not contributing to ventilation i.e. any trapped gas and may 
therefore underestimate any hyperinflation or poorly ventilated areas of the lung 
secondary to airway narrowing.96  By measuring the difference between FRC obtained 
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through plethysmography and MBW,  it is possible to obtain a broad estimate of the 
amount of gas trapping present.104 However, due to the relatively large variability in 
the measurement of lung volumes using MBW, the measurement of trapped gas may 
have limited use on an individual basis.  
 
Potential advantages of the MBW technique include: 
 It is useful for bedside measurements. 
 It can be undertaken in all ages including unsedated preterm and fullterm 
infants during the first few months of life.105,106 
 Provides an assessment of ventilation inhomogeneity.  
 
Disadvantages of the MBW technique include: 
 Only readily ventilated gas volume rather than any gas trapped behind closed 
or non-ventilated airways can be measured. This may lead to underestimation 
of lung volume. 
 A prolonged duration of washout may be necessary in subjects with marked 
airway obstruction. 
 Lack of commercially available and well validated equipment for MBW 
measurements; although this situation is currently being rectified. 
 
LCI has been shown to be correlated closely with structural chest CT changes in older 
children.64,107 CT has itself been advocated to be a sensitive surrogate marker of early 
CF lung disease even during infancy and early childhood.108-111 The relationship 
between LCI and CT structural lung disease has not been established in infants 
diagnosed through NBS. Hence in this study, LCI measured through MBW with SF6 
as the inert tracer gas was performed to investigate this relationship and to establish its 
role as a sensitive surrogate marker of structural CF lung disease.  
 
 
1.5 LITERATURE REVIEW OF LUNG FUNCTION TESTS IN CF 
INFANTS AND YOUNG CHILDREN   
In recent years, an increasing number of studies have explored the potential role of 
ILFT in the clinical management of CF infants or as an objective clinical trial endpoint 
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or outcome measure for research.60,62,67,82,83,112-115 Despite a wide range of tests shown 
to be well tolerated and feasible in infants, with plethysmography, RVRTC and MBW 
techniques being able to detect early CF lung disease, their application as clinical tools 
for routine assessments is limited by the need for sedation, highly specialised 
equipment and staff, inability to repeat frequently enough and lack of appropriate 
reference equations and information regarding between-test variability.50 On the other 
hand, there is convincing evidence for the use of ILFT to provide objective research 
outcome measures involving CF infants.  
 
Sections 1.5.1 and 1.5.2 describe the current literature about early lung function 
results in CF infants and young children at the inception of this thesis in December 
2011. Salient information from important research studies have been summarised and 
presented in tables which can be found in Appendix A1 due to word constraints in the 
main thesis. I concentrated mainly on studies published in the last decade to the end of 
2011 involving infants (≤2 years) and only briefly mention studies involving young 
children (≤5 years) or older children (≥6 years). In the Appendix A1-a summarises 
studies performed during the past decade which utilised ILFT to identify early 
functional change in either cross-sectional or longitudinal observational studies of CF 
infants (0-2 years). A review of earlier studies investigating lung function in infants 
with CF has been published by Gappa et al.70 Appendix A1-b summarises studies 
during this period involving children (≥3years) with CF limited to studies where LCI 
was measured, otherwise the literature would be massive if all lung function studies on 
children were included. Appendix A1-c summarises interventional studies using lung 
function parameters to assess response to interventions in infants, younger and older 
children. Studies published from January 2012 will be discussed in the final discussion 
chapter. Finally, this is followed by section 1.5.3 which describes the lung function 
results from the current London Cystic Fibrosis Collaboration (LCFC) cohort of NBS 
CF infants at 3 months of age. A brief summary of the use of LCI as an outcome 
measure in older children with CF during the past decade is presented in section 1.6. 
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 Lung function changes in clinically diagnosed infants and 
young children with CF 
The LCFC has shown that clinically diagnosed infants, including those without 
respiratory symptoms, have impaired airway function shortly after diagnosis79,116 and 
that this persists into school age with no improvement despite specialist treatment in 
CF centres.60,65,102 Lung function impairment was greater in those with previous PsA 
infections (even if apparently eradicated) with further reductions seen in the presence 
of wheeze on auscultation or recent cough.65 Cross sectional studies, including those 
from the LCFC have reported that abnormal LCI was evident even when no 
deterioration was observed in parameters derived using standard tests such as 
spirometry117 in preschoolers and older children and RVRTC in infants.83 Furthermore, 
an observational longitudinal LCFC study showed that a normal LCI at age 3-5 years 
in clinically diagnosed CF children was strongly predictive of normal lung function at 
age 6-10 years.102 In another longitudinal study involving LCI performed during 
infancy at time of clinical diagnosis of CF, infants were found to have elevated LCI. 
Tracking of LCI was present from infancy to school age, especially in those with the 
most severe disease. This study also showed that it was feasible to perform MBW tests 
in unsedated infants during their natural sleep.105  
 
FRCpleth has also been demonstrated to be significantly higher in CF compared to 
healthy infants indicating hyperinflation due to small airway obstruction.62,114 In a 
recent US multicentre study of infants with CF comprising of those diagnosed 
clinically or by NBS, FRCpleth was significantly elevated in CF infants by 2 years of 
age when compared with reference data from historical controls and was more feasibly 
conducted than RVRTC with respect to obtaining technically acceptable results across 
different centres with varying experience.62  
 
Kraemer et al confirmed that LCI predicted abnormalities earlier in life and reflected a 
more reliable functional progression in 6-20 year olds with clinically diagnosed CF 
than FEV1. Pulmonary hyperinflation, airway obstruction and ventilation 
inhomogeneity were associated with chronic PsA infection and specific CFTR 
genotypes. There was tracking of lung function from early childhood to adult life.72,76 
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Attempts to use ILFT to assess acute response to treatment in infants with CF have 
been limited due to the issue of sedation which is relatively contraindicated in acute 
exacerbations. A study of 11 symptomatic infants (mean age 102 weeks) who had 
ILFT at the start of a pulmonary exacerbation and 3 weeks later after treatment, 
unsurprisingly demonstrated significant improvements in FEV0.5 and FRCpleth after a 
course of intravenous antibiotics for pulmonary exacerbation. Although lung function 
parameters changed in response to the intervention given, it is not clear how clinically 
useful this would be in guiding clinical management.118 In an open label randomised 
cross over trial involving 9 clinically diagnosed stable CF infants, significant 
improvements were observed in V’maxFRC when infants were treated with nebulised 
DNase compared to nebulized normal saline,113 suggesting that objective assessments 
might be feasible in CF infants by using ILFT as outcome measures. 
 
LCI was sensitive and responded appropriately to interventional therapy in older CF 
children (aged 6-18 years) with mild lung disease (FEV1≥80% predicted) as seen by a 
reduction in LCI in those treated with nebulised DNase119 and hypertonic saline120 
even though no spirometric changes were observed. These studies suggest that LCI 
may be sensitive to acute changes even when evidence of clinical benefit is lacking. 
 
However, much less is known about the evolution of lung function in NBS CF infants. 
In my study, a range of lung function outcome variables (LCI, FRCpleth, FEFV) were 
used to detect early lung disease in NBS CF infants. These outcomes were used for 
longitudinal assessments during infancy to improve understanding of the evolution of 
lung disease in NBS CF infants. At the inception of this thesis (2011), information 
with respect to lung function outcomes in NBS CF infants was largely limited to that 
provided by the Australian Respiratory Early Surveillance Team for Cystic Fibrosis 
(AREST-CF) group, as discussed in section 1.5.2. 
 
 Early lung function in newborn screened infants with CF 
Newborn screening for CF has been in existence in Australia for nearly three decades. 
AREST-CF study is an early disease surveillance programme conducted at the Royal 
Children’s Hospital, Melbourne and the Princess Margaret Hospital for Children, 
Perth. All infants diagnosed with CF, whether through positive NBS or clinically 
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(including meconium ileus) were included in this early surveillance study. Eligible CF 
infants underwent ILFT when well and stable and the median age at testing was 59 
(range: 6-131) weeks in their first cross sectional study.82  
 
In their first publication, the AREST-CF team reported that FEFV were normal in 68 
NBS (50 exclusively diagnosed through NBS) and meconium ileus (8 presenting with 
meconium ileus) CF infants during the first 6 months of life, but declined rapidly 
thereafter compared to historical healthy controls.82 The normal lung function may 
reflect the small number of infants tested at <6 months of age and the fact that the 
raised volume technique was performed at 20 cmH2O which was below the 
recommended inflation pressure of 30 cmH2O as stated in the ATS/ERS guidelines.
56 
This meant that forced expiratory manoeuvres may not have been executed from TLC, 
reducing the sensitivity of detecting abnormalities in FEFV in very young NBS CF 
infants. 
 
The same group in a later publication performed RVRTC on 37 CF infants of whom 
28 were diagnosed through NBS from one centre using the standard ATS/ ERS 
guidelines with an inflation pressure of 30 cmH2O.
67  They demonstrated diminished 
FEV0.5 z-scores within the first 6 months of life with continued deterioration over the 
next two years of life.67 The mean (SD) FEV0.5 z-scores at the first, first year and 
second year visits were -1.4(1.2), -2.4(1.1) and -4.3(1.6) respectively. In both these 
studies, no contemporaneous healthy infants were tested and z-scores were derived 
from published data collected using entirely different equipment.  
 
In a US multicentre evaluation of infant lung function involving ten CF centres 
between 2003 and 2006, 100 CF infants diagnosed either antenatally, through NBS, 
meconium ileus or clinically, underwent ILFT at mean (SD) age 14 (6.2) months. 
Compared to historical healthy controls, CF infants showed significantly diminished 
FEF75 z-score; mean (95% CI): -0.52 (-0.78; -0.25) and elevated lung volumes, 
FRCpleth z-score; mean (95% CI): 1.92 (1.39; 2.45).
62 No reductions were seen in 
forced expiratory volumes. In this study, there was great variability in skill-mix and 
experience of the laboratories and hence measurement acceptability rates in lung 
function results. RVRTC measures were acceptable in 85% of tests performed in 
experienced centres compared to only 59% in less experienced centres, whilst FRC 
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measurements were deemed successful in both experienced (96%) and less 
experienced centres (85%). The low success rate for RVRTC measures could account 
for the lack of abnormal results seen in forced expiratory volumes. Once again lung 
function results were only compared to historical controls. Although these studies 
provided some information about the evolution of lung disease in NBS CF infants, 
there were several unanswered questions which led to the development of the current 
study (see section 1.6). 
 
 Early lung function in newborn screened infants: the LCFC 
study  
The LCFC NBS study (see Chapter Three) took place from January 2009 until July 
2011. Results from initial assessments at 3 months have been published recently,71 and 
are summarised below.  
 
Seventy nine CF infants and 54 contemporaneous healthy control (HC) infants were 
recruited and had their first lung function test measured at mean (SD) age of 11.4 (2.3) 
and 12.2 (2.0) weeks respectively. For clarity during these very early assessments, 
results from 8 infants with meconium ileus were excluded and data were reported from 
71 CF infants diagnosed purely by NBS. However, when analysis was repeated 
including results from the 8 infants with meconium ileus, results obtained were not 
significantly different. With the exception of a slightly lower, statistically significant 
but clinically trivial difference in gestational age [CF-HC: Mean (95%CI) -0.9 (-1.4; -
0.5) weeks]  and birth weight [CF-HC: Mean difference (95%CI) -0.35 (-0.67;-0.03) z-
score] in those with CF, background characteristics including the proportion of boys, 
those born to white mothers, pre- and postnatal exposure to tobacco smoke and 
maternal history of asthma were very similar when compared with contemporaneous 
controls. NBS CF infants were diagnosed by a median (IQR) age of 3.6 weeks (3.0–
4.4). 
 
All lung function measurements were expressed as z-scores to adjust for length, age 
and sex where appropriate.57-59 Baseline measurements at ~ 3-months of age showed 
increased ventilation inhomogeneity reflected by significantly elevated LCI z-score 
(CF-HC: Mean difference [95% CI]: 0.51[0.10; 0.91] z-score; p0.05) and evidence of 
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hyperinflation (CF-HC: Mean difference [95% CI] FRCpleth z-score: 0.85 [0.43; 1.28]; 
p <0.001). There was also significant gas trapping observed in NBS CF infants 
compared to HC (CF-HC: Mean difference [95% CI] ∆FRCpleth-FRCMBW z-score: 
(0.48 [0.08; 0.88]; p0.05). Airway obstruction was seen in NBS CF infants, who had 
significantly lower FEV0.5 z-scores (CF-HC: Mean difference [95%CI] z-score: -0.92[-
1.29; -0.56]; p<0.001) and FEF25-75 z-scores (-0.66[-1.10; -0.21]; p0.01) than 
controls. Passive lung mechanics (respiratory compliance and resistance; Crs and Rrs 
respectively) had a high failure rate due to infants waking up prior to completion of 
test protocol or technically unacceptable data. With the exception of tidal volume, 
which was slightly higher (0.4 z-scores) in those with CF, there were no significant 
differences for any of the tidal breathing outcomes or passive respiratory mechanics.  
To date, this is the largest prospective study of early pulmonary function in CF infants 
diagnosed by NBS. The study has a number of strengths: 
 Contemporaneous control infants were prospectively recruited and tested by 
the same team using the same equipment (Jaeger BabyBody MasterScreen 
system, v.4.6) and lung function protocols as used for the NBS CF infants.55  
 All CF and control infants were studied before 16 weeks of age in one single 
lung function laboratory by experienced staff and techniques were in 
accordance with international guidelines56,74 thus minimising any potential 
methodological and analytical bias. This is in contrast to the two previous 
AREST-CF studies when infants and young children with CF had their first 
test at different ages (6 weeks to 30 months).  
 The relatively large sample size of both CF and healthy controls provided 90% 
power to detect a 0.6 z-score difference in primary lung function parameters 
(i.e. LCI and FEV0.5) at the 5% significant level between infant groups. 
 Lung function data were expressed as z-scores to account for sex, age and body 
size at the time of testing. Reference data collected using the same equipment 
from healthy control infants provided appropriate reference equations for 
comparison of lung function in NBS CF infants.57-59 This allowed accurate 
identification of the extent to which abnormalities in lung function were 
present in individual infants. 
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 A wide range of physiological investigations was undertaken, giving 
information on lung volumes (FRCMBW, FRCpleth) and both proximal and 
peripheral airway function (FEV0.5, FEF% and LCI). The chance of missing 
early changes in lung function was minimised by performing this variety of 
LFT.51 
 
The results from this study indicated that despite early diagnosis and rapid 
implementation of therapy, including prophylactic antibiotics, a third of NBS CF 
infants have abnormalities of lung function within the first three months. The apparent 
clinical wellness of the cohort should not lead to complacency; prompt and aggressive 
treatment of any abnormal symptoms or clinical signs is vital.54  
 
 
1.6 RATIONALE FOR 1-YEAR LUNG FUNCTION TESTS IN 
THIS RESEARCH PROJECT 
Normal lung development is essential for attaining maximal lung health in 
adulthood.49,122 Early life factors have a significant impact on subsequent development 
of lung disease. Genetic predisposition, antenatal insults such as maternal smoking,123 
preterm delivery,124,125 intra-uterine growth retardation126 and neonatal respiratory 
disorders as well as early environmental insults such as postnatal passive smoking and 
impaired growth and nutrition,127 environmental pollution128 and childhood respiratory 
infections129 are all potential causes for preventing the attainment of maximal lung 
health which could lead to subsequent chronic obstructive pulmonary disease (COPD) 
in early adult life.  
 
There is considerable evidence which exists to show that diminished airway function 
in infancy and early years do track through childhood and early adulthood. The 
longitudinal Tucscon study of wheezy infants revealed that those with wheezing early 
in life were more likely to have lower forced expiratory flows in the first year of life 
and continued to have the lowest lung function as adults.130 A Dunedin cohort who 
had assessments at school age showed tracking of lung function from 9 to 26 years of 
age.131 Tracking of lung function was also demonstrated by the Melbourne asthma 
cohort,132 with lower lung function in those with asthma by 7 years of age (many of 
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whom developed COPD). Hence the monitoring of lung function early in life is 
important for detecting early lung disease. This may identify those most “at risk” of 
developing lung disease and minimise potential insults hence allowing lung 
development to reach its full potential. In the context of a CF child, the detection of 
early lung disease and the monitoring of lung function are vitally important aspects of 
CF care. Information obtained through ILFT may aid in the understanding of the 
evolution of early lung disease in CF infants and young children. 
   
Deterioration in lung function within the first year of life may indicate the need for 
early aggressive or novel treatments using physiological endpoints to detect benefit. 
However if lung function improves or remains stable with conventional CF treatment, 
then novel, molecular- based therapies5,7 may be deferred to a later date, at an age 
when it would be easier to monitor lung function and the potential risk of toxicity to 
the developing lung may be less.  
 
Results from the AREST-CF study suggested that lung function deteriorates from 1-
year and beyond, albeit when interpreting results in relation to published data or 
historical controls. It was therefore important to monitor lung function longitudinally 
in the current LCFC NBS cohort, in order to ascertain the extent to which the 
previously reported early changes in lung function persist throughout the first year of 
life. It is also essential to provide information on the natural history of lung disease in 
NBS CF infants, in direct comparison with contemporaneous healthy control infants. 
The ability to undertake identical serial measurements in healthy controls would 
facilitate interpretation of changes over time particularly with respect to the extent to 
which any longitudinal changes in lung function in those with CF were due to disease 
rather than normal growth and development. Such information would inform future 
study design with respect to calculation of sample sizes required for randomised 
control trials of treatment.  
 
A wide range of lung function tests were conducted in this study to ensure that as far 
as possible, no significant lung disease would be missed. During infancy, measures of 
LCI and forced expiratory parameters appear to be complementary tests which do not 
necessarily identify the same infants with abnormalities. By including both tests, 
detection rate for early lung disease may increase.83  
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Early CF lung disease occurring first in the lung periphery may manifest as 
hyperinflation and gas trapping and/or ventilation inhomogeneity (see section 1.5). 
For these reasons, plethysmography and MBW techniques were used to obtain 
FRCpleth and FRCMBW results and LCI as described in section 1.4.2.  The within-
subject difference between FRCpleth and FRCMBW gives an indication of ‘trapped gas’. 
Raised volume forced expiratory parameters measured during infancy are comparable 
to spirometric variables that will be performed throughout life. Passive lung mechanics 
parameters were not used in this 1 year study due to the high variability of results 
obtained and their lack of discrimination between CF and normal controls in the 3 
month data71. Apart from that, all other lung function measurements mentioned above 
could be useful in the long term monitoring of CF lung disease, hence the decision was 
to repeat all these lung function tests at a year of age.  
 
With the gap in knowledge on the evolution of lung function in NBS CF infants 
beyond the first three months of age as alluded to earlier (see section 1.5), this study 
was designed to improve understanding of lung function in these infants at a year of 
age when compared to contemporaneous healthy controls. The widespread uptake of 
NBS for CF has led to increased interest and a real need to develop and identify 
sensitive, appropriate and feasible surrogate markers for detecting early CF lung 
disease during infancy.50,62,133-135 
 
The second section of this introductory chapter pertains to chest computed 
tomography as a potential sensitive surrogate marker of early CF lung disease.  
 
 
1.7 LITERATURE REVIEW OF CHEST COMPUTED 
TOMOGRAPHY IN EARLY CF LUNG DISEASE 
Imaging techniques that can detect structural changes in CF lung disease have been of 
great interest for many years. The argument for using chest CT as an outcome 
surrogate for monitoring progression of lung disease in CF patients is the ability of CT 
to detect subtle lung changes more readily than can conventional CXR or spirometry. 
Therefore clinical trials that involve infants and young children with mild CF lung 
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disease have increasingly advocated the use of chest CT as a clinical trial 
endpoint.52,110,136 
 
 Structural information from chest CT 
Emerging evidence suggests that CF structural changes occur early in life109,111,137,138 
confirming previous autopsy results of clinically diagnosed children with CF  showing 
significant structural changes such as bronchial wall dilatation, bronchial wall 
thickening and mucous plugging from as early as the first four months of life.139 These 
are structural changes that one would hope to prevent with the introduction of NBS for 
CF. 
Changes observed in different stages of CF lung disease are as follows:  
 Bronchiectasis- defined as the size of the dilated bronchi relative to an 
accompanying vessel;  
 Peribronchial thickening- defined as a bronchial wall thickness greater than 2mm 
in the hilar region, 1mm in the central lung, or 0.5mm in the peripheral lung;  
 Parenchymal changes- opacities, areas of ground glass opacity, cysts or bullae;  
 Mucous plugging- defined as the presence of bronchial opacification of the lumen, 
centrilobular nodules, or peripheral branching structures;  
 Air trapping- defined as well-circumscribed areas of decreased parenchymal 
density on expiratory CT images.140 
Although mucous plugging and air trapping are not necessarily structural airway 
abnormalities, they are prevalent in CF lung disease and can improve with appropriate 
treatment. 
 
In established CF lung disease, a significant structural finding is bronchiectasis which 
is generally considered to be irreversible in the adult population. Although gross 
bronchiectasis might be detected on plain CXR, mild changes with regards to 
bronchial wall thickening or bronchial dilatation in young children would be difficult 
to detect on CXR. Chest CT could reveal more information with regards to lung 
disease however even if changes were identified, these changes may not necessarily be 
irreversible as CT images merely provide a snapshot view of lung disease at the time 
of imaging.141 It is important to be cautious in giving a radiological diagnosis of 
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bronchiectasis in children as diagnostic criteria were derived from adult studies that 
have not been validated in children.142  
 
Long et al showed that 10-20% of airways measured in 32 asymptomatic infants and 
toddlers with CF were bronchiectatic and 20% had bronchial wall thickening.143 In 
another study by the same group,137 clinically diagnosed and stable CF infants from 0-
5 years of age compared to infants who had a CT for non- respiratory reasons had 
significantly thicker airway walls and more dilated airways. Martinez et al138 also 
measured airway lumen and wall thickness in CF and control infants undergoing chest 
CT for non-respiratory reasons. Air trapping manifested by a significantly lower lung 
density at passive FRC was observed in CF infants compared to controls. Her group 
confirmed airway wall thickening in CF infants, however the airways were narrowed 
and not dilated as reported by Long et al.137 Possible explanations for this discrepancy 
included the fact that the average age of infants studied by Long et al was higher and 
therefore lung disease may have been more severe.   
 
Methodological differences with regard to different distending airway pressures during 
CT acquisition (section 1.8.1.2), different software for analysis and whether airway 
measurements were related to the diameter of the adjacent pulmonary artery must be 
considered carefully when designing future studies. 
 
Even with early diagnosis through NBS, CF infants and young children had bronchial 
wall thickening and dilatation, mucous obstruction and air trapping and these changes 
were more evident in those with greater degree of airway inflammation and 
infection.109,111 In the AREST-CF studies, radiologic evidence of structural lung 
disease on chest CT were common in infants at diagnosis and very young 
children.109,111  Sly et al reported abnormal CT findings in 80% of infants who had a 
CT performed at median age of ~3months; ~20% had bronchial dilatation; ~45% had 
bronchial wall thickening and ~65% had air trapping.109 Stick et al reported an 
incidence of bronchiectasis in the first year of life as 8.5%; this incidence increasing 
with advancing age such that a prevalence of 36% was reported by 4 years of age.111 
Both studies demonstrated significant associations between neutrophilic inflammation 
and structural CT changes. Increased inflammation was observed in the presence of 
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infection especially those with PsA infection and respiratory symptoms although the 
majority of infants who displayed inflammation and CT changes were clinically well. 
 
Information regarding the evolution of these early structural changes in infant and 
young children remains limited. The only longitudinal study investigating structural 
lung disease of CF infants diagnosed through NBS is from the AREST-CF team.108 In 
this study, 301 chest CT scans were performed in 143 NBS CF infants and young 
children aged 0.2-5.4 years. Median age of first scan was ~2 years (interquartile range, 
IQR: 1.2-3.3y) while the repeat scan was undertaken a year later at ~3 years (IQR:1.9-
4.0y). Bronchiectasis was detected on the first scan in 44% of scans performed with 
bronchiectasis extent score reported as median 0 (IQR= 0-2) out of a maximum extent 
score of 12 per scan. With repeated scans a year later, bronchiectasis persisted in 74% 
while 26% resolved. Of those who had no evidence of bronchiectasis the previous 
year, it was present in 50% a year later. Air trapping was present in 73% on the first 
scan with a median extent score of 2 (IQR: 0-5). With repeated scans a year later, air 
trapping persisted in 80% while 20% resolved. However of those who did not 
demonstrate air trapping on first scans, ~50% developed the abnormality on 
subsequent scans. Radiological progression of bronchiectasis and air trapping was 
associated with severe CFTR genotype, worsening neutrophilic inflammation and 
pulmonary infection. 
 
Results from these AREST-CF studies have provided useful insight into the early 
development of CF lung disease in NBS CF infants and the factors associated with 
persistence and progression of structural lung disease. The main limitation in these 
studies is the scoring system used. Only one radiologist scored the scans and the 
scoring system was not validated. As the authors stated, since there is currently no 
scoring system validated specifically for use in infants with CF they decided to use 
one based on a modification of the Brody-II scoring system.108 However, their binary 
scoring system may have oversimplified the detection and quantification process by 
allocating a score simply based on the presence or absence of change and, when 
change was present, simply dichotomising the abnormality as occupying either less or 
more than half of the lobe assessed. In young CF infants where milder abnormalities 
would be expected, this binary scoring system could potentially over-estimate the 
abnormalities detected, leading to an over-estimation of the incidence of 
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bronchiectasis and air trapping by the authors. In addition, it is important to note that 
of those classified as having bronchiectasis on first scan, classically defined as 
irreversible lung damage, 25% showed complete resolution in the subsequent scans. 
This suggests that CT changes detected were probably so subtle in the first instance 
that it was difficult to score changes consistently when using this binary scoring 
system. Besides, when mild and subtle changes were detected as in these young CF 
infants, bronchial dilatation seen during the first scan may have resolved with time, 
reflecting the paucity of knowledge that currently exists about the natural history of 
these so-called structural changes. Furthermore, there is no evidence regarding the 
clinical significance, if any, of these mild changes in NBS CF infants and young 
children. 
 
 Chest CT and its relationship with clinical measures 
Chest CT and CT scores have been used to evaluate and quantify pulmonary disease 
progression, response to treatment, prediction of future respiratory exacerbations, 
acquisition of PsA infection and future respiratory outcome in CF.144-149 The different 
scoring systems will be discussed in section 1.8.2. 
 
Improvements were reflected by Brody II CT scores in 17 young CF patients < 4 years 
of age treated with IV antibiotics for respiratory tract exacerbations. CT was able to 
identify pulmonary lobes with varying severity of disease. Regional differences in 
airway inflammation were closely correlated with Brody II scores, neutrophil count 
and Interleukin 8 (IL-8) in BAL taken from different lobes as identified through the 
CT scans. After IV antibiotics and intensified airway clearance therapy, improvement 
in total Brody-II and sub-scores for bronchial dilatation and hyperinflation were 
seen.144 Similar findings of improved CT scores were identified in older children and 
adults (mean age 17 years old; range 9-33) following treatment for acute respiratory 
exacerbations. Mucous plugging improved significantly after treatment suggestive of it 
being a reversible CT abnormality. Air trapping, bronchiectasis and bronchial wall 
thickening (BWT) did not significantly change after treatment, though there was a 
trend towards a decrease in BWT.146  
 
53 
 
Findings from a 1-year double blind placebo-controlled interventional trial of 
recombinant human deoxyribonuclease (rhDNase) in CF children with mild lung 
disease reported improvement in mucous plugging sub-score and total CT scores in the 
treatment group compared to the placebo group after 12 months of treatment.147 Hence 
it is necessary to understand which CT features of CF lung disease are reversible or 
irreversible with time so that outcome measures for trials using CT as an endpoint can 
be appropriately chosen. For example if the intervention involved a mucolytic, it may 
be more appropriate to monitor mucous plugging sub-score rather than bronchial 
dilatation sub-score.   
 
Total CT score and bronchiectasis sub-score were significantly associated with mucoid 
PsA infection in chest CT undertaken at mean age 11 years from the Wisconsin 
national screening programme.150 Bronchiectasis sub-score was the strongest predictor 
for increased respiratory tract exacerbation rate 2 years later in clinically diagnosed CF 
children and adults tested at median age of 12 years (range: 5-20 years); the more 
severe the bronchiectasis was, the higher the rate of respiratory tract exacerbations in 
subsequent years.145 
 
Chest CT severity showed good association with future lung disease in CF children 
who took part in the Wisconsin Neonatal Screening project. Every additional point 
accumulated in the Brody II score was associated with a reduction of about 3% in 
FEV1 when measured 2-10 years later.
149 Bronchiectasis sub-score from chest CT two 
years previously was most strongly associated with current spirometry. This is the first 
study to suggest the potential of using CT in early childhood to predict longer term 
outcome in NBS CF cohort.  
 
 Chest CT and its relationship with physiological measures 
Chest CT has been shown to be a sensitive measure of CF lung disease in older 
subjects and the clinical relevance of these structural abnormalities has been 
established through its relationship with other surrogate markers such as lung function 
tests,64,107,117,121,144,151-154 patient outcomes measures such as pulmonary 
exacerbations144-147,150,155 and long- term clinical outcomes such as morbidity and 
mortality.149 
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Despite many different scoring systems being available, most studies used either the 
original or modified Brody scoring system for quantification of CT-CF lung changes. 
The different CT scoring systems will be discussed later (section 1.8.2), while the 
rationale for using the Brody-II system in this research study will be discussed in 
section 1.9. Irrespective of which scoring system was used, chest CT has been shown 
to be more sensitive in detecting CF lung disease than conventional spirometry which 
displays limited ability to monitor progression of lung disease, especially in the early 
stages.152 In contrast, a higher CT score indicated worse lung function.156 De Jong et al 
reported progressive structural abnormalities detected on CT despite stable and normal 
spirometry in 48 children with first high resolution CT (HRCT) scan undertaken at 
mean age of 11 years and a repeat scan a mean age of 13 years.154 Brody et al 
demonstrated that chest CT using Brody II scoring system was more sensitive in 
detecting abnormalities than spirometry in 60 clinically diagnosed CF children aged 6-
10 years taking part in the Pulmozyme interventional trial.151  
 
However when compared with newer, more sensitive measures of lung function such 
as MBW, chest CT has been shown to be closely correlated with LCI with a similar 
number of abnormalities being detected by both techniques in clinically diagnosed CF 
children.64,107,117 In a retrospective study, LCI was shown to be strongly correlated 
with all structural abnormalities coded according to Brody II scoring system.64 
Gustafsson et al suggested that LCI may provide an alternative, safer measure than 
HRCT for detecting early pulmonary abnormalities in CF. These findings were 
confirmed by a prospective study in school age children showing good concordance 
between LCI and CT scores calculated according to the Bhalla scoring system.117 A 
prospective cross-sectional study by the LCFC in clinically diagnosed CF school age 
children demonstrated that LCI was abnormal as frequently as HRCT, and was 
abnormal more frequently than any other lung function indices derived from 
spirometry or plethysmography.107 Total CT scores correlated more closely with LCI 
than with spirometry. The close correlation between LCI and CT changes, both hailed 
as sensitive measures of early lung disease and potential clinical trial outcome 
measures, could enable LCI to be a screening tool for structural changes (i.e. only 
performing CT in those with normal LCI), hence reducing radiation burden associated 
with chest CT and its repeated use.107,157 Thus, even though considerable evidence 
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exists for the close relationship between LCI and CT changes detected on imaging in 
older children and adults,64,107  this relationship is less well understood in young NBS 
CF infants and children with mild disease. Two recent studies from Australia showed 
no correlation between LCI and CXR changes86 or between LCI and bronchiectasis or 
air trapping from CT scans86,121 when using a commercially available ultrasonic flow 
sensor (USFM) device for MBW with SF6 in NBS CF infants and very young CF 
children.   
 
Despite promising results on the use of chest CT as a surrogate measure of lung 
disease and hence a potential outcome in clinical trials involving older children, there 
are still several unanswered questions about the use of chest CT at a very young age. 
Firstly, although the AREST-CF group has provided some information about the 
evolution of CF lung disease in early childhood, this knowledge is still limited, 
particularly with respect to the early changes (bronchial wall thickening, dilatation and 
air trapping) detected in infants at a year of age and whether these lung changes were 
permanent or improve with time. Secondly, it remains unclear how these changes are 
related to functional abnormalities during infancy, or the long term clinical 
implications of these CT changes. Finally, the use of CT involves a significant amount 
of ionising radiation 158 which limits its routine use.159 
 
The second part of my research thesis will investigate if there was any association 
between CT changes and sensitive functional markers such as LCI in NBS CF infants 
at a year.  
 
 
1.8 CONSIDERATION OF CHEST CT AS AN OUTCOME IN 
MULTICENTRE TRIALS  
The literature indicates that significant airways disease is detectable by chest CT in 
infants and children with CF109,111 and that some of these changes may be 
reversible.108 Chest CT may have a role in future clinical trial as it has been shown to 
be a sensitive, reproducible and feasible outcome measure, albeit in studies involving 
older children. 
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Techniques for chest CT must be standardised if it is to be used as a multicentre trial 
outcome. This includes recommendations regarding the different types of scanner and 
settings recommended for use in infants and young children, types of images acquired 
(volumetric or limited slices; volume controlled or quiet breathing), the different 
scoring systems available to quantify CT specific CF lung disease and finally doses of 
radiation exposure with different CT techniques. Each of these criteria will be dealt 
with in sections 1.8.1, 1.8.2 and 1.8.3.   
 
 CT technique 
1.8.1.1 Scanner settings and parameters 
Chest CT is considered the gold standard for detecting bronchiectasis. However 
diagnostic ability is very much dependent on the images acquired.  
 
CT image quality depends on several factors: 
 Thin beam collimation (slice thickness) which in infants and young children is 
typically 0.5-1.0mm to obtain good resolution images of the smaller airways 
found in children of this size. 
 Cathode ray tube settings of beam energy (measured in kilovolt potential, 
kVp) to reduce degradation of image quality due to background quantum 
noise. Background ‘noise’ can also be reduced further by increasing tube 
current (measured in milliamperes, mA) and scan time. When scanning infants 
and small children, a lower tube voltage of 80-100 kVp and lower tube current 
of 10-20 mA has been recommended and according to these settings, radiation 
exposure could be reduced by 75%.160 
The young child must be as little exposed to radiation as possible with CT scanning, 
because of their greatly increased radiosensitivity. This may be achieved by adjusting 
scanners such that adequate quality images are obtained at a much lower radiation 
dose.157,161,162 If infants and young children are to be sedated or anaesthetised for 
volume-controlled ventilation images (see section: 1.8.1.2), this could allow scanning 
parameters and radiation exposure to be reduced further without degradation of image 
quality. This is possible due to the inherent contrast seen in the lung parenchymal 
tissue at higher lung volumes and the lack of movement artefact. The scanner settings 
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that were used in this research study were established by the Great Ormond Street 
Hospital radiology department and will be discussed in Chapter 4 (section: 4.2.1).  
 
1.8.1.2 Controlled lung volume imaging 
It is impossible for infants and young children either to lie still or sustain lung volumes 
near TLC and FRC voluntarily for inspiratory and expiratory scans. Hence in infants, 
lung volume controlled chest CT is usually acquired during GA or deep sedation with 
mask ventilation.160,163 In older children, controlled lung volume scan images can be 
achieved using a spirometer.164  
 
The volume at which the lung is scanned has a significant effect on what is 
detected.160,165 Long et al demonstrated the importance of detecting bronchiectasis at 
TLC (obtained by inflating the lungs to 25 cmH2O via a facemask during deep 
sedation) and air trapping at FRC (controlled ventilation at end expiratory pressure of 
0 cmH2O) in 16 infants and young children with mild CF. Bronchiectasis was detected 
in only 6% of the scans at FRC, compared with 30% when images were obtained near 
TLC. Data from previous studies suggested that early bronchial dilatation observed at 
a Peak Inspiratory Pressure (PIP) of 25 cmH2O cannot simply be iatrogenic due to 
effects of high inflation pressures during imaging.160 An inflation pressure of 25 
cmH2O in a sedated infant is within the physiologic range and is equivalent to the 
transmural pressure that occurs during a voluntary inspiration near TLC.160 In a study 
by Brown et al, effects of lung inflation on airway diameters showed that normal 
airways reach a maximal size with no further distension up to an airway pressure of 30 
cmH2O. Further evidence for this was demonstrated in a study involving 
asymptomatic CF infants and young children which showed early bronchiectasis on 
CT imaging using inflation pressures up to 25 cmH2O, whilst no bronchiectasis was 
seen in normal healthy controls.137   
 
In contrast to bronchiectasis, air trapping, as an indirect measure of small airway 
disease, was predominantly detected on expiratory scans at FRC rather than at TLC or 
during quiet breathing. This was demonstrated in a study of older CF children and 
healthy controls where inspiratory images were obtained at 25 cmH2O and expiratory 
scans at 0 cmH2O using a spirometer to guide breathing patterns. No difference in lung 
attenuation (i.e. air trapping) was seen between the CF and healthy children from the 
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inspiratory images whereas those with CF had significantly lower lung attenuation 
than the controls on the expiratory scans.165  
 
The Fleischner society has published criteria for specific CT features in lung disease 
hence enabling objective assessments of these abnormalities. Although for 
bronchiectasis, the guidelines state that it should include ‘bronchial dilatation with 
respect to the accompanying pulmonary artery, lack of tapering of bronchi and 
identification of bronchi within 1cm of pleural surface’,166 these guidelines do not 
stipulate what broncho-arterial ratio (BAR) should be to define bronchiectasis. 
Although generally, it has been accepted that bronchial dilatation is usually interpreted 
as a BAR >1, there is lack of international consensus on how to define bronchial 
dilation in infants and young children. It has been suggested that a BAR threshold of 
0.76, rather than 1, should be applied in children167 and higher BAR with increasing 
age.137 However measuring changes in small bronchial luminal size to define bronchial 
dilatation may be beyond current CT spatial resolution. The accuracy of assessing 
BARs, especially in health, is also critically dependent on reliably achieving full lung 
inflations.160 If images are obtained at varying lung volumes within-or between- 
subjects at different times, this would alter the size of distending bronchi in 
relationship to accompanying vessels which could confound interpretation and lead to 
non-standardised classification of bronchiectasis in research studies. Hence obtaining 
CT images at similar lung volumes is vitally important for multicentre or longitudinal 
studies. 
 
1.8.1.3 Scanning protocol: non-contiguous (limited slice) vs contiguous 
(volumetric) imaging 
Multislice (multidetector) scanners with 16 or more channels can provide contiguous 
(volumetric) imaging where very thin slices of the entire lung are imaged, or non-
contiguous imaging (so called high resolution CT, HRCT) whereby the lung is 
sampled with thin sections obtained at regular intervals.  
 
HRCT uses less radiation and can be performed quickly making it an adequate 
investigation to assess the presence or severity of CF lung disease. In an effort to 
reduce radiation further, limited slice protocols have been developed and used in 
research studies which typically involve three to six slices at anatomically designated 
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positions on inspiration and expiration. Using this approach, differences in airway 
dimensions and air trapping between CF and control children, as well as the response 
to different treatments,137,138,146,147 have been demonstrated. The main limitation of 
using limited slice HRCT protocol would be the danger of missing small lung 
abnormalities in areas that were not being sampled i.e. in between the levels that were 
sampled. For heterogeneous lung disease like CF, there is a danger of missing 
abnormalities using HRCT reduced slice imaging protocol. In one study, the ability of 
CT to detect and track bronchiectasis over time was lost with reduced slice 
frequency.168 The same group also reported a reduction of air trapping score based on 
Brody II scoring system when expiratory scans were reduced from volumetric to three 
slices expiratory scans, grossly underestimating the degree of air trapping with no 
progression in air trapping observed over time.169 Limited slice imaging protocols 
were therefore not recommended for quantifying CF lung disease in children 
especially in the context of multicentre trials. 
 
With the development of modern multidetector CT scanners, thin-slice volumetric 
images can be produced with rapid scanning times. The use of such scanners in 
research has been revolutionary. Contiguous imaging with dedicated software allows 
three-dimensional reconstructions to be generated. Bronchial tree and sub-segmental 
bronchial generations can be mapped out with accurate estimation of airway lumen 
and airway wall thickness without the need to resort to a comparison with the 
accompanying vessel. Quantitative assessment of air trapping is also feasible.140,170 For 
longitudinal research studies whereby monitoring of changes in airways over time is 
paramount, volumetric CT contiguous imaging has the ability to better match airways 
and regional air trapping to allow accurate comparisons over time.  
 
The main limitation of contiguous imaging is the increased radiation dose which has 
potentially serious implications for growing children. In view of the literature 
available on the sensitivity of detecting abnormalities based on the different scanning 
protocols (i.e. non-contiguous or contiguous volumetric) and the radiation risk 
associated with scanning, most research groups involved in the structural evaluation of 
CF lung disease or the use of CT as trial endpoint have performed a volumetric 
inspiratory scan with a 3-section expiratory scan. This approach is a compromise 
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between the need for detailed and accurate structural evaluation and the importance of 
reducing radiation dose.107,117,121,149  
 
In this research study, the initial plan was to perform a volumetric inspiratory CT scan 
at 25 cmH2O during GA and a 3-section limited expiratory scan at 0 cmH2O. A low 
dose scanning protocol was utilised as stated in chapter 4 (section: 4.2.1). 
 
 CT scoring systems  
1.8.2.1 Types of CT scoring systems 
The first CT scoring system was described by Bhalla and colleagues in 1991.171 Since 
then several other scoring systems have been published based largely on the Bhalla 
scoring system with modifications and have been validated for use in CF lung disease 
in older children and adults.146,171-174 
 
In all these scores, abnormalities were identified and the severity graded. Important 
abnormalities included in most of these scoring systems were bronchiectasis, airway 
wall thickening, mucous plugging and parenchyma opacities. Other abnormalities such 
as mosaic attenuations, small nodules, sacculations and air trapping on expiratory 
images were only included in some of the scoring systems.173 More recent CT studies 
have included expiratory images to document air trapping.146,172  
 
In the Bhalla scoring system, mucous plugging and peribronchial wall thickening were 
combined which limited the evaluation of individual findings. No anatomic 
localisation was identified so lobar distribution of abnormalities could not be assessed. 
There was no air trapping sub-score as no expiratory image was scored. Robinson et al 
modified the Bhalla scoring system; an abnormality that occupied less than 25% of the 
volume of the lobe received the same score as a lobe with no abnormality, hence 
reducing the discriminatory power of detecting mild abnormality and probably 
underestimating the extent of lung disease using this scoring system.146  
 
The system published by Nathanson et al evaluated only bronchiectasis and mucous 
plugging, with no evaluation of peribronchial thickening or the lung parenchyma.174 
To address these limitations, Brody et al developed the Brody scoring system which 
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was modified in 2006 in response to the need for better evaluation of structural lung 
disease in young CF subjects who were part of the Wisconsin Neonatal CF Screening 
project.140 This modified scoring system focussed on younger patients (6-10 years old) 
with milder lung disease even though this scoring system was first designed to 
describe a wide spectrum of CF lung disease; to encompass mild lung disease on one 
end of the scale to the most severe lung disease requiring lung transplant on the other 
end of the spectrum. In particular with the Brody-II scoring system, lobar location and 
extent of abnormality can be differentiated further into thirds of each lobe (i.e. one 
third of lobe affected vs 2/3 vs > 2/3) and severity of bronchiectasis, peri-bronchial 
wall thickening, mucous plugging and quantification of air trapping were 
emphasised.172 A detailed description of the Brody-II scoring system will be discussed 
in the methodology chapter for chest CT (chapter 4, section 4.4.2).  
 
To date, the most widely used validated CT scoring system that allows the most 
comprehensive assessment of CF lung changes is the Brody-II. The AREST-CF study 
devised a modification of the Brody scoring system to simplify scoring of 
abnormalities into a binary fashion as discussed earlier (section 1.7.1). No studies 
have established the use of any of these existing scoring systems in detecting and 
quantifying lung disease in NBS CF infants during the first year of life when changes 
may be presumed to be milder.   
 
1.8.2.2 Reproducibility of CT scoring systems 
If a CT scoring system is to be a sensitive outcome measure for trials, the variability or 
reproducibility of the scoring within and between observers must be known.  
A cross sectional study comparing five scoring systems revealed similar results for 
each. Twenty-five CT scans from subjects with CF aged 5 to 18 years with wide 
ranging lung function (FEV1 36-118% predicted) were scored and rescored after an 
interval of 1 to 2 weeks and again after 1 to 2 months by three observers.  Between- 
and within-observer agreement was good with intra-class correlation coefficients 
generally greater than 0.8.175 There was no difference in the ability of the 5 scoring 
systems to detect disease reflecting the contribution of the features common to these 
different systems.  
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The Brody-II scoring system has good inter-rater and intra-rater reproducibility of 
95% for the total score and reproducibility that are better within than between raters 
over time. The authors suggested that for scoring CT in longitudinal studies, the same 
individual should score the scans over time.172 de Jong et al employed the Brody-II 
system in a large clinical follow up study of children and adults with CF. The study 
demonstrated that CT scores were sensitive to lung changes with worsening of CT 
scores to document progression of abnormalities over time despite stable 
spiromtery.152 
 
The inter-observer and intra-observer variability of component CT scores (sub-scores) 
were poorer for some components than for the total scores. In the Brody-II validation 
study,172 Brody et al reported inter-observer agreement of 74% for bronchiectasis, 
89% for mucous plugging and 61% for air trapping. De Jong et al using the Brody-II 
scoring system showed different intra-class correlations (r value) between two 
observers for total scores and CT components; total score (r=0.92), bronchiectasis 
(r=0.88), opacities (r=0.80), mucous plugging (r=0.72), airway wall thickening 
(r=0.67), bulla and cysts (r=0.53) and air trapping (r=0.27).152 Owen et al reported 
structural CT changes in LCFC clinically diagnosed school-aged children (mean age: 
7.8 years) using the Brody-II scoring system.107 Inter-observer agreement for total 
scores and some sub-scores were reported as excellent using Kendall’s Tau statistics. 
Coefficient of agreement for different component scores were: Total CT score (0.76), 
bronchial dilatation (0.77), peribronchial wall thickening (0.74), mucous plugging 
(0.74), air trapping (0.59) and parenchyma change (0.40). 
 
Although generally total CT scores have good inter- and intra-observer variability, 
reproducibility was lower for certain components or sub-scores. This limited the 
ability of the scores to track changes in subcomponent features of CF over time. A 
possible reason for high variability in some sub-scores may be related to a lack of 
unambiguous definitions and reference images for defining an abnormality.173  There 
was also significant increase in variability between scores when the total scores were 
low, as in early lung disease when changes are mild. Early lung changes were more 
subtle making it potentially difficult for a subjective observer to assign broad ordinal 
scores in a consistent manner. This may be the case when scoring systems are used in 
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young infants.170 To date, no scoring systems have been developed and validated 
appropriately for scoring CT changes in young CF infants. 
 
 Radiation risk 
Radiation exposure is the main concern for considering the use of chest CT as an 
outcome measure in trials or as a monitoring tool. It is measured in terms of the 
quantity of radiation energy ‘absorbed’ by the body tissue and is expressed in 
millisieverts (mSv). This is a measure of radiation dose which accounts for the fact 
that ionising radiation can affect different parts of the body to a different extent. This 
then allows different sources of radiation to be compared. For example in an adult, a 
CXR has a radiation dose of 0.02 mSv, transatlantic flight: 0.07 mSv, total body CT 
scan: 10 mSv, level at which changes in blood cells can occur: 100 mSv, acute effects 
of radiation leading to cell death and organ failure: >1000 mSv and a dose which 
could be fatal: 5000 mSv (http://www.hpa.org.uk/topics/radiation/).  
 
With low dose ionising radiation associated with medical investigations, the principal 
concern is with respect to genomic damage leading to an increased lifetime risk of 
cancer. This risk is greatest in children < 10 years old.158 This is explained by the fact 
that young children face a larger lifetime background risk of cancer mortality which 
magnifies their relative risk per unit dose of radiation and that young children absorb a 
greater fraction of any given radiation dose.158 The natural risk of childhood cancer is 
1 in 5000 and the average annual background radiation in UK is ~2.5 mSv whilst in 
the United States of America, it is between 3.5-6.2 mSv (http://www.hpa.org.uk). The 
lifetime risk of subsequent malignancy with the use of a chest CT in a young child (<2 
years) will increase that risk of childhood cancer by 1 per 5000 cases.176  
 
It is therefore crucial that there must be judicious use of radiation associated imaging 
in CF infants and young children. If chest CT is required then there is a responsibility 
to ensure that images are obtained with the lowest possible radiation dose. 
Consequently, there is a concerted effort internationally to develop standardised low 
dose CT protocols.  
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1.9  RATIONALE FOR CHEST CT IN THIS RESEARCH 
PROJECT 
The second part of this research study was conducted to increase the understanding of 
structural lung changes in NBS CF infants at a very young age, specifically at 1 year. 
Although previous studies may have demonstrated structural lung changes in infants 
and young children through the use of chest CT, very few were in NBS CF infants at 1 
year. 
 
In addition, there are no established CT scoring systems available for scoring 
abnormalities during infancy. We opted to use the Brody-II scoring system to validate 
its use in infants through this study. The Brody-II scoring system was chosen due to its 
comprehensive assessment of structural lung changes which takes into account not just 
the presence of an abnormality but the extent and severity of the abnormalities with 
accurate lobar identification. In addition if a ‘simpler’ and hence quicker scoring 
system was required in the future, this could potentially be derived from the complex 
array of information documented in the Brody-II scoring system. 
 
As NBS CF infants had a flexible bronchoscopy and BAL as part of their first year 
annual review (details of which are beyond the scope of this thesis), a decision was 
made to perform the CT scan under the same GA just before the bronchoscopy. 
Volumetric inspiratory image was obtained at PIP of 25 cmH2O whilst 3-slice limited 
expiratory image was obtained at PEEP of 0 cmH2O for each CF infant. Since there is 
also a need for more information regarding the relationship between lung function and 
structure in NBS CF infants, efforts were made to ensure that ILFT and chest CT were 
performed within 1-2 weeks of each other and while the child remained in a clinically 
stable condition (see Chapter 4).  
 
 
1.10  HYPOTHESES, AIMS AND OBJECTIVES 
There is evidence, both from lung function testing and chest CT that there is early and 
progressive functional and structural airway disease in CF, despite diagnosis by NBS 
and the institution of modern therapy early in life. The main source of this evidence is 
AREST-CF. However, as described above, there are flaws and limitations in some of 
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these studies which mandate further investigation. This forms the basis of this research 
study. Limitations of previous studies were addressed so that results would provide 
more robust evidence for lung function and structure in NBS CF infants at a year of 
age. Without this accurate information, outcomes for future interventional trials cannot 
be devised.  
 
 Primary hypothesis, aims and objectives 
The primary hypothesis of this study pertained to the one year lung function of NBS 
CF infants. In view of impaired lung function with continual deterioration in the first 
year of life demonstrated in clinically diagnosed LCFC as well as in NBS CF infants 
from the AREST-CF studies, the primary hypothesis of this study was: 
1) Despite early diagnosis and specialist treatment, NBS CF infants have further 
loss of lung function from first diagnosis until a year of age.  
The primary aims were to: 
1) Compare lung function in NBS CF to that in healthy control infants at a year of 
age. 
2) Compare the changes in lung function during the first year between the two 
infant groups.  
The primary objectives were: 
1) To assess LCI, FRCpleth, gas trapping (∆ FRCpleth - FRCMBW), FEV0.5 and FEF75 
z- scores measured using MBW, plethysmography and RVRTC in NBS CF 
infants and healthy controls at a year of age, and compare these results between 
the two groups. 
2) To measure and compare the rate of change of lung function between 3 months 
to 1 year in NBS CF and healthy infants.  
3) To determine whether lung function at 3-months of age is predictive of 1-year 
lung function.   
 
 Secondary hypotheses, aims and objectives 
The secondary hypotheses of this research study were: 
1) At one year of age, NBS CF infants have evidence of significant lung disease 
detected on chest CT scan using the Brody-II scoring system.   
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2) In NBS CF infants, there are significant associations between lung 
abnormalities detected on chest CT and the various lung function outcomes 
described above when assessed at ~ 1 year of age.  
The secondary aims to address the hypotheses were: 
1) To perform chest CT at a year of age in NBS CF infants using standardised 
protocols across different study centres. 
2)  To explore the relationship between pulmonary changes detected on CT and 
functional abnormalities detected using MBW, plethysmography and RVRTC 
in NBS CF infants at a year of age. 
The secondary objectives were: 
1) To assess the feasibility and adherence to standardised CT and GA protocols in 
using chest CT as an outcome measure in this multicentre study. 
2) To assess inter and intra-observer agreement of Brody-II total CT and CT sub-
scores allocated to NBS CF infants at a year of age. 
3) To detect and quantify CF lung disease according to total and component CT 
scores (bronchial dilatation, airway wall thickening, parenchymal change, 
mucous plugging and air trapping) using the Brody-II scoring system by two 
experienced radiologists 
4) In NBS CF infants at a year of age, to assess whether LCI, FRCpleth, FEV0.5 and 
FEF75 were as sensitive as CT in identifying pulmonary abnormalities and 
which, if any of these lung function outcomes were best correlated to total CT 
scores and sub-scores for bronchial dilatation, airway wall thickening, 
parenchymal opacities, mucous plugging and/or air trapping. 
5) To determine potential clinical associations with physiological and structural 
lung outcomes of NBS CF infants at a year of age. 
 
 
1.11 SUMMARY 
Early detection and specialist treatment of CF lung disease is beneficial and can be 
achieved through NBS. It is vital to have a greater understanding of the evolution of 
lung disease in CF infants diagnosed through NBS so that novel interventions can be 
targeted appropriately, and randomised control trials can be adequately powered. In 
recent years, potentially sensitive, reproducible and feasible outcome measures for 
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quantifying lung disease in infants and young children have been identified which may 
prove to be important and crucial endpoints for clinical trials in this CF population.  
 
In this thesis, I will investigate lung function and structure in NBS CF infants at a year 
of age and assess whether these physiological and structural measures could be 
suitable endpoints for clinical trials in infants with CF. The next chapter describes the 
ILFT protocols, subjects and methods in detail.   
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2 LUNG FUNCTION IN NEWBORN SCREENED CF 
INFANTS: SUBJECTS & METHODS 
 
2.1 OVERVIEW OF STUDY  
The research described in this thesis was part of a prospective longitudinal cohort 
study investigating early lung function, structure and inflammation in NBS CF infants. 
These infants were referred from six paediatric tertiary respiratory centres within the 
Greater London region.  Healthy control infants were also recruited for lung function 
assessments. 
 
Following informed, written parental consent, ILFT were performed at around 3 
months and 1 year of age for all infants. All infants underwent the MBW test to 
measure LCI and FRCMBW, RVRTC to measure forced expiratory volumes and flows, 
as well as body plethysmography to measure FRCpleth. All ILFT were performed at one 
centre- Great Ormond Street Hospital for Children (GOSH). ILFT were performed in 
the order as stated in Figure 2-i. Protocols for ILFT will be discussed in this chapter 
with results presented in the next chapter. 
 
CF infants also underwent additional tests at 1 year on a separate hospital visit, namely 
chest CT and bronchoscopy under GA. These tests were performed at three of the 
referring hospitals, with infants from the remaining three referring hospitals 
undergoing CT/ bronchoscopy at GOSH (Figure 2-i). Protocols involved in the GA 
management and acquiring of CT scans, the process and methodology of scoring CT 
scans from these CF NBS infants will be discussed in Chapters 4 and 5 with the results 
of CT findings presented in Chapter 6. 
 
Flexible bronchoscopy and BAL were undertaken following the chest CT but the 
results of these investigations will not be discussed as this is beyond the remit of my 
thesis. 
  
69 
 
Figure 2-i: Schedule of testing in CF and control infants at 3months and 1year: 
Chest CT, Flexible Bronchoscopy and Broncho-Alveolar Lavage at ~1 year only 
performed in CF infants 
 
 
 
 
 
 
 
Multiple Breath Washout: 
                     -measuring LCI and FRCMBW 
 
                  Body Plethysmography: 
        -measuring FRCpleth 
 
                Tidal forced expiratory manoeuvres (tidal “squeeze”): 
-measuring V’maxFRC  
   
                 RVRTC: 
      -measuring FEV0.5, FVC, FEF75 and FEF25-75 
 
 
            End of lung function test protocol 
    Measure infant’s length and head circumference 
 
 
      Only in CF infants 
        In a separate visit after 1yr lung function: 
              Chest CT, followed by flexible bronchoscopy and broncho-alveolar lavage 
 
  
 Arrival of Infant to Lung Function 
Laboratory 
 Obtain parental written informed 
consent 
 Examine infant and perform routine observations.  
 Complete questionnaires 
 Collect cough swab samples in CF infants 
 Weigh infant and administer chloral hydrate as 
sedation. 
Once infant is asleep 
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 Ethical approval 
The study had full ethical approval by the National Research Ethics Service (NRES) 
Committee London-Bloomsbury REC (Ref No: 09H071314) and the Local Research 
Ethics Committees of each of the six collaborating centres. For all subjects, informed 
written consent was obtained. Written consent for photography was sought at the same 
time to obtain photos for publications and this thesis. 
 
 
2.2 SUBJECTS  
Two groups of subjects were recruited for this study, namely: 
1. CF infants diagnosed through NBS or presentation with meconium ileus; 
2. Healthy full term infants (≥36 weeks gestation)  
 
 Recruitment of CF infants 
Infants born in London and the surrounding areas who screened positive for CF were 
seen at one of the collaborating hospitals (GOSH, Royal Brompton Hospital, Royal 
London Hospital, Kings College Hospital, Lewisham University Hospital and East 
Surrey Teaching Hospital) for diagnostic sweat testing. Once the diagnosis was made, 
individual infants underwent comprehensive assessments and their families received 
detailed information and education regarding CF treatment and condition. 
 
Infants with CF were recruited to this study by their consultants when attending follow 
up approximately 2 weeks after a positive diagnosis of CF. The purpose of the study 
was explained verbally, and parents were given both the parental information sheet 
and additional illustrated leaflets (Appendix: A2 and A3). They were given time to 
consider the information before giving written consent for ILFT and CT/bronchoscopy 
(Appendix: A4). 
 
Those who were diagnosed with meconium ileus also underwent screening. Once CF 
genotype had been identified, they had a confirmatory sweat test. They were 
subsequently treated in accord with a pre-determined treatment protocol (Appendix: 
A7) 
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Inclusion Criteria:  
•  Infants diagnosed with CF by NBS within the Greater London catchment area  
 
Exclusion Criteria:  
• Infants with CF born <36 completed weeks of gestation 
• Severe congenital, cardiovascular or neuromuscular disorders that could impact 
on the development and function of the respiratory system  
• Inability of parents to understand and give informed consent  
• Recruitment contra-indicated based on psycho-social factors 
• History of apnoeic episodes or upper airway pathology  
• Family due to move out of area 
 
 Recruitment of Healthy Control (HC) Infants 
Healthy term infants with no congenital abnormalities, born ≥ greater than 36 weeks 
gestation were recruited from the community by specified research assistants or 
fellows working specially on this project.  
 
With permission from the Head of the Midwifery Services and the Consultant 
Paediatrician of the Homerton University Hospital, East London, monthly birth 
records were transcripted as a password protected Excel spreadsheet and forwarded to 
the research team. From the birth list, the research team carefully selected healthy 
infants who were likely to be eligible for recruitment (see the list of Inclusion and 
Exclusion criteria below). Letters were sent to the general practitioners (GPs) of the 
infants/families to investigate if it was appropriate to approach the families of selected 
healthy infants. Following replies and confirmation from GPs, detailed information 
sheet and additional illustrated leaflets were sent to parents of healthy infants 
(Appendix: A2). This was followed by a telephone call 7-10 days later from the 
research team to further discuss the study, particularly the need for chloral hydrate 
sedation. If parents were interested in participating in the study, an appointment for 
LFT was made over the phone with confirmatory letter sent subsequently.  
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Inclusion Criteria:  
•  Healthy term infants (≥36 weeks gestation) who lived within reasonable 
travelling distance of London for specialist ILFT, and whose parents consented 
to these measurements 
 Mainly of Caucasian descendance (matching the proportion of ethnic groups of 
CF cohort) 
 
Exclusion Criteria:  
•  Inability of parents to understand and give informed consent  
•  Recruitment contra-indicated on psycho-social factors  
•  History of apnoeic episodes or upper airway pathology  
•  History of chronic diarrhoea or failure to thrive  
•  History of neonatal lung disease, or coexistent heart, lung, neuromuscular or 
renal disease that could impact on the respiratory system  
•  Previous history and/or hospital admissions for lower respiratory tract 
infections  
 
Any healthy infant who was recruited into the study but was subsequently admitted to 
hospital with a respiratory infection, chronic diarrhoea or failure to thrive was also 
excluded from the control group, whereas any who developed a lower respiratory tract 
infection or wheezing illness that did not require hospitalisation, and had been tested at 
~3m and/or 1yr were retained within the cohort. 
 
 Preparation of infants for lung function test procedure 
Appointments for lung function tests were arranged to coincide with normal periods of 
day-time sleep. On arrival, parents were talked through the study protocol and 
encouraged to ask questions. They were reminded of the potential side effects of 
chloral hydrate, which was the enteral sedation used in the lung function laboratory, 
and about the bitter taste of the sedative syrup which often upset infants temporarily.   
 
Infants were assessed clinically including auscultation of the chest for wheeze or 
crackles. If there was evidence of coryza, nasal blockage or cough, the test was 
delayed for a minimum of 3 weeks. Routine clinical observations such as heart rate 
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and oxygen saturation were performed using the Masimo pulse oximeter (Masimo 
Radical-7, Irvine, CA, USA), and such vital signs were monitored continuously 
throughout the test session.  
 
Parents were advised to fast their infant for 4 hours (2 hours if the infant was 
breastfed) and to abstain from clear fluids for 2 hours prior to the ILFT in accordance 
with the NICE guidelines on sedation in children and young people published in 
December 2010 (http://www.nice.org.uk). An empty stomach from fasting enabled 
better and quicker absorption of the oral sedation, and reduced the risk of gastric 
aspiration. As soon as oral sedation was given, parents were encouraged to settle the 
baby to sleep. On rare occasions when the infant was fretful and unable to settle (more 
than one hour) post administration of oral sedation and feeding was overdue, a small 
drink or light feed was given.  
 
 Study questionnaires and smoking history 
Study questionnaires previously designed by our laboratory (Appendix: A5 and A6) 
were used to record background and medical information of CF and healthy infants. 
Relevant background information including parental and sibling (if any) health, 
ethnicity, any significant neonatal history, antenatal/postnatal cigarette smoke 
exposure, and parental occupation (hence socio- economic status) were recorded. 
Infants with CF also had date of diagnosis, genotype and sweat test results recorded in 
this initial questionnaire.  
 
For CF infants: 
Significant medical problems at birth and within the first year were recorded in the 
questionnaires completed at each test occasion and the clinical record forms (CRF), 
completed at each CF clinic visit. These included any surgery, the need for ventilatory 
support, hospital admissions and the use of additional intermittent antibiotics for 
respiratory causes, development of wheeze or allergy, as well as anthropometric 
measurements. CF infants were managed by each of the six CF centres through a 
standardised treatment protocol (Appendix: A7). The type, route and number of 
courses of antibiotic received were clearly documented. Current therapies subdivided 
into ‘pulmonary’ and ‘nutritional’ treatments, and the frequency and duration of 
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parental administered physiotherapy were recorded. Parents were asked about the 
recent occurrence and frequency of coughing. As parental identification of wheezing 
was more difficult, no quantification of this symptom was asked except for whether 
the infant had wheezed or not.(Appendix: A5) 
 
In addition, clinical information recorded for CF infants at each hospital clinic visit 
were reported prospectively onto a standardised CRF (Appendix: A8).   
 
For Healthy control infants: 
An adapted questionnaire similar to that used for CF infants was used for the healthy 
control infants (Appendix: A5). 
 
Smoking history 
Parental smoking history was elicited via the study questionnaire. Current non-
exposure to environmental tobacco smoke was validated by collecting a urine sample 
from infants (or cotinine assay) whose parents reported to be non-smokers. Cotinine is 
a by-product of nicotine and is a sensitive measure of recent smoke exposure, which 
allows discrimination between active, passive and non- smokers.177,178  The urine 
specimen was obtained by placing cotton wool balls in the nappy which were removed 
once saturated with urine, using disposable gloves to avoid potential contamination 
(from the investigator’s fingers), at the end of the test occasion. Clear urine was 
extracted from the cotton wool balls by placing them into a syringe and then using the 
plunger to squeeze the urine out into a plain specimen bottle (minimum amount: 0.2 
mL). Alternatively, if an infant urine sample could not be collected then a maternal 
salivary sample was obtained by placing a dental roll into the mother’s mouth for ~5-
10 minutes until it is saturated with saliva. The saturated dental roll was placed in a 
syringe and a saliva sample collected into a plain specimen bottle by squeezing down 
on the syringe plunger (minimum amount: 0.2 mL). 
 
Samples were immediately stored at ─20◦C prior to analysis. The frozen urine and 
salivary samples were sent periodically in batches for cotinine assay to the ABS 
Laboratories Ltd (BioPark, Broadwater Road, Welwyn Garden City; 
http://www.abslabs.com/contact.cfm). Urinary cotinine values <49.7ng/ mL and 
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salivary cotinine values <12ng/ mL are generally considered compatible with that 
from non-smokers.179 
 
 Microbiology 
Cough swabs were taken from infants with CF before the ILFT, unless one had been 
performed 7-10 days previously. A standard hospital swab (Transswab, Medical Wire 
and Equipment Co.Ltd., Wiltshire, England) was inserted above the tongue and the tip 
aimed towards the back of the oropharynx to elicit a cough. The swab was 
subsequently removed and inserted into a sterile container and was processed at the 
Camelia Botnar Laboratories, GOSH, for culture and sensitivity of any bacterial 
growth in accordance to CF Trust guidelines (www.cftrust.org.uk). 
 
Cough swabs were also taken from CF infants, during their regular 2-monthly clinic 
visit locally and whenever respiratory symptoms were reported by the parents. 
 
 Sedation 
Chloral Hydrate sedation was given at a standard dose of 60-100mg/kg body weight180 
( maximum of 1 gram regardless of body weight) in accordance to established 
guidelines. These doses have been administered to well over a thousand babies over 
the last three decades in this London and other respiratory function laboratories world-
wide with no major adverse effects. The majority of the infants were given chloral 
hydrate syrup orally although parents were able to request chloral hydrate 
suppositories in older infants who refused to take it orally or were able to spit out the 
syrup. 
 
Parents were advised of possible unsteadiness post sedation. Sub-optimal doses can 
result in hyperactivity and irritation. Although never required to date, an emergency 
trolley containing equipment for advanced cardiorespiratory resuscitation (including 
resuscitation bag and mask, tracheal suction apparatus with catheters, piped medical 
air and oxygen within the room where LFT were conducted) was available at  all times 
and all staff involved were trained in airway management and administration of 
advanced life support.181  
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 Anthropometric measurements  
Since respiratory parameters are closely related to body size, the infant’s weight and 
length were measured as accurately as possible. The infant’s naked weight was 
measured prior to sedation in order to calculate the dose of Chloral hydrate, using Seca 
electronic digital scales (Seca Ltd, Birmingham, England). Weight was recorded in 
kilograms to two decimal places.   
 
All other anthropometric parameters were usually measured after the respiratory 
function tests. Whilst the infant remained slightly sleepy, the infant’s crown-heel 
length was measured by two members of the research team using a calibrated 
Harpenden stadiometer/ infantometer (M K Scales LTD, Bletchley, UK 
http://www.mkscales.co.uk/products_486_34_Harpenden-Infantometer.html). One 
person gently held the infant’s head in a mid-line position, with the crown touching 
the top of the stadiometer, whilst the other gently depressed the infant’s knees to fully 
extend the legs. The sliding footplate was adjusted to rest firmly against the soles of 
the feet (Figure 2-ii). The measurement was repeated two to three times and the 
results reported as the mean of two measurements which were within 0.5 cm of each 
other. Length and weight were expressed as z-scores to adjust for age and sex.182  
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Figure 2-ii: Measuring crown-heel length of infant 
 
Legend: This photograph shows one investigator gently holding the infant’s head in 
the mid-line position with the crown touching the top of the stadiometer, with the other 
investigator depressing the infant’s knees to fully extend the legs. Written permission 
was obtained for the scientific use of all photographs presented in this thesis from the 
infants’ parents.  
 
 
2.3 LUNG FUNCTION PROTOCOL 
 Multiple breath inert gas washout technique (MBW) 
The MBW method was used to measure LCI and FRCMBW using a respiratory mass 
spectrometer and customised software for data collection and analysis.83 
 
2.3.1.1 MBW apparatus and calibration  
Two computer systems were used for the MBW test. One of these was attached both to 
the mass spectrometer and to the second PC which, loaded with the customised 
software, was used to collect respiratory data and subsequent analysis of MBW results.  
 
The gas analyser used in this study was an AMIS 2000 quadropole respiratory mass 
spectrometer (Innovision, Odense, Denmark). It operates by identifying gases 
according to their mass-charge ratio. A gas mixture is drawn into a vacuum chamber 
along a narrow-bore capillary tube. When it is in contact with an electrical filament, 
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positively charged ions are created which are then accelerated along a voltage gradient 
towards a receptor. The mass-charge ratio is determined by the molecular mass of the 
gas, so only gases of one mass-charge ratio (i.e. in most cases, only one gas) can reach 
the receptor at any one time. For this study, the AMIS 2000 was programmed to 
recognise helium (He), nitrogen (N2), oxygen (O2), carbon dioxide (CO2) and sulphur 
hexafluoride (SF6). The gas sampling rate of the AMIS 2000 is 15 mL/ min.  
 
As instructed by the manufacturer, the AMIS 2000 was calibrated prior to each test 
occasion using a certified concentration gas (alpha-gravimetric standard, British 
Oxygen Company, Guildford, UK), i.e. the “calibration” gas containing 3.97% He, 
3.98% SF6 , 7.04% CO2, 21% O2 and 64% N2. A signal-noise ratio of 100 or greater 
was deemed acceptable. The calibration procedure included an automatically 
performed re-optimisation of atomic mass unit peaks. A short one-point calibration 
check was performed prior to each measurement using the same gas mixture for 
calibration. 
 
Analogue outputs from the demodulator and from the mass spectrometer were 
recorded at 100 Hz using a desk-top computer (Dell Computers, Round Rock, TX, 
USA) through a 16-channel AD-conversion board (Model RS485, Keithley Metrabyte, 
Taunton, MA, USA), connected to a Laptop computer loaded with custom written 
software (by Per Gustafsson et al, Sweden) based on a commercially available data 
acquisition software pack (TestPoint, Capital Equipment Corp., Billerica, MA, USA). 
 
The pneumotachometer (size 0 Fleisch PNT; Lausanne, Switzerland), attached to a 
differential pressure transducer (Validyne, Model MP 45-14-871, Validyne Corp., Ca, 
USA) by means of two equal length of firm translucent vinyl tubings (AlteVin, UK) 
was calibrated at room temperature prior to use with separate calibration constants for 
inspiratory and expiratory flows using a 100mL precision syringe (Hans Rudolph, Inc; 
Shawnee, Kansas, USA).  
 
Gas samples and flow signals were aligned in time. Delay to the gas signal was 
measured using a custom-made delay switch (manufactured by Mr E Bergsten, 
Swedish Defense Research Agency, Department of Defence Medicine, Linköping, 
Sweden). This system measured the delay between gas appearing at the capillary inlet 
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of the mass spectrometer (enabled by opening the switch) and that gas bolus being 
recorded by the software. During the pre-test calibration process, a series of 20 delay 
recordings were performed, and the median delay and rise times obtained were used to 
align flow and gas signals from subsequent recordings. The software corrected the 
flow signal sample-by-sample for changes in dynamic viscosity caused by the 
variations in gas composition.  
 
Once the PNT has been calibrated, it was connected to a heating circuit (provided by 
the Biomedical Engineering department, GOSH: heater model FWS4D, Hugo Sachs 
Elektronik, Germany) and heated to 37°C prior to LF measurements. A facemask was 
connected to one end of the PNT and the gas sampling capillary from the respiratory 
mass spectrometer was inserted between the facemask and PNT via a short connector. 
  
During data collection, inspiratory and expiratory flows and volumes were 
automatically corrected to body temperature, barometric pressure and saturated with 
water vapour (BTPS) conditions and data were stored. The mass spectrometer 
measured the concentrations of the mixture of inert tracer gases contain in the “test” 
gas (used during the wash-in phase): i.e, SF6 and He, and all other respiratory gases 
(N2, O2, and CO2) as dry gas concentrations. Only SF6 data were used for analysis in 
this study.  
 
A Rendell-Baker Soucek size 1 or 2 (Rusch UK Ltd, High Wycombe, UK) facemask 
was placed over the sleeping infant’s nose and mouth during data recording (Figure 2-
iii). The size 1 mask was generally only used for infants  5kg in weight at time of the 
3m test. The majority of infants were tested with the size 2 mask. An air-tight seal was 
achieved using a rim of therapeutic putty (Patterson Medical, Sutton-in-Ashfield, UK) 
(Figure 2-iii). The facemask was connected to the inspiratory port of the PNT by a 
custom made connector which had a side port to accommodate the capillary inlet of 
the mass spectrometer. The expiratory port of the PNT was connected via a second 
custom-made connector to a T-piece (Intersurgical, Wokingham, UK) to which large 
bore anaesthetic breathing circuit tubing (elephant tubing) was attached. The afferent 
limb of the elephant tubing was attached to the cylinder of medical grade gas 
containing 4% SF6, 4% He, 21% O2 and balance N2. The efferent limb of the elephant 
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tubing was open to room air. The connector attached to the T-piece and the elephant 
tubing were collectively known as the bias flow apparatus. Dead space of facemask 
and different components were measured in previous validation studies using water 
displacement. The residual effective deadspace volume was 5ml and 7.5ml for the size 
1 and 2 facemasks respectively.183  
 
2.3.1.2 MBW data collection in infants 
The sleeping infant breathed through the PNT via a facemask which was applied to 
his/her face with a rim of therapeutic putty around it to ensure a tight seal. Figure 2-iii 
shows the set up for the wash-in phase of MBW. The flow and gas signal outputs were 
monitored in real time on the computer screen. Once the infant was in non-rapid eye 
movement (REM) or quiet sleep and breathing regularly, the distal end of the PNT 
was briefly occluded (i.e. a test occlusion) to ensure that there was no evidence of leak 
around the mask or PNT (Figure 2-iv).  
Figure 2-iii: Infant undergoing Multiple Breath Washout  
 
Legend: Sleeping infant with the facemask and Fleisch pneumotachometer(PNT) in 
situ. A ring of therapeutic putty (green material) is used to create a seal around the 
mask. A T-piece is used to connect the elephant tubing which enables the bias flow of 
air mixture to be delivered during the wash-in phase. 
 
Data collection was performed in two stages:  
a) the wash-in phase which involved the infant inspiring a bias flow of dry air mixture 
containing the tracer gas 4% SF6, 21% O2 and balance N2, and continued until 
inspiratory and expiratory SF6 concentrations were stable and equal to 4% for a 
Elephant tubing used 
to deliver a bias flow 
of air mixture  
Gas sampling capillary  
Fleisch PNT 
Rendell-Baker Soucek 
Size 2 facemask 
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minimum of 5-8 breaths. At this moment, the wash-in was stopped by disconnecting 
the bias flow assembly during the start of expiration, and  
b) the wash-out phase began with the infant inhaling room air and continued until end-
tidal SF6 concentration was consistently below 0.1%, i.e., < 
1/40
th of the starting 
concentration. The output obtained during the wash-out phase is displayed in Figure 
2-iv, a. 
 
A recording was considered technically acceptable if there was no evidence of leak 
during the latter part of the wash-in or at any stage during the wash-out. If the infant 
had a big “sigh”, respiratory pauses and irregular breathing pattern during the wash-
out, the recording was stopped and the test restarted (Figure 2-iv, b). A minimum of 
three wash-in-wash-out manoeuvres were recorded on each test occasion. MBW data 
were only acceptable if there was no evidence of mask or PNT leak and were analysed 
as described previously.81,89 
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Figure 2-iv: Washout Curve 
(a) Acceptable trace 
 
(b) Unacceptable trace 
 
 
Legend: (a) Acceptable trace: The sky blue trace represents flow (left axis). The green 
trace represents SF6 concentration (right axis). Point A indicates the end of wash-in 
when SF6 is constant at 4% with no ‘wobbling’ of horizontal line which would be 
suggestive of a leak. The bias flow is disconnected at point B, i.e., at the end of 
inspiration or beginning of expiration. From this point onwards, SF6 concentration 
during inspiration is zero as the child is inhaling room air. The SF6 concentration on 
expiration falls with each breath, as the resident gas of the lung is progressively 
diluted by the inspired room air. (b) Unacceptable trace: The green trace represents 
flow on the top panel (left axis). The bright blue trace represents SF6 concentration 
during washout. As can be seen, during the wash-out phase, several deep sighs and 
irregular breathing pattern took place. These were confirmed on the volume trace 
(lower panel) showing larger tidal volume with ‘sigh’ breaths and inconsistent tidal 
volumes during irregular breathing pattern (denoted by asteriks). 
A 
B 
* * 
* * 
Irregular breathing pattern with irregular flow 
and volumes 
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LCI is defined as the number of lung volume turnovers (or number of FRCs) that are 
required to clear the lungs of the inert tracer gas to 1/40
th of the starting concentration of 
the tracer gas, i.e.,  
LCI= [CEV] / [FRC]  
where CEV is the cumulative net (after adjustment for equipment dead space) expired 
volume (i.e., the sum of tidal volumes) during the wash-out phase.  
 
FRCMBW is calculated as follows: - 
     FRCMBW = [net volume of inert gas exhaled] / [Cet start – Cet end]                  
where Cet represents the concentration at end-tidal volume of the inert tracer gas, at 
the start (Cet start) and end (Cet end) of data collection during the wash-out phase. 
Results were reported as mean (standard deviation, SD) from three technically 
satisfactory MBW recordings for LCI and FRCMBW; in exceptional cases, a minimum 
of two recordings were used if results were within 5% of one another. 
 
 Body plethysmography 
2.3.2.1 Equipment 
The MasterScreen BabyBody System (CareFusionTM, USA; v 4.65) was used to 
measure the FRCpleth
184 and to perform the RVRTC manoeuvres (or infant 
“spirometry”).83 (Figure 2-v) 
 
Figure 2-v: CareFusionTM Masterscreen BabyBody Plethysmograph  
 
Legend: BabyBody Plethysmograph with lung function software 
incorporated into a computer in an infant lung function laboratory. 
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2.3.2.2 Masterscreen BabyBody system: calibration 
Prior to calibrating the infant plethysmograph (internal volume: 98 L), the Jaeger PNT 
with a resistive screen was connected to the pressure transducers, followed by the 
insertion of a shutter (with a latex balloon attached internally) to the distal end of the 
PNT. The infant system was then switched on for at least 20 minutes to allow for 
thermal equilibration. The ambient conditions (barometric pressure; room temperature, 
relative humidity) documented.  
 
The Babybox system was calibrated with windows and door closed to minimise 
disturbances and noise. The calibration procedure was carried out in two steps:  
a) the low-deadspace PNT was calibrated with a volume signal using a calibrated 
100 mL syringe. A pre-set pairs (e.g., 6-8) of complete stroke volumes were delivered 
and values within 1-2% were acceptable (i.e., recorded signals of 98-102mL); 
b) the plethysmograph (also known as the ‘box’) was calibrated with the hood 
closed following the activation of the “Box Calibration” software program. Prior to 
this, the estimated weight of the baby was keyed into the computer [Patient Data] 
record and the box was calibrated with whatever may potentially be included during 
the FRC test, e.g., a small towel, pulse oximeter and the RVRTC jacket. This was to 
ensure that the condition under which the box calibration took place was similar to that 
during actual testing condition.  
 
The software automatically performed three trials of the half-life time constant (in 
seconds) of the box by assessing the decay of a square wave signal, and calibration of 
the change in box pressure in response to a known cyclical volume changes using a 
built-in sine pump (8 mL at 0.5 Hz frequency). The calibration curve and the half-life 
time constant (acceptable range:  7s to 10s) were displayed on the computer screen and 
the ‘best’ trial (i.e., the median value without any distortions) was accepted and saved 
(Figure 2-vi). BTPS (barometric pressure, temperature and saturated water vapour) 
correction factors for the tidal volume signal were calculated automatically by the 
computer software, using the details of ambient conditions saved by the user. 
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Figure 2-vi: Screen display of “Box calibration” 
Calibration Report 7
th
 March 2013 
 
 
 
Legend: Three trials of the half-life constant were within 7-10 seconds during the box 
calibration and the trial with the median time constant (trial 2) was selected and saved 
in the calibration data.  
 
2.3.2.3 Data collection and analysis 
The sleeping infant is transferred from the cot onto the Jaeger infant system, lying 
supine with the head supported in the midline, and neck and shoulders slightly 
extended. The facemask, attached to the PNT, is placed over the mouth and nose with 
a rim of therapeutic putty to achieve an airtight seal as described above for the MBW 
technique (Figure 2-vii). 
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Figure 2-vii: Infant in the body plethysmograph 
 
Legend: A sleeping infant lying supine with head supported in the midline, neck and 
shoulders slightly extended. 
 
Data for the calculation of resting lung volume or FRCpleth were recorded with the 
hood lowered and the box closed (Figure 2-v). The FRCpleth software program enables 
the user to perform an airway occlusion (by inflating the shutter balloon, thereby 
occluding the lumen of the shutter situated immediately above the PNT) remotely by 
activating a specific function key on the keyboard. The default for the release of the 
airway occlusion was: a) once 3 respiratory efforts made by the infant have been 
detected, or b) after a duration of 10 seconds, whichever occurred first.  
 
During an airway occlusion, although airflow is occluded, the infant continues to make 
respiratory efforts such that the alveolar gas volume is alternately rarified and 
compressed as the chest expands and relaxes. The accompanying changes in chest wall 
movement result in reciprocal pressure changes within the plethysmograph, which 
have been previously calibrated in terms of volume change (section 2.3.2.2). By 
relating these changes in alveolar volume to changes in alveolar pressure (measured at 
the airway opening proximal to the shutter during periods of no flow when pressures 
equalise throughout the respiratory system, provided there is no significant airflow 
obstruction) and to the absolute initial pressure within the lung (atmospheric pressure), 
the total occluded volume of the lungs at end inspiration can be calculated. FRCpleth 
(volume at end expiration) is automatically derived by the program software by 
subtracting the inspired tidal volume immediately prior to occlusion and any apparatus 
deadspace from the total measured volume. 
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Measurements of FRCpleth
74 were undertaken according to the American Thoracic 
Society (ATS)/ European Respiratory Society (ERS) guidelines. After recording 6-10 
regular tidal breaths, a brief airway (test) occlusion was made to ensure that there was 
an airtight seal around the facemask before closing the plethysmograph. Immediately 
after closing the lid, the box volume signal tends to drift upwards due to a slight 
increase in temperature as the infant’s body heat and breath warms the interior of the 
box, indicating that thermal equilibrium has not occurred. It is important to wait for 
equilibrium to take place, before attempting to collect FRCpleth data.
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Once thermal equilibrium has been achieved (i.e., no drift of the box pressure signal) 
which takes ~2-3 minutes (Figure 2-viii), FRCpleth data collection began with 6-10 
tidal breaths being recorded prior to triggering the inflation of the balloon shutter to 
effect an airway occlusion. The occlusion was held for two to three respiratory efforts, 
during which time simultaneous changes in box pressure and pressure changes at the 
airway opening were recorded. Since infants tolerate airway occlusions better at a 
higher lung volume (less likely to make poor respiratory efforts, close their glottis or 
become restless), airway occlusions were performed at end-inspiration rather than at 
end-expiration, and FRCpleth calculations subsequently corrected to end-expiratory 
level. Eight to twelve breaths were recorded after release of the shutter to allow time 
for the infant to re-establish their end-expiratory level (EEL) to restore lung volume 
and enable any mask leak to be detected. If the infant did not re-establish EEL (i.e., the 
likelihood of a mask leak as indicated by a step-up in EEL after release of the airway 
occlusion), the plethysmograph was opened and the PNT and/or mask re-adjusted to 
eliminate any leaks (Figure 2-viii, a). Data were accepted if the changes in 
plethysmographic pressure and changes in mouth pressure recorded during the airway 
occlusion were in phase (Figure 2-viii, b).  
 
All tidal breathing based measurements such as MBW and plethysmography were 
performed before tidal squeeze and RVRTC as thoraco-abdominal compression and 
lung inflations could alter ventilation distribution and/or extent of gas trapping hence 
affecting results obtained from MBW and plethysmography.  
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Figure 2-viii: Screenshot during an FRCpleth measurement 
 
Legend: (a) After release of balloon shutter, the infant generally re-established end-
expiratory level within a few breaths. If a big ‘step up’ was seen, this could indicate a 
leak around the mask. If this was the case, then the plethysmograph was opened to 
adjust the infant’s mask or PNT. (b) This shows good phasing i.e. no ‘looping’, 
between changes in box volume and mouth pressure during airway occlusion. The 
mean (SD) of 3 measures of FRCpleth (minimum 2) that were within 10% were 
reported. 
 
 
 Raised Volume Rapid Thoraco-abdominal Compression 
technique (RVRTC) 
2.3.3.1 Equipment 
The RVRTC technique was performed using the Jaeger MasterScreen BabyBody 
System (CareFusion,v 4.65) and measurements were undertaken according to the 
ATS/ERS consensus.56 To acquire data generated from the raised volume forced 
expiratory manoeuvres, additional items of equipment were required.  
Inflatable bladder and polythene jacket 
 Clear rectangular polythene expandable bladders with a short wide-bore tube in the 
centre, which allowed connection to a built-in air compressor tank for inflation; 
available in three sizes: 17x19 cm, 19x22 cm and 21x22 cm (Medizinische 
Hochschule Hannover, Germany) (Figure 2-ix).  
(a) (b) 
Balloon shutter activated 
to perform airway 
occlusion for 3 
respiratory efforts. Note 
change in box pressure 
drift during the occlusion 
when no gas exchange 
into the box 
Thermal equilibrium 
reached within the 
plethysmograph as 
there is no drift in box 
volume signal prior to 
airway occlusion 
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 Width adjustable outer jacket (resembling a cummerbund), made of non-stretchable 
vinyl held together by Velcro strips at the front and back, which permitted 
adjustment of the circumference to accommodate infants of various sizes; available 
in three lengths of 16, 18 and 23 cm (Medizinische Hochschule Hannover, 
Germany). 
Large bore elephant tubing 
 The encased inflatable bladder was attached to a 55 L built-in air compressor tank 
by means of a rigid large-bore elephant tubing (3 cm internal diameter). This 
arrangement enabled a rapid supply of compressed air into the inflatable jacket to 
force expiration.  
 
Figure 2-ix: Polythene rectangular jacket bladder and a non-stretchable outer 
vinyl jacket used during RVRTC 
 
Legend: Velcro fittings available at the front and back of the vinyl jacket to allow for 
width adjustment.  
 
 
Neopuff infant resuscitator 
The Neopuff RD1000 system (Figure 2-x) allowed the setting of a pre-determined 
pressure, i.e., a positive inflation pressure of 30 cmH2O (2.94 kPa), using a flow of 
1012 L·min1 of air, to be delivered to the infant’s lungs to augment lung volume 
towards TLC during the RVRTC test. This was achieved by applying intermittent 
manual occlusions (i.e. PIP) at the T-piece opening (Figure 2-x)..  
 
(c) Large elephant tubing (not shown) 
connected to grey wide bore tube, 
allowing rapid deliverer of air from 
the air reservoir to inflate the clear 
polythene jacket, underneath the 
(a) Non- stretchable outer vinyl jacket 
(b) Rectangular bladder encased within jacket 
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Figure 2-x: Neopuff Infant Resuscitator and apparatus set up for the RVRTC 
manoeuvres 
 
Legend: This illustration shows the Neopuff Resuscitator connected to a supply of 
medical air (via the green tubing), and the T-piece tubing connecting the Neopuff 
device to the PNT and facemask. Infant’s lungs inflated using the neopuff infant 
resuscitator delivering a positive pressure of 30 cm H2O using 10-12 L·min
1 of air. 
 
 
2.3.3.2 Methods  
The inflatable bladder placed over the anterior aspect of the chest and abdomen; the 
outer jacket (extended from the level of the axillae to the symphysis pubis) was 
adjusted to fit over the bladder snugly (Figure 2-xi), allowing sufficient space 
between the sternum and chest to accommodate the insertion of three to four adult 
fingers.56 The arms remained outside the jacket to avoid splinting of the thorax.  
The encased inflatable bladder was attached, via a large-bore elephant tubing, to the 
pressurised air tank from which compressed air was delivered to inflate the bladder 
effecting a rapid chest/abdominal compression to force expiration, coinciding with the 
end of a passive inflation when the lung volume had been augmented towards TLC.  
 
 
The neopuff 
pressure relief 
valve was set to a 
positive pressure 
of 30 cmH2O 
during inflation   
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Figure 2-xi: Schematic diagram showing the apparatus set up for performing the 
raised volume manoeuvres  
 
 
Legend: Air from the air compressor tank was delivered via the elephant tubing and 
rapidly inflates the jacket bladder which was secured over the infant’s chest and 
abdomen by the outer jacket.  
 
 
Prior to performing the RVRTC, partial or tidal forced expiratory manoeuvres were 
undertaken to determine the optimal jacket compression pressure (Pj) at which flow 
limitation was achieved, i.e., the point at which no further increase in expiratory flow 
was observed despite further increases in applied jacket pressure (Figure 2-xii).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rigid large-bore 
elephant tubing 
92 
 
Figure 2-xii: Screenshot showing display of V’maxFRC results from an acceptable 
test 
 
Legend This screen display shows results of 3 reproducible PEFV curves, with 
window A showing a real-time trace from the 11th trial, illustrating jacket inflation 
pressure of 6.8 kPa (achieved using a reservoir pressure [Pr] of 9 kPa) which resulted 
in a V’maxFRC of 164 mL/s, is similar to V’maxFRC achieved when a Pr of 7 and 8 kPa had 
been used, resulting in Pj of 5.3 and 6.0 kPa respectively (window C and trend 
window). Since no further increase in V’maxFRC was observed with increasing Pj, it was 
evident that “flow limitation” had been reached in this child at an average Pj of 6.1 
kPa (Window C). 
 
The optimal Pj thus obtained was then used during the raised volume manoeuvres. To 
further assess the efficiency of chest/abdomen compression with the jacket in situ, the 
software program was able to estimate the magnitude of the external pressure being 
transmitted to the intra-thoracic structures (Figure 2-xiii). The transmission pressure 
(Pao-j) may be calculated by subtracting the value of Pao during an airway occlusion 
while breathing tidally [P1], from Pao value when chest/abdominal compression was 
applied while maintaining the airway occlusion [P2]. Under the condition of no air 
flow (i.e., during airway occlusion), Pao represents alveolar pressure (Palv), hence the 
change in Palv or Pao during tidal breathing and during chest/abdominal compression 
(P2 minus P1) provides an indication of the efficiency of jacket compression. In 
healthy infants, the Pao-j should be at least 2 kPa (but should not exceed 3 kPa), 
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whereas it may be < 2kPa in infants with airway disease in whom flow limitation is 
achieved at lower intra-thoracic pressures.  
Figure 2-xiii: Assessment of jacket pressure transmission (Pjtr) during tidal RTC 
 
Legend: During an airway occlusion, i.e., no air flow, pressure equilibrates rapidly 
within the respiratory system such that the pressure measured at the airway opening 
(Pao) represents the alveolar pressure (Palv).  
 
The time-based trace in window A illustrates the change in Pao during a brief airway 
occlusion prior to jacket inflation (indicated as P1), and during jacket inflation (P2). 
In this example, the difference between the absolute Pao values (Pao-j) (i.e., P2P1) 
was 2.14 kPa, or when expressed as percentage, jacket pressure transmitted (Pjtr) was 
35.5% (see red rectangular in window C).  
 
It is important not to apply inappropriately high jacket pressures to these infants since 
such manoeuvres are likely to result in glottis closure and/or negative flow 
dependence.185,186 (Figure 2-xiv) 
The Pj at which optimal Pao-j was achieved is used for the RVRTC manoeuvres, 
provided that the fitting of the jacket remained unchanged. 
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Figure 2-xiv: Screenshot showing reduced V'maxFRC in an infant with airway 
obstruction 
 
Legend: In infants with peripheral airway obstruction, it may not always be possible 
to achieve Pao-j close to 2 kPa if they are severely flow limited (window a). In this 
case, despite increasing the jacket pressure (Pj) on four occasions, there was no 
further increase in V’maxFRC (see the last four points starting from the blue, red, green 
and later grey dots). Negative flow dependence was seen with the green dot where 
V’maxFRC reduced with increasing jacket pressure (window b). 
 
To obtain a FEFV curve from raised volume, 3-6 passive lung inflations using a pre-
set pressure of 30 cmH2O (2.94 kPa) via the NeoPuff infant resuscitator device 
(Figure 2-xv) (Fisher & Paykel Healthcare, UK), were administered to induce muscle 
relaxation (by evoking the Hering-Breuer pulmonary stretch receptors before the 
jacket was inflated to the previously determined optimal Pj, at the end of full lung 
inflation of the final augmented breath. To aid relaxation and to ensure that the infant’s 
lungs were fully inflated towards TLC, the individual inflations were held until a 
pressure plateau was observed on the airway pressure trace (Figure 2-xvi). Thoraco-
abdominal compressions were performed at end inspiration and held until all volume 
had been expired or the next inspiration had commenced (Figure 2-xvii).  
 
 
 
 
Window (b) 
Window (a) 
No further increase 
in V’maxFRC 
observed despite 
increased jacket 
pressure, indicating 
that flow limitation 
had been reached 
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Figure 2-xv: RVRTC apparatus set up for measurement of RVRTC manoeuvres 
 
Legend: The photo shows the NeopuffTM resuscitator (left) connected to the T-piece 
and straight connector, which are inserted to the PNT to enable intermittent delivery 
of 3-5 augmented breaths at a positive inflation pressure of 30 cmH2O to raise or 
extend lung volume towards TLC prior to forced expiratory manoeuvre. 
 
Figure 2-xvi: Screenshot displaying five passive lung inflations to relax the 
respiratory muscles prior to the jacket compression 
 
Legend: Time-based trace showing five passively inflated breaths and timing of jacket 
compression during a raised volume squeeze manoeuvre. 
 
This procedure was repeated until three (a minimum of two) acceptable and 
reproducible FEFV curves were achieved. The “best” FEFV curve was defined as the 
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technically satisfactory curve with the highest sum of forced vital capacity (FVC) and 
forced expired volume at 0.4 second (FEV0.4), with at least one other curve within 
10% of  these values.56 The reason for using the parameter FEV0.4 instead of FEV0.5 is 
because often in the first few weeks of life, lung emptying occurs in less than half a 
second. Other parameters calculated from the “best” raised volume FEFV curve 
included forced expired volume at 0.5 second (FEV0.5), forced expired flows when 
75% of FVC had been expired (FEF75) and forced expired flow between 25-75% of 
FVC (FEF25-75). Forced expiratory flow-volume data were analysed according to 
international consensus statements.56  The criteria for technically acceptable forced 
expired flow-volume curves were: no mask or PNT leak, peak expiratory flow 
achieved prior to 30% of expired volume, complete expiration towards residual 
volume (RV) (i.e., no evidence of early inspiration), no marked flow transients or 
glottic closure, and airway inflation pressure within 5% of the pre-set 30 cmH2O (i.e., 
2.94 kPa; acceptable range: 2.8 to 3.1kPa).  
Figure 2-xvii: Screenshot displaying RVRTC measurement 
 
Legend: A screen display showing a technically acceptable RV squeeze manoeuvre, 
with jacket inflation synchronised with termination of passive lung augmentation 
(window A).  
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 Post study procedure 
2.3.4.1 Post sedation and discharge advice 
Although infants were not discharged home until they had fully woken up, parents 
were warned to be extra vigilant for up to 48 hours, since the half-life of trichloro-
ethanol, the active metabolite of chloral hydrate, is approximately 10-18 hours.187 
Parents were given an advice note stating the name and the possible effects of the 
sedative agent, together with the contact telephone numbers of the research team 
members directly involved with the study, in case of any problem or queries. A 
telephone call to the parents was made the following day to check on the well-being of 
the infant and to answer any further queries. 
 
 Lung function outcomes measured in this thesis 
2.3.5.1 Expression of results 
All results were expressed as z-scores to adjust for body size, sex and age where 
appropriate using reference equations derived from up to 140 healthy white infants 
studied in our department over the past decade using identical equipment and 
protocols.56-59,74 Reduced FEV0.5, FVC, and FEF75 were defined as those falling below 
the lower limit of normal (<2.5th centile) i.e. < –1.96 z-score. 
 
LCI, FRCMBW and FRCpleth were also expressed as z-scores using reference equations 
formulated from separate normative datasets obtained using identical equipment and 
methods.58,59,74 ‘Abnormal’ values were those falling above the upper limit of normal 
(>97.5th centile), i.e., >1.96 z-score. The reason for choosing the more conservative 
95% (1.96 z-score), rather than 90% (1.64 z-score) limits of normality as the threshold 
for determining ‘abnormal’ results was to reduce the possibility of over-diagnosing 
lung disease, which may have occurred had we used ±1.64 z-scores as commonly 
applied in lung function studies in older subjects. This choice took into account the 
rapid developmental changes that occur in the first year of life, which are associated 
with increased within and between-subject variability of lung function, as well as the 
fact that several different lung function outcomes were being examined statistically 
which may potentially increase the risk of false positives. 
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The rationale for using the following lung function parameters as outcome measures 
has been discussed in chapter 1, section 1.6. 
 
2.3.5.2 Primary outcome measures 
 LCI: a measure of global ventilation inhomogeneity, an indicator of early airway 
disease including that in the distal airways; 
 FEV0.5 : a measure of central airway obstruction;  
 FRCpleth: a measure of total thoracic lung volume at end expiration including any 
non- ventilated gas “ trapped” behind narrowed or obstructed airways.  
2.3.5.3 Secondary outcome measures 
 ∆FRC: a surrogate measure of ‘gas trapping’ which was calculated as the 
difference between FRCpleth− FRCMBW z-scores.  
 
 Statistical analysis and power of study 
Standard software packages were used to inspect data for distribution and calculate 
descriptive statistics (PASW Statistics v.18, Chicago, IL, US). Student t tests or 2 
analyses as appropriate were used to compare background characteristics and lung 
function results between CF and healthy controls at a year. Data were summarised 
using n (%), mean (SD) or ranges if parametric, or median (Inter-quartile range, IQR) 
if non-parametric; model estimates and differences between groups are presented with 
95% confidence intervals (CI).  
 
The proportion of CF infants with positive Staphylococcus Aureus (SA) and PsA 
growth in the first year of life was also recorded. Multiple linear regressions (MLR) 
were used to investigate how the lung function variables at one year varied according 
to potential determinants including background characteristics, clinical symptoms, 
antibiotic treatment, microbiological results and lung function at 3m of age.  
 
Taking into account three primary outcomes (LCI, FEV0.5 and FRCpleth), a sample size 
of 40 infants in each group would provide 80% power to detect a difference of 0.62 z-
scores at 5% significance level between infants with CF and healthy controls.188-190 
Hence we aimed to recruit at least 50 NBS CF babies born in the Greater London 
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catchment area over an 18 month period, and 50 matched controls, after allowing for 
attrition of 20%.   
 
 Database management  
In accordance to the Data Protection Act and requisite of the Ethics Committee, CF 
and healthy infants in the study were each assigned a unique identification number 
(Study ID) and all paper documentations (including scanned copies) were stored 
securely. Clinical and background information and lung function data were manually 
entered into the Re-BaseTM customised database (Re-Base Ltd, London, UK) using 
double-entry method. Once lung function data had been analysed, results were 
exported in numeral format as Excel worksheet and electronically transferred to the 
Re-BaseTM  database to avoid transcription errors. Dataset were double-checked to 
ensure results were transferred to the correct individual infant folders. 
 
Clinical information documented in CRF pertaining to the CF infants by the 
participating LCFC centres were analysed and summarised into password protected 
Excel sheet by the author and another researcher on the team. Cross-checking of 
clinical data was undertaken to ensure accuracy. The challenges involved in collecting 
detailed clinical information from the different centres will be discussed in detail in the 
final chapter (chapter 7, section 7.2.2). 
 
 
2.4 SUMMARY OF LUNG FUNCTION TESTING PROTOCOL 
Identical lung function protocols according to established international standards were 
adhered to at each testing occasion (3m and 1yr of age) at one centre (GOSH) for CF 
and control infants. The order of tests performed was as shown in the flowchart in the 
beginning of this chapter (Figure 2-i) and for reasons discussed in section 2.3.2.3. A 
wide range of tests was selected for this protocol to ensure that different physiological 
abnormalities due to early lung disease in NBS CF infants would be detected as 
mentioned in section 1.6. Results of these lung function tests will be presented in 
chapter 3.  
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3 LUNG FUNCTION IN NEWBORN SCREENED CF 
INFANTS AT ONE YEAR OF AGE: RESULTS  
 
3.1 INTRODUCTION  
This first results chapter summarises the lung function results at a year of age in CF 
infants compared to contemporaneous healthy controls, in order to test the primary 
hypothesis that despite early diagnosis and specialist treatment, NBS CF infants have 
abnormal lung function at a year of age.  
 
ILFT had previously been undertaken in NBS CF infants and healthy controls at 3m of 
age as part of this longitudinal observational study71, and some of these 3-month 
results will be included here. The predictive value of lung function results at 3 months 
of age (section: 3.5.6) and clinical determinants of lung function at a year of age will 
also be investigated in this chapter (section: 3.5.7). 
 
 
3.2 RECRUITMENT DATA 
The study was conducted from January 2009 through May 2012. The screening, 
recruitment and follow up of subjects are shown in Figure 3-i. 
CF infants 
Eligible infants were recruited from Jan 2009 until July 2011. A total of 116 infants 
screened positive for CF during this period, of whom 14 (12.1%) also presented with 
meconium ileus. Fifteen (13.0%) infants were ineligible for the study: 3 due to serious 
co-morbidities such as chromosomal abnormalities and significant cardiac defect, 1 
was born preterm at 32 weeks gestation, 1 died of sudden infant death and 10 had 
either complex social issues or were living beyond the catchment area for the study. 
The social issues included excessive parental anxiety and depression, living beyond 
the study area of recruitment and other complex psychosocial issues arising from 
complicated surgery for meconium ileus. Hence 101 (87%) infants were eligible and 
invited to participate in the study. 12 declined to be in the study and cited reasons of 
being “worried about the tests” or “not interested” in participating in 
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Figure 3-i: Flow diagram showing recruitment and retention of CF and control 
infants  
                a) NBS infants with CF                   b) Healthy control infants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 (87%) eligible & invited to 
participate 
12 (12%) declined: 
 “worried” 
  “not keen/interested” 
89 (88%) consented to study 
Not tested at 3m: n=9 (10%) 
  3 withdrew 
 6 became “too old” (>4 
months old) due to repeat 
deferral of appointments 
Technically satisfactory paired data: n=44  
(19% of those eligible) 
– LCI: n=41 (93%) 
– FRCMBW: n=42 (95%) 
– FRCpleth: n=36 (82%) 
– Raised volume RTC: n=40 (91%) 
 
At 1 year, total tested: n=44                    
(81% of those tested at 3 months) 
At 3 months, total tested: n= 80         
(79% of eligible) 
Not tested at 1y: n=8 (7%) 
  3 withdrew 
 5 to be tested 
At 1 year, total tested: n=72              
(90% of those tested at 3 months)                      
Technically satisfactory paired data: n= 72 
(71% of those eligible including 7 with MI) 
 
– LCI: n=70 (97%) 
– FRCMBW: n=70 (97%) 
– FRCpleth: n=55 (76%) 
– Raised volume RTC: n=67 (93%)  
116 screened positive                            
(including 14 with meconium ileus)  
15 (13%) not eligible: 
 2 chromosomal & 1 
cardiac abnormality 
 1 preterm 
 1 sudden infant death 
 10 psycho-social factors 
152 (65%) declined:  
  sedation issue: n=42  
  time constraint: n=40 
 “not interested”: n=70 
235 eligible & invited to participate 
39 (14%) ineligible 
  moving out of area: n=12 
  infant unwell prior to 
phone contact: n=15 
  language barrier: n=12 
 
560 potential   
term infants identified 
274 (49%) 
contacted 
286 (51%): no response 
83 (35% of eligible) agreed to LF 
tests 
Not tested at 3m: n=29 (35%) 
 
  15 infants became ineligible due to 
illness (8 respiratory and 7 non-
respiratory symptoms) 
  10 withdrew 
  4 became “too old” (> 4 months) due 
to repeat deferral of appointments 
At 3 months, total tested: n= 54       
(23% of eligible) 
Not tested at 1y: n=10(19%)           
 8 withdrew  
 2 developed chronic respiratory symptoms  
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the research study.191 Eventually 89 sets of parents (88% of those eligible) gave 
consent for their NBS CF infants to participate in the study. 
 
At the 3m ILFT, 9 consented infants did not undertake the test: 3 families withdrew 
from the entire study after further consideration, while 6 infants became too old due 
to repeated deferral of appointments as a result of coryzal symptoms. In total, 80 
(79% of eligible) CF infants underwent the 3m ILFTs. One of the CF infants who 
did not have 3m test due to repeated respiratory symptoms subsequently had ILFT as 
well as chest CT and bronchoscopy at a year of age (Figure 3-i); this infant was not 
included in the analysis in this chapter which is limited to those infants who had 
paired lung function at 3m and 1yr, but was included for analysis with regards to 
structural changes and its relationship with lung function (chapter 6, section 6.3)  
 
Seventy two infants (71% of those eligible) subsequently completed their 1yr ILFT. 
Of the remaining eight, three withdrew from the study after their first test and 5 were 
due to have their 1yr ILFT after writing up of this thesis so these infants were 
excluded from the analysis Hence satisfactory paired lung function data from 72 CF 
infants (including 7 with meconium ileus) will be presented within this chapter.  
 
Healthy control (HC) infants 
During the study, 560 potentially eligible healthy full-term infants were identified 
from the Homerton University Hospital birth lists (see chapter 2, section 2.2.2). 
Two hundred and eighty six (51% of potentially eligible) control infants were not 
contactable. Of those who could be contacted, 235/274 infants met the study 
inclusion criteria and were formally invited to participate in the study. Thirty nine of 
those contacted were deemed ineligible due to (a) not living within the local area 
(n=12), (b) language barrier which made the explanation of the study difficult (n=12) 
or (c) had been unwell prior to the first phone contact (n=15).  
 
Eighty-three (35% of eligible) consented to the study but only 54 (23% of all eligible 
contacted controls) actually attended their 3m ILFT. Twenty nine (35%) of those 
who agreed to ILFT did not attend their first test, including 15 who subsequently 
became unwell (8 respiratory and 7 non-respiratory events), and 10 who withdrew 
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from the study after initially consenting; and 4 who missed the age limit for first 3m 
test due to repeat deferral of appointments. 
 
Of the 54 HC infants who underwent baseline ILFT at 3m of age, eight withdrew 
from the study and 2 developed chronic respiratory symptoms following their first 
tests. The remaining 44 (81%) had successful repeat ILFT at 1yr.  
 
 
3.3 BACKGROUND CHARACTERISTICS OF CF AND 
HEALTHY CONTROL INFANTS 
The comparison of infant characteristics is shown in Table 3-i. NBS CF infants were 
born on average ~ a week earlier, with lower birth weights and a higher percentage 
born small-for-gestational age (i.e., birth weight < 10th percentile). These differences 
were statistically significant but clinically trivial. A higher proportion of parents of 
CF infants have manual occupations, suggesting a slight bias towards recruitment of 
healthy infants with more favourable or stable socio-economic background, or that 
such families were more familiar with research therefore more keen to participate. 
However, other important determinants of early lung function such as ethnicity,192 
maternal smoking during pregnancy,123 current maternal smoking and maternal 
history of asthma193 were similar in both CF and healthy controls.  
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Table 3-i: Comparison of background characteristics in infants with CF and 
healthy controls  
 
 
 
CF infants  
(n=72) 
Control infants 
(n=44) 
 (95% CI)  
CF– controls 
p 
value 
Male, n (%) 34 (47%) 21 (48%) –1% (–19%; 18%) 0.958 
Gestational age, weeks 39.1 (1.4) 40.3 (1.1) –1.1 (–1.6; –0.6) <0.001 
Birth weight, z-scorea –0.64 (0.84) 0.12 (0.81) –0.76 (–1.07;–0.45) <0.001 
Birth weight < 10th percentilea, n (%) 13 (18%) 2 (5%) 14% (1%; 24%) 0.014 
White mother, n (%) 61 (85%) 38 (86%) -2% (–14%; 13%) 0.806 
Maternal smoking during pregnancy, n (%) 8 (11%) 3 (7%) 4% (–8%; 15%) 0.419 
Current Maternal smoking, n (%) 9 (13%) 5 (11%) 1% (–13%; 13%) 0.854 
Mother in non-manual occupation  50 (69%) 38 (86%) –17% (–30%; -1%) 0.024 
Fathers in non-manual occupationb 43 (60%) 36 (82%) –22% (–37%; -5%) 0.007 
Maternal asthma, n (%) 14 (19%) 8 (18%) 1% (–14%; 15%) 0.865 
Footnote: Data shown as n (%) for categorical and mean (SD) for continuous 
variables. acalculated using UK-WHO algorithms182; bn=69 CF and n=53 control 
infants.  Abbreviations:  = difference between groups; CI=confidence interval of 
the difference between groups. 
 
 Validation of maternal report of smoking exposure 
In this study, the reported incidence of maternal smoking during pregnancy or 
postnatally was relatively low (7-13%; Table 3-i), when compared with an incidence 
of 21-32% from infants in London reported a decade ago by this department.60,83 
Table 3-ii summarises cotinine concentrations for infant urine and maternal saliva, 
collected from those whose mothers reported not smoking during pregnancy and 
postnatally (also see section 2.2.4). The results were well below the reported 
optimum cut-off values to distinguish non-smokers from smokers: i.e., 49.7ng/mL 
for urine and 12 ng/mL for salivary samples,177 suggesting that parental self-
reporting of non-smoking in this study was accurate, and that passive smoke 
exposure was likely to be minimal and therefore not likely to bias interpretation of 
ILFT in this study. 
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Table 3-ii: Urine and salivary cotinine results to validate maternal report of ‘no 
smoking’  
 n Infants with CF n Healthy controls 
Infant urine cotinine (ng/ml) 45 1.0 (1.0-3.0) 27 1.0 (1.0-15.5) 
Maternal saliva cotinine (ng/ml)  11 0.1 (0.1-0.2) 11 0.1 (0.1-0.3) 
Missing Data 7  1  
Footnote: Data expressed as median (range). Due to the cost of these assessments 
and the unlikelihood of any false positives, sample collection and analyses were 
limited to mothers who reported that they did not smoke during pregnancy or 
postnatally. 
 
 
3.4 CLINICAL CHARACTERISTICS OF CF INFANTS 
For NBS CF infants, the median (interquartile range (IQR)) age at diagnosis was 3.6 
(3.0–4.4) weeks with 7 (10%) infants presenting with meconium ileus. Since 
exclusion or inclusion of these infants did not affect the results (data not shown), 
they were included in the analysis. Clinical characteristics of CF subjects are 
summarised in Table 3-iii.  
 
The majority of the CF infants were in the ‘severe’ genotype class (Classes I-III, 
82%) and were pancreatic insufficient (93%) as measured by stool elastase. By the 
time of the 1yr ILFT, all the CF infants had experienced respiratory symptoms, 
ranging from cough, runny nose, evidence of physician diagnosed wheeze (33%) or 
crackles (8%) on chest auscultation within the first year of life. A majority of the 
healthy controls also had previous experiences of cough and runny nose with 10% 
having had a single episode of physician-diagnosed wheeze between 3m and a year. 
Two healthy controls had significant lower respiratory tract infections and chronic 
wheeze and were excluded from testing at 1yr of age. Efforts were made to test 
infants at least 3 weeks after a respiratory illness, however there were times when CF 
infants were tested slightly earlier (a minimum of 10-14 days of being 
asymptomatic) as they experienced repeated episodes of exacerbations. There were 
no infants with evidence of wheeze, crackles or breathlessness during the 2-3 weeks 
preceding the 1yr ILFT. During this pre-test period, 15 (21%) of CF infants were 
reported to have had a cough in the absence of other symptoms.  
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Table 3-iii: Clinical characteristics of CF infants (n=72) 
Age at diagnosis, postnatal age in weeks 3.9 (1.7) 
CFTR genotype  classes I-III 59 (82%) 
Presented with meconium ileus 7 (10%) 
Pancreatic sufficient 5 (7%) 
 
Prior to 1 year lung function assessments   
Respiratory symptoms, ever:  
Wheeze, physician diagnosed 24 (33%) 
Crackles, physician diagnosed 6 (8%) 
Cough within 3 weeks of 1 year lung function 15 (21%) 
  
Bacterial growth on cough swab, evera  
Pseudomonas aeruginosa194 25 (35%) 
Other significant bacterial growth 17 (24%) 
No growth 30 (42%) 
  
Additional treatment receivedb  
rhDNase 6 (8%) 
Intravenous antibiotics, number of courses 0 (0-3)c 
Gastro-oesophageal reflux treatment 38 (53%) 
Footnote: Results expressed as mean (SD) or n (%) unless otherwise stated. 
 a See section 3.4.1; 
 b in addition to the prophylactic flucloxacillin prescribed for all CF NBS infants; 
 c median (range).  
 
 Microbiology results of CF infants 
For infants participating in this study, a median of 9 (range: 4-17) cough swabs per 
child were sent for analysis during the first year of life. The results of these were 
obtained from the infant’s CRF (chapter 2, section: 2.2.5) which were collected 
prospectively and sent to me every 2-3 months. Results of cough swabs sent from the 
lung function laboratory were also recorded on the database. 
 
To study the effect of bacterial acquisition on lung function, infants were categorised 
into three groups, namely PsA growth ever, significant bacterial growth ever and no 
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growth/ non-significant bacterial growth ever. Numbers were insufficient to 
subdivide further for statistical analysis. The significant bacterial growth category 
consisted of those who isolated SA, Haemophilus influenza (HI), Stenotrophomonas 
maltophilia, Acromobacter xylosidans, Methicillin Resistant Staphylococcal Aureus 
(MRSA) or Aspergillus fumigatus with no previous PsA growth. No, or non-
significant, bacterial growth consisted of those with isolation of coliforms and upper 
respiratory tract flora only. 
 
During the first year of life, 25 (35%) of CF infants had isolated PsA on at least one 
occasion, 12 (17%) had isolated SA, 14 (19%) HI, 3 (4%) S maltophilia, 2 (3%) A 
xylosidans, 3 (4%) MRSA and 2 (3%) A fumigatus. Apart from one infant with 
chronic PsA and one with chronic SA, none had chronic bacterial growth, defined by 
the Leeds criteria194 within the first year of life. 30 (42%) of CF infants never had 
any significant bacterial growth. Viral polymerase chain reaction and molecular 
microbiology studies were not undertaken in the current study. The potential impact 
of non-standardised microbiological analyses of cough swabs from infants in 
different tertiary respiratory centres and shared care clinics that could determine 
accuracy of bacterial isolation of these CF infants will be discussed in chapter 7, 
section 7.2.2.1.  
 
 Additional treatment received by CF infants 
All CF infants were commenced on prophylactic flucloxacillin once diagnosis was 
confirmed (Appendix: A7). Antibiotics received by CF infants for respiratory 
symptoms (coryzal and cough) and/or positive cough swab results were recorded as 
additional courses; whilst those received for non-respiratory reasons were not 
counted as additional treatment. By 1yr of age, 19 (26%) of infants had received at 
least one course of intravenous antibiotics; whilst two required 3 courses. All infants 
had at least one additional course of oral antibiotics in the first year of life (range: 1-
14) (Table 3-iii). 
 
Inspection of CRFs and regular communication with consultants revealed excellent 
adherence to treatment protocols. 17 NBS CF infants had used an inhaled 
bronchodilator at some point by 1 year of age, all but one of whom commenced this 
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by 3 months. Of these 17 infants, only one still used it regularly by 1 year of age, 
with very intermittent use by the remaining 16. One infant was prescribed regular 
inhaled steroid by 1 year of age, while another had a single course of oral 
prednisolone for wheeze between 3 months and 1 year. Hypertonic saline had been 
used in three infants by age 1yr, one of whom started this at 3 months. Six patients 
received treatment with rhDNase between 3m–1yr. Within the limited power of 
study for such sub-group analysis, there was no significant differences for any 
anthropometric or lung function measurements at1yr, nor for the change in any of 
these measures between 3m to 1yr between those who did and did not receive 
rhDNase. However, there was a non–significant tendency for FRCpleth to be higher 
(mean [95% CI] difference: 0.62 [-0.35; 1.59] z-scores) and FEV0.5 to be lower (-
0.43[-1.31; 0.44] z-scores) at 1yr in the 6 infants who had been prescribed rhDNase, 
suggesting that this may have been prescribed for children with more severe 
symptoms. Fifty-three percent of the CF infants were treated medically for presumed 
or confirmed gastro-oesophageal reflux with proton pump inhibitors, histamine H2 
antagonists or motility drugs.  
 
After each LFT occasion, all parents received a telephone call from the research 
team a day later to check on the well-being of the infant and answer any further 
queries. The majority of CF and healthy infants did not have any adverse events 
apart from increased drowsiness for the first few hours after the completion of the 
ILFT. There were no serious adverse events.   
 
 
3.5 LUNG FUNCTION RESULTS 
 Feasibility of lung function measurements at 3 months and 
1year 
Although 72 CF and 44 healthy controls infants completed paired measurements, not 
all the LFT were successful. The relative success rate in obtaining technically 
satisfactory measurements on each occasion is summarised in Table 3-iv. High 
success rates of ≥ 95% were seen with all three lung function tests at 1yr of age, 
however at 3m of age, plethysmography was less well tolerated.  
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Table 3-iv: Success rates for obtaining technically satisfactory ILFT according 
to age in CF infants and healthy controls in whom paired assessments were 
undertaken 
 Acceptable results 
at 3 months 
Acceptable results 
at 1 year 
Successful paired results: 
3 months and 1 year 
 CF 
(n=72) 
Controls 
(n=44) 
CF 
(n=72) 
Controls 
(n=44) 
CF 
(n=72) 
Controls 
(n=44) 
LCI 71 (99%) 41 (93%) 71 (99%) 44 (100%) 70 (97%) 41 (93%) 
FRCpleth 57 (79%) 38 (86%) 70 (97%) 42 (95%) 55 (76%) 36 (82%) 
FEV0.5 68 (94%) 42 (95%) 69 (96%) 42 (95%) 66 (92%) 40 (91%) 
Footnote: Results are presented as n (%) successful measurements according to 
outcome. Majority of the tests were successfully performed at both test occasions for 
both infant groups except plethysmography which was less successful at 3 months.  
 
 Statistical analysis of lung function results 
Of the wide range of lung function tests performed on two occasions (3m and 1yr), 
inevitably some tests were unsuccessful due to physiological reasons (e.g., upper 
airway activity such as glottic closure), failure to meet quality control criteria, or 
measurements being omitted due to infant waking early or time constraint (hence 
“missing” data). In order to account for these missing values, a statistical method 
known as multiple imputations was used.  In this procedure, all the known covariates 
thought to be associated with lung function at 1yr were used to help predict the value 
of any missing data.  
 
The incomplete variables in this study were 3m LCI z-score, 3m FRCpleth z-score and 
3m FEV0.5 z-score. The observed covariates considered were sex, gestational age, 
birth weight z-score, maternal smoking, maternal and paternal occupations, somatic 
growth (between birth to 1yr and between 3m to 1yr), microbiology results (PsA 
ever, significant bacterial growth ever and no growth/ non-significant bacterial 
growth ever), respiratory signs (wheeze, crackles and cough) and treatment with 
rhDNase, intravenous antibiotics for respiratory symptoms or gastro-oesophageal 
reflux disease. One hundred imputations were performed using PASW Statistics v.18 
(Chicago, IL, US). The results using multiple imputations were similar to those 
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obtained using list-wise deletion. Regression analysis was also performed using 
multiple imputations. Independent and paired t-tests were used to compare numerical 
data between CF and control infants from non-imputed data. For multiple group 
comparisons, Bonferroni adjustments were used for multiple t-tests. 
 
 Group analyses at 3 months and 1 year 
 Age at first ILFT was slightly, albeit significantly, lower in NBS CF infants [mean 
difference (95%CI): -1.0 (-1.79; -0.12) weeks] but not at the second test [-1.32 (-3.1; 
0.5) weeks]. All lung function data were expressed as z-scores to adjust for age, sex 
and body size.57-59 Results are tabulated in Table 3-v.  
 
When tested at 3m, analysis of background data using independent t-test showed that 
CF infants had significantly lower weight, height and BMI z-scores when compared 
to healthy controls. They also had significantly higher z-scores for LCI and FRCpleth, 
indicative of increased ventilation inhomogeneity and hyperinflation respectively. 
There was no evidence of gas trapping as no discrepancy was seen between FRC 
values measured using the MBW method and plethysmography. NBS CF infants had 
evidence of airway obstruction since their FEV0.5, FVC and FEF75 were significantly 
lower when compared with HC.71  
 
By the 1yr test, differences in height, weight and BMI between the two groups were 
no longer seen, but differences in lung function remained apparent on cross-sectional 
comparisons. As seen in Table 3-v and Figure 3-ii, NBS CF infants had 
significantly increased ventilation inhomogeneity (LCI: 0.8 z-score higher), 
hyperinflation (FRCpleth: 0.8 z-score higher) and significant gas trapping 
(FRCpleth−FRCMBW: 0.75 z-score higher) compared with HC. NBS CF infants also 
had reduced airway function indicated by significantly lower forced expired volumes 
(FEV0.5 0.52 z-score and FVC 0.66 z-score lower) but there was no significant 
difference in FEF75 z-score between the two groups at a year of age.   
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Table 3-v: Anthropometric and lung function results at 3 months and 1 year of age  
  ~3 months ~1 year 
 CF HC Diff (95% CI) CF-HC CF HC Diff (95% CI) CF-HC 
Age, weeksa 11.2 (2.3) 12.1 (2.1) -1.0 (-1.8; -0.1)* 52.4 (5.3) 53.7 (4.4) -1.3 (-3.1; 0.5) 
Somatic growth       
Weight, z-scoreb -0.89 (1.03) 0.01 (0.97) -0.90 (-1.27; -0.52)*** 0.32 (0.90) 0.55 (1.21) -0.23 (-0.64; 0.19) 
Length, z-score -0.21 (1.01) 0.73 (0.0.92) -0.94 (-1.30; -0.58)*** 0.47 (1.01) 0.76 (1.20) -0.28 (-0.71; 0.15) 
Body mass index, z-score -1.08 (0.99) –0.55 (0.96) -0.53 (-0.90; -0.16)** 0.08 (0.83) 0.18 (1.12) -0.10 (-0.49; 0.29) 
Ventilation Inhomogeneity       
LCI, z-score  
0.83 (1.32) 0.36 (0.85) 0.47 (0.06; 0.87)* 1.05 (1.23) 0.25 (0.95) 0.80 (0.40; 1.21)*** 
Lung Volumes 
      
FRCMBW, z-score  0.24 (0.84) -0.15 (0.87) 0.39 (0.06; 0.72)* -0.45 (0.98) -0.52 (0.78) 0.08 (-0.25; 0.40) 
FRCpleth, z-score  0.76 (1.09) -0.01 (1.08) 0.77 (0.32; 1.22)** 0.72 (1.16) -0.05(0.96) 0.80 (0.40; 1.20)*** 
“Gas trapping” z-scorec 
0.59 (0.96) 0.22 (0.94) 0.37 (-0.03; 0.77) 1.21 (0.86) 0.46 (0.69) 0.75 (0.46; 1.05)*** 
Forced Expired Volumes                       
and Flows 
      
FEV0.5, z-score -1.23 (1.07) -0.16 (0.76) -1.07 (-1.42; -0.73)*** -0.41 (1.03) 0.12 (0.92) -0.52 (-0.89; -0.15)** 
FVC, z-score 
-0.50 (1.03) 0.23 (0.67) -0.74 (-1.06; -0.41)*** -0.43 (1.16) 0.23 (0.94) -0.66 (-1.05; -0.26)** 
FEF75, z-score -0.76 (1.25) -0.07 (0.96) -0.69 (-1.11; -0.27)** -0.09 (0.93) 0.09 (0.91) -0.18 (-0.54; 0.18) 
Footnote: a corrected for gestational age; b calculated according to Cole et al182; c “Gas Trapping” represents the 
within- subject difference in lung volumes measured by plethysmography and  MBW. CF=Cystic Fibrosis; 
HC=Healthy Control; CI=confidence interval of the difference;   *p<0.05; **p<0.01; ***p<0.001 
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Figure 3-ii: Significantly elevated LCI, FRCpleth and gas trapping and reduced FEV0.5 
but not FEF75 in NBS CF infants compared to healthy controls at  1-year of age  
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Legend: 
Symbols: closed red triangles = NBS CF 
infants; open blue circles = healthy             
controls. 
 
For FEV0.5 and FEF75, the horizontal               
dotted line indicates the lower 95% limit                   
of normality (2 z-score or 2.5th centile).  
For LCI, and FRCpleth  and “Gas Trapping”                                 
(FRCpleth− FRCMBW z-score) the horizontal 
dotted line indicates the upper 95% limit of 
normality (2 z-score or 97.5th centile).  
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 Longitudinal analysis between 3 months and 1 year 
When comparing lung function between 3m and 1yr of age in NBS CF and HC 
infants, significant improvements were observed in FEV0.5 and FEF75 in CF infants, 
but there was no significant change in either LCI, FRCpleth or gas trapping (Figure 3-
iii and Table 3-vii). Although LCI, FRCpleth and gas trapping z-scores remained 
significantly higher in CF than controls infants at a year, no further deterioration was 
observed, i.e., these lung function outcomes had remained stable since 3m of age. By 
contrast, airway function assessed using the RVRTC technique showed considerable 
improvement such that by a year, although FEV0.5 was still significantly lower in CF 
compared to control infants, the mean difference between the two infants groups was 
much reduced, whilst FEF75 was no longer significantly different between groups. In 
healthy infants, no significant changes were observed for any lung function outcome 
during this time period.  
 
Figure 3-iii: Comparison of changes in lung function z-scores between 3 months 
and 1 year in NBS CF infants and healthy controls 
 
Legend: Data are expressed as mean ± 95% confidence interval. Lung function 
outcomes were expressed as z- scores which adjusted for age, sex and body size as 
appropriate.57-59  
The horizontal line represents 0 z-score which equated to 100% predicted or the 50th 
centile for results derived from a healthy population.195 Significant improvement in 
FEV0.5 observed in CF infants within the first year whilst FRCpleth and LCI stabilised 
during that time.  
* p <0.05   
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Significant increases in z-scores for somatic growth were observed in both groups 
between 3-12 months, these changes being significantly greater in those with CF 
(Table 3-vii). Despite lower birth weight and test weight at 3m, NBS CF infants had 
considerable growth catch up such that by 1yr of age, there were no significant 
differences in body size when compared with controls.   
 
The percentages of CF NBS infants with abnormal lung function results at 3m and 
1yr of age (i.e., beyond the 95% limits of normal, see chapter 2, section 2.3.5.1) are 
summarised in Table 3-vi and Figure 3-ii). 
 
Table 3-iv: Number (percentage) of CF and healthy control infants with 
‘abnormal’ lung function at 3 months and 1 year of age. 
CF (n=72) FEV0.5 < 2z FEF75 < 2z LCI > 2z FRCpleth >2z “Trapped Gas” >2z 
3 months 18/68 (27%) 12/68 (18%) 12/71(17%) 9/57 (16%) 5/56 (9%) 
1 year 6/69 (9%) 2/69 (3%) 13/71(18%) 11/70 (16%) 10/69 (15%) 
HC (n= 44) FEV0.5 < 2 FEF75 < 2 LCI > 2 FRCpleth >2 “Trapped Gas” >2 
3 months 0 1/42 (2%) 1/41 (2%) 0 1/37 (3%) 
1 year 2/42 (5%) 0 2/44 (5%) 2/42 (5%) 2/42 (5%) 
Footnote: The percentage of CF infants with abnormally reduced forced expiratory 
volume and flow decreased by a year of age whilst the percentage with abnormally 
increased LCI and FRCpleth remained stable during the same time span. Although 
lung function at 1yr was correlated with that at 3m, those with abnormal lung 
function at 1yr were not necessarily abnormal at 3m. Percentage in bold represents 
significant difference.  
 
 
Although at a year, NBS CF infants continued to have impaired airway function 
compared to HC on cross-sectional analysis, the percentage with abnormally low 
FEV0.5 and FEF75 z-scores was significantly lower than at 3m. There was a 3 fold 
reduction in the percentage of CF infants with abnormally low forced expired 
volume (FEV0.5) and a 5 fold reduction in those with abnormally low forced expired 
flows (FEF75) at 1yr compared to baseline test at 3m of age. By contrast, the 
percentage of infants with abnormal LCI and FRCpleth remained stable between 3m 
and 1yr with no sign of deterioration. Although NBS CF infants had significant 
‘trapped gas’ by a year of age, overall there was no significant difference over the 9-
month period between the infant groups (Table 3-vii). Possible explanations for the 
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variation in lung function results using the different techniques will be discussed in 
section 3.6. No relationship was reported for change in weight z-score between 3m 
and 1yr and any change in lung function parameters between 3m and 1yr for the CF 
cohort.  
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Table 3-vii: Comparison of changes in anthropometry and lung function at 3 months and 1 year in NBS CF and healthy controls 
infants 
   
CF (1yr-3m) 
  
Healthy controls (1yr-3m) 
Difference (95% CI): 
CF– controls 
 
p values 
Change in Somatic growth n  n    
Weight, z-score 72 1.21 (0.82) 44 0.54 (0.85) 0.67 (0.35; 0.99)*** <0.0005 
Length, z-score 72 0.68 (0.71) 44 0.03 (0.73) 0.66 (0.38; 0.93)*** <0.0005 
Body mass index, z-score 72 1.16 (0.90) 44 0.72 (0.98) 0.44 (0.07; 0.80)* 0.019 
Change in Ventilation inhomogeneity       
LCI, z-score  70 0.24 (1.50) 41 -0.09 (1.18) 0.33 (-0.18; 0.84) 0.205 
Change in Lung Volumes       
FRCMBW, z-score  70 -0.68 (0.90) 42 0.37 (0.71) -0.31 (-0.62; -0.01)* 0.043 
FRCpleth, z-score  55 -0.04 (1.02) 36 -0.04 (1.20) 0.001 (-0.48; 0.49) 0.996 
Trapped gas, z-scorea 53 0.58 (1.14) 35 0.30 (1.12) 0.28 (-0.21; 0.77) 0.258 
Change in Forced Expired Volumes and Flow       
FEV0.5, z-score  66 0.83 (1.07) 40 0.24 (0.98) 0.59 (0.18; 0.99)** 0.005 
FVC, z-score 66 0.06 (0.96) 40 -0.02 (0.93) 0.08 (-0.29; 0.45) 0.688 
FEF75, z-score
 66 0.84 (1.45) 40 0.20 (1.16) 0.63 (0.12; 1.14)* 0.015 
Footnote: Data shown as mean (SD) or mean difference (95% CI) of change. a ‘Trapped gas’ represents the within-subject difference in lung volumes 
measured by plethysmography and  MBW.58,59 *p<0.05; **p<0.01; ***p<0.001 for differences in the rate of change between infants with CF and HC 
between 3-12 months. Significant changes over time within each group are shown in bold. 
Significant improvements of FEV0.5 and FEF75 within the first year by NBS CF infants refer to a significantly greater change than that seen in healthy 
controls in whom lung function remained stable within the first year .The change in LCI during the first year amongst CF and healthy control infants was 
not significantly different.CF infants showed a much greater improvement in their anthropometry compared to controls. 
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 Relationship between different lung function measurements at 1 year 
in CF NBS infants 
In this study, three methods of ILFT were performed to investigate and detect early lung 
disease. Contrary to previous studies involving older children that revealed greater sensitivity 
using LCI compared to spirometry  in detecting lung disease85,99,117, ILFT results in clinically 
diagnosed CF infants83 and in this cohort of NBS CF infants at 3m of age71 demonstrated that 
during infancy, both LCI and FEV0.5 obtained using the raised volume technique were 
similarly sensitive in detecting lung disease although they were not necessarily detected in 
the same infants. The relationship between selected ILFT outcomes in 1yr old NBS CF 
infants in this study was explored further as shown in Figure 3-iv. 
There was no significant relationship between the three primary outcomes: FEV0.5 and LCI       
(r= 0.17, p= 0.17), FRCpleth and LCI (r= 0.08, p= 0.49) and FRCpleth and FEV0.5 (r= 0.05, p= 
0.71). As expected, FEV0.5 and FEF75 were significantly correlated (r=0.74, p<0.001). 
‘Trapped Gas’ was significantly correlated with FRCpleth z-score (r=0.55, p<0.001) and with 
LCI (r = 0.49; p<0.001); indicating that gas trapping was associated with hyperinflation and 
increased ventilation inhomogeneity.  
 
At one year, 17% of CF infants had an LCI >2 z-scores, 16% had FRCpleth >2 z-scores 
whereas only 9% had an FEV0.5 <2 z-scores (Table 3-vi).  Only 17% (12/69) had 
abnormalities detected by both LCI and FEV0.5 at a year whilst at 3m, 12% (8/69) had similar 
abnormalities. However, if based on abnormality in either test, 23% (16/69) would be 
identified with abnormal results in LCI or FEV0.5 or 25% (17/69) identified with abnormal 
result in FRCpleth or FEV0.5 at a year. At 3m, this would have risen to 35% (24/69). Thirty six 
percent (25/69) of CF NBS infants had at least one abnormal result if based on LCI, FEV0.5 or 
FRCpleth at a year. Therefore, at a year of age, by increasing the number of ILFT performed, 
this can increase the detection rate of at least one lung function abnormality from 12% to 
36%. 
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Figure 3-iv: Relationship between different lung function parameters in CF 
infants at a year of age  
  
 
 
 
 
  
 
 
  
 
  
(a) (b) 
(c) (d) 
(e) (f) 
R= - 0.17 R= 0.08 
R= 0.05 R= 0.74* 
R= 0.55* R= 0.49* 
Legend: The horizontal dotted line for LCI indicates the 97.5th centile of normality (>2 z-score). The 
vertical and horizontal lines for FRCpleth z-score indicate the 97.5th centile of normality (>2 z-score). The 
vertical line for FEV0.5 and the horizontal line for FEF75 z-scores indicate the 2.5th centile of normality.  
*denotes significant Pearson correlation. Significant associations were found between FEV0.5 and FEF75 
as well as ‘trapped gas’ with FRCpleth and LCI although the associations were moderate. The three 
primary outcomes (FEV0.5, LCI and FRCpleth) were on the other hand poorly correlated with one 
another, suggesting they were reflecting different pathological changes.  
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 Relationship between 3 months and 1 year lung function 
results 
Significant correlations were found between lung function results at 3m and 1yr of 
age in NBS CF infants (Figure 3-v). Using univariable linear regression with 
multiple imputations to predict 1yr lung function from the 3m data, mean (95% CI) 
beta coefficients were: 0.48 (0.31;0.65) for FRCpleth, 0.42 (0.26;0.58) for FEV0.5, and 
0.32 (0.15;0.50) for LCI. These results indicate that for each unit increase in 
FRCpleth, FEV0.5 and LCI z-scores at 3m, on average FRCpleth, FEV0.5 and LCI would 
be 0.5, 0.4 and 0.3 z-scores higher, respectively, at 1 year.  
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Figure 3-v: Correlations between lung function at 3 months and 1 year in NBS 
CF infants 
 
  
 
R = Pearson correlation coefficient 
  
 
Legend: The 95% limits of ‘normal range’ (2 z-scores for LCI and FRCpleth and -2 z-
scores for FEV0.5) are represented by vertical dashed lines at 3m and horizontal 
lines at 1yr. Those with normal lung function on both occasions fall within the lower 
left quadrant for LCI and FRCpleth, and upper right quadrant for FEV0.5 (solid 
triangles lying within the blue squares); whilst those with abnormal results at 3 
months and 1 year lie within the red squares. Infants with abnormal LCI and 
FRCpleth at 3 months but normal LCI and FRCpleth at a year respectively, lie within 
the lower right quadrant (panel a and b), while those with abnormal  FEV0.5 at 3 
months which has normalised by 1 year are within the left  upper quadrant of panel 
c .  
 
All parameters of lung function at 3m were significantly associated with the 
respective parameters at 1yr. 
 
R = 0.32 R = 0.50 
R = 0.43 
a) b) 
c) 
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 Clinical determinants of 1 year lung function 
Previous published data from this cohort of NBS CF infants at 3m of age revealed that apart 
from having the status of CF, there were no significant associations between lung function 
and any other potential determinants such as sex, gestational age, birth weight z-score, pre- or 
postnatal maternal smoking and maternal asthma using multivariable analyses.71 Among CF 
infants at 1yr, a significantly lower FEV0.5 (mean regression coefficient (95%CI): 0.70 
[1.29 to 0.10] z-scores; univariable analysis) was observed in those who had received any 
additional antibiotics for symptoms or positive cough swab. There were no significant 
associations between other lung function outcomes and the infants’ genotype, clinical status 
or treatment prior to lung function tests at ~3 months of age.71 
 
Table 3-viii demonstrates possible determinants of 1yr lung function outcomes using 
univariable regression analysis. Besides demonstrating that 3m lung function data were 
predictive of lung function results at a year (section: 3.5.6), other significant associations 
were: 
 CF status: Having CF itself was associated with impaired lung function at a year (increased 
LCI, FRCpleth and reduced FEV0.5 z-scores).   
 1yr LCI: This was significantly negatively associated with change in weight z-score from 
birth to 3m old (a greater increase in weight gain from birth led to a decrease in LCI at a 
year). The presence of wheeze and treatment for gastro-oesophageal reflux disease were 
both significantly associated with an increased LCI at 1yr. 
 1yr FRCpleth:  A higher FRCpleth, indicative of hyperinflation, was significantly associated 
with prior PsA infection ever, IV antibiotics use, GORD treatment and the presence of 
wheeze ever in the first year of life. For example, isolation of PsA ever in CF babies was 
associated with 1 z-score increase in FRCpleth at 1 year when compared with CF babies 
without PsA. 
 1yr FEV0.5: this was significantly associated with wheeze, cough within 3 weeks of 1yr 
LFT and treatment for GORD such that presence of any of these clinical determinants was 
associated with a reduction in airway function, reflected by reduced FEV0.5 of ~0.5 z-scores. 
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On multivariable linear regression, lung function at 3 months was predictive of that at 1 yr 
for all lung function outcomes. Significant determinants of: 
 1yr LCI z-score were: CF status [mean regression coefficient (95% CI): 0.48 (0.04; 0.93) 
z-score, p=0.032]; 3m LCI [0.24 (0.07; 0.41) z-score, p=0.005]; history of clinician 
diagnosed wheeze [0.59 (0.05; 1.12) z-score, p=0.031] and change in weight z-score 
between birth and 3m [-0.18 (-0.35; -0.01) z-score, p=0.042].  
 1yr FRCpleth z-score was significantly associated with FRCpleth at 3m [0.43 (0.27; 0.59) z-
score, p<0.0005], history of PsA infection [0.71 (0.24; 1.17) z-score, p=0.003] and change 
in weight z-score between 3m and 1yr [-0.20 (-0.41; 0.003) z-score, p=0.054]. After 
adjustment for these factors, other variables including CF status were no longer 
significantly associated with 1yr FRCpleth.   
 1yr FEV0.5 z-score was only significantly associated with FEV0.5 z-score at 3m. 
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Table 3-viii: Univariable linear regression with multiple imputations: 
determinants of lung function at 1 year 
 
1yr LCI z-score 1yr FRCpleth  z-
score 
1yr FEV0.5  z-
score 
CF 0.82 (0.39; 1.24) 
p<0.0001 
0.79 (0.38; 1.20) 
p<0.0001 
-0.49 (-0.88; 0.10) 
p=0.02 
3m LF 0.32 (0.15; 0.50) 
p<0.0001 
0.48 (0.31; 0.65) 
p<0.0001 
0.42 (0.26; 0.58) 
p<0.0001 
Male 0.35 (-0.09; 0.78) 
p=0.12 
0.39 (-0.03; 0.81) 
p=0.07 
-0.01 (-0.39; 0.38) 
p=0.98 
Gestational age -0.02 (-0.17; 0.14) 
p=0.83 
-0.11 (-0.26; 0.04) 
p=0.14 
0.15 (0.02; 0.29) 
p=0.02 
Birth weight z-score -0.19 (-0.43; 0.06) 
p=0.14 
-0.11 (-0.35; 0.13) 
p=0.37 
0.27 (0.06; 0.49) 
p=0.01 
Maternal smoking during 
pregnancy 
-0.48 (-1.22; 0.27) 
p=0.21 
-0.08 (-0.81; 0.65) 
p=0.83 
0.52 (-0.13; 1.18) 
p=0.12 
Current maternal smoking -0.38 (-1.04; 0.29) 
p=0.27 
0.24 (-0.42; 0.89) 
p=0.48 
0.47 (-0.12; 1.05) 
p=0.12 
Mother in non-manual 
occupation 
-0.43 (-0.95; 0.09) 
p=0.10 
-0.30 (-0.79; 0.18) 
p=0.22 
0.12 (-0.34; 0.57) 
p=0.62 
Father in non-manual 
occupation 
-0.22 (-0.70; 0.25) 
p=0.35 
0.07 (-0.38; 0.52) 
p=0.76 
0.17 (-0.24; 0.58) 
p=0.41 
∆Weight (3m-birth), z-
score 
-0.19 (-0.39; -
0.003)   
p=.04        
-0.01 (-0.20; 0.18) 
p=0.93 
-0.01 (-0.19; 0.16) 
p=0.90 
∆Weight (1yr-3m), z-
score 
0.20 (-0.04; 0.45) 
p=0.11 
-0.11 (-0.35; 0.13) 
p=0.36 
-0.21 (-0.42; 
0.001) 
p=0.05 
Pseudomonas aeruginosa 0.53 (-0.03; 1.08) 
p=0.06 
0.94 (0.46; 1.42) 
p<0.0001 
-0.37 (-0.84; 0.11) 
p=0.13 
Significant bacterial 
growth 
0.35 (-0.17;0.87) 
p=0.18 
0.22 (-0.26; 0.70) 
p=0.36 
-0.18 (-0.64; 0.28) 
p=0.45 
Wheeze, ever 0.99 (0.48; 1.50) 
p<.0001 
0.71 (0.21; 1.21) 
p=0.006 
-0.52 (-0.98; -
0.07)       p=0.02 
Crackles, ever 0.70 (-0.28; 1.68) 
p=0.16 
0.85 (-0.08; 1.78) 
p=0.07 
-0.60 (-1.44; 0.24) 
p=0.16 
Cough, within 3 weeks of 
1y lung function 
0.44 (-0.21; 1.09) 
p=0.19 
0.61 (-0.01; 1.22) 
p=0.05 
-0.71 (-1.25; -
0.16) 
p=0.01 
rhDNase treatment, ever 0.31 (-0.68; 1.30) 
p=0.54 
0.92 (-0.01; 1.85) 
p=0.55 
-0.63 (-1.46; 0.21) 
p=0.14 
IV antibiotics, number of 
courses 
0.27 (-0.10; 0.64) 
p=0.16 
0.54 (0.21; 0.87)                
p=0.001   
-0.28 (-0.59; 0.02) 
p=0.07 
GORD treatment, ever 0.59 (0.13; 1.05) 
p=0.01 
0.52 (0.08; 0.95)           
p=0.02  
-0.44 (-0.84; -
0.04) 
p=0.03  
Footnote: Data are shown as mean regression coefficient (95% CI). ∆Weight: 
differences in weight between the 2 time periods. Significant associations are shown 
in bold and red. Abbreviations: IV: intravenous; rhDAase: Pulmozyme; GORD: 
Gastro-oesophageal reflux.  
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3.6 SUMMARY OF LUNG FUNCTION RESULTS AND 
PRELIMINARY DISCUSSION 
This chapter has described the results of a study undertaken to address the primary 
hypothesis that, despite early diagnosis and specialist, protocol-driven management, 
at a year of age, NBS CF infants have abnormal lung function with further 
deterioration since 3 months of age when compared to contemporaneous healthy 
controls.  
 
Despite their lower birth-weight and test weight at 3m, there was considerable catch 
up growth among infants with CF such that by 1yr of age there were no significant 
differences in body size between the groups. These observations are in contrast to 
previous findings in clinically diagnosed CF infants60 but in keeping with the 
growing evidence regarding the nutritional benefits of newborn screening for cystic 
fibrosis.22,26   
 
As for the 1yr lung function results, NBS CF infants had significantly increased 
ventilation inhomogeneity, hyperinflation, gas trapping and central airway 
obstruction compared to healthy controls. Contrary to the study hypothesis, NBS CF 
infants did not show any deterioration in lung function but instead an improvement 
in forced expired volumes and flows with stability of other outcomes. The 
percentage of NBS CF infants with abnormal LCI and FRCpleth at 1yr was similar to 
that at 3m, and there was a significant reduction in those with abnormal FEV0.5 
during this period.  Potential reasons for the discrepant results according to selected 
outcome will be discussed in chapter 7, section 7.1.1. 
 
In considering the use of ILFT as an outcome measure, although FRCpleth detected 
abnormalities of lung function in NBS CF infants as readily as LCI or FEV0.5, it was 
not as well tolerated by the younger infants. This would make FRCpleth less feasible 
as an outcome variable at 3m of age, or in longitudinal studies commencing at this 
age. This may be accounted by the fact that young infants arouse very readily before 
3m of age and are less tolerant of brief airway occlusions than older infants. The 
success of obtaining plethysmographic FRC measurements improved from 79% to 
97% by 1yr. 
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Infants were tested when asymptomatic. LFT were deferred until 3 weeks after a 
cold. As a result of family commitments or frequent upper respiratory tract 
infections, whereby only very short intervals were occurring before the infant caught 
another “cold”, 15 CF infants were tested slightly sooner than the prescribed 3 weeks 
interval; although never less than 7 days after a cold.  
 
Early lung function at 3m of age predicted lung function at 1yr, as did clinical 
determinants such as a history of physician diagnosed wheeze, history of PsA 
infection and suboptimal weight gain. The implications of these findings will be 
discussed further in (chapter 7, section 7.4). 
 
The overall strengths and limitations of this study will be discussed in Chapter 7, 
together with the relevance of the results to both clinical practice and research, and 
their relationship to the published literature. 
 
In the next chapter (Chapter 4), the development of standardised chest CT imaging 
for NBS CF infants in a multi-centre trial will be explored. This is followed by 
Chapter 5 which addresses some of the challenges faced in using chest CT as an 
outcome measure, including the validation of Brody-II scoring system in CF infants. 
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4 DEVELOPMENT OF STANDARDISED CHEST 
COMPUTED TOMOGRAPHY IN NEWBORN 
SCREENED CF INFANTS: METHODS  
 
4.1 INTRODUCTION 
Chapter 4 focuses on the use of contiguous thin section CT scanning of chest to 
investigate the extent of any structural changes in these NBS CF infants at 1yr of 
age. This chapter will address the methodology used in acquiring chest CT under GA 
in the current study and the challenges faced when attempting to standardise the 
acquisition of chest CT scans in a multicentre study to detect early lung disease. The 
scoring system used to quantify lung disease in NBS CF infants 1yr of age and the 
challenges in scoring chest CTs in the presence of mild disease will be addressed in 
Chapter 5. Chapter 6 will focus on exploring the relationship between structural and 
functional lung changes in these NBS CF infants and investigate any potential 
clinical determinants of pulmonary structural changes. Chapter 5 and 6 will address 
the secondary hypotheses of this research study i.e. that significant structural 
changes are present in NBS CF infants by a year of age and that these structural 
changes are closely related to lung function parameters. 
 
Chest CT under GA was performed in NBS CF infants at about one year of age on a 
separate hospital visit shortly after their 1yr ILFT. These procedures coincided with 
the CF infant’s first year annual review assessment which included a flexible 
bronchoscopy and BAL under the same GA. Healthy control infants recruited into 
the study did not have chest CT and flexible bronchoscopy. 
 
 
4.2 CHEST TOMOGRAPHY SCANNING PROTOCOL 
Prior to the commencement of the combined CT scan, bronchoscopy and BAL 
procedure under GA, investigators from participating centres realised that specialised 
equipment and personnel were required to carry out these procedures. They could 
only be established in a standardised fashion in three of the six participating centres 
(Great Ormond Street Hospital, GOSH; Royal Brompton Hospital, RBH and Royal 
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London Hospital, RLH). Recruited infants from the remaining three centres (King’s 
College Hospital, KCH; Lewisham University Hospital and East Surrey Teaching 
Hospital) underwent combined CT scan and bronchoscopy at GOSH. These 
procedures took place as day cases and CF infants were discharged home on the 
same day, after several hours of normal observation on the day-case ward of each 
hospital unless clinically contraindicated. 
 
CF infants underwent chest CT, flexible bronchoscopy and BAL 2-3 weeks after 
their 1yr ILFT. If the interval between the two procedures was > 3 weeks or if the 
infant experienced any respiratory exacerbation between the ILFT and the chest CT 
and bronchoscopy, the ILFT was then repeated to ensure that lung functional and 
structural information were both obtained at the same clinical status. This occurred 
in five out of the 72 infants tested. Figure 4-i details the schedule of investigations 
in CF and healthy control infants at a year of age. 
 
Figure 4-i: Schedule of investigations at 1 year of age in CF NBS and healthy 
control infants 
 
 
 
 
 
 
At a separate hospital visit after ~1y ILFT   
Chest CT then flexible bronchoscopy and BAL 
 
 
 
 
 
 
CF NBS infants 
Infant Lung Function tests at Great Ormond Street Hospital 
Only in CF infants; 
within ≤ 3 weeks 
Within ≤ 3 weeks 
Healthy Control infants 
Legend: Only CF NBS infants underwent chest CT and BAL under GA. 
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 Type of CT scanner and scanning parameters 
Multi-detector CT scanners were used in this study across three centres. These 
scanners allowed thin slice volumetric inspiratory and expiratory images to be 
obtained with rapid scanning times (Table 4-i).  
Table 4-i: Details of CT scanners* used across the three centres  
Centre Multidetector CT scanner model 
A Somatom Sensation (64 slice) 
B Somatom Definition Dual- source (64 slice) 
C Somatom Definition Flash (128 slice)* 
Footnote: * Siemens Healthcare, Forchheim, Germany 
 
Radiographers used a pre-determined CT technique for the acquisition of CT images 
with controlled ventilation provided by paediatric anaesthetists. The scanning 
parameters were selected to produce diagnostic high quality images (images which 
are ‘fit for purpose’) with low radiation exposure.157 The CT tube current settings 
used for infants in this study represented a five- fold reduction in what would 
normally be used in adult studies. It was possible to still obtain good image quality 
due to improved inherent contrast in the lung parenchyma tissue with controlled 
ventilation. During inspiratory scanning, the inherent contrast is most obvious so 
only a low tube reference current was required in the protocol. This had to be 
increased slightly during expiratory scans as the inherent contrast at PEEP=0 would 
be reduced.  The gantry rotation time was reduced to half of what is normally used (1 
second) in adults to proportionally reduce exposure time and hence radiation dose 
and its associated risks.176    
 
In order to further reduce the amount of radiation exposure, a topogram (planning 
scan) was obtained at PIP=25 cmH2O so that, based on the topogram, scanning 
ranges for inspiratory and expiratory scans could be individually tailored for each 
infant. This allowed all essential images to be taken without exposing the infant to 
excessive radiation. The topogram encompassed the top of the lung apices to the 
costo-phrenic angles, allowing the planning for full volumetric inspiratory scanning 
at the same lung inflation of PIP=25 cmH2O. The expiratory scanning range was 
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then automatically calculated as being 30mm shorter than the inspiratory range. The 
scanning ranges used were kept to a minimum.  By adhering to this strict low dose 
standardised protocol for imaging across all three sites, the aim was to ensure that 
consistent diagnostic images were obtained, with all infants receiving similar 
radiation dose despite CT scanners of different models being used at different 
hospitals. Detailed scanning parameters used in this study can be found in the 
Appendix A10    
 
Each CT scan was sent for clinical reporting at the child’s referral hospital and 
anonymised for subsequent scoring at GOSH. 
 
 CT images 
The first eight scans after the project commenced comprised a full volumetric 
inspiratory scan, followed by an expiratory scan which comprised only 3 sample 
slices of the lungs (the first slice at the carina of the trachea, the third slice at the 
costo-phrenic angles and finally the second slice positioned between the first and 
third slices, as practised in routine clinical assessments).107,168  Initial experience 
from these scans showed small, subtle patchy areas of air trapping in two of the eight 
patients (Figure 4-ii).  
 
Furthermore, evidence from emerging literature and discussions with international 
experts in the field of chest imaging for early lung disease in CF (Dr C Owens from 
GOSH, Dr H Tiddens from the Netherlands, Dr S Stick and Dr S Ranganathan from 
Australia, Dr A Brody from Cincinnati) suggested that subtle changes and air 
trapping may be missed or underestimated if only three expiratory images are 
performed.169,196  
 
Consensus opinion was that the increased scientific information obtained from full 
volumetric imaging would justify the inevitable slight increase in radiation exposure.  
Following ethical committee approval for this amendment, the imaging protocol was 
therefore amended such that all subsequent scans included volumetric scanning of 
the entire lung in inspiration and expiration. Parents were given an amended 
information sheet about the slight additional radiation risk associated with the 
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amended CT protocol and were given the option of withdrawing from the study even 
if they had previously given consent. More details about parental information can be 
found in section 4.2.3.  
 
Figure 4-ii: Examples of CT images demonstrating anaesthetic-related basal 
atelectasis and small areas of focal air trapping 
 
Legend: These were CT images from NBS CF infants undertaken at 1yr of age in 
this study. Images (a) and (b) demonstrated typical linear and wedges shaped basal 
dependent atelectasis secondary to GA respectively (indicated by the red rings). 
Axial slice (c) and coronal section (d) images of expiratory scan revealed subtle 
areas of focal air trapping (hypodense areas indicated by blue rings). 
 
 Radiation dose 
Modern CT scanners typically display two dose indices: CT dose index (CTDIvol, 
unit mGy) and dose length product (DLP, unit mGy-cm). These doses indices are 
based on two standard CTDI phantoms (16 or 32-cm diameter phantoms). Phantom 
is a standard measurement tool that all CT manufacturers have and is used in the 
calculation of CTDIvol. However CTDvol  represents the radiation produced by the 
CT scanner and not necessarily the radiation dose transmitted to an individual 
patient.197 In paediatric patients, what the CT scanner report as the radiation dose 
may not represent what the patient has actually received. In order to have a better 
(a) 
(b) (d) 
(c) 
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estimate, special formula incorporating correction factors to account for paediatric 
imaging was devised which provided an improved estimate of the paediatric 
radiation dose termed as the effective dose.197 The effective dose (E) is estimated by 
taking the DLP and applying a paediatric age specific conversion coefficient that is 
0.026 for a child between 4 months and 1 year, and a correction factor of 2 to 
correct for the use of a 32 cm rather than 16 cm phantom. The formula thus used in 
this study was: DLP x 2 x 0.026 = estimated effective dose in milliSievert 
(EmSv).198,199  
 
Radiation exposure in this study was minimised using automated dose modulation 
that performs real time assessment of body thickness and adjusts tube current to 
provide consistent image quality whilst keeping radiation dose to a minimum. Only 
one CT scan was performed in each infant during the study period and patient dose 
information was recorded for each examination. The above radiation formula was 
then applied to obtain the effective radiation dose received by each patient. 
 
The initial estimated radiation dose of a volumetric inspiratory and limited 3-slice 
expiratory scan was 1.3 mSv which increased to ~1.5 mSv with the combined 
volumetric inspiratory and expiratory scan. The planned radiation dose range for the 
entire scan using the amended protocol was ≤2.0 mSv with a target of ~1.5mSv 
(annual background radiation exposure in the UK ~ 2.5mSv).200-202 
 
Informed consent regarding the chest CT 
Families of eligible infants were asked to provide separate written informed consent 
for each part of this observational study. With respect to the CT scan under GA, they 
were provided with written information augmented by verbal explanations about the 
potential risk associated with the small additional radiation exposure with having the 
CT scan at 1yr of age. They were advised that: 
 All radiation (including the background environmental radiation to which we 
are all exposed) carries a small risk of damage to cells, which may lead to 
cancer after many years or decades.   
 The natural risk of childhood cancer is 10 in 5,000. The lifetime risk of 
subsequent malignancy with the use of a chest CT in a young child (<2 
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years) will increase that risk of childhood cancer by 1 per 5000 cases or 20 
per 100,000 cases.176   
 The extra radiation from having one CT scan using the proposed protocol for 
this study would be equivalent to about half that which their child would 
receive each year from background sources. 
 
 
4.3 GENERAL ANAESTHETIC AND IMAGING PROTOCOLS 
The anaesthetic and imaging protocols used in this study were standardised in 
accordance with current practice107 and international standards140,203 for providing 
safe and effective GA to infants as well as producing high quality images which are 
‘fit for purpose’; and with low radiation exposure.157 Specifically they were 
developed in collaboration with the AREST-CF team109,111,170 in Australia through 
practical advice from Dr Sarath Ranganathan who has been monitoring early lung 
disease in NBS CF infants through annual chest CT and bronchoscopy under GA for 
many years.  
 
Gaseous induction of anaesthesia using oxygen, nitrous oxide and sevoflurane was 
generally used unless contraindicated or at the clinical judgement of the anaesthetist. 
Intravenous anaesthesia with IV propofol could also be used. The infant was 
paralysed with atracurium and then intubated with an appropriately sized 
endotracheal tube to ensure minimal leak up to inflation pressures of 35 cmH2O 
(which were required for a few breaths prior to the scan to minimise any anaesthetic 
related atelectasis (see below) and sufficient calibre to ensure the passage of a 
2.8mm bronchoscope. Anaesthesia was maintained for the CT scan with sevoflurane 
or IV propofol, oxygen and air. 
 
During the initial mask ventilation prior to intubation, there could be a tendency for 
air to enter the stomach which would distort the scan image. To avoid this, a 
nasogastric (NG) tube or suction catheter was passed into the stomach with suction 
applied to the end of the NG tube or suction catheter to reduce any gastric distension 
prior to initial topography. 
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Baseline ventilatory settings prior to imaging, via the anaesthetic machine to 
maintain pCO2 between 4.5-6kPa were: 
- Pressure controlled Intermittent Positive Pressure Ventilation (IPPV) 
- Respiratory rate 20 breaths per minute 
- I: E ratio 1:2 
- Tidal volume (VT) 8-10 ml/kg 
- PEEP: 5 cmH2O 
 
A written protocol (Appendix: A10) was given to all anaesthetists after detailed 
explanations of the procedure. The importance of adhering to protocol in order to 
minimise anaesthesia-related atelectasis and obtain all CT images at standardised 
lung volumes were stressed. Whenever possible the anaesthetist and radiographer 
rehearsed the verbal instructions for each stage of the imaging protocol prior to 
commencing the procedure. A handheld manometer monitoring the ventilatory 
pressures delivered during the scanning protocol was attached to the handheld 
bagging circuit. The anaesthetist was guided by this manometer during lung 
inflations (Figure 4-iii). 
 
The main concern with having GA for chest CT was anaesthesia-induced atelectasis 
which would affect image quality and make CT scoring difficult. Densities observed 
in dependent regions of lungs on chest CT during anaesthesia have been previously 
reported to be due to atelectasis.204,205 Atelectasis occurs with any form of 
anaesthesia whether inhalational or intravenous, with or without paralysing agents. 
Ensuring vital capacity manoeuvres (VCM) using slower and larger inflation 
pressures (up to a PIP 35-40 cmH2O) can completely abolish atelectasis. No adverse 
haemodynamic or pulmonary effects have been reported when using intermittent 
VCM.205,206 A high PEEP after induction and throughout GA can consistently reopen 
lung tissue205 and prevent further atelectasis. Lower concentrations of oxygen during 
induction, maintenance of GA and/or just before extubation have also been shown to 
reduce the amount of atelectasis. Nonetheless inspired oxygen concentration was 
maintained between 30-35% to ensure normal arterial oxygen tension, even if V/Q 
mismatch and shunting occurred due to any atelectasis.    
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During the study CT-GA protocol, recruitment manoeuvres using slower and larger 
inflations and maintaining a PEEP of 5 cmH2O prior to scanning were applied.
206 
When the radiographer was ready to perform the topogram, the anaesthetist inflated 
the infant’s lungs to a PIP of 25 cmH2O and held them at that pressure while 
instructing the radiographer to perform the topogram. Upon completion of the 
topogram, the anaesthetist returned to normal ventilation through the handheld 
circuit while waiting for the radiographer to finish planning for the inspiratory and 
expiratory acquisition parameters. Prior to the inspiratory scan, ten slow inflations 
were performed at a PIP of 25 cmH2O and a PEEP of 5 cmH2O. The inspiratory scan 
was obtained while the airway opening pressure was held steady at PIP 25 cmH2O 
during the last of the 10 slow inflations. Once the inspiratory scan was completed, 
this was immediately followed by release of the inflation bag such that there was 
complete deflation of the lung down to zero PEEP. There was an automatic 6- 
second scan delay programmed into the CT scanning protocol to ensure full lung 
emptying before the expiratory scan was performed. Upon completion of the CT 
scan, normal ventilatory support was resumed (Figure 4-iv). This was the initial 
protocol when the study first started and was used when obtaining CT under GA in 
the first 23 patients.  
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Figure 4-iii: Chest CT scan being performed in an anaesthetised, ventilated 
infant 
 
 
Legend: An anaesthetist used the handheld manometer to guide delivery of the 
appropriate inflation pressures at different scan stages. The paralysed, intubated 
and ventilated infant was placed in the centre of the scanner for image acquisition. 
The position of the infant is important to ensure good images are acquired with 
minimal radiation exposure. The infant’s arms were placed above the head i.e. away 
from the chest. 
 
Figure 4-iv: Initial protocol- summary of inflation pressures during the various 
stages of scan acquisition 
Breath hold at PIP 25 cmH2O    TOPOGRAM 
Slow inflations: 10 at 25/5 cmH2O   
Then breath hold at PIP 25 cmH2O   INSPIRATORY SCAN 
 
Zero PEEP       EXPIRATORY SCAN 
Legend: This protocol was used in the first 23 scans but the protocol was 
subsequently altered and replaced by the ‘definitive’ protocol, as described in 
(Figure). 
 
Despite these attempts, excessive basal atelectasis was observed in 16/23 (70%) of 
the initial study scans from CF infants. This raised concerns that inflations provided 
Handheld manometer 
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during the recruitment stage or inspiratory image acquisition as stipulated in the 
protocol may not be sufficiently large to prevent dependent atelectasis. Following 
further discussions with a member of the AREST- CF team (Dr Sarath 
Ranganathan), the GA protocol was subsequently amended to ensure higher PIP was 
used to recruit lung volume.207 The initial protocol consisted of 10 slow inflations at 
PIP 25 and PEEP 5 cmH2O prior to inspiratory image acquisition. This was changed 
to 6 slow inflations at PIP 35 and PEEP 6 cmH2O followed by 4 slow inflations at 
PIP 25 and PEEP 5 cmH2O. See Figure 4-v for the amended protocol which became 
the final definitive protocol that was used for the rest of the study (42 scans). The 
aim of this amended GA protocol was to reverse any GA- related chest CT changes. 
With this change in GA protocol, the incidence of dependent atelectasis decreased 
slightly to 25/42 (59.5%) although this reduction was not statistically significant 
compared to that observed during the original, lower inflation pressure protocol. 
 
 
Figure 4-v: Definitive final protocol: summary of inflation pressures during the 
various stages of scan acquisition 
Breath hold at PIP 25 cmH2O    TOPOGRAM 
Slow inflations: 6 at 35/6 cmH2O, 
followed by 4 at 25/5 cmH2O   
Then breath hold at PIP 25 cmH2O   INSPIRATORY SCAN 
 
Zero PEEP       EXPIRATORY SCAN 
Legend: Amended GA protocol showing different inflation pressures during image 
acquisitions. Sentence in red indicated the change in pressure for this amended 
protocol, which was followed for the remainder of the study (Appendix A10). 
Training sessions were undertaken in the three CT assessment centres to ensure that 
radiographers and anaesthetists were familiar with the research protocol both before 
commencing the study and at regular intervals throughout the duration of the study. 
Every effort was made to involve a dedicated group of radiographers and 
anaesthetists at each site to ensure smooth execution of the standardised protocol 
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these CF NBS infants. Unfortunately, due to pressures from clinical NHS workload, 
it was not always possible to limit these procedures to a dedicated team anaesthetists 
or radiographers. As discussed below, it soon became apparent that when someone 
less familiar with the research protocol undertook the procedure, disparities were 
likely to occur.  
 
4.4 OBJECTIVE MEASUREMENT USING NICO2® 
RESPIRATORY MONITOR 
 Why was objective measurement of ventilation required? 
After I was appointed and commenced work on this project, I attended all the 
remaining procedures (50 CT-GA) to advise and coordinate all the personnel 
involved in the CT and bronchoscopy under GA at the three centres. This helped to 
ensure smooth execution of the study protocol even if someone less familiar with the 
study from the three centres was involved in the procedure.  
 
As I attended these procedures, I noticed variations in the way recruitment 
manoeuvres were performed and in the pressures implemented during ventilation. 
Uniform ventilatory pressures such as pressure during recruitment manoeuvres were 
not undertaken consistently, ensuring PEEP was always maintained until full 
expiration for expiratory film acquisition were not consistently provided during the 
scanning procedure by different anaesthetists in the three centres (Figure 4-viii). Not 
infrequently, when a different anaesthetist became involved in the study, there was 
lack of familiarity with the protocol. Consequently, I decided to objectively measure 
all ventilatory pressures and volumes whenever possible for the remaining 
procedures using the NICO2
® respiratory monitor (Philips Respironics, USA) 208,209 
so that immediate feedback could be provided to the anaesthetists concerned.  
 
 How does NICO2® measure ventilatory pattern? 
The NICO2
® is a respiratory monitor (Figure 4-vi) that measures flow, pressure and 
time instantaneously at the airway opening via a disposable fixed orifice differential 
flow-sensor and pressure transducer attached between the infant’s tracheal tube and 
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the ventilator circuit. From the integrated flow signal, inflation volumes were 
calculated. 
 
The NICO2
® contains the same hardware platform and algorithms as its predecessor, 
the CO2SMO
®Plus! respiratory monitor; which was thoroughly validated for use in 
the paediatric intensive care unit by members of the Portex respiratory unit.208,209 
The neonatal combined CO2/ flow sensor (combined apparatus deadspace 0.8ml) 
was used for these recordings. These neonatal sensors were capable of measuring 
volume changes between 2-300ml within 1% accuracy, and pressure changes 
between 2-60 cmH2O (0.2-5.9 kilopascals) within ±2% of those measured by the 
electronic manometer (Digitron- pressure manometer P200UL).208 The disposable 
NICO2
® sensors were factory calibrated and are recommended for use without 
further calibration. However, during previous validation studies in this department, 
frequent calibration checks were undertaken using a Hans Rudolf calibrated syringe 
and the signal was always found to be well within the narrow expected range. Hence 
the NICO2
® machine did not require calibration prior to use. 
 
Throughout the CT scanning procedure, all the inflation breaths were recorded. 
Ventilatory pressures were visualised and recorded on the screen of the NICO2
® 
machine and if grossly discrepant pressures were applied at different stages of 
imaging, this provided immediate feedback to the anaesthetists, providing the 
opportunity to adhere more closely to protocol. Data were also automatically 
exported into an Excel file from the NICO2
® which allowed off-line detailed analysis 
at a later stage.   
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Figure 4-vi: NICO2® machine and neonatal flow sensor
 
Legend: The white end of the neonatal combined CO2/ flow sensor (*) is attached to 
the NICO2
® machine (*) and the other end is attached between the infant’s 
endotracheal tube and the ventilator circuit. The CO2/ flow sensor is a single use 
disposable respiratory sensor. 
 
  Outcomes measured using the NICO2® 
Using the NICO2
® respiratory monitor, PIP before topogram, PIP and PEEP 
administered during the recruitment manoeuvres, PIP before inspiratory scan and 
PEEP during the expiratory scan were recorded and analysed to assess whether the 
scans obtained were indeed undertaken in accordance with the standardised 
protocols. Figure 4-vii are screenshots of ‘ideal’ measurements recorded using the 
respiratory monitor during different image acquisitions. Conversely, Figure 4-viii 
are examples of when the anaesthetist did not adhere closely to the protocol. 
Neonatal flow sensor 
* 
* 
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Figure 4-vii: Examples of ‘ideal’ patterns of ventilatory support during various stages of the CT scan as   monitored by the 
NICO2® machine 
 
    
Topogram scan performed once PIP reached 25 cmH2O  Throughout topography, the lung is held inflated at 25cmH2O 
Legend: The top trace (purple) records the flow, middle trace (turquoise) records the pressure and the bottom trace (yellow) records the volume of each inflated 
breath during GA. Prior to performing the topogram, baseline ventilation was initially provided via the anaesthetic machine using tidal volumes of 8-10 ml/kg and 
PEEP 5 cmH2O. Once ready for topogram, ventilation was switched to manual ventilation. During the topogram, the infant’s lungs were inflated to a PIP of ~25 
cmH2O and when this pressure was attained, the topogram was acquired during the breath hold at PIP 25 cmH2O. 
(a) During the Topogram 
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      6 slow large inflations ~35/6 cmH2O   4 slow inflations ~ 25/5 cmH2O   
                   
               Inspiratory scan performed 
Legend: Prior to the inspiratory scan being acquired, 6 larger and slower inflations of PIP 35-40/6 cm H2O were administered to 
reverse any GA-related atelectasis followed by 4 smaller and slow inflations of 25/5 cm H2O. During the last of the 4 smaller inflations, 
the inflation was held at 25 cm H2O and once attained, the inspiratory image was acquired. 
 
 
(b) During recruitment manoeuvres and inspiratory scan 
PIP= 25 cmH2O 
PEEP= 5 cmH2O 
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         Expiratory scan performed once lungs were fully deflated.  
Legend: Immediately following the acquisition of the inspiratory scan, the inflation was released and the infant’s lungs were allowed to 
deflate down to their elastic equilibrium volume, FRC (zero PEEP), before the expiratory scan was performed.    
 
(c) During Expiratory scan   
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Figure 4-viii: Screenshot of NICO2® measurements showing examples of when  anaesthetist  did not adhere closely to protocol when 
manually ventilating the infant. 
 
 
 
 
 
 
Legend: Different anaesthetists from the three centres varied in the ventilation provided for the infants during the imaging protocol. Using the NICO2® machine, it 
was possible to visualise on screen where the problems were so that changes could be implemented before the images were taken. (a)During the recruitment 
manoeuvre, pressures provided were higher than stipulated in the protocol. (b)PEEP was held at a higher pressure than stated in the protocol. (c)In between 
inflations, PEEP should be maintained at 5 but in this scenario, PEEP was zero in between inflations.  
144 
 
4.5 RESULTS FROM NICO2® MONITORING ACROSS 
CENTRES 
65 CTs were performed at a year of age in NBS CF infants with corresponding 1yr 
lung function results.  
 
I attended 50/65 (77%) of the CT procedures in all three centres; the initial 15 
procedures were performed prior to my appointment to this project. I obtained 
objective records of manual ventilation patterns by using the NICO2
® respiratory 
monitor in 37/65 (57%) of all CT scans performed. Of the 65 scans, 15% were 
performed at centre A, 58% at centre B and 26% at centre C. See Table 4-ii for a 
summary of scans performed, attendance of research team and objective monitoring 
in each centre. 
 
Table 4-ii: The number (percentage) of scans performed, attendance of research 
team and objective monitoring in each centre 
 n Centre A Centre B Centre C 
No (%)  scans 
performed/centre 
65 10/65    
(15%) 
38/65 
(58%) 
17/65 
(26%) 
No (%) cases attended 
by research team 
    50/65    
(77%) 
7/10            
(70%)  
28/38        
(74%) 
15/17         
(88%) 
No (%) of cases with 
objective monitoring 
37/65 
(58%) 
5/10         
(50%) 
19/38 
(50%) 
13/17 
(76%) 
 
Due to their non-parametric distribution, ventilatory pressures used were compared 
using Kruskal Wallis (K-W) for significance testing of differences and post-hoc 
Bonferroni adjustment for multiple Mann Whitney U test to compare the median and 
IQR across the three centres. 
 
Evidence from the respiratory monitor indicated that ventilatory pattern was similar 
across the three centres (Table 4-iii). A slightly higher than intended PEEP during 
the recruitment inflations was seen across the three centres [overall median 
(interquartile range) PEEP delivered being 7.2 (5.4; 8.8) cmH2O], this being 
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significantly higher in Centre B compared to Centre C (p=0.012) (Figure 4-ix). No 
difference was observed between Centres A and B. 
 
There were no significant differences between centres with respect to PIP during 
either recruitment inflations  or the breath-hold during inspiratory image acquisition, 
overall median IQR across the three centres being close to that specified in the 
protocol [32.9(30.6; 35.1) and 26.2(24.5;27.9) cmH2O respectively].   
Table 4-iii: Ventilatory pressures during different scanning stages from the 
three participating centres 
 Procedures monitored using NICO2 ® 
 Centre A           
(n=5/10)  
Centre B              
(n=19/38) 
Centre C             
(n=13/17) 
Overall         
(n= 37/65) 
PIP during 
recruitment 
32.8 (30.4;34.2) 32.6 (30.1;35.5) 33.0 (30.7;35.5) 32.9 (30.6;35.1) 
PEEP during 
recruitment 
7.4 (6.1;9.8) 8.0 (6.5;9.1)* 5.2 (2.9;7.6)* 7.2 (5.4;8.8) 
PIP  during 
breath-hold 
26.0 (16.3;28.8) 27.6 (25.5;29.0) 25.1 (23.7;26.2) 26.2 (24.5;27.9) 
Footnote: n: number of cases monitored/number of scans performed; All results expressed 
as median (Inter quartile ranges) All pressures reported in cmH2O.  *significant difference 
between centres B and C: p<0.05, see Figure 4-ix. 
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Figure 4-ix: Diagram showing peak end-expiratory pressures during 
recruitment inflations across the three centres   
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Legend: Median and interquartile ranges of peak end- expiratory pressure during recruitment 
inflations according to centre. Using Mann Whitney U test * p <0.05. This was the only ventilatory 
parameter that showed a significant difference between the centres.  
 
4.6 RESULTS OF RADIATION DOSES FROM CHEST CT 
ACROSS CENTRES 
The first eight scans performed were limited to 3-slices expiratory scans so have 
been excluded from these calculations. With these limited expiratory scans (n=8), 
median (IQR) radiation dose was 1.07(0.92;1.34) mSv. Of the remaining 57 full 
volumetric scans, precise radiation dose for 4 of the later scans could not be 
calculated due to the lack of available qualified staff.  
 
Due to their non-parametric distribution, radiation doses were also compared using 
Kruskal Wallis (K-W) for significance testing of differences and post-hoc Bonferroni 
adjustment for multiple Mann Whitney U test to compare the median and IQR across 
the three centres. 
 
For the remaining 53 scans, the median (IQR) effective radiation  exposure across all 
centres was 1.5(1.2; 1.8) mSv, with  centres A and B achieving median doses close 
to the target dose of 1.5 mSv, exposure was significantly higher at centre C (Table 
4-v and Figure 4-x). Three infants in centre C received ≥3mSv; 2 due to sub-optimal 
positioning. These cases were appropriately investigated and dealt with. Even when 
these three infants’ radiation doses were not included in the analysis, median 
radiation dose reported in centre C (median (IQR) 2.18, (1.78 to 2.43) mSv was still 
* 
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significantly higher than centres A and B. The greater variability in radiation doses 
observed in centre C may be due to the slightly different type of scanner (Table 4-i) 
and/or the fact that it was not possible to organise a dedicated radiographer to 
perform procedures within that hospital such that they were not as familiar with the 
tight scanning control required. 
 
In general, exposures of ≤1.5mSv were achieved in 58% of infants; 79% received an 
effective dose of ≤2 mSv. 
 
Table 4-iv: Table of radiation doses from volumetric inspiratory and expiratory 
chest CT scans across three centres  
 
Centre A  (n=7) Centre B (n=31) Centre C (n=15) 
Overall 
dose 
Median (mSv) 1.53 1.31 2.38 1.50 
Inter- quartile 
range (mSv) 
1.37; 1.65 0.86; 2.02 1.14; 3.75 1.24; 1.84 
Footnote: n= number of scans performed in each centre. mSv= milliSievert, unit of 
measuring ionising radiation.  
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Figure 4-x: Radiation doses from chest CT across three centres 
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Legend: Solid black horizontal line demonstrates the median radiation 
doses from each centre. Purple dashed horizontal line denotes targeted 
radiation dose, which was achieved in 58% of infants (i.e those at or below 
the line). ~80% of infants received less than the upper limit of ‘acceptable’ 
dose (below the black dashed line). Radiation dose in Centre C was 
significantly higher than that in both centre A (**p<0.01) and B 
***p<0.001 using Mann Whitney U tests. 
 
4.7 FLEXIBLE BRONCHOSCOPY, BRONCHO-ALVEOLAR 
LAVAGE AND POST GENERAL ANAESTHESIA 
PROCEDURES 
Flexible bronchoscopy and BAL were performed immediately after the chest CT 
scan. BAL samples were obtained bilaterally; mainly 3 samples from the right 
middle lobe and one sample from the lingula, unless an area was identified as being 
the site of more severe disease either by CT scan or during bronchoscopy. This 
occurred in about 7/65 (~10%) of the NBS CF infants that were lavaged whereby 
other lobes with apparently more disease were lavaged. Lavage samples were 
analysed and quantified for bacterial, fungal and mycobacterial growth and virus 
detection through immunofluorescence (Appendix: A11).  
 
Targeted radiation 
dose ≤1.5 mSv 
Upper limit of 
‘acceptable’ 
radiation dose ≤ 2 
mSv 
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Once the CT scan and BAL were completed, and the infant had roused and was 
clinically stable, the child was transferred back to the ward. They were observed for 
at least 2-4 hours to ensure that they were fully awake with stable observations 
before being discharged. Infants were subsequently followed up in their respective 
CF centres where the results from the lung function, chest CT and bronchoscopy and 
BAL results were conveyed to the parents of the CF infant by the consultant 
responsible for their care.   
 
Detailed results of the bronchoscopy and BAL are not included in this thesis as they 
do not contribute towards any of the hypotheses, aims or objective in this study; 
being beyond the scope of the current thesis. Culture results from BAL will be 
reported in chapter 6, section 6.1.1. 
 
 
4.8 SUMMARY  
This chapter discussed the standardised protocol for obtaining chest CT scans and 
the associated challenges and difficulties encountered when conducting chest CT 
under GA in CF infants and when using chest CT as a potential outcome measure to 
detect early CF lung disease in multicentre studies. Despite the rigour involved in 
attempting to standardise procedures through written protocols, specialised training 
of anaesthetists and radiographers and the attendance of research personnel when 
available, differences occurred with respect to the pressure delivered during GA and 
radiation exposure. The extent to which deviations in GA and scanning protocols 
could affect the chest CT results will be discussed in chapter 6, section 5.3.5.  It is 
vital that these challenges are anticipated and addressed when considering the use of 
chest CT as a potential outcome measure or clinical trial endpoint in multicentre 
studies, otherwise comparability of results between centres will be compromised. 
 
In addition to the difficulties in obtaining research CT scans, there is minimal 
information on the best scoring system for use in CF infants diagnosed through NBS, 
who are likely to have much milder disease than those for whom scoring systems 
have been developed and validated in the past. In the next chapter (Chapter 5), the 
validity of using the Brody-II CT scoring system to evaluate early lung disease in 
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young NBS CF infants will be addressed, using inter-observer and intra-observer 
agreement of scores following a standardised training programme. The relationship 
of CT-demonstrated lung changes with physiological lung function will also be 
explored in Chapter 6. 
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5 CHALLENGES IN SCORING CHEST COMPUTED 
TOMOGRAPHY CHANGES IN NEWBORN 
SCREENED  CF INFANTS  
 
5.1 INTRODUCTION 
Although there are several existing specific CT scoring systems, which identify and 
assess severity of various abnormalities, none has been validated for use in early 
infancy. In addition it is not known which scoring system is most sensitive to detect 
clinically relevant changes in the presence of mild lung disease. The different 
scoring systems that are currently available was discussed in the introductory 
chapter 1, section 1.8.2. 
 
The Brody II (modified Brody scoring system) is one of the most widely used scores 
for use in subjects with CF and has been shown to provide the most comprehensive 
assessment of the extent and severity of lung abnormalities in CF patients. It has also 
been assessed in several validation studies involving older children149,151,155,172 and 
the rationale for using this scoring system as compared to other scoring systems was 
previously discussed in chapter 1, section 1.8.2.2 and 1.9. Although, in keeping 
with all other published scoring systems 146,171,172,174,175,205, its use has yet to be 
established in young NBS CF infants, it has been validated in studies involving older 
children and adults with CF, showing low within- and between- observer 
variability154,172; and good correlation with LCI107 and clinical outcomes such as 
pulmonary exacerbations155,210. It was therefore selected for use in this study, with 
the specific aim of establishing whether Brody II could detect and score changes in 
young CF infants with mild lung disease reliably and to measure inter and intra 
observer agreement using this scoring system.  
 
This chapter consists of two sections: the first describes the CT scoring methodology 
while the second section reports on the scoring results of CT changes. 
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5.2 SCORING METHDOLOGY 
 The Brody-II scoring system 
Brody-II scoring is a modification of the original Brody scoring system.211 This 
scoring system assesses the severity and extent of bronchial dilatation, bronchial wall 
thickening, parenchymal changes of consolidation and ground glass opacification, 
mucous plugging and air trapping (based on expiratory scans) in each lobe. 
Distribution of each abnormality is described according to its central or peripheral 
location within each lobe. Peripheral lung is defined as the portion of lung within 2 
cm of the costal or diaphragmatic pleura whilst central portion accounted for the rest 
of the lung. Each subject’s lungs are divided into 6 lobes, three on each side. A score 
sheet is filled out for each lobe of the lung, including the lingula as a separate lobe 
(Appendix: A12). 
 
Bronchiectasis is identified by the presence of one or more of the following criteria: 
a broncho-arterial ratio (BAR) >1, a non-tapering bronchus, a bronchus within 1 cm 
of the costal pleura or abutting the mediastinal pleura.166 A critical nuance of this is 
whether bronchial diameter is evaluated from outer wall to outer wall, or as luminal 
diameter. While rarely specified in reports, when it is, it is the luminal, rather than 
external diameter that should be recorded, as was used in the present study. The 
severity of bronchiectasis is defined as mild if the bronchus is less than twice the size 
of the accompanying vessel, moderate if two or three times and severe if the 
diameter is greater than three times the size of the vessel. Bronchial wall thickening 
is defined as a bronchial thickness > 2mm in the hila region, 1mm in the central 
portion of the lung and 0.5mm in the peripheral lung. Central mucous plugging is 
defined as an opacity filling a defined bronchus and peripheral plugging defined as 
the presence of either dilated mucus-filled bronchi or peripheral thin branching 
structures or centrilobular nodules in the peripheral lung. Air trapping is defined as 
areas of lung attenuation when compared with the appearance on the inspiratory 
images. Due to the decrease in lung air content during expiration, normal lung would 
show an increase in density on expiratory images. Air trapping is further 
characterised by sub-segmental or segmental distribution of the low attenuation 
areas.212(Figure 5-i) 
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Figure 5-i: Examples of Chest CT slices demonstrating air trapping   
 
 
 
 
Legend: (a) On inspiratory image, there is an area of segmental abnormality of the 
centrilobular bronchi in the posterior segment of the right upper lobe. No obvious 
reduced attenuation noted on inspiratory image, whilst in the expiratory image (b) 
there is a corresponding segmental area of air trapping clearly demarcated. (c) 
Coronal CT slice demonstrating mosaicism indicative of air trapping in another 
patient. (d) Sagittal CT slice demonstrating the same areas of segmental and 
subsegmental air trapping depicted in the coronal section.  
 
 
Assessment for severity and extent was performed by assessing the severity of the 
abnormality using the described criteria and estimating the volume of the lobe 
showing the abnormality. The lobar area was determined by estimating the area that 
showed the abnormality within each slice which was then combined to estimate the 
volume of the lobe showing the abnormality. Average bronchiectasis was defined as 
the degree of dilation most frequently seen. Both severity and extent contributed to 
the increasing score for bronchiectasis and bronchial wall thickening.  
 
 
(a) Inspiratory (b) Expiratory 
(c) Coronal section (d) Sagittal section 
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A score was calculated for each abnormality and the scores added to provide a total 
disease severity score for that lobe and finally scores for the six lobes were added to 
provide a total patient score. The weighting system used in this scoring system was 
based on a review of published scoring systems171,211,213 and experience of the 
radiologists involved in developing the Brody-II system. The total severity score can 
range from 0 (normal) to 243 (severe abnormality seen in all categories affecting 
every lobe of the lung). Parenchymal changes (consolidation, cyst and ground glass 
opacity) could be found in combination in each lobe, hence these finding were 
grouped together as one category in this modified scoring system. The ranges for 
bronchiectasis and air trapping scores were 0-72 and 0-27 respectively for each scan. 
 
A summary description of the abnormalities and the scores allocated as described in 
this section is in Table 5-i. 
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Table 5-i: Brody- II scoring system  
 
Footnote: Each subscore applied to each lobe such that there are 3 lobes on the 
right (upper, middle and lower) and on the left (upper, lower and lingula). The 
maximum possible score for bronchial dilatation is 12 x 6= 72; for air trapping 4.5 x 
6=27; for peribronchial thickening 9 x 6=54; for mucous plugging= 6 x 6= 36 and 
for parenchyma score 9 x 6= 54. The maximum possible CT total score is 243; 
higher scores indicating more severe disease. 
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 Training scans and scoring 
All CT scans undertaken were anonymised before the commencement of scoring. 
Studies were scored independently without prior clinical or laboratory information 
by two consultant radiologists using the Brody-II scores,151,172 Dr Alan Brody (AB: 
25 years’ experience of paediatric chest CT, 13 years’ experience scoring CF lung 
disease and who had devised and validated the Brody CT scoring system.151,154,172) 
and Dr Alistair Calder (AC: 7 years’ experience of paediatric chest CT, 5 years’ 
experience scoring CF lung disease).   
 
Prior to scoring any CTs from this study, both scorers studied a PowerPoint 
presentation which explained the Brody II scoring system and definitions of the 
different abnormalities described in the scoring system. CT images were shown in 
the presentation to visually illustrate these abnormalities. This training package was 
developed by the Eramus medical centre in Rotterdam, The Netherlands in 
partnership with international collaborators in an attempt to have a consensus 
proposal for quantifying structural abnormalities in CF. Following this, both scorers 
undertook an initial training period using 12 training scans provided by the AREST-
CF team from children with CF aged 1- 5 years of age in whom data had been 
acquired using a similar protocol to the current study. Each scan comprised of a 
volumetric inspiratory and expiratory image. These ‘training scans’ were scored in 
two batches of 6. The two scorers independently evaluated the 1st training batch 
followed by video-conference to clarify the definitions used for bronchial dilatation 
and a further group of six training studies were then independently evaluated 
(training batch 2). Scores from these training batches were compared, results of 
which are reported in the second part of this chapter in section 5.3.3. 
 
 Process of scoring study scans 
This section describes the process of the different scoring stages of the study scans 
performed in NBS CF infants at a year of age. Results of these scores are presented 
later in this chapter. 
 
Scoring of LCFC scans took place within 6 weeks of completing training. All patient 
clinical information and lung function results were concealed from the scorers. 
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Scores from both observers were analysed and compared by me who was not 
involved in scoring. LCFC scans with discrepant sub-scores were returned to both 
scorers (without details of prior scores allocated) for subsequent re-assessment to 
investigate whether closer agreement could potentially be achieved. A random 
selection of LCFC scans was completely re-scored after ~8 months to assess inter- 
and intra-observer agreement over time.  
 
After the first evaluation of study scans (initial LCFC study round; n=65), a record 
of all discrepant observations from this initial study round without any details of 
scores allocated, was sent to both observers by me for subsequent re-assessment 
(discrepant LCFC study round; n=50) to investigate whether closer agreement 
could potentially be achieved in future with further training and scoring only in 
components that were scored differently at the initial study round. Finally randomly 
selected studies underwent complete re-scoring (Rescore LCFC study round; 
n=22), 8 months after the initial LCFC study round to assess inter and intra- observer 
agreement of scores. Calculations and comparison of all scores in the three study 
rounds (scoring rounds described as stated in brackets in italics above) (Figure 5-ii) 
were undertaken by me (LT).  
 
Figure 5-ii: Flowchart showing the different scoring rounds, the number of 
scans scored and the relevant time intervals  
 
 
 
 
 
 
 
 
 
Training Batch 1 (n=6) 
Training Batch 2 (n=6) 
Initial LCFC Study Round (n=65) 
6 weeks later 
Discrepant LCFC Study Round (n=50; partial rescore 
of 50 scans with discrepant observations) 
3 months later 
Re-score LCFC Study Round (n=22; of randomly 
selected scans from study population)  
5 months later 
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 Outcome measures and statistical analysis of CT scores  
Outcomes measures included total Brody II scores and sub-scores for bronchial 
dilatation, air trapping, bronchial wall thickening, mucous plugging and parenchymal 
opacities. The comparison of these CT abnormalities to various lung function 
outcomes listed in chapter 2 (section: 2.3.5) and potential clinical determinants will 
be presented in the next chapter (chapter 6). 
 
Data were inspected for distribution, calculation of descriptive statistics (PASW 
Statistics v.18, Chicago, IL, US) and summarised using n (%), mean (SD) or median 
(interquartile range, IQR). Each CT sub-score from each scorer was compared, for 
both training rounds and all three study rounds. Agreement for each sub-score was 
assessed using Cohen’s kappa statistic with linear weighting (MedCal for Windows, 
statistical software version 12.3.0, Mariakerke, Belgium). Kappa coefficient with 
95% confidence interval (CI) will be presented for bronchial dilatation and air 
trapping sub-scores and total CT scores. Results for kappa statistics are interpreted as 
follows:214 0-0.2: poor agreement; 0.21-0.4: fair agreement; 0.41-0.6: moderate 
agreement; 0.61-0.8: strong agreement; 0.81-1.0: excellent agreement. Kappa 
statistics were used to measure the level of agreement between the two scorers as a 
way of verifying that agreement exceeds chance level i.e. ‘chance-corrected measure 
of agreement’.  
 
 
5.3 SCORING RESULTS  
 Introduction 
The previous section described the scoring process while this section will 
concentrate on the chest CT results and will test the secondary hypothesis which 
states that significant abnormal changes can be detected on chest CT even at an early 
age of 1yr in NBS CF infants. 
 
Despite the availability of numerous CT scoring systems,146,171,172,174,175,205 none have 
been validated for use in young CF infants.  Therefore in order to validate the use of 
Brody II scoring system for use in CF infants, it was essential to investigate the  
applicability of this scoring system, with respect to its intra and inter-observer 
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variability in detecting and quantifying CT changes in young infants with CF when 
only very mild (if any) changes may be present.  
 
 Study Population 
Of the 72 NBS infants with CF who underwent paired 3 month and 1 year lung 
function tests, 63 (87.5%) also underwent a chest CT and flexible bronchoscopy 
under GA. Parents of the remaining nine (12.5%) CF infants declined these tests due 
to concerns about having a general anaesthetic and radiation from CT; interestingly, 
the concern over GA was greater than the radiation risk (Figure 5-iii).  
 
In addition, there were 2 CF infants who did not have ILFT at 3m but underwent 
lung function and chest CT at a year of age. One of these infants did not have the 
three- month ILFT due to repeated respiratory illnesses within the first three months 
of age whilst the other had borderline screen positive CF results which were only 
confirmed through positive extended genotype (c.1521_1523delCTT/c.617T>G) at 3 
months of age.  
 
Hence in total, there were 65 CF infants who had 1 year lung function test and chest 
CT; 63 of whom also had lung function assessed at ~3m. Clinical characteristics of 
this subgroup of CF infants will be presented in chapter 6 (section 6.1.1) 
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Figure 5-iii: Flow diagram showing recruitment and retention of CF only 
(shown previously in Figure 3-i ) who completed the 1 year study  
                  NBS infants with CF                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: This flow diagram shows the recruitment and retention of NBS CF infants 
who completed the lung function tests and chest CT. Information within bold boxes 
has been presented in previous flowchart found in chapter 3, Figure 3-i. Detailed 
reasons for ineligibility, decline or not tested can be found in that same flowchart. 
101 (87%) eligible & invited to participate 
12 (12%) declined 
89 (88%) consented to study 
Not tested at 3m: n=9 (10%) 
At 3 months, total tested: n= 80 (79% of 
eligible) 
Not tested at 1y: n=8 (10%) 
At 1 year, total tested: n=72 (90% of those 
tested at 3 months) 
Technically satisfactory paired data: n=72 
(including 7 with meconium ileus) 
 
116 screened positive                             
(including 14 with meconium ileus)  
15 (13%) not eligible 
+
  9 (12.5%) refused CT scan 
2 infants had CT scans with 1- year 
lung function only 
63 (87.5%) had CT scan and paired 
lung function 
 
 
 
–  
 
9 (12.5%) declined CT scan 
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 Scoring results from training scans 
Training scans used for practice scoring between the two scorers were provided by 
the AREST-CF team as described in chapter 5, section 5.2.2. These 12 scans were 
obtained from infants and young children aged 1.2 to 4.2 years (median 2.3 years), 
but only 5 were scanned before 1.3 years. The vast majority of the LCFC infants 
were studied at less than 1.2 years of age with a few as young as 0.8 years. Despite 
training scans being undertaken in infants of a slightly older age range, there was 
still an overlap age range with the current LCFC study. However, with hindsight the 
use of training scans in age matched infants would have been preferable. 
 
Table 5-ii shows the agreement between the two scorers according to the Brody–II 
scoring system for the two training batches. The level of agreement for bronchial 
dilatation with training batch 2 improved when compared to training batch 1 and was 
deemed acceptable by both scorers, who then progressed to the scoring of CT scans 
obtained as part of the definitive LCFC study of NBS CF infants. Agreement 
improved during training batch 2 for the bronchial wall thickening sub-score, 
whereas that for mucous plugging (which initially showed strong agreement), and 
parenchymal change (with moderate initial agreement), showed less agreement. 
Agreement between scorers on the air trapping sub-score remained strong for both 
training batches.  
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Table 5-ii: Agreement of scores according to Brody-II scoring system during the 
two training batches 
 Training batch 1 
(n=6) 
Training batch 2 
(n=6) 
Age of infants (years)* 2.0 (1.2; 2.6) 2.3 (1.4; 3.0) 
Bronchial dilatation# 0.27 (0.08; 0.46) 0.45 (0.17; 0.72) 
Air trapping# 0.82 (0.68; 0.95) 0.79 (0.67; 0.92) 
Bronchial wall thickening# 0.44 (0.19; 0.70) 0.79 (0.67; 0.92) 
Mucous plugging# 0.62 (0.42; 0.81) 0.00 (0.00; 0.00) 
Parenchymal change# 0.41 (0.16; 0.66) 0.30 (0.03; 0.58) 
Total CT scores# 0.75 (0.61; 0.90) 0.43 (0.10; 0.75) 
Footnote: * Ages expressed as median (interquartile ranges) in years. 
# Agreement expressed as mean Kappa coefficient (95% confidence interval) using 
linear weighted Kappa statistics. Agreement for kappa statistics are interpreted as 
follows:214 0-0.2: poor; 0.21-0.4: fair; 0.41-0.6: moderate; 0.61-0.8: strong and 
0.81-1.0: excellent. 
Agreement for bronchial dilatation improved with the second training batch 
although it was only moderate; whilst for air trapping, agreement remained strong 
for both training batches. 
 
 
Figure 5-iv shows graphical representation of paired scores allocated by scorer A 
and B for each training scan in terms of bronchial dilatation and air trapping sub-
scores and total CT scores with first batch scores represented by plots a-c and second 
batch scores represented by plots d-f. In first training batch, scorer A gave higher 
bronchial dilatation score and total score compared to scorer B (Figure 5-iv, a & c) 
but subsequently allocated more similar scores during the second training batch 
(Figure 5-iv, d & f).  There appeared to be higher scores during the 1st than 2nd batch 
for both bronchial dilatation [Batch 1: scorer A (median, range): 3(0-16) and scorer 
B: 0(0-9) vs.  Batch 2: scorer A: 1(0-7) and scorer B: 1.5(0-6)], and for total CT 
scores [Batch 1: scorer A 7 (2-60) and scorer B 7 (2-46) vs. Batch 2: scorer A: 4.5 
(1-37) and scorer B 11.5 (0-36)] (Table 5-iii). With air trapping (Figure 5-iv, b & e), 
both observers were consistent with their scores during the first and second training 
batches. Scans from both batches were similar in terms of severity for air trapping 
(Table 5-iii).
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Figure 5-iv: Scores allocated by scorers A and B for the two batches of training 
scans (n=12) 
 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
(f) 
Training batch 1 (n=6) Training batch 2 (n=6) 
 
ĸ=0.27  
(0.08; 0.46) 
2 
2 
ĸ=0.82 
(0.68; 0.95) 
ĸ=0.71 
(0.61; 0.90) 
ĸ=0.45 
(0.17; 0.72) 
ĸ=0.79 
(0.67; 0.92) 
(e) 
ĸ=0.43 
(0.10; 0.75) 
Legend: Bolder circles represent overlapping results from both scorers with the numbers of 
overlapping data next to it. ĸ =Kappa coefficient (95% CI) 
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Table 5-iii: Sub-scores and total CT scores allocated for the two training batches 
by both scorers A and B 
Total scores or 
sub-scores 
First training batch Second training batch 
Scorer A Scorer B Scorer A Scorer B 
Bronchial 
dilatation 
(max score = 72) 
3 (0; 16) 0 (0; 9) 1 (0; 7) 1.5 (0; 6) 
Air trapping 
(max score = 27) 
0.5 (0; 8) 2.5 (0; 15) 2 (0; 18) 6.5 (0; 19) 
Bronchial wall 
thickening 
(max score = 54) 
0 (0; 8) 0 (0; 7) 0 (0; 4) 0 (0; 9) 
Mucous plugging 
(max score = 36) 
0.5 (0; 10) 0 (0; 6) 0 (0; 0) 0 (0; 1) 
Parenchymal 
changes 
(max score = 54) 
2.5 (1; 8) 4.5 (0; 9) 1 (1; 8) 4.5 (0; 7) 
Total CT scores 
(max score = 243) 
7 (2; 60) 7 (2; 46) 4.5 (1; 37) 11.5 (0; 36) 
Footnote: CT total and sub-scores presented as median (ranges) by both scorers for 
each training batch.   
Although higher scores were generally allocated to older children (i.e. those ≥ 2 years 
old); significant bronchial dilatation and air trapping was observed in one infant who 
was only 1.5 years. With these training scans, there was a high prevalence of bronchial 
dilatation (50-67% of scans) and air trapping (50-75% of scans) reported by both 
scorers.  
 
 Scoring results from LCFC scans 
Scoring of the 65 LCFC study scans commenced within 6 weeks of training with 
completion of this initial LCFC scoring round within a month. The second scoring 
round, which consisted of re-scoring the discrepant observations (discrepant LCFC) 
that occurred in 50 scans, blinded to previous results, took place 3 months after the first 
initial LCFC study round and was completed within a month. Finally a randomly 
selected group of 22 scans (a third of the original cohort) was re-scored in entirety 
(rescore LCFC) ~4 months after the discrepant LCFC study round (i.e. ~8 months after 
the initial LCFC round). See Figure 5-ii for flowchart of scoring rounds. 
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5.3.4.1 Inter-observer agreement for the initial scoring of LCFC scans  
At initial LCFC scoring round consisting of 65 scans, there was fair agreement between 
scorers for bronchial dilatation [mean Kappa (CI) = 0.21(0.04; 0.37)] and strong 
agreement for air-trapping [mean Kappa (CI) = 0.66(0.49; 0.83)]. Bronchial wall 
thickening, parenchymal change, mucous plugging sub-scores and total scores all 
showed only fair agreement between both scorers at the first scoring round (Table 5-iv).  
 
Table 5-iv: Linear weighted Kappa analysis between both scorers at initial LCFC 
scoring round of entire cohort   
 Kappa#  (n=65) 
Bronchial dilatation 0.21 (0.05; 0.37) 
Air trapping 0.66 (0.49; 0.83) 
Bronchial wall thickening 0.27 (-0.01; 0.55) 
Parenchyma change 0.25 (0.12; 0.38) 
Mucous plugging 0.26 (-0.12; 0.63) 
Total score 0.34 (0.20; 0.49) 
Footnote: #Agreement expressed as mean Kappa coefficient (95% confidence interval) 
using linear weighted Kappa statistics. Agreement for kappa statistics are interpreted as 
follows:214 0-0.2: poor; 0.21-0.4: fair; 0.41-0.6: moderate; 0.61-0.8: strong and 0.81-
1.0: excellent. 
 
Individual scores allocated by each scorer are represented in Table 5-v. Scorer A 
appeared to allocate lower scores compared to scorer B at the initial LCFC scoring 
round for bronchial dilatation and total CT scores.  
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Table 5-v: Inter-observer agreement for CT scores allocated to NBS CF infants at 
1 year of age during initial scoring of LCFC scans 
a) Bronchial dilatation (Max  score 72) 
ĸ= 0.21 
(0.05; 0.37) 
Scorer A 
0 1 2 3 4 5 
Scorer 
B 
0 48 - - - -  
1 6 - - - - - 
2 4 3 1 - - - 
3 1 - - - - - 
4 1 - - - - - 
5 - 1 - - - - 
 
b) Air trapping (maximum possible score =27) 
ĸ= 0.66 
(0.49; 0.83) 
Scorer A 
0 1 2 3 4 5 7 8 15 16 
 
 
 
 
 
Scorer 
B 
0 37 - 1 - - - - - - - 
1 6 3 - - - - - - - - 
2 3 - 1 1 - - - - - - 
3 1 1 1 2 - - - - - - 
4 - - - - 2 - - - - - 
5 - - - - 2 - - - - - 
7 - - - - - 1 - - - - 
8 1 - - 1 - - - - - - 
15 - - - - - - - - - 1 
16 - - - - - - - - - - 
   
c) Total CT score (maximum possible score = 243) 
 
ĸ= 0.34 
(0.20; 0.49) 
Scorer A 
0 1 2 3 4 5 6 7 8 9 10 
12 
13 14 17 19 25 30 
 
 
 
 
 
Scorer 
B 
0 7 - - - - - - - - - - - - - - - - - 
1 5 5 - - - - - - - - - - - - - - - - 
2 7 1 - - - - - - - - - - - - - - - - 
3 5 - 2 1 - - - - - - - - - - - - - - 
4 3 1 - 2 - 1 - - - - - - - - - - - - 
5 - 4 1 1 - 1 - - - - - - - - - - - - 
6 1 - 1 - 1 - - - - - - - - - - - - - 
7 1 1 1 - - 1 - - - - - - - - - - - - 
8 1 - - 1 - - - - - - - - - - - - - - 
9 - - - - 1 - - - - - - - - - - - - - 
10 - - - - - - - - - - 1 - - - - - - - 
12 - - - - - 1 - - - - - - - - - - - - 
13 - - - - - 2 - - - - - - - - - - - - 
14 1 - - - - - - - - - - - - - - - - - 
17 - - - - - - - 1 - - - - - - - - - - 
19 - - - - - - - - - - - 1 - - - - - - 
25 - - - - - - - - - - - - - - - - - - 
30 - - - - - -- - - - - - - - - - - 1 - 
Footnote: Shaded cells across the diagonals within each table represent identical 
results by scorers A & B. Numbers within each cell represent the number of infants with 
each combination of scores. For air trapping scores ≥5 and total CT scores ≥12, only 
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those for which any values were obtained are shown. Scorer A appeared to allocate 
lower scores compared to scorer B at the initial LCFC scoring round for bronchial 
dilatation and total CT scores. For total CT scores, darker shaded column and row 
represent total CT scores whereby it is 5% of the total maximum CT scores. For scorer 
A, only 2 (3%) scan whilst for scorer B 7(11%) scans had ≥ 5% of the maximum score.  
 
 
Although scorer B identified more abnormalities on scans than scorer A as indicated by 
values generally falling below the shaded diagonal cells [17(26%) vs 5(7%) for 
bronchial dilatation; 27(42%) vs 17(26%) for air trapping], the severity of changes were 
generally very minor, with only 7(11%) and 2(3%) of patients having a total CT score 
≥12 or 5% of total possible score. It can be seen that the majority of discrepancies for 
bronchial dilatation occurred when changes were deemed to be very minor [1-3] by one 
scorer and absent [0] by the other.  
 
5.3.4.2 Re-assessment of discrepant sub-scores following initial LCFC scoring and 
LCFC rescores 
After comparing scores between the two observers during the initial scoring of the 65 
LCFC scans, a record of all discrepant observations from a total of 50 scans was 
prepared by me (LT). Apart from both scorers knowing that their scores differed, all 
discrepant observations were re-scored independently, blinded to their own and their 
counterpart’s initial scores, following a short general discussion about the scoring 
system. Analysis of the discrepant cases showed that 90% of these differences were 
between score of 0 (normal), and 1 (minimal to mild disease) (Table 5-v).  
 
Good agreement was observed for bronchial dilatation [Mean Kappa coefficient=0.62 
(95% CI: 0.39; 0.86)] and excellent agreement seen for air-trapping [Mean Kappa 
coefficient=0.88 (95% CI: 0.81; 0.96)] when the discrepant observations were re-scored. 
These Kappa coefficients for agreement were higher than those obtained during initial 
scoring of the LCFC scans. This reassured both scorers that improved inter-observer 
agreement could be achieved before undertaking complete rescoring of a randomly 
selected subset of 22 LCFC scans 8 months after initial scoring, although as discussed 
below, this did not prove to be the case.  
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The subset of 22 scans that underwent rescoring was selected by picking out every third 
scan from the list of study participants by LT who was not involved in the scoring 
process; the process thus was not biased towards previously discrepant scans. Inter-
observer agreement between initial and re-scoring LCFC rounds can be seen in Table  
5- vi. When 22 randomly selected scans (re-scoring LCFC round), representing one third 
of the whole cohort were completely re-scored 8 months after completing  the initial 
LCFC round, agreement between scorers was no better than on the first occasion, direct 
comparisons being made  with respect to the same 22 scans on the two different 
occasions. There was fair agreement between scorers for bronchial dilatation and strong 
agreement for air trapping, both during initial scoring of all 65 LCFC scans, and when 
re-scoring the selected subset of 22 LCFC scans (Table 5-vi and Figure 5-iv).  
 
Table 5-vi: Kappa between both scorers at initial LCFC scoring round of whole 
cohort, and at initial and repeat LCFC scoring rounds of a randomly selected 
subset 
 Initial scoring*  
(n=65) 
 Initial scoring† 
 (Subset: n=22) 
Rescoring†  
(n=22) 
Bronchial dilatation  0.21 (0.05; 0.37)  0.38 (0.01; 0.76) 0.24 (−0.27; 0.75) 
Air trapping  0.66 (0.49; 0.83)  0.58 (0.37; 0.79) 0.80 (0.67; 0.93) 
Total CT scores 0.34 (0.20; 0.49)  0.38 (0.13; 0.62) 0.67 (0.48; 0.86) 
Footnote: Results presented as mean (95% CI) linear weighted Kappa coefficient.* 
Entire study cohort of 65 scans.  †scans from 22 infants were selected from the entire 
cohort (n=65 by LT), results of which are summarised for both initial and repeat 
scoring. Rescoring of a subset 8 months later showed no improvement in agreement for 
bronchial dilatation although better agreement was observed for air trapping and total 
CT scores.  
 
Figure 5-v illustrates CT scores allocated by scorers A and B for the subset of 22 scans 
during initial and rescoring rounds. During initial scoring of the subset, scores allocated 
by scorer B were generally higher than those by scorer A for bronchial dilatation and 
total scores (panels a & c). More consistent scores with good agreement were seen for 
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air trapping (panel b). During rescoring of this subset, scores were more similar 
although only fair agreement was again seen for bronchial dilatation (panel d), while 
good agreement was observed for air trapping and total scores (panels e & f).  
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Figure 5-v: Inter-observer agreement between initial and rescoring LCFC rounds 
 
Legend: While all 22 pairs of results have been plotted, overlap of some data, particularly those with zero scores 
means that not all results can be identified individually. Bold circles represent data that overlaid each other, the 
number next to the circles representing the number of infants with each combination of scores.                                  
ĸ= Kappa coefficient (95% confidence interval.) BD: bronchial dilatation. AT: air trapping.
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As can be seen in Figure 5-vi, the 22 scans selected for re-score (panels d-f) were 
representative of those from the entire cohort (panels a-c) in terms of changes detected 
on CT and extent of severity seen. Although scorer B identified a higher incidence of 
changes for all outcomes with respect both to the entire cohort and the selected subset, 
the severity of changes was generally very minor, with only 2(3%) and 7(11%) of 
patients having a total CT score ≥12 (≥5% of maximum score, denoted by the horizontal 
broken line), as can be seen by comparing the left and right-hand panels (c&f). The 
large number of negative (no change/zero total score) means that many data points are 
overlaid. At initial scoring, according to scorer A, no changes were detected for any 
Brody-II components in 31 scans (48%) whilst 7 (11%) of the scans had  no changes 
detected by scorer B.  
 
In summary, during the various LCFC scoring rounds, agreement between scorers in the 
bronchial dilatation sub-score was only fair to moderate whilst within and between 
occasion agreement for the air trapping sub-score was substantial. For the purpose of 
this thesis, since air trapping sub-score and total CT scores were more reliably scored by 
both scorers, these sub-scores will be utilized to investigate the relationship between 
structural changes or changes seen on chest CT and lung function. Despite poor 
agreement between scorers for bronchial dilatation, this CT sub-score will also be 
investigated so that comparison to previous published literature can be undertaken. 
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Figure 5-vi: Comparison of results between two scorers during initial LCFC 
scoring of both entire cohort and the randomly selected subset
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Maximum air trapping (AT) score= 27 
Maximum total CT score= 243 
INITIAL LCFC SCORING (n=65) SUBSET FROM INITIAL SCORING (n=22) 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
Scorer A 
AT= 17 (26%) 
 
Scorer B 
AT= 27 (42%) 
Scorer A 
BD= 2 (9%) 
 
Scorer B 
BD= 5 (23%) 
Scorer A 
AT= 5 (23%) 
 
Scorer B 
AT= 8 (36%) 
Maximum bronchial dilatation (BD) score= 72 
Scorer A 
BD= 5 (7%) 
 
Scorer B 
BD= 17 (26%) 
Legend: Total scores and bronchial dilatation (BD) and air trapping sub-scores allocated 
by both scorers at the initial LCFC scoring round and subset randomly selected for 
rescoring LCFC round. The subset selected was fairly similar to the initial group. 
(f) 
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5.3.4.3 Inter-observer agreement regarding the presence or absence of 
changes detected on CT   
Although the Kappa score was only fair for bronchial dilatation with minimal 
improvement at subsequent scoring, the extent to which scorers agreed about the 
presence or absence of significant bronchial dilatation or air trapping was 
consistently achieved in >80% of the scans on initial and rescoring LCFC rounds 
(Table 5-vii).  
 
Table 5-vii: Inter-observer agreement with respect to presence or absence of 
bronchial dilatation and air trapping during initial and rescoring rounds  
LCFC scans Bronchial Dilatation, n (%) Air trapping, n (%)  
 Present Absent 
Total % 
agreed 
Present Absent 
Total % 
agreed 
initial scoring of 
all 65 scans 
5 (8%) 48 (74%) 82% 16 (25%) 37 (57%) 82% 
initial scoring of 
subset (n=22) 
2 (9%) 17 (77%) 86% 5 (23%) 14 (67%) 90% 
repeat scoring of  
subset (n=22) 
1 (4.5%) 17 (77%) 81.5% 5 (23%) 14 (64%) 87% 
Footnote: In this table, scans with bronchial dilatation or air trapping sub-scores 
>0 were considered as having the presence of bronchial dilatation or air trapping 
respectively, irrespective of the severity of the abnormality.  
 
 
5.3.4.4 Intra-observer agreement of scores over time 
Figure 5-vii presents the scores allocated by the two scorers for the subset of 22 
scans that were rescored 8 months after the initial LCFC scoring round to assess 
intra-observer agreement. Intra-observer agreement after ~8 months was only fair for 
bronchial dilatation [Scorer A: Kappa=0.24 (−0.13; 0.60); B=0.35 (−0.06; 0.76)] but 
strong for air-trapping [A:Kappa=0.72 (0.59; 0.85); B:Kappa=0.72 (0.55; 0.88)]. For 
total CT score, scorer A showed strong agreement while scorer B showed moderate 
agreement [A:Kappa=0.66(0.42;0.90); B:Kappa=0.51(0.29;0.73)]. Both scorers 
detected an identical proportion of changes when re-scoring but those identified were 
not necessarily from the same infants.  
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Figure 5-vii: Intra-observer agreement for scorers A and B when rescoring 
bronchial dilatation, air trapping and total score after an interval of 8 months 
 
 
 
 
 
 
 
 
Legend: Scores allocated by scorer A represented as blue circles and by scorer B 
represented as red circles. Bolder circles represent overlapping results with the number of 
overlapping data next to it. ĸ= Kappa coefficient (95% CI): fair intra-observer agreement 
for bronchial dilatation and total scores (panels a & b and e & f) and strong intra-observer 
agreement for air trapping (panels c & d). Although similar percentages of changes were 
detected on both occasions, the observers did not necessarily detect changes in the same 
infants during the two separate rounds.  
SCORER B 
ĸ=0.35 
(-0.06; 0.76) 
ĸ=0.24 
(-0.13; 0.60) 
 
ĸ=0.72 
(0.55; 0.88) 
 
 
ĸ=0.7 
(0.59; 0.85) 
 
SCORER A  
ĸ=0.66 
(0.42; 0.90) 
 
 
ĸ=0.51 
(0.29; 0.73) 
19 
15 
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 Relationship between ventilatory pattern during anaesthesia 
and CT changes 
As described in chapter 4 (section 4.4), the NICO2
® respiratory monitor was used to 
objectively monitor the ventilation provided during acquisition of CT scans under 
GA. Among the 37 (58%) infants thus assessed, ventilatory pattern was similar 
across the three centres, with the exception of a slightly higher PEEP in Centre B 
(chapter 4, Table 4-iv). There was no apparent relationship between pattern of 
ventilation, including applied PEEP, and any of the CT sub-scores or total score, 
irrespective of scorer. Similarly there was no significant difference in any of the CT 
outcomes between those with or without objective monitoring. There were also no 
apparent differences seen in the scoring results between scans that were performed 
with the original protocol of lower recruitment pressures and the amended protocol 
using higher pressures. Air trapping sub-scores allocated were no different between 
scans that had the limited 3 expiratory images and those that had volumetric 
expiratory images obtained.  
 
 Summary 
No apparent reasons were identified for the variation in scores allocated by each 
scorer during the two training rounds. It did not appear to be related to the severity of 
changes observed as both batches showed similar total CT scores and sub-scores 
(Figure 5-iv and Table 5-iii) although the changes detected in the training batches 
were mild which may account for fair to moderate agreement only. The improved 
agreement with respect to bronchial dilatation during the second training batch may, 
however, be related to the fact that the two scorers had been through the observed 
discrepancies after completing training batch 1 and refined their definition of the 
various abnormalities.  
 
Despite prior training and discussion on training scans with subsequent reasonable 
agreement, when it came to scoring the study CTs of NBS CF infants, agreement 
was only fair for bronchial dilatation, which did not improve when a random 
selection of the original study cohort was re-scored 8 months later. Although good 
reproducibility of air trapping sub-scores was seen between and within scorers, it is 
important to note that despite being present during early CF lung disease,108,109 it’s 
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longer term clinical significance is unknown since air trapping per se is neither a 
structural abnormality nor an irreversible change seen on CT.108 As for total CT 
score, this was also only fair in agreement, although this did improve slightly with 
rescoring. Agreement between the two scorers was better when deciding if bronchial 
dilatation or air trapping was present or absent as a binary outcome as opposed to the 
individual CT scores.    
 
A possible explanation for the apparently better agreement seen during the scoring of 
training scans when compared with study scans may be related to the difference in 
subject’s age and  severity of scans between the training and study scans, this being 
greater in the training scans than in the study population (Figure 5-iv and Table 5-
iii). Within the training scans, bronchial dilatation was detected in 50-67% of scans 
with higher degree of severity whilst air trapping was detected in 50-75% of scans. 
With the LCFC scans, very few abnormalities were detected and when they were 
present, these changes were so mild that they could be interpreted as either normal 
(thus scoring zero) or mild (gaining a score of 1) within and between observers 
sessions (Figure 5-vi). The total percentage with any ‘bronchial dilatation score was 
only 9-26 % depending on who scored the LCFC scans. The better agreement for air 
trapping score during both training and LCFC study scans probably relates to the 
higher proportion of scans showing this abnormality in both sets of data, with air 
trapping being present in 26-42% of the initial LCFC scoring round. The increased 
agreement may also reflect the way in which air trapping is scored when using the 
Brody-II scoring system, whereby a score for either presence or absence of a change 
is allocated in a binary fashion, without the need to measure the size of change to be 
allocated a score. Since time constraints precluded rescoring all scans from the entire 
cohort, a subset of 22 LCFC scans were randomly selected. This rescoring exercise 
demonstrated that, as for the between-observer comparisons performed on the same 
occasion, inter and intra observer agreements of the CT scores over time were only 
fair. 
 
Previous literature160,215 has demonstrated the importance of performing controlled 
ventilation chest CT for standardisation of scans obtained and comparison of 
bronchial size in relation to its accompanying vessel. In this study, variations in CT 
scores are unlikely to have been influenced by variations in ventilatory support as the 
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adherence to protocolised pressures was generally achieved in the three centres, 
especially once procedures were monitored objectively. While findings need to be 
interpreted cautiously due to the limited sample size and large within-centre 
variability, there was no significant between-centre differences in either CT scores or 
pattern of support provided. The challenges faced, even by those with considerable 
expertise in the field, in discriminating very mild changes that could be attributed to 
bronchial dilation or air trapping from normal is illustrated in Figure 5-viii.  
 
Figure 5-viii: Examples of CT images from CF infants showing mild 
abnormalities in bronchial dilatation and air trapping leading to discrepancy in 
scoring 
 
Legend: (a) An example of thin section CT of the right lung in an infant with CF 
taken at 1 year of age showing discrepancies in scoring bronchial dilation (circled). 
This was scored as normal by scorer A, but mild by scorer B during the initial study 
round, whereas during the subsequent re-scoring round ~ 8 months later, scorer A 
scored this as mild bronchial dilatation, while scorer B scored as normal. 
 
 (b) Subtle tiny areas of hyperlucency in some of the scattered secondary pulmonary 
lobules of the lower lobes in keeping with air trapping (ringed by oval). During the 
initial scoring round, scorer A scored this as mild air trapping while scorer B 
labelled it as no air trapping. During the rescoring round, both scorers allocated 
mild air trapping. 
 
 
(a) (b) 
178 
 
With regards to the use of CT as an outcome measure involving CF infants in a 
multicentre study, there are definite challenges to overcome in order to standardise 
the different procedures involved. Nevertheless, with close supervision and objective 
monitoring, adherence to protocols was good and the minor variations which did 
arise in the study did not appear to be of clinical significance. Although bronchial 
dilatation and air trapping were reported in between 9-26% and 26-42% infants 
respectively in this study according to either observer, even when these changes 
were detected, they were very mild. Hence I have disproved the secondary 
hypothesis by demonstrating that most NBS CF infants do not have significantly 
abnormal chest CT at 1 year of age. 
As shown in this chapter, only air trapping sub-score and total CT scores 
demonstrated reasonable reproducibility between both scorers. These scores will be 
compared with lung function results at a year of age to establish if any relationship 
existed between chest CT changes and lung function. Despite poor or at best fair 
agreement between scorers for bronchial dilatation in this age group, comparison to 
lung function will also be explored as bronchial dilatation in previous studies were 
considered to be an established structural abnormality which might reveal better 
correlation with lung function compared to air trapping which strictly speaking is not 
a structural abnormality. The relationship between lung function and CT changes 
will be explored in the next chapter. 
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6 THE RELATIONSHIP BETWEEN CHEST CT 
CHANGES AND LUNG FUNCTION IN NBS CF 
INFANTS AT A YEAR OF AGE: RESULTS 
 
6.1 INTRODUCTION 
Clinical characteristics of the 65 CF infants  (48%) boys who had chest CT (Table 6-
i) were similar to those of the entire group of 72 CF infants who had paired lung 
function measurements at 3m and 1yr as described in chapter 3 (Table 3-iii).  
Median age of diagnosis was 3.4 weeks although one infant was not diagnosed until 
3m of age due to an ambiguous initial neonatal screening result, and in whom a CF 
genotype was only confirmed later. This infant was included in the flowchart in 
chapter 5 (Figure 5-ii) as one of the infants who only had CT and 1-year lung 
function.  
 Clinical characteristics of CF infants who had chest CT 
Chest CT scans were performed at a median age of 52 (range: 43-64) weeks. There 
were no significant differences in anthropometry or lung function at a year of age 
between those who did or did not have a chest CT except for age at 1 year lung 
function testing whereby lung function was assessed, on average, a month earlier in 
those who had CT compared to those who did not have a CT (With CT vs no CT: 
mean difference (95% CI): −4.3 (−7.9; −0.7) weeks; p=0.02) (Table 6-i). This was 
purely due to logistical arrangements in trying to ensure that lung function was 
performed before bronchoscopy which took place generally at 11-12 months of age. 
Hence lung function appointments were prioritised for those who were having CT 
and bronchoscopy in precedence over those who were not having these procedures. 
CF infants not having CT and bronchoscopy were then scheduled for lung function 
slightly later. Apart from their slightly younger age, there were no significant 
differences in anthropometry or lung function between those who did and did not 
have a CT.  
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Table 6-i: Anthropometry and Lung Function in ~ 1 year NBS CF infants with 
or without chest CT 
Infants with CF With CT 
(n=65) 
Without CT 
(n=9) 
Difference (95% CI): 
With and without CT 
Age at lung function test 
(weeks) 
51.8 (4.7) 56.1 (7.8) -4.3 (-7.9; -0.7)*  
Somatic growth    
Weight, z-score 0.34 (0.90) 0.20 (0.84) 0.13 (-0.50; 0.76) 
Length, z-score 0.49 (0.97) 0.37 (1.29) 0.12 (-0.60; 0.83) 
Body mass index, z-score 0.09 (0.84) 0.00 (0.66) 0.09 (-0.49; 0.67) 
Ventilation inhomogeneity    
LCI, z-score  1.08 (1.31) a 1.19 (1.48) -0.11 (-1.05; 0.84) 
Lung Volumes    
FRCpleth, z-score  0.87 (1.25)
 b 0.51 (1.07) 0.36 (-0.51; 1.24) 
FRCMBW, z-score 0.25 (0.25)
 c 0.17 (0.77) 0.08 (-0.53; 0.68) 
Trapped gas, z-score # 1.23 (0.89)  1.30 (0.86) -0.07 (-0.70; 0.56) 
Forced Expiratory Volume and 
Flow 
   
FEV0.5, z-score
 -0.40 (1.07)d  -0.36 (0.65) -0.04 (-0.77; 0.69) 
FVC, z-score -0.52 (1.14) 0.17 (1.15) -0.69 (-1.51; 0.12) 
FEF75,  z-score
  -0.07 (1.00)d -0.00 (0.44) -0.07 (-0.75; 0.61) 
Footnote: Data shown as mean (SD).*p<0.05. aSuccessful LCI, n=64; bSuccessful 
FRCpleth, n=63; 
cSuccessful FRCMBW, 
dFEV0.5, FVC and FEF75, n=62; # Trapped 
gas: estimated from z-FRCpleth − z-FRCMBW. 
There was no difference in lung function or anthropometry between infants who had 
chest CT and those who did not. Hence the chest CT results should be representative 
of the whole cohort and without any significant bias related to those without chest 
CT. 
 
By the time of the 1 year assessment in CF infants, a third had physician-diagnosed 
wheeze, ~10% had evidence of chest crackles and all infants had experienced a 
cough. Only 17% had intermittent cough within 3 weeks of the 1yr ILFT whilst the 
remaining infants tested when well. With regards to additional treatment received 
within the first year, ~11% had had a trial of nebulised DNAse and 32% had had at 
least one course of IV antibiotics for respiratory exacerbations (Table 6-ii).   
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Table 6-ii: Clinical characteristics of CF infants who had 1- year lung function 
and chest CT   
Postnatal age at diagnosis: (weeks) 3.4 (3.0;4.6)a. 
CFTR genotype  classes I-III 54 (83%) 
Presented with meconium ileus 7 (11%) 
Pancreatic sufficient 4 (6%) 
  
Prior to 1 year assessments   
Respiratory symptoms, ever:  
Wheeze, physician diagnosed 22 (34%) 
Crackles, physician diagnosed 7 (11%) 
Cough within 3 weeks of 1 year lung function 11 (17%) 
  
Bacterial growth on cough swab ± BAL, everb  
Pseudomonas aeruginosac 21 (32%) 
Other significant bacterial growthd 18 (28%) 
No growthe 26 (40%) 
  
Additional treatment received  
rhDNase 7 (11%) 
Intravenous antibiotics, number of courses 0 (0; 3) f 
Gastro-Oesophageal reflux treatment 35 (54%) 
Footnote: CF infants with 1 year lung function and chest CT, n=65. Results 
expressed as mean (SD) or n (%) unless otherwise stated. a median (interquartile 
range), bbased on the presence of bacteria ever isolated in the first year. cdefinition 
of colonisation according to Lee et al194; only 2/65 (3%) infants had any evidence of 
PsA on BAL or cough swab within 5 days of the CT scan. d Significant bacterial 
growth consisted of those who had Methicillin Sensitive or Methicillin Resistant 
Staphylococcus aureus (MSSA or MRSA respectively), Haemophilus influenza (HI), 
Stenotrophomonas maltophilia, Acromobacter xylosidans, or Aspergillus fumigatus 
with no previous Pseudomonas aeruginosa growth. e No bacterial growth consisted 
of those with isolation of coliforms and upper respiratory tract flora only. f median 
(range). 
This sub group of the CF cohort who had chest CTs was similar in clinical 
characteristics to the whole CF cohort in this study.
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 Microbiology from cough swabs and BAL 
Among the NBS CF infants who had chest CT, 32% (21/65 infants) isolated PsA 
from cough swabs on at least one occasion during the first year of life. None of the 
infants had chronic PsA infection in the first year of life as defined by the Leeds 
criteria194 
 
Significant bacterial growth on cough swabs within the first year was defined as 
those who had MSSA or MRSA, HI, Stenotrophomonas maltophilia, Acromobacter 
xylosidans, or Aspergillus fumigatus with no previous PsA growth. No infant had 
Burkholderia cepacia. Twenty-eight percent (18/65 infants) had at least one of these 
‘significant’ bacterial infections which were treated with a course of antibiotics. No 
significant bacterial growth apart from coliforms and upper respiratory tract flora 
were isolated in 40% (26/65) of infants (Table 6-ii).  
 
This group of NBS CF infants also underwent flexible bronchoscopy and BAL at a 
year of age. In their 1yr BAL samples, 6/65 (9%) isolated SA of which two were new 
cases of SA, not previously detected in any cough swabs within the first year. Three 
(3/65; 5%) isolated HI, whilst only 3/65 (5%) isolated PsA of which one was the first 
isolation whilst the other two had this isolated on previous cough swabs.  
 
Among the NBS CF infants who underwent BAL, 39/65 also had cough swabs 
performed just prior to the BAL (Table 6-iii). Based on this subset and concentrating 
on the 3 main common CF pathogens (PA, SA and HI), only 3/39 (7%) of the cough 
swabs had positive growth whereas with BAL, 6/39 (14%) isolated positive bacterial 
growth. Of the three infants who had positive bacterial growth on cough swabs, there 
was one infant with PsA, one with SA and another with HI. BAL detected one with 
PsA and SA growth, while another infant only isolated SA. Four infants isolated only 
HI in BAL. All the positive BAL resulted in a new course of antibiotics being 
prescribed for the infants in accordance with the standardised treatment protocol 
(Appendix A7). 
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Table 6-iii: Comparison of bacterial growth isolated in 1 year BAL and prior 
cough swabs in a cohort of 39 NBS CF infants 
Number of infants with the bacterial growth Cough swabs BAL 
Pseudomonas aeruginosa (PsA) 1 1 
Staphylococcus aureus (SA) 1 2 
Haemophilus influenza (HI) 1 4 
Footnote: More infants with significant bacteria were detected on lavage fluid 
compared to cough swab obtained just prior to BAL. Even when both cough swabs 
and BAL had positive bacterial growth, they did not necessarily detect the same 
organisms; swabs and BAL showed poor concordance.  
 
Even when a cough swab taken at the time of the bronchoscopy had positive 
bacterial growth, it did not necessarily reflect the same organism in BAL.   
 
For PsA, no concordance was observed (Table 6-iii); one infant isolated both PsA 
and SA on BAL but not on cough swab although this particular infant had isolated SA 
but not PsA previously in other surveillance cough swabs within the first year of life 
which was treated with oral antibiotics. The other infant isolated PsA on cough swab 
but not BAL which is somewhat surprising. In this case, the infant had isolated PsA 
previously and was already on nebulised colomycin at the time of bronchoscopy. It is 
possible that this infant’s positive cough swab culture was reflective of 
oropharyngeal/ upper airway and not lower airway infection or it may be due to 
regional sampling during the BAL process which may have missed organisms in 
lobes of the lungs that were not lavaged.216,217   
 
For SA, concordance was 50%. The case detected by BAL but not cough swab 
immediately prior to the bronchoscopy had isolated SA on previous routine 
surveillance cough swab within the first year of life which was treated. Despite that, 
at 1yr of age, SA was isolated on BAL. The other child in whom SA was detected in 
both BAL and cough swab was an infant who had previously had SA and PsA on 
routine surveillance swabs and had already received treatment. Although PsA was 
not isolated on BAL, SA was still detected. It was not possible to determine if this 
was the same strain as previous SA in routine surveillance swabs as there was no 
further bacterial typing analysis. 
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For HI, concordance was 25%. There were three cases detected on BAL and not 
cough swabs that were completely new isolates that were not previously detected in 
surveillance cough swabs. One case detected on cough swab at bronchoscopy and 
BAL had isolated HI within the first year on routine surveillance swabs and was 
previously treated with co-amoxiclav. 
 
Therefore, although the number of infants with positive bacterial growth in the BAL 
samples in this study was too small to allow any meaningful interpretation or any 
further statistical analysis, it echoes other studies in the literature showing poor 
concordance between cough swabs and BAL.218,219 Taking into account not just 
cough swabs taken at the time of bronchoscopy but all swabs obtained in the first 
year of life from this subset of 39 infants, the result of BAL at 1 year changed the 
bacterial status in 4/39 (10%) infants (1 had PsA and never before in cough swabs 
whilst 3 had HI on BAL and never before in any swabs).  
 
 
6.2 ASSOCIATION BETWEEN CT CHANGES AT 1 YEAR AND 
CLINICAL FEATURES  
In the previous chapter on scoring results, inter-observer agreement was poor for 
many of the sub-scores, thereby shedding considerable doubt on their reliability. But 
for the purposes of comparisons with the literature in which comparisons have been 
made on basis of one observer only, as well as the fact that despite the poor 
agreement, one scorer’s set of CT scores may demonstrate closer relationship than 
the other. Hence, CF score results were analysed for each scorer independently. 
Despite this, minimal associations with clinical features were found for both scorers, 
and even when these were found, the lack of intra and inter-observer agreement shed 
much doubt on the reliability of CT scoring in young infants. 
 
Based on scorer A’s allocated scores for CT changes, there were no significant 
associations between the presence of bronchial dilatation, air trapping, bronchial wall 
thickening or  mucous plugging with any clinical features including microbiological 
status, presence of clinical symptoms within the first year or additional medication 
use ( IV antibiotics, rhDNase or gastro-oesophageal reflux treatment).  Significant 
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associations did however exist between PsA infection ever during the first year of 
life [Logistic regression coefficient: Odds Ratio, OR= 4.64(1.51;14.26) p=0.01] and 
the use of IV antibiotics [OR=2.27(1.12;4.57) p=0.02] with the presence of 
parenchymal changes sub-score. 
 
Similarly, when based on scorer B’s allocated CT scores, there were no significant 
associations between the presence of bronchial dilatation, air trapping, bronchial wall 
thickening and parenchymal changes with any the of clinical features stated above. A 
history of IV antibiotics use was significantly associated with the presence of 
mucous plugging [OR=3.69(1.18;11.55) p=0.03]. In summary, irrespective of whose 
scores were used, there were minimal associations between changes observed on CT 
and the child’s previous clinical history.  
 
 
6.3 RELATIONSHIP BETWEEN CT CHANGES AND LUNG 
FUNCTION IN NBS CF INFANTS AT A YEAR OF AGE 
Of the 65 infants in whom CT scans were performed, lung function data at 1 year 
were completed for 64(98%)LCI, 63(97%)FRCpleth and 62(95%)FEV0.5. The original 
aim of the study had been to investigate determinants of both total CT score and all 
the individual sub-scores as well as investigating associations between each CT 
outcome and selected measures of lung function. However, given the complete lack 
of reliability for many of these CT outcomes with poor agreement within and 
between observers (section 5.3.4), results in the following section have been limited 
to the relationship between the various lung function outcomes and air trapping sub-
score, total CT score and a binary assessment of whether the specialist observers felt 
that the CT was normal or abnormal based on the presence of any bronchial 
dilatation, air trapping sub-score >6/27 or total CT score ≥12/243 (≥5% of the total 
score).64,107 Despite its poor repeatability, the association between bronchial dilation 
on CT and lung function is also presented to allow comparison with previous 
literature in which this is a frequently reported outcome. In order to ensure the most 
comprehensive investigation, these analyses were undertaken for each scorer and 
also with respect to abnormalities detected by EITHER scorer.  
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Correlation analysis is shown in Figure 6.i, Figure 6.ii and Figure 6-iii.  Lung 
function parameters such as LCI, FRCpleth and physiological gas trapping and FEF75 
may indicate more peripheral or distal airway disease and might demonstrate an 
association with CT air trapping sub-score. In this study, some relationship was 
found for CT air trapping sub-score with LCI, FRCpleth and physiological gas 
trapping but not FEF75. More proximal airway disease such as bronchial dilatation or 
bronchial wall thickening on CT may demonstrate some relationship with FEV0.5 but 
in this study this was not the case. 
 
 Association between CT and lung function results 
While a significant association did exist between both the CT air trapping (Figure 6-
i) and total CT score (Figure 6-ii) allocated by either scorer with several of the lung 
function outcomes, particularly LCI and physiological ‘trapped gas’ (FRCpleth-
FRCMBW), these associations were generally weak and of minimal predictive value in 
individual infants. The correlation coefficients were re-calculated after excluding the 
outlier who had an air-trapping score of ~15 and a total CT score of  >25 (see Figure 
6-i and Figure 6-ii) by both scorers in the presence of lung function outcomes that 
all fell within the normal range but this had minimal effect on results. No apparent 
reasons in terms of clinical characteristics were accountable for the extremely high 
air trapping and total CT scores in this particular infant apart from the fact that there 
was a longer than usual interval (4 weeks delay) between the performance of 1yr 
ILFT and chest CT due to hospital logistical issues. This infant was reported as being 
clinically well during this interval. This was the only case whereby 1yr lung function 
was not repeated before the chest CT when there was an interval time of more than 3 
weeks. There was however no association between bronchial dilatation and any of 
the selected lung function outcomes (Figure 6-iii).  
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Figure 6-i: Association between lung function and air trapping sub-score 
according to each scorer 
 
 
 
 
 
 
 
 
 
 
R= −0.26; 
p=0.037 
R= −0.23; 
p=0.063 
R= 0.43; 
p=0.000 
R= 0.47; 
p=0.000 
R= 0.25; 
p=0.049 
R= 0.16; 
p=0.212 
R= 0.28; 
p=0.025 
R= 0.35; 
p=0.004 
Legend: R= correlation coefficient using Spearman’s correlation; significance 
defined as p<0.05. Physiological gas trapping; FRCpleth-FRCMBW. 
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Figure 6-ii: Association between lung function and total CT scores according to 
each scorer
 
 
 
 
 
 
 
 
 
 
R= −0.22; 
p=0.092 
R= −0.28; 
p=0.030 
R= 0.30; 
p=0.018 
R= 0.40; 
p=0.001 
R= 0.12; 
p=0.351 
R= 0.09 
p=0.510 
R= 0.18; 
p=0.164 
Legend: Correlation coefficient using Spearman’s correlation; significance 
defined as p<0.05; Physiological gas trapping; FRCpleth-FRCMBW. 
 
R= 0.27; 
p=0.029 
B : 
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Figure 6-iii: Association between lung function and bronchial dilatation 
according to each scorer
 
 
 
 
 
 
 
 
 
R=159; 
p=0.207 
R= 0.07; 
p=0.601 
R= −0.22; 
p=0.081 
R= −0.01; 
p=0.951 
R= 0.09; 
p=0.465 
R= 0.16; 
p=0.200 
R= −0.18; 
p=0.153 
R=−0.12; 
p=0.332 
Legend: R= correlation coefficient using Spearman’s correlation; significance 
defined as p<0.05; Physiological gas trapping; FRCpleth-FRCMBW. 
 
orrelation coefficient; ns= non significant 
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 Regression analysis of CT scores and lung function  
In addition to assessing the correlation between 1yr lung function and structural 
changes on CT (Figure 6-i, Figure 6-ii and Figure 6-iii), logistic regression was 
used to measure the size of associations between the presence or absence of 
bronchial dilatation or air trapping with 1yr lung function data and any potential 
clinical determinants. The reproducible dependent variables of interest for relating 
structural changes to lung function were air trapping sub-score and total CT scores at 
a year. These CT scores were non-parametrically distributed and were analysed as 
binary outcome measures (i.e. presence or absence denoted by a change seen on CT 
with any scan of an allocated score >0 contributing towards the category with 
abnormal scan). 
 
When comparing CT and lung function results, multiple imputations was used to 
predict values for any missing clinical or lung function data, using all known 
covariates thought to be associated with 1yr CT scores. This was calculated 
separately for the two different scorers. The observed covariates considered were 
maternal and parental smoking, somatic growth between 3 months to 1 year, 
microbiology results (PsA, significant bacterial growth ever and no growth/ non-
significant bacterial growth ever), respiratory signs (wheeze, crackles and cough) 
and history of treatment with rhDNase, anti-gastro-oesophageal reflux disease 
medication and IV antibiotics for respiratory symptoms; genetic mutation, presence 
of meconium  ileus and/or pancreatic insufficiency and the CT scores allocated by 
each scorer. Twenty imputations were performed using IBM SPSS Statistics v.21. 
The results using multiple imputations were similar to those obtained using list-wise 
deletion.  
 
Table 6-iv shows univariable binary logistic regression analysis using multiple 
imputations for the presence of different CT changes as allocated by either scorer in 
relation to the major lung function outcomes. Significant associations between lung 
function and CT scores allocated by either scorer were only identified between CT 
air trapping sub-scores and LCI and physiological ‘Trapped gas’ [(FRCpleth-
FRCMBW) z-score] at 1yr:   
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 For each unit increase in 1yr LCI z-score, the odd ratios for air trapping on 
CT as identified by scorers A and B were 2.5 (1.3; 4.6); p=0.004 and 1.8 (1.1; 
2.9); p=0.02 respectively.  
 For each unit increase in 1 yr ‘Trapped gas’, the odds ratios for CT air 
trapping were 4.6 (1.7; 12.3); p=0.002 by scorer A and 3.3(1.4; 7.8); p=0.01 
by scorer B. 
No associations were observed between any CT outcome and FEV0.5 and FEF75 z-
scores at 1yr by either scorer, which is not surprising given that most children had 
normal FEV0.5 and FEF75 by that age. In addition, no relationship was observed 
between FRCpleth and the presence of any CT changes as detected by either scorer.  
 
On multivariable analysis of scorer A’s allocated scores using each of the four 1yr 
lung function outcomes (i.e. z-scores for FEV0.5, LCI and FRCpleth and ‘Trapped 
gas’), the only significant association was between CT air trapping sub-score and 
physiological ‘Trapped gas’ z-score, such that for any unit increase in ‘Trapped gas’ 
z-score, the odds ratio (95% CI) for air trapping was: 4.00 (1.09; 14.68); p=0.04); 
similar to results obtained using univariable analysis. No significant associations 
were observed when undertaking the same multivariable analysis using scorer B’s 
allocated CT scores.  
 
In chapter 3 section 3.5.6, significant correlations were found between all 
parameters of lung function at 3m and 1yr of age in NBS CF infants. In this chapter, 
most lung function parameters at 1yr were not significantly associated with chest CT 
changes at 1yr. Only LCI and ‘Trapped gas’ z-scores in the first year were 
significantly associated with CT-air trapping sub-score. Lung function at 3m did not 
show any significant contributions towards chest CT scores by either scorer. Hence 
in contrast to lung function at 1yr, 3m lung function did not predict changes seen on 
chest CT at a year of age. 
192 
 
Table 6-iv: Univariable logistic regression with multiple imputations: Presence or absence of CT changes allocated by scorer A and B 
and 1- year lung function measurements   
Per unit increase 
in 1-year lung 
function  z-score 
Based on 
scorer 
Bronchial 
Dilatation 
Air trapping 
Bronchial wall 
thickening 
Mucous 
Plugging 
Parenchyma 
change 
Abnormal 
scan# 
Total score* 
LCI 
A 
2.0(1.0;3.8) 
p=0.05 
2.5(1.3;4.6)** 1.1(0.5;2.6) 
p=0.82 
1.0(0.4;2.4) 
p=0.94 
1.1(0.8;1.7) 
p=0.94 
1.6(0.7;3.7) 
p=0.23 
−0.1(−1.0;0.
7) p=0.51 
B 
1.2(0.8;1.8) 
p=0.45 
1.8(1.1;2.9)* 1.2(0.8;1.8) 
p=0.44 
2.3(1.0;5.0) 
p=0.05 
0.9(0.6;1.4) 
p=0.62 
1.2(0.7;2.0) 
p=0.47 
0.2(−1.0;1.4) 
p=0.72 
FRCpleth 
 
A 
0.5(0.2;1.2) 
p=0.12 
1.3(0.8; 2.0) 
p=0.36 
2.0(0.7;5.6) 
p=0.20 
1.4(0.5;3.6) 
p=0.55 
1.6(0.8;1.8) 
p=0.51 
0.7(0.3;1.8) 
p=0.47 
0.1(−0.9;1.1) 
p=0.84 
B 
1.0(0.6;1.6) 
p=0.94 
1.6(1.0;2.5) 
p=0.06 
0.8(0.5;1.3) 
p=0.35 
1.2(0.5;3.3) 
p=0.67 
1.3(0.8;2.0) 
p=0.36 
1.0(0.5;1.7) 
p=0.47 
0.1(−1.0;1.4) 
p=0.88 
‘Trapped gas’ 
A 
1.4(0.5;3.7) 
p=0.51 
4.6(1.7;12.3)** 1.4(0.4;4.7) 
p=0.63 
1.1(0.3;4.1) 
p=0.84 
1.4(0.7;2.5) 
p=0.31 
1.0(0.2;4.4) 
p=1.00 
1.0(−0.5;2.6) 
p=0.18 
B 
1.2(0.7;2.3) 
p=0.52 
3.3(1.4;7.8)* 1.1(0.6;2.0) 
p=0.76 
2.3(0.7;7.5) 
p=0.15 
1.0(0.5;2.0) 
p=1.00 
0.9(0.4;2.3) 
p=0.86 
1.0(−1.1;3.1) 
p=0.37 
FEV0.5 
A 
0.7(0.3;1.5) 
p=0.34 
0.6 (0.4;1.0) 
p=0.07 
0.7(0.3;2.1) 
p=0.58 
2.4(0.6;9.5) 
p=0.21 
0.8(0.5;1.2) 
p=0.24 
1.1(0.5;2.5) 
p=0.81 
−0.3(−1.2;0.
6) p=0.52 
B 
0.7(0.4;1.2) 
p=0.25 
0.6(0.4;1.0) 
p=0.05 
0.7(0.4;1.2) 
p=0.24 
0.8(0.3;2.3) 
p=0.70 
0.7(0.4;1.31) 
p=0.28 
0.8(0.5;1.4) 
p=0.49 
−0.5(−1.7;0.
8) p=0.47 
 
Footnote: Dependent variables are CT outcomes presented as a binary outcome (‘Yes’ for any score >0 and ‘No’ for =0) unless otherwise stated.  # Abnormal scan 
defined as presence of any bronchial dilatation or air trapping score >6 or total score ≥12.*Total score as numerical dependent variable and linear regression 
used for this analysis. Independent variables are 1 yr lung function z-scores. Significant associations highlighted in red: *p<0.05; **p<0.01. Results presented as 
odds ratio (95% confidence interval) except for total score, where results presented as mean regression coefficient (95% confidence interval). 
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 Comparison of lung function between NBS CF infants with 
and without CT changes at a year of age 
When comparing lung function at 1yr in infants with (i.e. CT-air trapping sub-score 
>0) and without CT evidence of air trapping, both LCI [mean difference (95% CI) = 
1.33(0.66; 2.00); p<0.0001] and physiological ‘Trapped gas’ (∆FRC) [0.96(0.51; 
1.40); p<0.001) z-scores were significantly higher in infants with evidence of CT-air 
trapping when using scores allocated by scorer A. With scorer B’s allocated  CT-air 
trapping sub-score, infants with evidence of CT-air trapping also had significantly 
increased ventilation homogeneity [mean difference in LCI z-score = 0.89(0.26; 
1.52); p=0.006) and physiological gas trapping [∆FRC z-score mean 
difference=0.76(0.34; 1.18); p=0.001) but in addition, infants with CT air trapping 
had  significant hyperinflation [FRCpleth z-score mean difference=0.63(0.04;1.22); 
p=0.04] and airway obstruction [FEV0.5 z-score mean difference= 
−0.61(−1.16;−0.07); p=0.03] when compared with infants without CT- air trapping 
(Figure 6-iv). 
 
In terms of comparing 1yr lung function with different total CT scores, infants were 
categorised into three groups: Group 1 (G1): zero total CT score i.e. no changes 
detected at all in CT, Group 2 (G2): CT score 1-10 and Group 3 (G3): CT score ≥12,  
i.e. >5% of the maximum Brody-II scores (Table 6-v). With scorer A’s allocated 
total CT scores, significant differences were observed between infants with total 
scores between 1-10 (G1) and those without any changes detected (total score=0; 
(N)) with respect to physiological trapped gas (∆FRC) and FEV0.5 z-scores. There 
were however no significant differences in LCI and FRCpleth between the three 
subgroups. No significant differences in lung function were noted between and 
within the three NBS CF infant groups when using total CT scores allocated by 
scorer B.  
194 
 
Figure 6-iv: Comparing selected 1 year lung function in infants with or without air trapping according to each scorer
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Legend: Comparing selected 1yr lung function of infants as a group; those with or without air trapping as described 
by either scorer. Significant increases in LCI and physiological gas trapping were observed in infants with CT air 
trapping compared to those without as described by scorer A and B. *** p<0.0001;* p<0.05 using unpaired t test 
analysis. A: Scorer A; B: Scorer B; Y: Air trapping present; N: Air trapping not present  
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Table 6-v: Comparison of lung function between infants with different total CT scores at 1 year of age by each scorer 
  Total CT scores by scorer A Total CT scores by scorer B 
 
>12 (G2)* 1-12 (G1)# 0 (N)† 
p value 
(ANOVA) 
Diff 
(95%CI): 
G1-N‡ 
>12 (G2)* 1-12 (G1)# 0 (N) † 
p value  
(ANOVA) 
Diff 
(95%CI):         
G2-N‡ 
LCI, z-
scoreǁ 
0.76 (0.87) 
n=2 
1.49 (1.55) 
n=31 
0.70 (0.93) 
n=31 
0.05 0.79 
(−0.00; 
1.59) 
2.11 (2.01) 
n=7 
1.00 (1.23) 
n=50 
0.67 (0.34) 
n=7 
0.07 
1.44 
(−0.24;3.12)     
FRCpleth, 
z-scoreǁ 
1.60 (0.74) 
n=2 
0.79 (1.23) 
n=32 
0.77 (1.17) 
n=29 
0.64 0.01 
(−0.74; 
0.76) 
0.96 (1.04) 
n=7 
0.85 (1.25) 
n=49 
0.34 (0.75) 
n=7 
0.54 
0.62 
(−0.95;2.19)  
Trapped 
Gas,     
z-scoreǁ 
1.17 (0.01) 
n=2 
1.58 (0.95) 
n=31 
n=1.00 (0.76) 
n=29 
0.04 0.57 (0.03; 
1.12) 
p=0.037 
1.86 (0.96) 
n=7 
1.27 (0.89) 
n=48 
0.87 (0.59) 
n=7 
0.11 0.98 (−0.17; 
2.13)      
FEV0.5, 
z-score  
0.07 (0.48) 
n=2 
−0.80 (1.09) 
n=32 
−0.09 (1.01) 
n=28 
0.03 −0.71(−1.3
7; −0.05) 
p=0.032 
−0.83 (1.30) 
n=7 
−0.50(1.07) 
n=49 
0.44(0.41) 
n=6 
0.08 −1.28 (−0.27; 
0.17)   
 
 
Footnote: CI=confidence interval of the difference; Trapped gas is the difference in FRCpleth−FRCmbw, a measure of physiological gas trapping. 
* based on those 
with total score ≥12 (>5% of the maximum Brody II scores) (G2); #based on those with total score 1-12 (G1); †based on those with no changes detected i.e. total 
score=0 (N). ‡Based on post-hoc Bonferroni adjustment for multiple t tests between and within groups. Assessments of  significant differences using ANOVA was 
limited to comparisons between infants with total scores between 1-12(G1) and those without any changes detected (total score=0 (N) when using scores 
allocated by scorer A due to the extremely low number of infants (n=2) with total score >12 . There were no significant differences in LCI and FRCpleth between 
the subgroups. For total scores allocated by scorer B, no significant difference was noted in any 1 yr lung function parameters between and within the three NBS 
CF infant groups.   
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6.4 SUMMARY OF THE RELATIONSHIP BETWEEN CT 
CHANGES AND LUNG FUNCTION 
When using scores allocated by scorer A, a unit increase in LCI z-score at a year of 
age increased the chance of observing bronchial dilatation by 90% (i.e. odds ratio 
1.9). This relationship was not significant when using scores allocated by scorer B. 
On the other hand, both LCI and physiological ‘gas trapping’ at a year had 
significant associations with the presence of air trapping on CT, with a unit increase 
in LCI z-score increasing the odds of observing air trapping by 1.8-2.5 times 
according to scorer.  In addition, with a unit increase in physiological ‘gas trapping’ 
z-score i.e. (∆FRC), the odds of detecting air trapping was increased by 3.5-4.5 
times.  No significant associations were observed for outcomes derived from the 
RVRTC and the presence of CT changes by either scorer except for scorer B where a 
unit increase in FEV0.5 z-score reduced the chance of seeing air trapping on CT by 
40%.  
 
The use of regression rather than simple correlation analysis allowed the strength and 
size of associations to be determined with confidence intervals around the mean 
estimate whereas with correlation analysis, only a linear relationship would have 
been explored with no measurement of size of impact. In addition, the data were 
non-parametrically distributed with small sample sizes in the modelling process. The 
danger of this was that even if a significant linear relationship existed with 
correlation analysis, this may not necessarily indicate a clinically relevant or 
plausible association. By using regression analysis with appropriate display of 
confidence intervals, it was possible to delineate and decide whether the association 
was potentially ‘clinically significant’, rather than simply being of statistical 
significance as the result of a small sample or biased distribution with just a few 
outliers that skewed the association.  
 
In summary, some NBS CF infants had a few changes on chest CT at a year of age 
though the number and severity of changes seen were low. Even when such changes 
were observed, Brody-II scores were poorly reproducible between and within 
scorers. This demonstrated the limitations of the current scoring system for 
quantifying mild changes in young CF infants as well as the questionable utility of 
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chest CT to detect and quantify structural changes in young NBS CF infants. At the 
time of writing this thesis, no consensus has been reached with regards to the 
definitive CT scoring system to use in NBS CF infants. To provide further 
information in this field, comparison of potential structure-function relationships 
have been presented separately for the two scorers.  As will be discussed further in 
chapter 7 (section 7.4.2), given all the challenges in acquiring standardised chest 
CTs under GA in infants, the lack of robust relationship between lung function and 
structure and the poor inter- and intra-scorer repeatability when scoring chest CT 
scans, these results suggests that, in their current form, chest CTs cannot be 
recommended for either routine clinical use or as a trial endpoint in the first year of 
life in NBS CF infants. 
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7 DISCUSSION 
 
7.1 INTRODUCTION AND SUMMARY OF MAIN FINDINGS 
Limited information about the evolution of lung function in NBS CF infants and the 
need to establish suitable objective outcome measures for the early detection of CF 
lung disease have led to the development of the hypotheses, aims and objectives of 
this study. If a suitable trial endpoint was available, this could potentially enable 
infants to be recruited into future interventional trials.  
 
As stated in chapter 1, section 1.10, the primary hypothesis of this study was that 
NBS CF infants would demonstrate further loss in lung function from diagnosis until 
a year of age hence lung function at a year of age and the change in lung function 
within the first year were compared between NBS CF infants and contemporaneous 
healthy controls. Secondary hypotheses were that significant lung disease could be 
detected through chest CT with significant associations observed between chest CT 
and lung function at a year.  
 
A summary of the main findings in addressing these hypotheses will be presented 
here with further discussion in the following sections (7.1.1 and 7.1.2). 
 
 Diminished lung function at 3m of age in NBS CF infants improved 
significantly in FEV0.5 whilst LCI and FRCpleth demonstrated no further 
deterioration within the first year of life compared to contemporaneous 
healthy controls who demonstrated no change in their lung function in the 
first year. Impaired lung function at 1yr was predicted by lung function at 
3m.  
 
 Chest CT in this study revealed mild CF changes in terms of bronchial 
dilatation and air trapping. No significant association existed between 
bronchial dilatation and any lung function parameters, whilst both CT air 
trapping sub-score and total CT score were weakly associated with LCI and 
physiological ‘trapped gas’ (∆FRC: FRCpleth-FRCMBW). Despite prior training 
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on the Brody-II scoring system, both scorers showed low reproducibility in 
the scores allocated. 
 
 Interpretation of lung function results 
In this observational study investigating the evolution of lung disease in NBS CF 
infants, despite the presence of abnormal lung function by 3m of age, there was 
significant improvement in FEVF whilst maintaining stability in other lung function 
parameters such as LCI and FRCpleth by one year of age. 
 
There was a relatively poor correlation between results from the RVRTC and other 
lung function outcomes (section 3.5.5, Figure 3-iv) reflecting the fact that different 
ILFT identify different types of respiratory pathophysiology. While spirometry is the 
most widely used outcome in older subjects with CF and is a valuable measure of 
airway obstruction within the conducting (proximal) airways, it is known to be less 
sensitive than LCI for detection of mild lung disease in preschool children with 
CF.60,79,85 However, during infancy FEV0.5 has been shown to be a sensitive outcome 
in clinically diagnosed CF infants. This may be due to the relatively rapid lung 
emptying in infancy, such that FEV0.5 often includes expired volume down to low 
lung volumes, and that in the presence of highly compliant chest wall and airways, 
airway narrowing and flow limitation will occur more readily than in older 
subjects.83 While many NBS CF infants were also found to have a diminished FEV0.5 
at 3m age71 by 1 year far fewer NBS infants were identified by the raised volume 
technique than either plethysmography or LCI. This may reflect the mild nature of 
lung disease at 1yr in our NBS cohort when compared with those diagnosed 
clinically and the decreasing sensitivity of forced expiratory manoeuvres to mild 
lung disease as both airway and chest-wall compliance decrease with increasing 
maturity.220  
 
By contrast LCI, as a measure of ventilation inhomogeneity, FRCpleth, as a measure 
of hyperinflation, and ΔFRC (FRCpleth- FRCMBW), as a measure of physiological gas 
trapping, are more sensitive to peripheral airway obstruction and, since they are 
obtained during tidal breathing, are less dependent on developmental changes in the 
chest wall. A further reason for the relatively poor association between spirometric 
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outcomes and LCI is that, at least during the early stages of CF lung disease, the 
latter may simply reflect mucous plugging in the more peripheral airways which 
would not necessarily result in abnormal spirometry. In contrast to the lack of 
correlation between FEV0.5 and other lung function outcomes on either test occasion, 
there were significant associations between LCI, FRCpleth and physiological gas 
trapping (as measured by ΔFRC), all of which are thought to be sensitive measures 
of peripheral airway disease throughout childhood (Table 3-viii). 
 
Recent studies on newborn CF piglets have shed further light on the pathogenesis of 
lung disease in CF.221,222 Newborn CF piglets have air trapping and airflow 
obstruction even before the onset of airway infection, inflammation or mucus 
accumulation compared to non CF piglets. Smaller trachea222 and proximal airway 
lumen size have been found in newborn CF piglets.221 These developmental 
abnormalities may be due to CFTR dysfunction in chondrocytes or airway smooth 
muscle bundles resulting in the reduction of airway size and affecting the 
development of airways in utero. Therefore the authors suggested that congenital 
airway abnormalities might in part contribute to the early airway obstruction and air 
trapping demonstrated in NBS CF infants.67,71 However the improvement observed 
in FEV0.5, a reflection of proximal airway function within the first year of life in 
NBS CF cohort in this study, may suggest that large airway cartilage abnormalities 
seen in CF piglets may not be entirely relevant in humans or completely accountable 
for the initial abnormalities and subsequent improvement in ILFT. Within the first 
year as one would expect continual deterioration if abnormal lung function was due 
to congenital abnormalities. 
 
The likelihood of missing evidence of early lung disease in this study was reduced 
by applying a wide range of tests to assess different aspects of underlying 
pathophysiology.71 Had only one LFT been used in this study, abnormalities would 
have only been detected in ~17% of infants, but this increased to 36% by using LCI, 
FEV0.5 and FRCpleth as the three primary outcomes. Consequently, when selecting 
outcome measures for intervention trials in NBS CF infants,110 reliance should not be 
placed solely on the raised volume technique, since measures of LCI appear essential 
if mild abnormalities are to be detected.  While hyperinflation and gas trapping also 
proved to be sensitive outcomes at 1 year, routine inclusion of these outcomes 
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shortly after birth may be limited both by equipment costs and increased failure rate 
of FRCpleth in young infants (Table 3-iv). These lung function parameters were 
selected in view of the fact that they were sensitive markers for detecting early lung 
disease.  
 
Despite the reduction in the number of infants with abnormal FEV0.5 between 3 
months to one year during this period, the percentage of NBS CF infants with 
abnormal LCI and FRCpleth at 1yr was similar to that at 3m. These were, however, 
not necessarily the same infants. Thus, while impaired lung function at 1yr was 
predicted by lung function at 3m such that assessment of lung function at 3m could 
allow groups of infants most at risk of impaired lung function at a later stage to be 
identified, such tests would be poorly predictive for individual infants .  
 
Clinical determinants such as a history of clinician-diagnosed wheeze (LCI), poor 
weight gain (LCI and FRCpleth) and prior FRCpleth were also useful indicators for 
detecting groups of CF infants most at risk of early lung disease (Table 3-viii). Such 
infants may be potential candidates for early interventional trials as they represent 
those in whom any effects of interventions are most likely to be demonstrated. 
Furthermore, since they represent the sub-set of NBS CF infants most likely to 
benefit from more intensive therapy, parental consent to and compliance with such a 
trial are likely to be enhanced.  
 
Discussion on the clinical implications of these lung function results in relation to 
selecting outcome measures for clinical trials and the calculation of number required 
for trials will be discussed in detail in section 7.4.  
 
 Interpretation of Chest CT results 
There is no consensus on which CT scoring system should be used to quantify the 
severity of changes, particularly in the presence of mild CF lung disease.175 The most 
widely used scoring system is the modified version of the Brody score (Brody-II CT 
score).172 This has been widely validated and used in school-aged children with 
moderate to severe CF and shown to objectively quantify CF lung disease in such 
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children.107,203 However, its use in infants with very mild disease, such as may occur 
following diagnosis by NBS, has yet to be established.  
 
This is the first study specifically to assess the reproducibility, and hence validity, of 
CT evaluation of lung disease in CF infants. Despite scoring being undertaken by 
experienced observers with prior training, with the exception of air trapping, the 
Brody-II score was not reproducible in this age range. The most obvious 
interpretation of these findings is that the mild nature of any CT changes at 1yr of 
age precluded reproducible evaluation of most parameters.   
 
Very few abnormalities were found in this group of CF infants and when present 
were mild in severity. Seventy five percent (50/65) of the scans showed inconsistent 
agreement of the CT scores between both scorers in terms of the abnormalities 
found. Although bronchial dilatation is the best validated and most reproducible 
score in children in other studies,172 this was not demonstrated in this age group of 
NBS CF infants. The only reproducible score between scorers on any one occasion 
or within scorers across time was that relating to CT air trapping which in studies 
involving older NBS CF infants and young children was present relatively 
frequently.108,109,111,223 In the AREST-CF study, although a significant proportion 
(~88%) of infants demonstrated air trapping on chest CT, these changes were not 
consistently present in the first few years of life.108 Therefore, air trapping as a CT 
feature of early lung disease may not necessarily represent or predict irreversible 
structural lung changes. During infancy, it also remains unclear how these changes 
are related to functional abnormalities.  
 
Compared to studies in older subjects64,107,117,154 which have reported good 
correlations between CT changes and lung function results, especially LCI, this 
study on 1yr old NBS CF infants did not show a close relationship between lung 
function and structure. This may be due to the mild structural disease seen in these 
asymptomatic CF infants who were diagnosed early and rapidly commenced on CF 
therapy. Such mild changes did not necessarily result in functional decline, and may 
in fact be reversible. In addition, infants in this age group were tested with sensitive 
methods of lung function that could differentiate and detect subtle changes in lung 
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disease which may not be revealed on CT scans, resulting in the discordant, or lack 
of, relationship between lung function and structure observed in this study. 
 
As for clinical determinants of lung structure, there were no indicators to predict the 
presence of bronchial dilatation or air trapping. This is in contrast to other studies 
which have reported increased incidence of bronchial dilatation with PsA infection 
and wheeze with presence of air trapping on CT scan.109,111 The only associations 
found were between a)  use of IV antibiotics and either parenchymal changes 
detected by scorer A or mucous plugging by scorer B; and b) a history of PsA 
infection within the first year with the parenchymal changes detected by scorer A . 
However parenchymal change and mucous plugging were not reproducible CT sub-
scores as shown in Table 5-iv. Thus irrespective of whose scores were used, there 
were minimal associations between changes observed on CT and the child’s previous 
clinical history. This lack of association likely reflects the very mild nature of CT 
changes observed in these NBS CF infants and the fact that CT represents a single 
snap-shot of the child’s disease when clinically stable. In general, this cohort of NBS 
CF infants were clinically well with significant catch-up growth profile.  
 
In contrast to 1-year lung function outcomes whereby significant associations were 
noted with clinical determinants such as PsA infection, weight gain between 3 
months and birth, presence of wheeze, cough or gastro-oesophageal reflex disease 
ever and the use of IV antibiotics, such clinical determinants were not associated 
with any reproducible CT scores. Hence neither lung function at 1 year of age nor 
clinical determinants were predictive of any CT outcomes. 
 
An informal survey conducted to establish whether CT findings resulted in any 
change in management among the clinicians responsible for the care of these NBS 
CF infants confirmed that very few management plans were instituted based purely 
on the results of the scans. Amongst scans with the most changes seen, only 1 infant 
had a change in treatment while 2 had additional investigations looking for gastro-
oesophageal reflux. Of the 65 infants in whom scans were conducted for this study, 
only 3 (4.6%) infants had a change in management plans following reporting of CT 
results. 
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A label of bronchial dilatation in the presence of very mild lung disease should 
therefore be applied cautiously, at least using current methods and definitions. In 
addition to all the challenges in performing GA and the lack of relationship observed 
between lung function and structure, the poor inter and intra-subject variability when 
scoring chest CT scans suggests that CT in its current form is not ready for either 
widespread clinical use or as a trial endpoint in the first year of life in NBS CF 
infants.   
 
 
7.2 STRENGTHS AND LIMITATIONS OF THE STUDY 
 Strengths 
The major strength of this study was that a large cohort of NBS CF infants and local 
healthy controls were recruited and measured within a 2.5y period by a highly 
experienced team within a single location. With exception of socio-economic 
circumstances which were slightly less favourable among the CF infants than in the 
controls (see below), the two groups were well matched. Maternal report of smoking 
history was validated using cotinine analysis.   
 
All lung function measurements were performed at defined time points using 
ATS/ERS international standards to minimise methodological or analytical bias.57-59 
Furthermore all results, including the LCI, which has now been shown to be 
dependent on body size during early life,58 were interpreted using appropriate 
reference equations. These were derived from  a large number of healthy subjects 
studied with identical equipment and protocols,57-59 over the past decade which 
facilitated accurate interpretation of results. The confidence with which changes over 
time due to CF lung disease could be detected after adjusting for growth was greatly 
increased by serial measures in contemporaneous healthy infants over an identical 
time period and by the extremely high retention rate both for infants with CF and 
controls.224 This increases the power of the study and once results expressed and 
compared as z-scores, it simplifies the statistical analysis between the two groups. As 
mentioned above, the likelihood of missing evidence of early lung disease was 
decreased by applying a wide range of tests to assess different aspects of underlying 
pathophysiology.71 The tidal and RVRTC techniques were always performed at the 
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end of the lung function protocol, to ensure that the subsequent forced expirations 
and/or lung inflations did not bias results from MBW and plethysmography by 
altering ventilation distribution and/or the extent of gas trapping. 
 
In terms of investigating structural changes in NBS CF infants, in addition to being 
the first study to examine the within- and between-observer reproducibility of CT 
scorers, this is the first study to investigate NBS CF infants using both volumetric 
inspiratory and expiratory images which enabled detailed imaging to be performed. 
This method of performing CT is particularly useful for longitudinal assessment in 
research studies as it allows images and airways to be matched for direct 
comparison.168,169,196 Use of both inspiratory and expiratory volumetric scans 
reduced the risk of missing subtle abnormalities, thereby increasing the likely 
accuracy of the reported changes.  
 
Radiation dose was kept to a minimum through expertise from the radiology 
department by altering scanning parameters and individualising scanning ranges of 
infants in order to obtain ‘fit for purpose’ images.157  
 
This study took place at a defined time point of age (1yr) with all CF infants 
diagnosed through NBS. Functional assessment was timed to be close to the 
performance of chest CT when the child was as well as possible, which allowed the 
relationship between structure and function to be investigated under clinically stable 
conditions. This is in contrast to the AREST-CF study whereby 35% of infants 
studied were symptomatic at the test of testing.67 
 
Several challenges in performing thoracic CT in this age group were experienced in 
this study. Despite clear protocols and briefing the anaesthetic and radiology teams 
across all centres, there was variability in the image acquisition parameters in terms 
of airway pressures and radiation doses delivered. The greater variability in radiation 
doses in centre C may be due to the slightly different type of scanner (Table 4-i) 
and/or the fact that it was not possible to organise a dedicated radiographer to 
perform procedures within that hospital, the latter being a problem likely to be 
encountered in clinical practice as well as multi-centre trials. Presence of an 
investigator to monitor all procedures did improve compliance, but is unlikely to be 
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feasible in clinical practice or most clinical trials. This is the only study to ascertain 
pressures delivered objectively through the use of the NICO2
® during controlled 
volume ventilation to obtain volumetric CT images. Therefore, as an essential part of 
designing a multicentre study, considerable effort was invested to ensure that all 
procedures were standardised according to international guidelines. Quality of data 
collection was further enhanced by establishment of a dedicated research team, 
objective measurement of adherence to protocols and my attendance at the majority 
of CTs to ensure the smooth running of these tests. Prior to this study the challenges 
encountered when using CT as a multicentre outcome measure had never been 
reported, let alone any information about adherence to standardised protocols, issues 
that were addressed in this study. 
 
Finally, in this study the use of Brody-II scoring system in infants was evaluated by 
measuring inter- and intra-agreement of scores by two highly experienced scorers. 
These two scorers underwent training using scans from young CF children 
immediately before scoring the LCFC scans so as to ensure consistent interpretation. 
Previous studies involving infants have only reported results from non-validated 
scoring system involving only one scorer.108,148 
 
 Limitations 
7.2.2.1 Recruitment of subjects and study design 
There are inevitably some limitations to this study; the observation period is 
currently short and further follow-up will be essential to establish the clinical 
implications of any abnormalities detected through lung function tests and chest CT 
at 1 year of age. With an observational study, we can only demonstrate association 
not causation of potential determinants of 1 year lung function. Despite the high 
retention of CF and healthy control infants, there were several who were lost to 
follow up for different reasons. Although the CF and control groups were equally 
matched with respect to their background characteristics, there was a significant 
difference with regard to their socioeconomic status. More CF infants were from 
lower socioeconomic groups compared to healthy controls. Some studies have 
suggested that lower socioeconomic group may be associated with a more chaotic 
life style, increased exposure to tobacco smoking and sub-optimal adherence to 
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treatment for the CF families225-227 that could bias the results observed. Since this 
study was not designed to measure adherence we were unable to comment on how 
this would vary with different socioeconomic groups. However, the percentage of 
infants exposed to antenatal, maternal and postnatal household smoking which is 
strongly associated with reduced lung function228 was relatively low and similar 
between the CF infants and healthy controls.  
 
Another potential weakness of the study was that healthy controls were only eligible 
for recruitment if they had no prior history of respiratory symptoms or illness before 
the first baseline study at 3 months. These criteria could potentially mean that the 
cohort of NBS CF infants were compared to a ‘super-healthy’ group of controls 
which is not representative of the general population. This in turn could amplify the 
observed difference in lung function at 3m of age between CF infants compared to 
controls.  The decision to limit recruitment of healthy infants to those without prior 
illness was pragmatic and arose from the need to study all infants within the first few 
months of life.  In contrast to NBS CF infants virtually all of whom were diagnosed 
within the first month of life, it took longer to identify and screen controls to 
ascertain suitability for recruitment (including waiting for GP approval). 
Appointments then had to be organised rapidly, such that there was usually 
insufficient time to wait for at least 3-weeks before re-arranging the lung function 
tests in an otherwise healthy child who developed a respiratory infection, if the ILFT 
were to be performed within the first 4 months of life. Healthy control infants with a 
history of neonatal lung disease, or coexistent heart, lung, neuromuscular or renal 
disease that could impact on the respiratory system were ineligible for the study. 
However once healthy controls infants were recruited and had had their first lung 
function performed at 3m of age, they were not excluded from further follow up 
during the first year of life if they subsequently developed a lower respiratory tract 
infection or wheezing illness, unless this necessitated hospital admission or 
symptoms were chronic. Only 2 healthy control infants were withdrawn from the 
study at a year of age due to chronic respiratory symptoms and none of the healthy 
control cohort had failure to thrive. 
 
At time of study, very few CT scans from 1yr old NBS CF infants were available, on 
which to train.  The lack of normal chest CTs measured under the same conditions 
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from healthy age-matched infants or appropriate controls at a similarly young age for 
comparison with NBS CF infants is an obvious limitation, but one that would have 
been almost impossible to overcome due to ethical issues regarding radiation 
exposure in healthy individuals for a research study. Since clinical CT scans in 
children with normal lungs undertaken for other clinical indications (for example, 
screening for metastases) would not have included volume controlled inspiratory or 
expiratory images under GA unless specifically requested for research purposes, 
even this group would not provide adequate controls.  
 
7.2.2.2 Clinical details of CF infants 
Prospective clinical information with regards to clinical status, antibiotic usage and 
bacterial infections over the course of the first year were collected at regular time 
intervals through CRF sent to me by the respective tertiary centres. In common with 
all multicentre studies such as the current one which recruited CF infants who were 
managed in different tertiary respiratory centres, it was difficult to be absolutely 
certain that there was complete adherence to the standardised treatment protocol. 
Consequently, it is possible that some variation in treatment across different centres 
might have influenced the evolution of lung disease. There was variation in the 
number of CRFs submitted for each CF infant from the different centres. In order not 
to miss any vital information on clinical status, bacterial infection and treatment the 
CF infants would have received, I gathered additional clinical information from 
clinic letters, annual review letters, parental study questionnaires obtained during 
lung function testing and where possible, respective hospital microbiology 
laboratory results. 
 
In the CRF, as parental identification of wheezing was more difficult, no 
quantification of this symptom was asked except for whether the infant wheezed or 
not. The fact that identification of wheeze was based on parental identification 
without any formal training or use of video sleep questionnaires rather than being 
physician-diagnosed; is a potential weakness of this study. Cough swabs were taken 
from CF infants, who were seen regularly once every 2 months in respiratory clinics. 
Additional cough swabs were undertaken whenever respiratory symptoms were 
reported. Since cough swabs were analysed in the different microbiology 
laboratories within the tertiary respiratory centres and shared care clinics, the 
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accuracy of bacterial isolation could have potentially been influenced by the use of 
non-standardised microbiological analyses of cough swabs.  Nevertheless even 
though there was a wide range of cough swabs obtained, at least four were collected 
per child in the course of the year which was compliant with local hospital guidelines 
on obtaining surveillance cough swabs in CF children. 
 
When 1yr lung function results were compared among the 4 CF centres who 
recruited most of the CF infants (RLH, GOSH, RBH and KCH), there were no 
significant differences between the groups in terms of 1yr LCI, FRCpleth, FEV0.5 and 
FEF75 z-scores. This suggests that even if there were slight variations from the 
standardised treatment protocol that were not apparent from the CRFs, this did not 
result in any major differences in primary outcome measures at a year (Table 7-i). 
However it is important to be aware that numbers in each group were small and the 
study was not powered to detect anything other than large differences between the 
different centres.   
 
Table 7-i: Table showing 1 year lung function results among the 4 main CF 
centres 
1 year 
ILFT       
(z-scores) 
Centre 1 
 
Centre 2 
 
Centre 3 
 
Centre 4 Overall 
LCI 
n 
1.3 (1.1) 
11 
1.0 (1.1) 
16 
1.0 (1.2) 
31 
0.9 (1.7) 
11 
1.0 (1.2) 
69 
FRCpleth 
n 
0.8 (1.0) 
11 
0.6 (1.1) 
17 
0.6 (1.2) 
30 
1.0 (1.1) 
10 
0.7 (1.1) 
68 
FEV0.5 
n 
-0.6 (0.9) 
11 
-0.4 (1.2) 
17 
-0.5 (1.0) 
29 
-0.1 (0.9) 
10 
-0.4 (1.0) 
67 
FEF75 
n 
-0.1 (0.6) 
11 
-0.1 (1.0) 
17 
-0.0 (0.9) 
29 
-0.2 (1.3) 
10 
-0.1 (0.9) 
67 
Footnote: Lung function results presented as mean (SD). Using ANOVA for 
comparison between the different centres, no significant differences were detected 
for any of the 1yr outcomes. n= number of successful tests. 
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7.2.2.3 Technical challenges in acquiring standardised CTs 
Despite clear protocols and briefing the anaesthetic and radiology teams across all 
centres, there was variability in the image acquisition parameters in terms of airway 
pressures and radiation doses delivered. The greater variability in radiation doses in 
centre C may be due to the slightly different type of scanner (Table 4-i) and/or the 
fact that it was not possible to organise a dedicated radiographer to perform 
procedures within that hospital, the latter being a problem likely to be encountered in 
clinical practice as well as multi-centre trials. Presence of an investigator and/ or 
dedicated radiographer and anaesthetist whenever possible to monitor all procedures 
improved compliance, but is unlikely to be feasible in clinical practice or most 
clinical trials. It would also be unrealistic to completely standardise all CT scanners 
used in the different centres. When these potential limitations were recognised in the 
design of the study and during the first few months of data collection, every effort 
was made to address these issues through rigorous objective monitoring. 
 
7.2.2.4 CT scoring system 
Another limitation of this study was the time and expertise involved in the use of the 
Brody-II scoring system. A CT scan scored through Brody-II is time consuming, 
especially in scans with significant and numerous CT changes where it can take up to 
30mins to score each scan. Ideally all the scans in this study would have been re-
scored after 8 months, but this was precluded by time constraints – this exercise 
being limited instead to the subgroup of 22 LCFC scans. Fortunately, the random 
selection of scans for re-score several months later proved to be representative of the 
whole cohort. Due to the time-consuming nature of the reproducibility studies, no 
other CT scoring system was used, but given that most CT scoring system use 
components which overlap with Brody-II, it is unlikely that results would have been 
very different. 
 
The Brody –II scoring system in its present format has limitations in scoring minor 
CT changes such that with study scans, changes in bronchial size were so mild and 
subtle that both scorers changed their minds with regard to the score allocated during 
different scoring rounds. Furthermore, measuring changes in small bronchial luminal 
size in young infants to define bronchial dilatation may be beyond current CT spatial 
resolving ability, resulting in the whole scoring process becoming a real challenge. 
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7.3 COMPARISON WITH THE LITERATURE 
 Clinical status 
The percentage of NBS CF infants in this study with at least one infection of PsA 
within the first year of life was 35%. The median age of first infection with PsA was 
27.7 weeks (range: 6.1-52.4 weeks.). By the first year ILFT, only 1 infant had 
chronic PsA infection, defined by the Leeds criteria.194 The incidence of PsA found 
in this study is comparable to that reported previously, which ranges between 9 to 
42% in the first 2 years of life,229 depending on the clinical status at time of 
sampling54,230,231 and type of microbiological samples (cough swab, sputum, 
BAL).219,232  
 
Anthropometric measurements in NBS CF infants were significantly lower 
compared to contemporaneous healthy controls despite early detection through NBS.  
This LCFC NBS cohort demonstrated improved somatic growth compared to the 
previous LCFC clinically diagnosed cohort.233Comparable to previous studies on the 
nutritional benefits of NBS,29,39,234 significant catch up growth took place such that 
by a year, there were no differences observed between LCFC NBS CF infants and 
healthy controls.  
 
 Infant lung function studies 
Results regarding evolution of early lung disease in CF infants diagnosed by NBS 
have been conflicting (Figure 7-i). The AREST-CF study has reported both normal82 
and reduced67 ILFT in such infants within the first 6 months of life, with further 
rapid deterioration over the first year of life (mean FEV0.5 being -2.4 z-scores by 
~1yr of age). 
 
In the current study, lung function was abnormal by 3m,71 but stabilised or improved 
thereafter. As can be seen from Figure 7.i, 1yr lung function in the LCFC NBS 
cohort was significantly better than that in previous clinically-diagnosed LCFC 
cohorts60,83 or in the AREST-CF NBS cohort at similar age.67,82 Reasons for the 
discrepancies between our results and those for AREST-CF are unclear. While the 
standardised protocol adhered to by the LCFC differs in some respects from that 
used by most centres in the USA, Australia and Europe (e.g., use of flucloxacillin 
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prophylaxis), the results should be a benchmark for other centres, and could serve as 
the basis for quality improvement.235 Median age at first test in this study is younger 
than that in AREST-CF, which may reflect earlier diagnosis and implementation of 
treatment within the narrow geographical area of S.E England from which infants 
were recruited for this study, thereby halting progression of any early lung disease. It 
is possible that infants recruited to AREST-CF were sicker, or deteriorated faster due 
to differences in modifier genes, environment or adherence to treatment, when 
compared with those in London. Most importantly, in contrast to the current study, 
AREST-CF data were not compared with contemporaneous controls, historical 
controls being used initially,82 with subsequent results (obtained using higher 
inflation pressures67) being interpreted using reference data based on different 
equipment, which can bias interpretation.55,57   
 
Figure 7-i: Comparison of current lung function results in infants with cystic 
fibrosis and healthy controls  
 
Legend: Comparison of current lung function results in infants with CF and healthy controls 
(C) at ∼1yr of age, with previously published results. NBS: newborn screening. Data 
expressed as mean (95% CI). To allow direct comparison with previously published studies, 
Lung Clearance Index is presented in absolute units, whereas FEV0.5 is expressed as z-
scores, based on different reference equations according to each author. The dashed 
horizontal line at 0 z-scores equates to 100% predicted based on a healthy population. 
Control data were not available in all studies. 
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In keeping with the study by Lum et al in clinically diagnosed CF infants which 
found elevated levels of LCI in the first year of life83, Belessis et al demonstrated in 
a prospective cross-sectional study that it has the ability to detect pre-symptomatic 
disease in NBS CF infants and very young children (≤ 3 years of age). Fifty five CF 
(mean age: 1.96 years) and 36 healthy control (mean age: 1.26 years) infants and 
young children showed good repeatability and reproducibility of LCI in both groups 
and LCI was elevated in CF compared to healthy control infants. This study also 
demonstrated greater airway inflammation and elevated LCI in those with PsA 
infections.86 Another study published by the AREST-CF team using the same 
commercially available, ultrasonic device, found similar LCI readings as the Belessis 
et al study even though LCI was not significantly associated with CT air trapping or 
bronchiectasis in NBS CF infants in contrast to what have been published in older 
children and adults. 121 When interpreting published data using commercial devices, 
discrepancies can occur between studies due to the fact that only prototype versions 
of the commercial device were available at the time of testing, with frequent 
amendments of software and algorithms236 that would require substantial re-analysis 
of results. This can lead to discrepant results between different devices, despite being 
produced by the same company.237 
 
In the US multicentre evaluation of infant lung function, compared to historical 
healthy controls, CF infants showed significantly diminished flow [FEF75 z-score; 
mean (95% CI): -0.52 (-0.78; -0.25)] and elevated lung volumes [FRCpleth z-score; 
mean (95% CI): 1.92 (1.39; 2.45)]; with no reductions seen in forced expiratory 
volumes. Although some hyperinflation is expected, it is somewhat surprising to see 
the extent of elevated FRCpleth without corresponding reduced airway function. This 
might be related to the quality of the test centres in performing these tests. The low 
success rate for RVRTC measures due to great variability in skill-mix and 
experience of the laboratories and hence measurement acceptability rates in lung 
function results could account for the lack of abnormal results seen in forced 
expiratory volumes. Furthermore lung function results were only compared to 
historical controls in this study. Hence the feasibility of performing different ILFT is 
important to take into account when considering it as a multicentre clinical trial 
endpoint.   
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While improvements in lung function following treatment with IV antibiotics for 
acute exacerbations in 11 infants with CF have been demonstrated in a retrospective 
study;118  the current LCFC study of NBS infants is the first to document 
improvements in FEV0.5 in infants treated with standard therapy, studied during 
periods of clinical stability. The prospective Infant Study of Inhaled Saline (ISIS) in 
Cystic Fibrosis trial reported greater increases in FEV0.5 over a 48-week period in 22 
infants and young children treated with hypertonic saline compared with 23 
randomised to isotonic saline (mean (95% CI) difference:38(1-76) mL).229,238 
However, from the data presented, it was impossible to ascertain whether this 
reflected stability, improvement or simply less deterioration over time with active 
treatment, once effects of lung and somatic growth had been accounted for. The 
authors did not discuss the reason why results were not expressed as z-scores which 
would have accounted for growth.  
 
A small group of infants and preschool children in the ISIS trial also underwent LCI 
measurements using mass spectrometry and SF6 in one centre. The authors 
concluded that all infants in this pilot study had normal LCI. All except one infant on 
hypertonic saline showed stabilisation of LCI whilst those treated with isotonic 
saline showed worsening of LCI during the 48 weeks trial. As for pre-schoolers, 
those on hypertonic saline showed an improvement in LCI compared to those on 
isotonic saline; however there is a great variation in the LCI results within each 
individual. Findings suggested a beneficial treatment effect but this is a small study 
comprising of only 25 patients, 12 on hypertonic saline and 13 on isotonic saline.238 
Despite the apparent improvement in infant lung function in this subgroup of CF 
infants, the use of inhaled hypertonic saline compared to isotonic saline did not 
reduce the rate of pulmonary exacerbations over the treatment period.  
 
  Comparison of CT findings 
Use of different scoring systems makes direct comparisons difficult, particularly 
when attempting to quantify severity of changes. While changes could be identified 
on at least one Brody-II sub-score in 34/65 (52 %) of the LCFC infants, the 
magnitude of these changes was often trivial. Important changes (defined either by 
215 
 
visual inspection and/or a total CT score ≥5% maximum possible) were only 
detected in 2% of infants by scorer A and 11% by scorer B (Table 5-v).   
 
Although AREST-CF detected chest CT changes in 81% of NBS CF infants at a 
median age of 3.6 months, bronchial dilation was only found in 11/57(19%) at this 
age,109 and remained low through the first two years of life (~8% at both 1 and 2yrs 
of age) before increasing markedly to ~36% by 4yr.111 In the most recent publication 
from this group, prevalence of bronchial dilatation in CF children during the first 
4yrs of life was ~60%,19,239 ~80% of whom had evidence of bronchial dilatation at 
some time during the first 3 years. Bronchiectasis as classically defined refers to 
irreversible dilatation due to damaged bronchi.  The “apparent improvement” in 
bronchiectasis reported in some of the AREST-CF children could be associated with 
mild and borderline normal bronchi (see below). The AREST-CF studies also report 
more air-trapping (67% at ~4m,109 62% at ~1y111 and 69% at ~3y19) than in the 
current study. These discrepancies may be partially explained by the fact that in 
contrast to the AREST-CF study, LCFC children were only studied when 
asymptomatic. Bronchial dilatation was significantly more likely (60.0% vs 10.2% in 
asymptomatic) and more severe in AREST-CF infants with respiratory symptoms at 
the time of CT.109 In this LCFC study, all the infants were tested close to their first 
birthday whereas in the AREST-CF study most infants were studied at a slightly 
older age. While not emphasised in the various reports from the AREST-CF study, 
only minimal changes CT were detected at around 1 year of age, the increase in 
frequency and severity commencing beyond 2-3 years of age.   
 
7.3.3.1 Comparison of inter and intra-observer agreement for CT scores 
with previous studies 
The poor inter-observer agreement when using Brody-II in NBS CF infants contrasts 
markedly with previous studies in older subjects (including those in which scorers A 
and B participated, Table 7-ii). Previous studies have found bronchial dilatation to 
be the most reliably reproducible element when evaluating CF lung disease.154,172,240 
The poor agreement in the current study likely reflects the subtlety of changes 
observed. A single scorer scored all the AREST-CF scans with good intra-observer 
agreement after a 6-12 month interval.111 (Table 7-ii) Separate assessments for 
younger children in whom bronchial dilatation was infrequent and milder were not 
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however reported. While use of a single dedicated observer to score all scans 
109,111,241 could provide more consistent outcomes, such an approach is impractical in 
clinical practice and unlikely to be either generalisable or feasible in large multi-
centre trials. In the absence of measures of repeatability, the extent to which inter- 
and intra-observer variation contributes to reported CT findings in other studies 
cannot be established.  
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Table 7-ii: Comparison of measures of within- and between-observer variability used in the current and selected previous studies 
Study Current study Brody*172 Owens†107 Brody*151  
 
De Jong 154  
 
Stick109  
Population 
studied 
NBS CF 
NBS and clinically 
diagnosed CF 
Clinically 
diagnosed CF 
Clinically 
diagnosed CF 
Clinically 
diagnosed CF 
NBS CF 
Age: years ‡ 1.0 (0.1)   10.5 (0.7)   7.8 (1.3)   6-10  § 5-52 § 1.1(0.3-3.3)║ 
Scoring 
system 
Brody-II Brody-II Brody-II Brody-II Brody-II Specific** 
Measure of 
variability 
Between 
Obs kappa 
Within Obs 
kappa 
Between Obs 
variability   
Within Obs 
variability 
Between Obs  
Kendall's tau 
Within Obs 
kappa 
Between Obs  
ICC  
Within Obs 
kappa 
Bronchial 
dilatation 
0.21 0.24/0.35 0.04 0.06 0.77 0.64 0.88 0.64 
Air trapping 0.66 0.72/0.72 0.07 0.04 0.59 0.55 0.27 0.55 
Footnote: *Studies included scorer A as an observer. †Studies including scorer B as an observer.  Obs = Observer; ICC = Intraclass correlation 
‡Age at time of CT scan, expressed as mean (SD) unless otherwise stated. § Age expressed as range. ║Age as median (inter-quartile range) ** 
AREST-CF CT scoring system  
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Additional problems in interpreting CT scans relate to lack of international 
consensus on how to define bronchial dilation, especially in infants. A broncho-
arterial ratio (BAR) >1 as specified in Brody II was used both in the current study 
and AREST-CF. This speeds up evaluation as judging whether the bronchus is 
bigger than the adjoining vessel can be assessed subjectively more easily than 
calculating a ratio. It has been suggested that a threshold of 0.76, rather than 1, 
should be applied in children137,167 but given the poor inter- and intra-observer 
agreement even when using BAR≥1 in infants with mild CF lung disease, it is 
unlikely that this would be effective without the use of calliper measurements which 
would be time and labour intensive. This would limit its use as an outcome measure 
in multicentre studies. Furthermore measuring changes in small bronchial luminal 
size to define bronchial dilatation may be beyond current CT spatial resolving 
ability. The accuracy of assessing BARs, especially in health, is also critically 
dependent on reliably achieving full lung inflations. Therefore it is vitally crucial for 
any multi-centre study to obtain standardised CT for accurate and consistent 
interpretation. 
 
7.3.3.2 Methodological differences in acquiring chest CT in infants and 
young children  
To date there is no consensus on the optimal method of acquiring CT scans in young 
children to ensure maximum information with minimal radiation exposure. 
Following discussions with the AREST-CF team, the approach of obtaining end-
inspiratory scans at 25 cmH2O PIP and end-expiratory scans at 0 cmH2O, together 
with recruitment manoeuvres to minimise procedure-related atelectasis were 
undertaken. However, in this study a volumetric technique that images the entire 
lung volume was used in contrast to the initial studies by AREST-CF where only 3 
thin-slice scans were obtained during inspiration and expiration.109,111,241 Volumetric 
imaging should enable fewer changes to be missed.169,196 Limiting the dataset to 3 
images, compared to ≥20 for the volumetric technique, severely limits the number of 
airways that can be evaluated and matched for comparison in longitudinal studies, 
such that if bronchi were sampled and imaged at the point of bifurcation, this would 
over-estimate the size of the bronchial lumen, potentially leading to over-detection of 
bronchial dilatation. This may have contributed to the differences in reported CT 
changes between this study and those published by AREST-CF. 109,111,241 In addition 
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concerns about radiation exposure warrant further studies to elucidate the minimum 
number of CT slices required for optimum evaluation of early CF lung disease at the 
lowest possible radiation burden. 
 
Volumetric CT scanning in infants and young children requires sedation or GA if 
lung volumes are to be standardised within- or between centres during image 
acquisition. Images obtained at varying lung volumes can greatly affect the reporting 
of changes detected on CT thus creating inaccuracies both within individuals studied 
longitudinally and between subjects studied within and between centres. If 
inspiratory images were obtained not at TLC, this may underestimate the bronchial 
dilatation sub-score while air trapping sub-score may be underestimated if expiratory 
images were obtained not at FRC. Without standardisation, any changes reported 
may not be a true reflection of the extent of disease in patients but rather a result of 
the technical variation during imaging. However, the optimum inflation pressure at 
which to acquire standardised lung volumes has yet to be ascertained.  
 
7.3.3.3 Association between lung function and CT changes 
Compared to studies in older subjects64,107,117,154 which have reported good 
correlations between lung function outcomes, especially LCI, and CT changes, Hall 
et al showed that among 49 NBS CF infants studied at one of the CF centres in the 
AREST-CF study, air trapping on chest CT was only weakly associated with 
moment ratios as a measure of ventilation inhomogeneity, and not with LCI.121 In 
this LCFC study on 1 year old NBS CF infants, there was lack of close relationship 
between lung function and structure. This may be due to the mild structural disease 
seen in these asymptomatic CF infants who were diagnosed early and rapidly 
commenced on CF therapy. Such mild CT changes did not necessarily result in 
functional decline, and may in fact be reversible.108 In addition, infants in this age 
group were tested with sensitive methods of lung function that could differentiate 
and detect subtle changes in lung disease which may not yet be detected through CT 
changes. Hence a discordant or lack of relationship was observed between lung 
function and CT changes in this study.  
 
In the study by Belessis et al, no chest CT was performed. Structural changes were 
described using the CF-specific CXR scoring system. Only mild structural lung 
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disease was identified on CXR which could not be distinguished between CF 
children with infection and those without. There was no correlation found between 
LCI and CXR structural changes as very few changes were detected. In the 
multicentre study by Davis et al, there was no chest CT performed for comparison. 
 
 
7.4 CLINICAL IMPLICATIONS  
The need for sensitive measures to be developed for the detection of early CF lung 
disease is crucial. CF lung disease starts early in life139 and often progresses even in 
the absence of clinical symptoms. With the emergent therapeutic options and 
increasing drug development,5,7 it would be important for infants and young children 
to be involved in clinical trials involving these therapeutic options to halt disease 
progression. Other than the ISIS trial,229 there is no single randomised controlled 
trial in infants or pre-school children, so all recommendations are based on the 
weakest level of evidence, namely consensus documents. To choose appropriate 
outcome measures in infants and young children for interventional trials is extremely 
challenging as not only are these measurements complex and time consuming to 
undertake, but pulmonary changes may be so mild that any tests performed may be 
unable to differentiate between those due to disease and those associated with 
ongoing lung growth and development in this age group, unless very large numbers 
of subjects are studied.  
 
Clinical endpoints such as respiratory exacerbations were not explored in this thesis. 
Defining these clinical endpoints is both challenging and complex within the CF 
adult population let alone among infants and young children when often many of 
these criteria do not apply. Therefore for the purpose of this thesis, only infant lung 
function and chest CT changes were explored as objective outcome measures.   
 
 Infant lung function tests as an outcome measure 
Results in this study have implications for both clinical practice and research. This 
study indicates that despite early diagnosis and rapid implementation of therapy, 
including prophylactic antibiotics, a substantial number of NBS infants with CF have 
abnormalities of lung function within the first 3m of life. The apparent wellness of 
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the cohort should not lead to complacency, and prompt and aggressive treatment of 
any abnormal symptoms or signs is vital.  
 
Although ILFT represent only one of the potential outcomes that can be used during 
early life,110 with additional information gleaned from inflammatory markers and 
CT,242 they represent the mainstay of clinical management and a major outcome in 
randomised controlled trials in both older children and adults. Since lung function 
tracks from late infancy into later life, in both clinically diagnosed CF60,102 and non-
CF cohort studies130,132 accurate identification of early abnormalities is imperative. 
Furthermore, given the increasing number of centres undertaking ‘clinical’ ILFT,243 
the current study may facilitate more meaningful interpretation of results by 
providing vital evidence regarding the natural changes that can occur over time in 
both healthy infants and those with lung disease, in the absence of any specific 
interventions. How well ILFT tracks from early infancy especially in those 
diagnosed through NBS is still unclear.  
 
Even when both physiological gas trapping and CT air trapping are present at a year, 
they are likely to represent dynamic changes dependent on current or recent clinical 
status which may be reversible with standard treatment during infancy. It is possible 
that abnormalities in lung function and CT changes in young infants are more readily 
reversible than when observed in older subjects. Based on this observational study, 
24 CF infants had abnormal FEV0.5 or LCI identified at 3m but by a year of age, 
14/24 (58%) of these infants normalised both FEV0.5 and LCI. This would have 
meant that more than half of the infants would have been unnecessarily treated if 
they were commenced on specific treatment in an interventional study based on 
abnormal lung function at 3m. This throws doubt on the use of lung function testing 
as outcome measures during infancy and raises the question as to whether objective 
lung function monitoring should wait until the preschool years. 
 
We have shown that both lung function and somatic growth during the first year of 
life are significantly better in infants diagnosed by NBS in the UK than in their 
counterparts who were clinically diagnosed a decade earlier60,83 (Figure 7-i). It is, 
however, of concern that LCI remains abnormal at 1yr (Figure 7-i), albeit to a mild 
degree.83  Further follow-up is required to establish the extent to which these changes 
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predict later outcome beyond infancy. Nevertheless, in this study, normal lung 
function was sustained in at least 50% NBS CF infants to 1yr of age. The significant 
improvement in FEV0.5 and stability of distal airway function during early life when 
on ‘standard therapy’, and the relatively small deficits in lung function in NBS CF 
infants at 1yr have important implications for design of future randomised 
intervention trials in this age group. Despite considerable within-subject variability, 
the main predictor of lung function at 1yr was that at 3m, allowing us to identify a 
‘high-risk’ group who could potentially be targeted for future intervention trials.   
 
Using data from this study, results from ~ 85 infants per arm would be required to 
detect relatively small differences in lung function (i.e. equivalent to 0.5 z-scores 
which equates to differences of ~ 4-7% depending on outcome) that might occur in 
response to an intervention if unselected NBS CF were recruited to such a trial.  By 
contrast, were recruitment to such a randomised controlled trial limited to a ‘high 
risk group’ (i.e. abnormal ILFT by 3m, see Table 7-iii and Table 7-iv), a larger 
treatment effect would be expected, with only 22 infants per arm being required to 
detect a difference of 1 z-score (equivalent to ~ 9% for LCI), with 90% power. Such 
an approach could optimise recruitment since not only would parents of infants with 
early lung function abnormalities be more likely to consent, but this approach would 
minimise exposure of children to unnecessary side effects with potentially little to 
gain from therapy.  
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Table 7-iii: Summary of anthropometry and pulmonary function at ~3 months and 1 year in CF NBS infants with normal and abnormal 
lung function on the 3-months test occasion versus healthy controls 
  
At 3 months 
 
At 1 year 
 
Abnormal* (A) Normal† (N) Controls (C) 
p value  
(ANOVA)
 ‡ 
 Abnormal* (A) Normal† (N) Controls (C) 
p value   
(ANOVA)
 ‡ 
n 19 45 37  19 45 37  
Age, weeks§ 11.1 (2.3) 11.1 (2.2) 11.9 (2.0) 0.22 55.0 (5.1) 51.7 (5.3) 53.5 (4.5) 0.05 
Weight, z-scoreǁ −0.67 (0.89) −1.00 (1.07) −0.03 (0.97) <0.001 0.36 (0.80) 0.25 (0.95) 0.51 (1.29) 0.56 
Length, z-scoreǁ 0.12 (0.92) −0.40 (0.96) 0.67 (0.93) <0.001 0.76 (0.98) 0.28 (0.96) 0.73 (1.25) 0.11 
LCI, z-score  1.22 (1.85) 0.51 (0.91) 0.37 (0.89) 0.03 1.64 (0.98) 0.78 (1.23) 0.31 (0.97) <0.001 
FEV0.5, z-score −2.29 (0.79) −0.71 (0.80) −0.13 (0.77) <0.001 −0.67 (0.95) −0.24 (1.04) 0.13 (0.94) 0.02 
Footnote: Comparisons between groups were undertaken using ANOVA. Dataset used for this analysis were limited to those infants with technically 
successful LCI and FEV0.5 results on both test occasions. 
* (A): based on those with abnormal LCI and/or FEV0.5 at 3m (i.e. outside the 95% limits of 
normality found in healthy infants); †(N): based on those with normal LCI and FEV0.5 at 3m.
 §corrected for gestational age; ǁcalculated according to Cole 
et al182 
 ‡Based on post-hoc Bonferroni adjustment for multiple t tests between and within groups. Significant difference in anthropometry at 3m identified by 
ANOVA was seen between healthy controls and CF infants with abnormal or normal ILFT at 3m (Table 7-iv). There were no significant anthropometric 
differences between the two subgroups of CF infants, nor between those with abnormal or normal lung function and controls at 1 year. Significantly 
reduced lung function was found between those with abnormal lung function and healthy controls at 3 months which persist to 1 year of age.  
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Table 7-iv: Comparison of anthropometry and pulmonary function at ~3 months and 1 year between CF NBS infants with normal and 
abnormal lung function at 3 months and healthy controls. 
 At 3 months At 1 year 
 Diff (95%CI):A-N* 
p value 
Diff (95%CI):N-C* 
p value 
Diff (95%CI):A-C* 
p value 
Diff (95%CI):A-N* 
p value 
Diff (95%CI):N-C* 
p value 
Diff (95%CI):A-C* 
p value 
Age, weeks† -0.02 (-1.30; 1.25) 
0.97 
-0.77 (-1.70; 0.15) 
0.10 
-0.80 (-2.07; 0.46) 
0.20 
3.3 (0.38; 6.16) 
0.028 
-1.79 (-3.94; 0.37) 
0.10 
1.48 (-1.35; 4.31) 
0.29 
Weight, z-score‡ 0.34 (-0.19; 0.86) 
0.620 
-0.97 (-1.42; -0.52) 
<0.001 
-0.64 (-1.16; -0.11) 
0.018 
0.10 (-0.37; 0.57) 
0.66 
-0.25 (-0.76; 0.25) 
0.32 
-0.15 (-0.71; 0.41) 
0.59 
Length, z-score‡ 0.52 (0.004; 1.04) 
0.048 
-1.07 (-1.49; -0.65) 
<0.001 
-0.55 (-1.08; -0.02) 
0.041 
0.48 (-0.06; 1.02) 
0.082 
-0.45 (-0.94; 0.04) 
0.076 
0.03 (-0.59; 0.64) 
0.93 
LCI, z-score  0.71 (-0.21; 1.63) 
0.12 
0.14 (-0.26; 0.54) 
0.49 
0.85 (0.12; 1.58) 
0.023 
0.87 (0.28; 1.45) 
0.005 
0.46 (-0.02; 0.95) 
0.059 
1.33 (0.787; 1.89) 
<0.001 
FEV0.5, z-score -1.57 (-2.01; -1.13) 
<0.001 
-0.59 (-0.93; -0.24) 
0.001 
-2.16 (-2.61; -1.71) 
<0.001 
-0.44 (-0.98; 0.11) 
0.11 
-0.36 (-0.80; 0.07) 
0.10 
-0.80 (-1.34; -0.26) 
0.005 
Footnote: Dataset used for this analysis were limited to those infants with technically successful LCI and FEV0.5 results on both test occasions. 
CI=confidence interval of the difference; A: CF infants with abnormal LCI and/or FEV0.5 at 3m; N: CF infants with normal
 LCI and FEV0.5 at 
3m; C: controls *Based on student’s t-test; †corrected for gestational age; ‡calculated according to Cole et al 182; significant differences are 
shown in bold. 
When the CF cohort was subdivided into those with normal or abnormal lung function at 3m, there was a greater significant difference detected 
between those with abnormal lung function results compared to healthy controls which may be important in designing interventional trials (in 
grey shaded boxes).  
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Thus a trial designed to detect a 1 z-score improvement in lung function in response 
to an intervention would only require 22 infants in each arm for 90% power at the 
5% significance level. Nevertheless, since abnormalities at 3m were only observed in 
30% of our infants when based on the 2 most feasible PFTs (LCI and FEV0.5), after 
allowing for attrition and exclusions it would still be necessary to access a 
population of (22 x 2) x (100/62) x (100/30) i.e. ~237 NBS CF infants to obtain 90% 
power in a RCT. This is more than double the number identified in the South-East of 
England over a 2.5 year period during the present study and would hence inevitably 
require a multi-centre study if to be completed in a timely manner. This adds to the 
body of evidence that if ILFT is used as an outcome measure, such a study would 
require multicentre collaboration for adequate number of patients to be recruited. 
 
 Chest CT as outcome measure 
In terms of the evaluation of chest CT changes seen in early CF lung disease, results 
from this study suggest that both the acquisition and interpretation of CT scans need 
further evaluation before being applicable either as a clinical tool or research 
outcome measure in NBS CF infants at least at a year of age. This study highlighted 
the complexities involved in obtaining standardised best quality images that are fit 
for accurate interpretation. It also revealed that only half of NBS CF infants had any 
changes seen on chest CT, and of these the majority of changes were very mild. 
There is currently no knowledge about the long-term clinical significance of such 
mild changes in young infants with CF, nor any data to suggest that mild changes 
lead to alterations in clinical management or long term clinical outcomes. It is 
questionable whether the risks of exposing young infants to additional ionising 
radiation currently outweigh the benefits.  
 
An informal survey conducted to establish whether CT findings resulted in any 
change in management among the clinicians responsible for the care of these NBS 
CF infants within the LCFC collaboration confirmed that very few management 
plans were instituted based purely on the results of the scans. Amongst scans with 
the most changes seen, only 1 infant had a change in treatment, while 2 had 
additional investigations looking for gastro-oesophageal reflux. Hence out of the 65 
scans conducted in this study, only 3 (4.6%) infants had a change in management 
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plans. As a result of the findings in this study, none of the respiratory paediatricians 
who participated in the LCFC study of NBS CF infants are performing chest CT 
unless clinically indicated.  
 
With increased longevity of CF patients, repeated use of chest CT to monitor 
progression has raised concerns especially in growing children.176,244 Consequently, 
there have been several studies conducted to establish the relationship between LCI 
and structural CT changes, as both are considered sensitive. Older CF children 
diagnosed clinically with significant changes seen on CT have demonstrated a 
correspondingly high LCI.64,107 The prospect of LCI being a potential surrogate 
marker for changes observed on CT is exciting as MBW can potentially be 
performed across all ages. By using LCI as a screening or monitoring tool of CF 
lung disease, the number of CT scans performed could be reduced hence minimising 
the risks associated with repeated radiation exposure. However, whether this 
approach could be extended to infancy would depend on how well LCI tracks 
between infancy and later childhood and the availability of robust commercially 
available equipment for assessing LCI during the first few years of life. Preliminary 
analysis of this NBS CF cohort suggests that LCI tracks poorly from early infancy to 
2 years of age.245 These issues will be discussed in detail in the following sections 
7.5.1 and 7.5.2.  
 
In contrast to other studies which have reported increased incidence of bronchial 
dilatation with PsA infection and wheeze with presence of air trapping on CT 
scan,109,111 in this study there were no indicators to predict the presence of bronchial 
dilatation or air trapping.  Although the use of IV antibiotics was associated with 
parenchymal changes in scorer A and mucous plugging in scorer B and a history of 
PsA infection within the first year significantly associated with parenchymal changes 
by scorer A only; both parenchymal change and mucous plugging were not 
reproducible CT sub-scores as shown in Table 5-iv. In contrast to 1yr lung function 
outcomes whereby significant associations were noted with clinical associations such 
as PsA infection, weight gain between 3 months and birth, presence of wheeze, 
cough or gastro-oesophageal reflex disease ever and the use of IV antibiotics, such 
clinical determinants did not appear to be associated with any reproducible CT 
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scores. Hence neither lung function at 1yr of age nor any clinical determinants were 
associated with CT outcomes. 
 
As a research endpoint, there is an international momentum advocating the use of 
chest CT as a sensitive objective measure of early CF lung disease.110 Until 
refinement of CT scoring has been established and validated for mild disease, 
caution should be exercised when reporting bronchial dilatation in NBS CF infants, 
the incidence of which appears low in the first year of life. If CT changes are used as 
outcome measures in their current form, based on the incidence of bronchial 
dilatation detected by both scorers in this study, between 190-850 infants per group 
would be required in order to detect a reduction in bronchial dilatation by 50% in the 
interventional group with 90% power at 5% significance level at 1yr of age, this 
number rising further after accounting for those ineligible for such a trial or whose 
parents decline.191 It should be noted that recent suggestions that such a study would 
be feasible with only 100/group were based on incidence of bronchiectasis at four, 
not one year of age.111 Ensuring standardisation in the performance of chest CT and 
obtaining images in multicentre studies for scoring must be considered carefully. In 
this study, formal monitoring during the GA process took place during CT imaging 
which was useful to show the variation that could potentially occur across different 
centres. If imaging was to be used as outcome measure in a multicentre study, it 
would be impractical and labour intensive to have formal monitoring of the GA 
process across different centres. Therefore the utility of these tests during infancy 
requires rigorous investigation if they are to be employed in interventional studies 
involving infants. 
 
Determining useful outcomes as clinical trial endpoints whether ILFT or CT have 
been much more difficult than we had previously envisaged. Using lung function or 
chest CT as outcome measures will require a large population to adequately power 
the study in view of the mild abnormalities detected in this NBS CF cohort. Besides 
there is uncertainty about the long term tracking of these mild changes detected 
during infancy. It may be safer to defer novel CF therapies with potential toxicity to 
the growing lung beyond the first year of life. 
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7.5 UNANSWERED QUESTIONS AND FUTURE RESEARCH 
 The evolution of lung function beyond 1 year of age 
In this LCFC NBS CF study, lung function was already impaired compared to HC 
infants by 3m of age despite early diagnosis through NBS and early intervention to 
optimise respiratory and nutritional support. One year after the positive diagnosis, 
significant improvement was observed in some measures of airway function. It is, 
however, of concern that LCI remains abnormal at 1-year (Figure 7-i), albeit to a 
mild degree. The need for long term follow-up to evaluate the significance and 
consistency of outcomes during infancy requires a major ongoing effort. Further 
funding has already been obtained from the CF Trust and Action Medical Research 
to follow-up this cohort of NBS CF infants and HC to 2yrs of age using ILFT under 
sedation, and from 3 years upwards in awake children using specially adapted 
preschool tests to assess LCI, plethysmographic specific airways resistance and 
spirometry.  
 
Preliminary analysis of data from 55 CF NBS and 28 healthy control infants who 
have completed 3 tests occasions  to date ( 3m, 1yr and 2yrs) (Table 7-v) has been 
completed recently.245,246 Mildly elevated LCI and FRCpleth at 3m remained stable 
from 3m to 1yr with no further deterioration by 2yrs even though LCI and FRCpleth 
were on average higher in CF than in HC across all three tests occasions. In contrast, 
a significant reduction in FEV0.5 was only evident at 3m of age in CF NBS infants 
with significant improvement observed from 3m to 1yr such that by 1 and 2 yrs, 
FEV0.5 was comparable between CF NBS and HC infants.  Sustained improvement 
in FEV0.5 was evident to 2yrs of age in CF NBS infants. Thus far, this is also the first 
study to demonstrate stable lung function to 2 years in NBS CF infants managed on 
standard CF therapy.245,246   
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Table 7-v: Lung function results (in z-scores) at 3 months, 1 year and 2 year in 
CF NBS infants 
 Mean (SD) Difference mean (95% CI) 
3m 1y 2y 1y-3m 2y-1y 
Z-FEV0.5  −1.4 (1.1) −0.4 (1.1) −0.4 (1.0) 1.0 (0.7;1.3)* 0.0 (−0.3;0.3) 
Z-LCI 0.7 (1.3) 1.0 (1.2) 0.9 (1.0) 0.3 (−0.1;0.7) −0.0 (−0.4;0.4) 
Z-FRCpleth 1.0 (1.0) 0.9 (1.0) 1.0 (1.5) −0.2 (−0.5;0.2) 0.2 (−0.2;0.5) 
Footnote: Results from healthy controls are not shown in the table. Results highlighted in 
bold denote significant difference (p<0.05) in lung function between CF and healthy 
controls at the three test occasions and the interval change between the test 
occasions.*Represent significant difference observed in FEV0.5 in CF infants at 1 yr to 3m 
(p<0.001). 
 
Although tracking of lung function may be present in clinically diagnosed CF 
infants60 and children102 this does not appear to be so clearly demonstrated in this 
NBS CF cohort. As shown in Figure 7-ii, as a group analysis, there was weak 
correlation in LCI from 1yr to 2yrs with better correlation observed in FEV0.5. 
Figure 7-iii demonstrates individual lung function measurements of CF infants with 
abnormal lung function detected at 3m of age and the evolution of lung function 
within the first 2 years. For individual patients, variation in lung function was 
evident in the first two years of life. Lung function at 1yr was not predictive of that 
at 2yrs of age. These inconsistencies suggest that perhaps lung function should wait 
until preschool years for objective outcomes. These results are currently being 
prepared for publication. 
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Figure 7-ii: Association between 1-year and 2-year lung function in NBS CF 
infants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R=0.2 
R=0.5 
 
Legend: Cross plots showing LCI (a) and FEV0.5 (b) at 1yr vs 2yrs of NBS CF cohort. 
R: Correlation coefficient using Pearsons correlation analysis. 
(a)Those with abnormally high LCI at 1-year all normalised such that none was 
abnormal by 2yr (green box), yet those with abnormal LCI at 2yr all had normal LCI at 
1yr (brown box). (b)Those with abnormally lower airway function at 1yr all normalised 
by 2yr (green box) whilst those with low airway function at 2yr were normal at 1yr 
(brown box). Hence lung function at 1yr is not predictive of that at 2yrs. 
(a) 
(b) 
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Figure 7-iii: Longitudinal lung function results of CF infants with abnormal 
lung function at 3months 
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Legend: (a &b)Majority of CF infants who had abnormally high LCI and FRCpleth z-score 
at 3m  of age improved by 1yr with sustained improvement seen at 2y. (c) All with 
abnormally low FEV0.5 z-score improved significantly at 1yr with normal airway function 
by 1yr which was sustained through to 2yr.  
(a) 
(b) 
(c) 
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Although spirometric measurements have long been recognised as a valid surrogate 
measure for lung disease in the older CF population and have been shown to be 
related to structural lung damage and clinical parameters such as pulmonary 
exacerbations,145,155 quality of life247 and survival,248  it is well recognised that they 
are relatively insensitive to early CF lung disease.77,85,102 While LCI has been shown 
to be more sensitive in detecting early lung disease than spirometry64,83,90,107 with 
more centres advocating its use for clinical purposes and as a clinical trial endpoint, 
the long term clinical implication of an abnormal LCI has yet to be established. 
Among clinically diagnosed CF children, preschool LCI predicted the LCI at school-
age.102 It will be important to continue to monitor LCI in these NBS CF infants 
beyond the first year of age to ascertain whether the same evolution can be observed 
in the NBS cohort. LCI and physiological gas trapping (∆FRC) may represent 
dynamic changes dependent on current or recent clinical status which are reversible 
with appropriate treatment. This would make LCI and ∆FRC potentially sensitive 
short term measures for monitoring response to an intervention but would make 
them less suitable for predicting long term prognosis.  
 
Despite our attempts only to study children when well, the effects of any 
exacerbations may last several weeks and it is possible that mild abnormalities in 
lung function in infants and young children primarily reflect the current clinical 
status with respect to airway inflammation and/ or mild obstruction and ventilation 
inhomogeneities due to mucus and secretions, and as such are far more reversible 
than when such changes are observed in later childhood. Further research, including 
follow up through the preschool and school-age years is essential to address these 
uncertainties.  
 
 Future validation studies of commercial lung function 
equipment  
The ability to undertake longitudinal studies during infancy is currently limited by 
the time consuming nature of the tests and the need for sedation. Equipment required 
for infant lung function testing has cost implications. In the past, most MBW studies 
were performed using mass spectrometry and SF6 as a tracer gas, both of which are 
available only in specialist centres. This has impeded the universal use of MBW 
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technique to measure ventilation inhomogeneity. Reference data for LCI are limited 
when using commercial equipment in infants and young children and are currently 
only available from assessments over a limited age range using SF6 in infants.
105  
 
There are three commercially available recording systems (ultrasonic mainstream 
Exhalyzer D Ecomedics,86 ultrasonic sidestream EasyOne Pro Lab NDD,249 and 
infrared Innocor Innovision91) that are potentially available for use in children. In 
view of the different deadspace or response time, measurements are currently 
possible for children from at least 5 years of age for the two ultrasonic systems and 
from 10 years of age with the infrared system. Modifications to these commercially 
available systems are required for their use in younger children and infants. Rigorous 
quality control is essential for consistent reporting of lung function results if these 
systems are to be utilised for clinical or research purposes.237 Studies involving older 
children and adults are available using nitrogen washout with the ultrasonic 
systems72,249 whilst the infra- red system is based on the use of SF6 as inert gas 
washout.91 Only the Exhalyzer D Ecomedics system has been modified for use in 
infants based on SF6
86,121 but recent adaptations have been designed to allow this 
system to be applied to infants using nitrogen washout.250  
 
As mentioned in chapter 1 (section 1.4.2.3), the influence of hyperoxia during 
nitrogen washout on the respiratory control of infants is unclear. In a recent study by 
Singer et al,250 CF and HC infants (n=31; age range 3-13 weeks were studied during 
natural sleep whilst older infants (n=8) age range of 13-14 months were sedated with 
chloral hydrate) were prospectively allocated to protocols comprising of classical 1-
step nitrogen washout protocol with a switch from ambient to 100% oxygen or to a 
new 2-step protocol, introducing infants first to 40% oxygen for 30 breaths before 
the introduction of 100% oxygen. LCI was measured using a mainstream ultrasonic 
flow meter (Exhalyzer D, Ecomedics). This is the first published study to report the 
feasibility of using this approach in healthy and CF infants even though it does 
influence the ventilatory control of infants. However if infants were first introduced 
to 40% oxygen prior to the nitrogen washout with 100% oxygen, this appeared to 
induce tolerance to hyperoxia with less impact on the quality of tidal breathing. The 
preliminary safety result looked promising and will warrant further work to 
investigate the use of nitrogen washout commercial systems in infants.  
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A recent study has compared N2-LCI using the Exhalyzer D and SF6-LCI using 
Amis 2000 mass spectrometer in 62 HC and 61 CF children from 3-18 years old.251 
In CF children, N2-LCI was higher than SF6-LCI and the difference in values found 
between the two systems was double that seen in HC which in contrast demonstrated 
good agreement between the two systems. There was a clear bias towards 
disproportionately higher LCI obtained through N2 washout than SF6; the higher the 
mean values were for LCI, the higher the discrepancy. The authors concluded that 
although both systems have similar discriminative power and repeatability, values 
obtained by both systems were not inter-changeable. Any future studies should 
include independent normative values. It would simply be inappropriate and 
scientifically unfounded to switch from SF6 to N2 LCI without further validation 
studies. Important issues such as problems associated with the indirect measurement 
of nitrogen, the physiological effects of pure oxygen in young children and infants 
and the back diffusion of nitrogen from blood and tissue within the time frame of a 
normal washout test must be addressed.  
 
In addition to utilising commercial systems for MBW tests, there are research studies 
in progress to determine the possibility of reducing testing time for MBW which will 
be particularly useful when measuring infants and pre-schoolers. Adult MBW 
guidelines recommend three technically acceptable tests with FRC values within 
10% whilst preschool guidelines recommend two such tests for the calculation of 
LCI. No recommendations were made for infants although for the purpose of this 
study and other validation studies, three technically acceptable tests were used. 
Robinson et al252 in a retrospective study demonstrated that if adult MBW guidelines 
were used in paediatric subjects, LCI would not be routinely applicable across the 
paediatric age range and would lengthen the test session. Using two technically 
acceptable tests irrespective of FRC repeatability did not significantly affect the 
mean LCI or compromise the sensitivity of the test to detect abnormal peripheral 
airway function in CF subjects. The findings from this cohort will need further 
replication and corroboration in other cohorts using cross sectional and 
interventional study designs and in other disease groups. The ability to shorten test 
duration without compromising quality would be beneficial for incorporating the 
assessment of MBW for routine clinical testing protocol.    
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 The evolution of mild chest CT changes and its clinical impact 
Bronchiectasis and trapped air are important components of end stage CF lung 
disease.253 Total CT scores and other sub-scores (except bronchiectasis sub-score) 
have been shown to improve with treatment in previous studies.144,147 Although 
strictly speaking bronchiectasis is irreversible structural change, the AREST-CF 
longitudinal study has shown improvement in the bronchiectasis sub-score.108 This 
‘apparent improvement’ in bronchiectasis suggests that when changes are very mild, 
there may still be reversible. Therefore if changes observed were so mild in NBS CF 
infants that they normalised within a year, the clinical impact associated with these 
CT changes may not be significant enough to justify exposing all CF infants to a 
routine clinical chest CT at such a young age.  
 
Before chest CT can be advocated for widespread usage, especially in infants and 
very young children, standardised CT scanning protocols, which can be readily 
applied across multiple centres are also essential. Given the radiation burden and the 
costly expense of even limited, low dose annual CT scans, it is essential to ensure 
that information obtained is useful. Indeed there is a strong case for a randomised 
controlled study of whether CT actually improves outcome, analogous to the recent 
Australasian bronchoscopy study.254 It will be important to study the effects of 
antibiotics, mucolytics or disease modifiers in the development of bronchiectasis to 
further validate the response to treatment. It would also be necessary to demonstrate 
the effect of an intervention on the CT score and to predict the effect on true clinical 
endpoints such as respiratory tract infections and quality of life which have been 
seen in a few studies involving older children and adults.145,148,149,155,169,248  
 
Furthermore, the clinical significance of  ‘mild’ changes detected on chest CT  is not 
known and would require repeat follow up scans to monitor the evolution of these 
CT changes, which in itself has ethical implications with respect to subjecting CF 
infants to potentially unnecessary ionising radiation without current evidence of any 
real benefit. This highlights the urgent need for a randomised study in assessing the 
usefulness of routine clinical CT scans in infants and young children. There are 
currently several international consensus groups who are trying to tackle the 
problems associated with standardising the acquisition of images, establishing 
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scoring systems for mild disease for clinical monitoring255 or investigating the 
feasibility of CT as an outcome measure in trials.52,110,136,256   
 
 Validated CT scoring system as trial endpoint in infants 
Although emerging technology may allow high quality volumetric inspiratory and 
expiratory chest CT images to be obtained at low radiation doses, image analysis 
remains problematic. This study has shown that due to the mild subtle changes 
observed, scores from the commonly used Brody- II CF CT scoring system, were not 
reproducible in NBS CF infants at a year of age and hence not suitable as a research 
trial endpoint in such infants. A more robust approach to CT scoring in CF infants 
may be required. Analysis strategies that can identify early disease more sensitively 
than dichotomous outcomes for a given abnormality may reflect disease 
heterogeneity better than a crude discrete score with low resolution. International 
collaborations are investigating improved scoring systems for documenting mild 
disease. Current relatively subjective methods by expert scorers could be augmented 
by publishing visual standards for comparison or by the more widespread use of 
formal airway measurements and quantitative assessment of air-trapping through 
semi or fully automated scoring software.147,257 While expert visual scoring like the 
Brody scoring system may include more features of CF lung disease than can be 
evaluated by automated software, it is time consuming, labour intensive and limited 
by the number of expert scorers. In contrast, automated computer analysis does not 
require specially trained scorers which may avoid inter-observer bias and variability, 
offer better standardisation and may be more sensitive in detecting subtle changes.257 
Automated systems are able to report on the number of visible airways seen 
especially in the periphery which may be a surrogate of bronchiectasis on CT scans, 
whilst air trapping due to small airway obstruction may be indicated by abnormally 
low attenuation on expiratory CT images which have been quantified using a variety 
of lung density approaches.147,167,257,258 Such systems may improve the accuracy of 
chest CT as a surrogate endpoint. However, currently available automated 
quantitative scoring systems are still in their infancy and require extensive validation 
in CF patients of all ages, during both cross sectional and longitudinal studies. 
Furthermore, whether CT changes are scored by expert observers or through 
automated CT software, it is extremely important to establish what CT changes are 
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clinically relevant, which changes are responsive to the different interventions and 
the time taken for these changes to occur; hence necessitating the need for future 
comparative and longitudinal studies to establish the trends of different CT features 
over time. A greater understanding of these CT changes may allow the development 
of suitable inclusion and exclusion criteria during the recruitment process as well as 
the study design for interventional trials involving different therapeutic options259 
using CT as trial endpoints.   
 
 Magnetic resonance imaging of chest as a possible imaging 
modality 
Magnetic resonance imaging (MRI) of the chest is gaining popularity as a radiation 
free imaging modality and has been shown to be comparable to chest CT in detecting 
morphological changes in children and adults with stable CF lung disease.260 In a 
study involving 35 CF patients from infancy to adults (range 0.5- 42 years, mean 
15.3 years, median 15 years with interquartile ranges 8-20 years) with a wide 
spectrum of CF lung disease, MRI scores allocated were reproducible for a wide 
spectrum of disease and were equally reproducible at milder end of the disease 
spectrum. In addition, MRI scanning has the added advantage of being able to assess 
functional changes such as pulmonary perfusion260 through the use of contrast during 
scanning which may allow differentiation between reversible and irreversible lung 
changes.  
 
The use of hyperpolarised helium MRI may provide high resolution images of lung 
ventilation that correspond to ventilation inhomogeneity measured through gas 
washout methods. In a study of 4 CF patients (age 11.8 [SD 2.9] years with FEV1% 
predicted 95[13]), preliminary results showed that ventilation abnormalities were 
observed more readily using hyperpolarised helium MRI compared to LCI or 
conventional lung function tests, hence suggesting the possibility of using such an 
imaging modality for detecting early CF lung disease.261 Although more validation 
work is underway in the field of MRI and CT imaging, more research is still needed 
to correlate MRI findings with CT images and lung function, and to correlate 
changes seen on imaging with long term clinical outcomes, especially in infants and 
young children with early and mild disease where this form of imaging may be 
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particularly useful. However, before the use of such an imaging technique becomes 
common place, it is important to realise that its use will be limited by the lack of 
specialised facilities and the high costs involved for utilising this sort of imaging for 
routine clinical care. 
 
 
7.6 FINAL CONCLUSIONS 
NBS for CF allows early diagnosis and implementation of treatment to optimise 
nutrition and pulmonary health, potentially leading to a marked improvement in the 
prognosis of CF. In this study, despite early diagnosis and protocol-driven treatment 
in specialist centres, abnormal anthropometry and lung function were evident in 
many NBS CF infants by 3m of age. Increased ventilation inhomogeneity, 
hyperinflation and diminished airway function were observed in CF infants 
compared to contemporaneous HC.  Contrary to my primary hypothesis of continual 
deterioration in lung function within the first year, most CF infants showed marked 
improvements in spirometric measures of pulmonary function with no further 
deterioration in measures of ventilation inhomogeneity and gas trapping. 
Improvement in growth profile was seen such that no anthropometric differences 
existed when compared with HC. The majority of NBS CF infants in this study 
revealed minor or no bronchial dilatation and air trapping on CT at a year. Minimal 
associations existed between CT changes and lung function with weak correlations 
reported between CT air trapping score with LCI and physiological “Trapped gas”. 
The clinical significance of this association is not well understood and will require a 
longitudinal follow up before these findings can be interpreted appropriately. Hence 
secondary hypotheses have also been disproved through results arising from this 
study. 
 
Parental attitudes to involvement in this study were positive, and both recruitment 
and retention of subjects were excellent,191 providing important evidence for the 
design of future early therapeutic intervention trials aimed at minimising or 
preventing lung disease in young children with CF.  
 
Treatment has normally been targeted at the downstream consequences of CFTR 
dysfunction, but there has been a shift to develop genotype class-specific therapies. It 
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seems likely that these novel therapies will be most effective in early stage disease, 
before irreversible airway damage has developed. It is therefore essential to 
understand the evolution of lung function in NBS CF infants given standard 
treatment, in order to determine objective outcomes or trial endpoints. Through this 
study, lung function changes observed were mild. Furthermore, CT scoring of mild 
changes was poorly reproducible with different scorers and at different times. 
Despite increasing interest in the use of chest CT either clinically or as a trial 
endpoint,110 this cannot be recommended for NBS CF infants in the first year of life 
until refinement of CT scoring has been established and validated in this age group. 
 
Choosing correct trial endpoints for different interventions is vitally important as the 
methodologies used should be tailored to individual trials and the interventions 
studied. Adequately powered intervention studies that use objective measures of lung 
function and structure in an unselected cohort of infants will therefore need to be 
much larger than previously thought. It may be safer to defer novel CF therapies 
with potential toxicity to the growing lung until beyond the first year of life when 
objective measures may be carried out more easily in the preschool years. Ongoing 
follow up of the current cohort through to school age will help address the important 
question of whether detailed assessments of lung function, structure and 
inflammation in the first year of life help to predict future outcome. 
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Introduction 
Aim 
Methods 
•High Resolution Computed Tomography (HRCT) of  the 
chest has been advocated as sensitive surrogate 
measure of early  CF lung disease  
•Bronchiectasis and gas trapping have been reported in 
CF Newborn Screened (NBS) infants in AREST-CF 1,2 
•Brody-II CT scores have been validated and used 
objectively to quantify CF lung disease in children but its  
use in infants is not yet established 3  
To score HRCT scans from CF NBS infants using Brody II 
scoring system and assess inter-observer agreement 
• Prospective observational study of CF NBS infants 
recruited 2009 - 2011 across 6 London centers  
• Chest HRCT under general anaesthesia at 1y of age at 
3 sites using identical protocols 
• Volumetric inspiratory and expiratory images obtained 
(Figures 1 & 2) 
• After specialist training, anonymised scans scored 
independently by Dr Brody and experienced paediatric 
thoracic radiologist using Brody-II scoring system 
Figure 1: Anaesthetist using a 
manometer to inflate infant’s lungs 
to  protocolised pressure  
Figure 2: NICO2 
® respiratory monitor 
used to record ventilatory pattern 
throughout  procedure 
26th  Annual North American Cystic Fibrosis Conference; October 11-13, 2012; Orlando, Florida USA  
Table 1: Inter-rater agreement of CT scores 
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• Scans obtained in 59 CF NBS infants at  mean 52(SD:4) wks 
• Mean age of diagnosis: 4 weeks (range: 1-12w) 
• 85% CFTR genotype classes I-III  
• 95% pancreatic insufficient; 5(8%) with meconium ileus 
• Prophylactic flucloxacillin, pancreatic enzymes (if pancreatic 
insufficient) and multivitamins from diagnosis 
• Managed  by standardised treatment protocols  
Results 
Background characteristics 
CT Scores 
High Resolution Computed Tomography in 1 Year Old CF Newborn Screened  Infants: 
Not a Useful Outcome Measure  
Thia LP1; Calder A2; Owens C2; Young C2; Bush A3; Wallis C4; Stocks J1; Brody A5     
On behalf of the London CF Collaboration (LCFC)                  
1 Portex Respiratory Unit, UCL, London UK, 2Dept of Paediatric Radiology, Great Ormond Street Hospital for Children (GOSH), London UK, 3Royal Brompton 
Hospital, London UK; 4Dept of Respiratory Medicine, GOSH, London UK, 5 Dept Of Radiology, Cincinnati Children’s Hospital, Cincinnati, Ohio, USA. 
manometer 
• No CT changes were detected in 46% of infants by scorer 
A and in 8% by scorer B (Figure 3)  
• Substantially discrepant scores were allocated to the 
different components  
• Allocated scores suggested mild changes only 
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CT scores Kappa coefficient  
Bronchial Dilatation 0.2 
Peribronchial Wall Thickening 0.2 
Mucus Plugging 0.3 
Parenchymal changes 0.3 
Air trapping 0.7 
• Fewer CT changes (majority mild) were 
seen in current study of CF NBS infants 
than reported previously. 
• Poor agreement was observed even 
between experienced and trained scorers.  
• A new robust CT scoring system for 
evaluating mild early CF lung disease is 
needed before HRCT can be useful either 
clinically or as a trial endpoint in 
screened infants.  
Conclusions 
• The only sub-score with substantial agreement 
between scorers  was air-trapping (Table 1) 
Figure 3: Percentage of scans where CT 
changes  detected according to the two scorers 
  Early Detection of Lung Disease in infants with Cystic Fibrosis diagnosed by 
Newborn Screening 
Lena Thia 1, Janet Stocks 1, Ah-Fong Hoo 1,2, Jane Chudleigh 2, Sooky Lum 1, Ammani Prasad 2, Andrew Bush 3 , 
Colin Wallis 2  and on behalf of the LCFC  
 NACFC, Baltimore, USA 2010 
• Infants with CF were recruited from the London CF Collaboration 
comprising 6  tertiary CF centres –  
•  Barts & the Royal London Hospital 
•  Great Ormond Street Hospital 
•  Royal Brompton Hospital 
•  Lewisham University Hospital  
•  King’s College Hospital  
•  St Helier’s Hospital 
• Healthy controls recruited from Homerton University Hospital. 
  Lung function tests were undertaken by ~3 months postnatal age 
following chloral hydrate sedation (60–100 mg/kg) at the Great 
Ormond Street Hospital, using the 
 
a) Multiple Breath Washout (MBW):  
- Lung Clearance Index (LCI), FRCMBW 
b) Plethysmography: FRCpleth 
c) Raised Volume Technique (RVRTC): forced expired volumes 
and flows 
 
 
 
 
 
Recruitment 
• 84 infants were screened positive for CF in the last 20mths. 
• 8 not eligible for the study. 
• 73 were approached and 53 recruited for the study (73%). 
• 51 CF infants had baseline lung function at 3mths. 
• 36 healthy controls had 3m lung function. 
Background Characteristics (mean [SD] or %) 
CF 
(n=51) 
Controls 
(n=36) 
Mean diff  
(95% CI) 
Male, n (%) 29 (57%) 17 (47%) 10% (–11%; 29%) 
Gestation, w 39.1 (1.7) 40.0 (1.3) –0.9 (–1.5; –0.3)** 
Birth weight, z-score –0.7 (1.1) –0.2 (0.8) –0.5 (–0.9; –0.1)* 
Maternal smoking during 
pregnancy, n (%) 
8 (16%) 4 (11%) 5% (–11%; 19%) 
p values: * <0.05;  ** <0.01, *** <0.0001  
Details at time of test ~3m (mean [SD]) 
CF 
(n=51) 
Controls 
(n=36) 
Mean diff  
(95% CI) 
Corrected age, w 10.9 (2.3) 12.4 (2.3) –1.5 (–2.7; –0.5)** 
Weight z-score –0.8 (1.1) 0.3 (1.2) –1.1 (–1.7; –0.6)*** 
Length z-score –0.1(0.9) 0.8 (0.9) –0.9 (–1.3; –0.4)*** 
Lung Clearance Index  FEV0.5 z-score
2  
• 20/50 (40%) of CF infants had 
either abnormal LCI or FEV0.5  z-
score. 
• Only 8 infants had abnormal 
results identified by both methods. 
• The difference in results 
demonstrated that these 
techniques measure different 
aspects of lung function 3. 
Lung function according to bacterial status in 
screened infants with CF  
• There was no obvious pattern observed in association with prior 
clinical symptoms or genotypes.   
• Despite early diagnosis & treatment, lung  function was abnormal by 
~3 months in 40% of screened CF infants, 2/3 of whom had no prior 
growth on cough swab. 
• Incidence of abnormalities would have been under-estimated had 
either the MBW or RVRTC techniques been used in isolation. 
References 
1 Linnane BM et al. Am J Respir Crit Care Med 2008;  2 Lum S et al. Ped Pulm 2010; 3 Lum S et al. Thorax 2009 
This project is funded by the Cystic Fibrosis Trust, UK, and Great Ormond Street Hospital Special Trustees 
1Portex Respiratory Unit, Institute of Child Health, UCL, London; 2Respiratory Unit, Great Ormond Street Hospital for 
Children NHS Trust, London; 3Respiratory Unit, Royal Brompton and Harefield Hospitals NHS Trust, London, UK 
Introduction 
• Newborn screening (NBS) for cystic fibrosis (CF) has been available 
in the UK since 2007. 
• NBS offers the potential for early intervention in order to preserve 
lung function and nutritional status. 
• It has been suggested that lung function is normal shortly after 
diagnosis in infants with CF detected by NBS1. However, relatively 
few infants were studied before 3m of age. 
Aim 
To determine baseline lung function by ~3 months in NBS CF infants 
in comparison with prospective age-matched healthy controls 
 
Subjects and Methods 
LLN: Lower limit of normal (–1.96 z-score) ULN: Upper limit of normal (=8.3 in healthy infants) 
• 17/48 (35%) screened  CF infants 
had positive bacterial growth on 
cough swab; of whom 7 (40%)  have 
abnormal LCI or FEV0.5 z-score. 
• 31/48 (65%) screened CF infants 
had no bacterial growth on cough 
swab; of whom 20 (65%) had either 
abnormal LCI or FEV0.5 z-score. 
Table A1-a: Table summarising studies that have assessed lung function and structure in infants and young children (age ≤2 
years) with CF 
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Castile114 
2004 
 
Prospective               
Cross sectional 
Observational 
Aim of study: 
To compare trapped 
gas volumes in 
normal and CF 
infants  
Clinically 
diagnosed CF 
n=29            
age: 1-36m  
 
Healthy 
controls          
n=30              
age: 1-34m  
 
RTC, RVRTC 
(inflation= 30 
cmH2O) using 
custom built 
equipment, 
followed by 
plethysmograph 
and Nitrogen 
washout (FRC-
N2)  
 
 
FEF25-75, 
FEF75 
FVC 
TLC, RV, 
RV/TLC 
V’maxFRC 
FRCpleth and 
FRC-N2.,  
 
 
Significant differences in FEFV, FRC-N2, FRCpleth, 
RV and RV/TLC between CF and healthy controls. 
CF infants showed significant small amounts of 
trapped gas compared to healthy controls. 
Both CF and normal infants had evidence of 
hyperinflation and gas trapping. This may be due to 
glottic closure at low lung volumes during the 
measurement. 
Conclusions: Normal infants and CF infants have 
modest amounts of trapped gas. When assessed 
after the RVRTC manoeuvres, trapped gas 
measured as FRCpleth-FRC-N2 did not distinguish 
between minimally symptomatic CF infants and 
normal infants.  
Ranganathan
60 
2004 
(LCFC) 
Prospective, 
Longitudinal 
Observational  
Aim of study: 
To determine if 
initial impairment 
in clinically 
diagnosed CF 
persists and asso.  
Clinically 
diagnosed CF 
n= 34               
1st test:17-43w 
2nd test:48-69w 
Healthy 
controls: 
n=32 
1st test: 6-9 w  
2nd test:28-50w  
RVRTC: from 30 
cmH2O Custom 
built equipment 
(RASP).  
 
FEV0.5, FVC,  
FEF75 z-scores 
FEV0.5 was significantly lower than healthy 
controls after diagnosis and 6 months later. 72% CF 
infants  have abnormally low FEV0.5 <1.64 z-scores 
(i.e <5th percentile). No improvement seen with 
growth. CF infants experienced a mean reduction in 
FEV0.5 of 20% when compared with healthy 
controls.   
Conclusions: Airway function is diminished soon 
after diagnosis in CF infants and does not catch up 
during infancy and early childhood. 
 
Footnote: RTC raised tidal compression technique.  V’maxFRC  maximal flow at functional residual capacity. RVRTC Raised Volume Rapid Thoraco-abdominal 
compression technique. FEFV (forced expiratory flows and volumes). FEV0.5 forced expiratory volume at 0.5 seconds. FVC Forced vital capacity. FEF75 Forced 
expiratory flow when 75% of FVC expired. TLC total lung capacity. RV Residual Volume. FRCpleth Functional Residual Capacity measured through plethsmography. 
FRC-N2 Functional Residual Capacity measured through nitrogen washout. RASP Respiratory Analysis Software program. 
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Lum83 
2007 
(LCFC) 
Prospective               
Cross sectional 
Observational  
Aim of study: 
To compare MBW 
and RVRTC tests in 
detecting abnormal 
lung function in 
clinically diagnosed 
infants with CF 
Clinically 
diagnosed CF   
n= 39                
age: 7.6-94.1w 
Healthy 
controls       n= 
21                
age:15.3-7.9w 
MBW (using 
mass spectrometer 
and SF6  
RVRTC (Jaeger 
Masterscreen) 
from 30cm H2O 
LCI, FEV0.5 
and FEF25-75 z-
scores 
Infants with CF had higher LCI and lower FEFV 
parameters compared with controls. 
Conclusions: Both MBW and RVRTC detected 
similar proportion of lung function abnormalities 
although they did not identify identical infants, so 
both techniques are required for early detection of 
lung disease. 
Linnane82 
2008 
(AREST-
CF) 
 
 
Prospective                
Cross sectional 
Observational  
Aim of study: 
To measure lung 
function in infants 
and describe 
association with 
pulmonary 
infection and 
inflammation 
NBS and 
clinically 
diagnosed CF 
n= 68 at 2 
centres        age: 
6w- 2.5y 
Historical 
Healthy 
controls  
 
 
 
RVRTC from 20 
cmH2O: Custom 
made equipment 
using reference 
equations from 
historical 
controls.  
 
 
 
FEV0.5, FVC 
and FEF75 z-
scores 
 
 
CF infants had reduced FEV0.5 z score as a whole 
cohort, although no significant reduction in airway 
function was noted in infants < 6 months of age. 
 
No association between diminished lung function 
and airway inflammation and infection. 
 
Conclusions:  Lung function is normal shortly 
after diagnosis by NBS but is diminished in older 
infants despite good nutrition and care in specialist 
centres. There may be a window of opportunity to 
intervene to maintain normal lung function as it 
appears to be normal within the first 6 months of 
life.  
 
 
 
 
Footnote: NBS Newborn screened. RVRTC Raised Volume Rapid Thoraco-abdominal compression technique. MBW Multiple Breath Washout. LCI 
Lung Clearance Index. SF6 SulphurHexafluoride gas. FEV0.5 forced expiratory volume at 0.5 seconds. FVC Forced vital capacity. FEF25-75: Forced 
expiratory flow when 25-75% of FVC expired. FEF75 Forced expiratory flow when 75% of FVC expired. 
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Pillarisetti67 
2011 
(AREST-
CF) 
 
Prospective 
Longitudinal 
Observational  
Aim of study: 
To describe 
longitudinal change 
in lung function and 
its association with 
pulmonary 
infection and 
inflammation 
NBS CF   n=37           
age: ≤ 2y 
Historical 
Healthy 
controls: None 
RVRTC from 
30cmH2O Custom 
made equipment 
using reference 
equations from 
historical 
controls. 
Measured at ~4m, 
~1y, ~2y 
FEV0.5, FVC 
and FEF75 z-
scores 
 
 
Lung function impaired at all three test occasions 
and further deterioration with advancing age. 
 
Significantly greater decline in FEV0.5 z-scores 
occurred in those infected with Staphylococcus 
aureus or Pseudomonas aeruginosa. 
Conclusions: Decline in lung function over time in 
clinically well CF infants is associated with 
neutrophilic airway inflammation and pulmonary 
infection with Staphylococcus aureus and 
Pseudomonas aeruginosa detected by surveillance 
BAL.   
Hall121 
2011 
(AREST-
CF) 
 
Prospective                   
Cross sectional 
Observational  
Aim of study: 
To assess 
relationship 
between structural 
lung damage using 
chest CT and 
ventilation 
distribution 
NBS CF            
n=49            
age:8.7-112.1w 
 
Healthy 
Controls: None 
MBW 
(Mainstream 
USFS: Exhalyzer; 
Ecomedics using 
SF6) 
 
 
LCI, FRCMBW,  
M1/M0 and  
M2/M0  
CT under 
GA: CT 
scores (1 
radiologist) –
bronchiectasis 
and 
airtrapping 
recorded in 
binary 
function. If 
present, then 
extent  
LCI and M1/M0 not significantly increased in 
infants with bronchiectasis or airtrapping. 
M2/M0 significantly increased in presence of CT 
airtrapping (p= 0.049) but not with bronchiectasis 
(p=0.60).  
Presence of: 
 Bronchiectasis 13(27%) 
 Airtrapping 24 (49%) 
In early CF lung disease, there are weak 
associations between ventilation distribution 
reported as M2/M0 and CT airtrapping.  
Conclusions: LCI cannot be used as surrogate 
marker for chest CT outcomes in CF NBS infants. 
LCI may detect early inflammation and infection 
but not onset of structural lung disease. 
 
Footnote: BAL Bronchoalveolar lavage. USFS Ultrasonic Flowmeter System. SF6 Sulphur Hexafluoride 6 gas. FRCMBW Functional Residual 
Capacity measured through multiple breath washout technique. M1/M0 First moment ratio. M2/M0 Second moment ratio. FEV0.5 forced expiratory 
volume at 0.5 seconds CT under GA Chest Computed Tomography under General Anaesthesia. 
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Davis62 
2010 
Prospective 
Longitudinal 
Observational 
Aim of study: 
To evaluate safety, 
feasibility and 
ability to detect 
abnormalities in 
serial pulmonary 
function tests in CF 
infants 
Clinically 
diagnosed CF 
(79%) and 
NBS or 
prenatal 
screened CF 
(21%)            
n=100 at 10 
centres        age: 
1.6-26.4m 
Historical 
Healthy 
controls 
 
RVRTC from 
30cmH2O. 
(nSpire Infant 
Pulmonology 
Lab).  
Plethysmography  
 
 
FEV0.5, FVC, 
FEF75 z-scores 
FRCpleth, RV, 
FRC/TLC, 
RV/TLC 
FRC measurements (89%) were more feasible and 
with higher rate of technical acceptability  across 
the centres than RVRTC (72%)  
Compared to historical controls, CF infants showed 
reduced forced expired flows but not volumes. Also 
had elevated FRCpleth and other fractional lung 
volumes. Impairment in lung function increased 
with advancing age. 
Conclusions: The feasibility of ILFT as a 
multicentre outcome is variable and depends on the 
experience of the centre. Potentially a large sample 
size is required to detect reasonable treatment 
effects. This precludes its use as a primary efficacy 
endpoint especially at inexperienced sites.  
Kieninger105 
2011 
Retrospective 
Longitudinal 
Observational 
Aim of study: 
To describe the 
longitudinal course 
of LCI from time of 
clinical diagnosis 
during infancy to 
school age.  
Clinically 
diagnosed CF 
n=11 
Infant study: 
(median age: 
21.9w)  School 
age 
study:(median 
age:9.7y) 
Historical  
Infant study: 
unsedated using 
Exhalyzer , 
EcoMedics using 
SF6 
School age 
study: Exhalyzer  
EcoMedics using 
nitrogen washout) 
LCI z-scores 
using 
reference data 
from healthy 
historical 
controls 
measured 
using similar 
protocols.  
 
Elevated LCI was present during infancy in 7/11 
cases, especially in those with later clinical 
diagnosis. 
Tracking of infancy LCI to school-age present in 4 
of the most severe cases. 
Conclusions: MBW during natural sleep is feasible 
in infants. Tracking of LCI is seen from infancy to 
school age clinically diagnosed CF, especially in 
those with most severe disease. 
 
 
 
 
 
 
 
 
 
 
Footnote: FEV0.5 Forced expiratory volume at 0.5 second. FVC Forced vital capacity. FEF75 Forced expiratory flow when 75% of 
FVC expired. RV Residual volume, TLC Total lung capacity,  FRCpleth, Functional residual capacity measured through 
plethysmography. LCI Lung clearance index. MBW Multiple breath washout test. NBS Newborn screening. 
Table A1-b: Table summarising studies that have measured Lung Clearance Index in children ≥3 years with CF  
Author 
 
Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Gustafsson63 
2003 
Prospective                
Cross sectional 
Observational 
Aim of study: 
To determine if 
ventilation 
distribution is 
impaired in early 
CF lung disease and 
abnormal more 
frequently than 
spirometry 
Clinically 
diagnosed CF 
n= 43              
age: 3-18 y 
Healthy 
controls          
n= 28            
age: 4-19 y 
 
MBW: Respiratory 
MS using SF6 
Spirometry: Jaeger  
Masterscreen + 
Body-
plethysmograph  
 
FRCpleth, LCI 
and mixing 
ratio. 
FEV1, FEF75 % 
predicted 
LCI and mixing ratio were significantly elevated in 
children with CF with majority of those with CF 
being above the upper limit of normality. 
CF with chronic bacterial airway infection had 
significantly worse lung function from all tests. 
Conclusions: Abnormal ventilation distribution 
exists in the majority of CF children, including those 
with normal spirometry. Findings suggest that 
destructive processes may start early and in the 
peripheral airways which may not be evident from 
conventional spirometry. 
Aurora85 
2005 
(LCFC) 
 
Prospective                        
Cross sectional 
Observational 
Aim of study: 
To compare the 
relationship 
between LCI, sRaw 
and FEV0.5 and 
FEF25-75 in 
clinically diagnosed 
pre-school children 
with CF 
 
 
Clinically 
diagnosed CF 
n= 30            
age: 2-5y 
Healthy 
controls       
n= 30         
age: 2-5y 
MBW: Respiratory 
MS using SF6 
sRaw using Jaeger 
Masterscreen 
plethysmography 
Incentive 
spirometry using 
Jaeger spirometer 
 
LCI, zsRaw, 
zFEV0.5 and          
zFEF 25-75. 
 
CF children had significantly higher LCI and sRaw 
and significantly lower FEV0.5 than healthy controls. 
Those with PsA infection had significantly higher 
LCI. 
LCI was the most sensitive outcome for detecting 
abnormal lung function. 
Conclusion: MBW, plethysmography and spirometry 
were all feasible in preschool children. MBW detects 
abnormal lung function more readily than 
plethysmography or spirometry. 
 
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Footnote: MBW Multiple Breath Washout.  FEV1 forced expiratory volume at 1 second. FEF75 Forced expiratory flow when 75% of 
FVC expired. FEF25-75: Forced expiratory flow when 25-75% of FVC expired. Respiratory MS Respiratory Mass Spectrometer. SF6 
Sulphur Hexafluoride 6 gas. LCI Lung Clearance Index. FRCpleth Functional Residual Capacity measured through plethysmography. 
sRaw Specific airway resistance. 
Kraemer72 
2005 
 
 
 
 
 
 
 
 
 
 
Prospective 
Cross sectional 
Observational 
Aim of study: 
To investigate 
changes in lung 
volume, flow 
limitation and 
ventilation 
distribution in CF 
patients from age 6 
to 20 years. 
 
Clinically 
diagnosed CF 
n=142 
age: 6-20y  
 
No healthy 
controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plethysmography  
MBW using 
nitrogen washout  
 
Spirometry  
 
 
 
 
FRCpleth, sReff 
LCI and  FRC-
N2, FRCpleth-
FRC-N2 
(trapped gas) 
FVC, FEV1 and 
FEF50 
Highest progression of pulmonary dysfunction found 
in FRCpleth, followed by LCI, trapped gas and then 
FEF50.  
Median age at onset of abnormal LCI, FEF50, FEV1, 
FRCpleth and trapped gas volume were 6.3y, 7.2y, 
8.6y, 8.9y, 13.0y respectively 
LCI and FEF50 detected more abnormalities than 
FEV1 
All lung function parameters associated with onset of 
chronic Pseudomonas aeruginosa infection. 
Conclusions: LCI predicts earlier in life and 
represented better functional progression than FEV1. 
However no single functional predictor of CF 
progression exists. Onset of chronic Pseudomonas 
aeruginosa, genotype, hyperinflation, airway 
obstruction and ventilation inhomogeneities are 
important pathophysiologic processes that should be 
evaluated as determinants of lung progression in CF. 
 
 
 
 
Footnote: sReff Specific effective resistance. FRCpleth Function Residual Capacity measured through plethysmography. FRC-N2 
Functional Residual Capacity measured through nitrogen washout technique. FRCpleth-FRC-N2 measurement for trapped gas using the 
two different systems. LCI Lung clearance index. FEV1 Forced expiratory volume at 1 second. FVC Forced vital capacity. FEF50  
Forced expiratory flow when 50% of FVC expired.  
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Kraemer76 
2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prospective 
Longitudinal 
Observational 
Aim of study: 
1) To investigate 
whether or not 
hyperinflation 
and/ or trapped 
gas reflect 
functional 
deterioration 
during 
childhood. 
2) Role of specific 
CFTR 
genotypes and 
PsA infection 
on rates of 
disease 
progression. 
3) To demonstrate 
whether there is 
functional 
tracking over 
time of 
respiratory 
dysfunction. 
Clinically 
diagnosed CF 
n=152 
age: 6-18 
years 
Analysis made 
according to 4 
groups: 
 Normal 
FRCpleth and 
LCI at entry 
(FN) 
 Normal 
FRCpleth but 
high LCI 
(VIH) 
 FRCpleth 
high, high 
LCI but 
normal 
trapped gas 
(PH) 
 FRCpleth, 
trapped gas 
and LCI 
high 
(PH&TG) 
 
 
 
 
 
Plethysmography  
Spirometry [Jaeger 
BodyScreen then 
Jaeger Masterlab 
with electronic 
compensation] 
 MBW using 
nitrogen washout 
[Sensormedics 
2200] 
 
FRCpleth; sReff 
FVC, FEV1 and 
FEF50 
 
 
LCI, FRC-N2 
and             
FRCpleth-        
FRC-N2 
(trapped gas) 
 
 
 
FRCpleth and trapped gas volume increase from age 6 
to 18 years of age. Abnormal hyperinflation detected 
in 38% of subjects at age 6 which ↑ to 67% by 18y. 
Abnormal trapped gas volume increased from 15% to 
54% during this period. 
These abnormal lung function parameters appeared to 
track from early childhood to adulthood. However 
even in those with normal lung function initially or 
no hyperinflation but increased LCI i.e. FN and VIH 
groups, these groups also showed progression of 
FRCpleth and trapped gas. 
Age related tracking of lung function parameters 
commences early in life and is significantly 
influenced by specific CFTR genotypes. 
Group with chronic Pseudomonas aeruginosa had the 
most rapid deterioration while chronic 
Staphylococcus aereus had the slowest rate of 
progression. LCI was the most sensitive discriminator 
between the 3 types of infection examined. 
 
 
Footnote: sReff Specific effective resistance. FRCpleth Function Residual Capacity measured through plethysmography. FRC-N2 
Functional Residual Capacity measured through nitrogen washout technique. FRCpleth-FRC-N2 measurement for trapped gas using the 
two different systems. LCI Lung clearance index. FEV1 Forced expiratory volume at 1 second. FVC Forced vital capacity. FEF50  
Forced expiratory flow when 50% of FVC expired.  
Author Type & Aim of 
study 
 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Gustafsson64 
2008 
Retrospective              
Cross sectional 
Observational 
Aim of study: 
To determine 
correlation between  
LCI and spirometry 
with structural lung 
disease 
Clinically 
diagnosed CF 
n= 44          
age: 5-19y 
No healthy 
controls 
MBW: Respiratory 
MS using SF6 
Spirometry: Jaeger  
Masterscreen  
Plethysmography:  
HRCT: Non- 
contiguous 
scanning in 
inspiration and 3- 
slice images during 
expiration 
LCI, zFEV1 and 
zFEF75. 
CT scoring: 
Brody-II scoring 
by 1 
experienced 
radiologist 
Composite and 
Component CT 
scores for 
different 
structural 
abnormalities 
LCI was more sensitive in detecting abnormal lung 
function than FEV1 or FEF75. 
LCI correlated better with CT scores than FEV1 
Conclusion: LCI is more sensitive than spirometry 
for detecting structural lung disease in CF. Normal 
LCI excludes CT abnormalities. Abnormal LCI with 
normal scan suggests that LCI may be even more 
sensitive than CT for detecting lung involvement in 
CF.   
Fuchs93 
2008 
Prospective                    
Cross sectional 
Observational 
Aim of study: To 
assess feasibility of 
using sidestream 
USFS prototype 
device in CF 
children and adults. 
Clinically 
diagnosed CF 
n= 26               
age: 7-19y 
Healthy 
controls       
n= 22         
age: 5-18y 
 
 
 
 
 
 
MBW: Side stream 
USFS (EasyOne 
Pro, NDD) using 
SF6 
Spirometry: Jaeger  
Masterscreen 
plethysmograph  
 
LCI, FRCMBW, 
zFEV1 
Chest 
radiograph: 
Crispin Norman 
score 
 
LCI similar to that obtained through mass 
spectrometry. It is more sensitive than spirometry. 
LCI correlated with CN score while FEV1 did not. 
Conclusions: Sidestream ultrasonic MBW is a valid 
and simple alternative to mass spectrometry for 
assessing ventilation inhomogeneity in children.  
Footnote: Respiratory MS Respiratory mass spectrometer. USFS Ultrasonic Flowmeter System. SF6 Sulphur Hexafluoride 6 gas. FEV1 
Forced expiratory volume at 1 second. FEF75.  Forced expiratory flow when 75% of FVC expired. LCI Lung clearance index. FRCMBW 
Functional Residual capacity measured through multiple gas washout technique. CN Crispin Norman CXR. score. LCI Lung clearance 
Index 
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Horsley90 
2008 
Prospective   Cross 
sectional 
Observational 
Aim of study: 
1. To investigate 
the feasibility 
of obtaining 
LCI using 
modified 
Innocor device 
in healthy and 
CF children and 
adults. 
2. To assess how 
LCI changes 
with age and 
the 
reproducibility 
in healthy 
volunteers. 
3. To use adapted 
Innocor to 
measure FRC 
and LCI in 
normal and CF 
subjects and 
compare LCI to 
spirometry. 
 
 
 
 
 
Clinically 
diagnosed CF 
Adults: n= 33 
age: 17-49y 
 
Healthy 
controls 
Adults: n= 49 
non-smokers 
age: 19-58y 
Child: n=13 
age: 6-16y 
Modified Innocor 
device (Innovision, 
Denmark) using 
SF6 (0.2%) 
Spirometry using 
ECCS predicted 
values for FEV1 in 
adults and 
Rosenthal for 
children (≤ 16y) 
 
 
 
LCI and FRC 
 
 
 
FEV1 
 
 Both Innocor and MS had↓signal:noise ratio as 
concentration ↓ but Innocor signal quality 
remained superior to MS. 
 Slower rise time with Innocor (150ms) vs MS 
(60ms); may not be usable in infants and younger 
children with faster resp rate. 
 LCI showed high reproducibility within and 
between visits for healthy and CF adults and 
healthy children. 
 No relationship between age (≥16y) and LCI. 
LCI restricted to a narrow range in healthy 
controls. 
 LCI in healthy adults was significantly different 
from CF. LCI detected more CF adults with 
abnormality compared to FEV1. 
 LCI is highly sensitive: 97% in detecting CF 
compared to 70% in FEV1. 
 
Conclusion: First adult study showing LCI more 
sensitive than FEV1 in detecting lung abnormalities 
and that it is reproducible with little change over 
height and age, using a commercially available robust 
compact apparatus.  
 
 
 
Footnote: SF6 Sulphur Hexafluoride 6 gas. FEV1 Forced expiratory volume at 1 second. LCI Lung clearance index MS Mass 
Spectrometer. ms milliseconds. 
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Ellemunter11
7 
2010 
Prospective               
Cross sectional 
Observational 
Aim of study: 
To investigate the 
diagnostic accuracy 
of LCI in 
comparison to CT 
in CF patients with 
early lung disease 
(normal FEV1>80% 
pred) 
NBS (13), 
Mec ileus (4), 
Family 
history (4), 
Clinically 
diagnosed 
(13) 
n= 34 
age: 6-26 y 
No healthy 
controls 
 
MBW: Side stream 
USFS system 
(EasyOne Pro, 
NDD) using SF6 
Spirometry: Jaeger  
Masterscreen 
Plethysmograph  
CT scan: Ultra low 
dose volumetric 
thin section multi-
detector CT.  
LCI, zFRCMBW, 
zFEV1  
Inspiratory 
images during a 
single deep 
inspiration. No 
expiratory 
images. 
CT scoring: 
Bhalla scores (2 
independent 
experienced 
radiologists).  
MBW revealed abnormal results in majority of 
patients (76.5%). Using Bhalla scores, 76.5% of 
patients have abnormal findings. 
Good concordance between LCI and CT scores 
(82.3%). No correlation seen between FEV1 and CT 
total or subscores. 
Sensitivity and specificity of LCI were high (88% 
and 63% respectively) when compared to CT.  
Conclusion: LCI can be used as a surrogate marker 
for detecting early structural CF lung disease and 
hence minimise the need for CT scans and reduce 
radiation burden. More longitudinal data required for 
evolution of CT changes.  
Owens107 
2010 
(LCFC)  
 
Prospective 
Cross sectional 
Observational 
 
Aim of study: 
To assess whether 
LCI is as effective 
as HRCT in 
identifying 
pulmonary 
abnormalities and 
to explore its 
relationship with 
other lung function  
Clinically 
diagnosed CF 
n= 60 
age: 6-10y 
n= 57 (lung 
function and 
CT)  
 
Healthy 
controls 
n= 54 
age: 5.5-10y 
(lung function 
only) 
 
 
 
 
 
MBW: Respiratory 
MS using SF6 
Spirometry+sRaw 
(Jaeger 
Masterscreen 
plethysmograph 
HRCT: Volumetric 
inspiratory and 3 
slices on  
expiration 
LCI, zFRCMBW 
zFEV1, zFVC, 
zFEF25-75, sRaw, 
zFRCpleth, zRV, 
zTLC 
CT scoring: 
Composite and 
component CT 
scores using 
Brody II scored 
by 2 
experienced 
radiologists. 
CF children had significantly impaired lung function 
compared to healthy controls in all lung function 
parameters. LCI was the most sensitive parameter, 
detecting abnormalities in 85% of CF with strongest 
correlation with total CT scores and sub-scores.  
Scans were classified as abnormal in 84% of children 
with CF. Both scorers had good agreement in total 
CT scores and subscores. 
Conclusion: LCI and HRCT have similar sensitivity. 
Good correlation between LCI, total scores and 
subscores; best concordance in severe lung disease.  
Author Type & Aim of 
study 
Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Aurora102 
2011 
(LCFC) 
Prospective 
Longitudinal 
Observational  
Aim of study: 
To determine if 
preschool 
spirometry and LCI 
predict subsequent 
abnormal lung 
function at early 
school age 
 
Clinically 
diagnosed CF 
n= 48 
Tested at 3-5y 
with follow-up 
test at 6-10y  
Healthy 
controls 
n=45 
Tested at 3-5y 
with follow-up 
at 6-10y  
MBW: Respiratory 
MS using SF6 
Incentive 
spirometry  
 
LCI and FEV1 
z-score 
 
Majority of preschool CF children have abnormal 
LCI even when spirometry normal. LCI more 
sensitive in detecting abnormalities.   
Normal preschool LCI associated with normal 
school-age lung function. Preschool LCI had a high 
PPV (94%) and NPV (62%) for predicting abnormal 
school-age result  
Conclusion: Abnormal preschool LCI predicts 
subsequent lung function abnormalities. MBW may 
be a useful research and clinical outcome.  
 
 
 
 
 
Footnote: MBW Multiple Breath Washout. MS Mass Spectrometer. SF6 Sulphur Hexafluoride 6 gas. LCI Lung Clearance Index.. 
FEV1 Forced expiratory volume at 1 second. PPV Positive Predictive Value. NPV Negative Predictive Value. 
Table A1-c: Table summarising studies using ILFT and/or LCI as outcome measures in interventional trials involving infants 
and older children with CF  
Author Type & Aim of study Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Berge113 
2003 
Prospective 
Interventional, Open-label, 
Randomised cross-over   
Nebulised DNase vs 0.9% 
saline 
Aim of study:  
To examine the feasibility 
and sensitivity of clinical 
endpoints to assess effects 
of inhaled DNase in CF 
infants. 
Clinically 
diagnosed CF 
n=9 
mean age: 1.4 ± 
0.16y 
2-3 weeks cross 
over trial with 
DNase or 0.9% 
saline once daily 
 
Jaeger Baby-
Body  
Oxygen 
saturations, 
respiratory and 
pulse rate 
Daily symptom 
scores 
V’maxFRC and 
FRCpleth 
Significant improvement in V’maxFRC seen in infants while 
on DNAse with no significant improvement while on 
normal saline. 
No significant improvement in FRCpleth whether on DNAse 
or normal saline. 
No significant difference observed in oxygen saturations or 
clinical symptoms between infants on DNAse or normal 
saline. 
Conclusion: Objective assessment of the effects of DNase 
is feasible in infants with CF who have few or no 
respiratory symptoms. Results warrant a larger randomized 
placebo-controlled trial. 
Amin120 
2010 
Prospective 
Interventional  
Cross over trial 
Hypertonic (HS) vs 
isotonic(IS) saline 
Aim of study: 
The ability of LCI to 
detect a treatment response 
to hypertonic saline in CF 
patients with normal 
spirometry. 
Clinically 
diagnosed CF 
n= 17 
mean age: 10.5 
(4.3-16.7) y 
 
No healthy 
controls 
12w cross over  
with 7% HS or 
0.9% IS twice 
daily for 4w 
followed by 4w 
washout then 4w 
other treatment. 
MBW-MS(SF6) 
Spirometry 
(Viasys Cardinal 
Health)  
Primary 
outcome:  
LCI 
Secondary 
outcomes: FEV1, 
FVC, FEF25-75 z-
scores using 
Stanojevic  
reference 
equations and 
CFQR scores. 
 
 
 
LCI, spirometry and CFQR at baseline between HS and IS 
groups were similar. 
LCI significantly lower after 4w of HS inhalation 
compared with IS but no difference detected by spirometry 
and CFQR domains. 
Conclusion: LCI but not spirometry can detect treatment 
effect from hypertonic saline inhalation in CF patients with 
mild disease. 
Footnote: w weeks. V’maxFRC Maximal flow at functional residual capacity. FRCpleth Functional Residual Capacity measured through plethysmography. 
CFQR Cystic Fibrosis Questionnaire-Revised. LCI Lung Clearance Index. FEV1 Forced expiratory volume at 1 second. FVC Forced Vital capacity. 
FEF25-75 Forced expiratory flow when 25-75% of FVC expired. MBW-MS (SF6) Multiple Breath Washout Technique using Respiratory Mass 
Spectrometer and Sulphur Hexafluoride 6 Gas. FEF25-75 z - Forced expiratory flow when 25-75% of FVC expired. 
Author Type & Aim of study Subjects Methods & 
Equipment 
Outcomes Results and Authors’ Conclusions 
Amin119 
2011 
Prospective 
Interventional 
Cross over trial 
Dornase vs placebo 
Aim of study: 
To determine if LCI can 
detect treatment response 
to dornase alfa in 
paediatric CF patients with 
normal spirometry 
Clinically 
diagnosed CF 
n= 17 
age: 3.5-17.1y  
 
Historical 
healthy 
controls         
28 healthy 
Canadian 
children; age 
10-13 years 
 
12 w cross over 
trial with 2.4ml 
dornase alfa or 
placebo once 
daily for 4w, 
followed by 4w 
of washout then 
4w of the other 
treatment. 
MBW-MS (SF6)   
Spirometry  
(Viasys Cardinal 
Health USA) 
Primary 
outcome:  
LCI 
 
Secondary 
outcomes: FEV1, 
FVC, FEF25-75, z-
scores using 
Stanojevic  
reference 
equations and 
CFQR scores 
LCI in CF worse than historical controls. All CF had 
abnormal LCI at baseline while only 18% had abnormal 
FEF25-75. 
Significant improvement in LCI compared with placebo 
after 4 weeks treatment with dornase alfa. 
FEV1, FVC and CFQR scores not significantly different 
between treatment and placebo groups. FEF25-75 
significantly better with dornase treatment group.   
Strongest correlation seen between LCI and FEF25-75. 
Conclusion: Dornase alfa significantly improved LCI, 
suggesting it may be a sensitive and responsive outcome 
measure with the ability to identify treatment responders. 
 
 
Footnote: w weeks. CFQR Cystic Fibrosis Questionnaire-Revised. LCI Lung Clearance Index. FEV1 Forced expiratory volume at 1 second .FVC 
Forced Vital capacity. FEF25-75 Forced expiratory flow when 25-75% of FVC expired. MBW-MS (SF6) Multiple Breath Washout Technique using 
Respiratory Mass Spectrometer and Sulphur Hexafluoride 6 Gas. 
A2 Parent Information Leaflets  
 
 For CF Infants 
 
 
 For Healthy Control Infants 
 
 
 
 
A3 Breathing Tests in Babies Leaflet 
 
 
 
A4 Consent Forms for ILFT for CF and Healthy Control 
Infants 
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Parent Information Sheet 
 
Early detection of lung disease in infants with CF diagnosed by newborn screening 
NREC Number: _09H071314  
 
 
Thank you for taking the time to read this information document. 
 
PART 1: Essential elements of the study 
 
We would like to invite you to take part in a research study to find out the best ways of detecting 
early lung disease in babies who have been diagnosed with cystic fibrosis (CF) through the 
national UK newborn screening programme.  We are approaching you as a parent of a baby that 
has recently been diagnosed with CF. 
 
Before you decide whether to take part, you need to understand why the research is being done 
and what it would involve for you and your baby. Please take time to read the information in this 
document, which is six pages long, carefully. Talk to others about the study if you wish. Ask us if 
there is anything that is not clear or if you would like more information. If you would like your 
child to take part once you have understood what the project is about, we will ask you to sign a 
consent form.  You will be given a copy of this information and consent form to keep 
 
 
What is the purpose of this study? 
 
Newborn screening for CF is undertaken routinely the UK. This means that we can identify 
babies who have CF very early, often while they are still healthy. However, there will be no 
benefits to newborn screening unless we develop suitable treatments which will minimise lung 
damage during the critical first two years of life when the lungs are growing and developing very 
quickly.  
 
Worsening lung disease is a major problem in CF. The changes which happen in the lung can 
begin very early in life, often before the child develops obvious problems. Early lung disease of 
CF begins at the edges of the lungs and can only be detected by using special tests. We know 
that some of these tests are good at detecting problems but as yet we do not know if they are 
good enough to pick up very early lung disease. We also need to know if these tests can show 
us whether the lungs are getting better, staying the same or getting worse. We hope to answer 
these questions with our research project by undertaking three tests during the first year, which 
are explained below. We will also ask you to fill out a questionnaire about your experience of 
taking part in this study. 
 
 
Do we have to take part in this study? 
 
You do not have to take part in this research project if you don’t want to. It is up to you to decide. 
If you decide not to take part, this will not affect your child’s general care in the CF clinic in any 
way. We will describe the study and go through this information sheet with you. You will then be 
given the sheet to take away and think about whether you would like to be involved in this study. 
If you would like to participate, we will the ask you to sign a consent form to show you have 
agreed to take part.  You are free to withdraw at any time, without giving a reason. Again, this 
will not affect the care your baby receives at the hospital in any way. Many of the tests included 
in this study are part of our routine care at Great Ormond Street Hospital and so your baby will 
be having them anyway. If you decide not to take part in the main study we would like you to 
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consider whether you would be happy for us to use the results of the routine tests you have 
during normal clinic visits as these will also help us to understand more about CF in babies 
diagnosed by newborn screening.  
 
 
What are the three tests in the study? 
The tests we will be doing for the study are describe below but you will also be given some 
separate leaflets which explain each test in more detail.  
 
1. Breathing tests 
Breathing tests in babies are very safe and painless. You can stay with your child while they are 
being done. These are highly specialised tests which can only be performed at Great Ormond 
Street Hospital for children (GOSH). We will arrange the timing of these visits to suit your family 
and all travel expenses will be refunded. 
 
Older children and adults do breathing tests by taking deep breaths and blowing through special 
equipment. Babies are unable to cooperate in this way and therefore need to be asleep for the 
tests to be done. Babies do not always sleep for long during the day, so we give them a mild 
sleeping syrup called chloral hydrate to help them fall asleep. This medicine is often used in 
children and has been used for breathing tests in babies for over 25 years. Your baby will be 
able to feed before the tests and eat/drink normally as soon as they wake up. The tests do not 
upset the babies, who usually sleep through the whole process. It usually only takes about an 
hour to do all the tests but it is difficult to predict how quickly the baby will fall asleep, so it is best 
to allow about three hours for the visit. During the visit a research doctor will examine the baby 
and ask a few health questions.  
 
While the measurements are being made we will collect a urine sample from your baby. This will 
be sent to the laboratory to examine it for a substance which is produced when inflammation is 
broken down in the lungs and also for a substance which indicates passive exposure to smoke. 
This urine sample will be stored securely for six years and at the end of that time destroyed. The 
reason for storing extra sample is that in future we may want to look at the sample again for 
some further testing. You can be informed of any extended analysis if you wish. 
 
We will carry out the tests on two separate occasions about 9 months apart. We use four types 
of measurements to see how your baby’s lungs are developing and growing 
 
a) Breathing Patterns using Electrical impedance tomography (EIT) and Structured Light 
Plethysmography (SLP) 
 
Most of the lung function tests we make require babies to be fast asleep, which is why we need 
to give some sedative syrup before we start. However, some new approaches are now being 
developed that could make it easier to obtain similar results without sedation. This would mean 
we could offer these assessments to far more babies with breathing problems and in hospitals 
without the special facilities available at GOS. The first technique simply involves placing small 
sticky pads around the baby’s chest. This allows us to record tiny changes which occur as the 
baby breathes in and out and tells us whether the air breathed in is being spread evenly over the 
lungs, or whether there are some parts of the lung which are getting less air (for example due to 
some obstruction of the airway). The pads will remain on the baby’s chest throughout the testing 
session.  
 
The second approach (SLP) is even more straightforward and simply involves projecting a light 
grid onto the baby’s chest and recording the movements of this grid as they breathe with two 
overhead cameras.  Several sets of measurements will be taken, each lasting around 1 minute. 
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The technique is entirely painless and non-invasive and does not require anything to be 
connected to your child.  There is no radiation involved. 
 
b) Multiple breath washout test 
This test is designed to find out how evenly your child breathes. The baby breathes in a special 
air mixture through a face mask which contains a small amount of a gas called Sulphur 
Hexafluoride (or SF6). SF6 is inert which means that it does not cross from your child’s lungs into 
the blood stream, and has no taste or smell. The gas has been used safely at GOSH in babies 
and young children for the past 10 years and is used at many other specialist hospitals 
throughout the world. The baby breathes this mixture for a few minutes so that it mixes through 
the lungs. After a few minutes the gas mixture is swapped for normal air and we measure how 
quickly the baby breathes (or “washes”) out the SF6 from the lungs. Babies with normal lungs 
quickly wash out SF6 whereas babies with early lung disease take longer to clear the gas from 
their lungs.  
 
c) Lung volumes 
The third test measures how big the lungs are (lung volume). In order to do this the baby lies in 
a special cot (which looks a bit like a large incubator) and breathes air through a face mask. The 
cot has a transparent hood which is closed for 2-3 minutes so that we can record the tiny 
pressure changes that occur while your baby is breathing quietly.  
 
d) Forced expiration 
This test measures how quickly your baby can breathe out. An inflatable jacket (like a small life 
jacket) is placed around the baby’s chest and tummy. Once the baby has taken a breath in we 
inflate the jacket. This gives a gentle squeeze to the chest and encourages air to be breathed out 
quickly. Babies with lung disease cannot blow out as much air or as quickly as babies with normal 
lungs.  
 
2. Bronchoscopy and Broncho-alveolar lavage 
 
Lung disease in CF is caused by infections that damage the lungs. Sometimes infections occur 
without any obvious signs, such as cough or breathing problems. Older children and adults often 
produce sputum (phlegm) when they have infections and this is sent to the laboratory to find out 
what is causing the infection. Babies and young children cannot cough out sputum. Instead we 
take mucus samples from the lungs during a procedure called a bronchoscopy and send them to 
the laboratory. If we find infection we change the baby’s treatment to fight the infection.  
 
Bronchoscopy is widely used in children and adults. Many CF centres (including GOSH) already 
use it routinely in babies they look after. For this study, one research bronchoscopy will be 
performed at around about 12 months of age, and at a time when your baby is well. This will not 
be extra to the routine bronchoscopy your baby would be having as a routine part of his/her care 
at GOSH.  
 
The test will generally be performed at your specialist CF centre by your CF consultant. All of the 
consultants in the specialist centres involved in this study are experienced in the use of this 
technique in babies. The bronchoscope, which is like a flexible telescope, is passed through the 
baby’s mouth or nose into his/her lungs while they are under a light general anaesthetic. We 
take the sample by putting a small amount of saline in to the lungs through the bronchoscope 
and sucking it back, together with some mucus (this is called broncho-alveolar lavage). The 
sample is sent to the hospital microbiology lab to find out what, if any, infection is in the lungs.  
 
Infection in the lungs also causes inflammation and some of the sample collected will be sent to 
our research lab to look at how much inflammation is present in the lungs. We will use the 
opportunity of the anaesthetic to take a blood test, which we do routinely each year on all 
children with CF as part of their annual review. For this study we would like to ask your 
PIS_ Parents of infant with CF  v4 19th May09 
V1 
        4 
 
permission to take an extra 3ml (less than a teaspoon) of blood to look for any signs of 
inflammation in the lungs. 
 
Any remaining samples from the broncho-alveolar lavage and blood test will be stored securely 
for 6 years and at the end of that time destroyed. The reason for storing extra samples is that in 
future we may want to look at them again for some further testing. You can be informed of any 
extended analysis if you wish. 
 
 
3. Computed Tomography Scan (CT scan) 
 
CT scans are being used more and more to find out how CF is affecting the lungs of children.  
For this study just one CT scan will be performed when your baby is about one year of age. This 
is the only extra test your baby will have which is different from their routine care at GOSH. 
 
The CT scan will usually be done at your own specialist CF centre during the same anaesthetic 
that is needed for the bronchoscopy, to ensure that your baby lies quietly during the scan. CT 
scans are a specialised type of x-ray which allows us to look at the structure of the lungs in 
detail. Although this type of scan involves a higher dose of radiation than a normal chest x-ray, 
the results are far more informative, especially in the presence of early lung disease. New 
scanning techniques mean that we can get excellent pictures without exposing the child to high 
doses of radiation. The technique used in this study only exposes the child to a level of radiation 
which is about half of what we all receive each year from background sources.  
 
What is the questionnaire for? 
It is important that we know how parents feel about being asked to take part in studies such as 
this. We would also like to know about your views and experiences of being a part of this study. 
We will ask you to fill out a questionnaire once at the beginning and once at the end of the study.  
 
Are there any other tests or measurements? 
Any other measurements or results of tests which will be used for this study are all part of your 
baby’s routine care at your CF centre.  
 
What will we have to do if we take part? 
Whether or not you take part in this study, we will see your baby regularly in clinic (just as is the 
case normally), but in addition your baby will have three other visits to have the tests described 
above. At GOSH all but the CT scan are part of our routine care and as this is done on the same 
day as the bronchoscopy, there will be no additional visits. 
 
On the first and second visits (at around 3 months and one year of age ) we will invite you to 
Great Ormond St Hospital to measure your child’s lung function. Each visit will take about 3 
hours in total. You can take your child home when he/she is fully awake. 
 
The third visit will take place in your own specialist CF centre, about two weeks after the second 
lung function test. At this visit your child will have an anaesthetic for the bronchoscopy and CT 
scan described earlier. The procedure itself takes no longer than 30-45 minutes but you should 
expect to be in the hospital for 6-8 hours (to allow for examination, preparation for the 
anaesthetic and waking up time). In addition to this information sheet you will receive the 
standard hospital information about how to prepare your child for an anaesthetic and what time 
to come to the hospital. You will be asked to sign another consent form for these tests as is 
normal hospital procedure.  
 
 
Are there any risks or discomfort for my baby? 
Breathing tests:  Since we can only perform the breathing tests while babies are sleeping quietly, 
we make sure that they remain comfortable at all times. The only time when they might object is 
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while they are being given the spoonful of syrup (which has a slightly bitter taste), and when we 
are measuring them to see how long they are. While the medicine is wearing off, which may take 
a few hours, you baby may remain a little sleepy and need to be watched carefully to ensure 
they do not tumble if they have already started to walk 
 
 
Bronchoscopy: Although any general anaesthetic is associated with a slight risk (such as 
reaction to the anaesthetic medication), all bronchoscopies for this study will be undertaken by 
expert paediatric anaesthetists and consultant respiratory paediatricians. Under such conditions, 
risks are considered to be extremely low. Some children develop a slight fever for 24 hours 
following the test, especially if there are signs of a respiratory infection at the time of the 
bronchoscopy. This can be treated with medication such as paracetamol, but rarely occurs if the 
bronchoscopy is timed for when the child is well. 
 
CT scan: Since this will be undertaken under the same anaesthetic as the bronchoscopy, there 
will be no additional discomfort for the child. The scan does involve some radiation exposure, but 
this will be kept very low by selection of appropriate techniques performed by specialists.    
You will be given the name and telephone number of a doctor or nurse whom you can contact at 
any time should you have any concerns once you are back home after the tests. 
 
PART 2: Additional Information to be read before you decide whether to participate or not. 
 
Why is this study important? 
Children with Cystic Fibrosis are more prone to chest infections and repeated infections lead to 
lung damage. These infections may occur very early in life and some can go unnoticed (because 
the baby does not have an obvious cough or other symptoms). The two most common bugs 
seen in young children with CF are Staphylococcus aureus (SA) and Pseudomonas aeruginosa 
(PA). It is very important that these infections are detected and treated rapidly, using tests like 
the ones in this study, to prevent irreversible damage to the lungs which may limit the child’s 
physical ability and lifestyle.  
 
Who will this study help? 
We cannot promise that participating in this study will help your baby specifically, but the 
information we obtain will help improve the treatment of all children born with CF in the future. It 
will help us to understand more about CF lung disease in the first few years of life, and which 
test or combination of tests is likely to be most useful in detecting early changes in the lungs. 
 
For your baby specifically, the advantages of taking part in the study are that s/he will be 
monitored very closely throughout the period of the study both by her/his specialist CF team and 
by the research team. Your baby will also have the opportunity to have specialised assessments 
such as infant lung function (breathing) tests and CT scans. Such tests are not widely available 
yet, but have been shown to be accurate and reliable in monitoring lung growth and identifying 
early problems, which can then be treated more promptly. If any problems are picked up as a 
result of the tests you will be informed and your baby’s treatment changed if and as necessary.  
 
Results from all these tests will be sent to your consultant who will then be able to discuss them 
with you. 
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and any information about you or your child will be 
handled in strictest confidence and will only be used in a way that will not allow you or your baby 
to be identified. 
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What will happen if we don’t want to carry on with the study?  
You can withdraw from the study at any time without having to explain why. You would continue 
to attend clinic every 2 months when cough swabs would be taken, and lung function tests and  
bronchoscopy would be scheduled during the first year of life as is current routine practice at 
GOSH. Your child would not have the CT scan at one year of age as part of the study.  
 
What will happen when the study stops? 
Once your child is one year old, we will not require you to attend for any additional visits, but 
would like permission to continue to track your child’s clinical progress (from the information we 
get at routine clinic visits) so that we can assess how well these early tests predict future 
outcome at school age. This would not involve any extra effort from you or your family as it 
would be based on routine medical records 
 
How will I learn about the results of this study?  
 We can send you a summary of the study once all the results have been analysed 
(approximately 2013). 
  We will be giving talks about the results to other doctors and nurses around the world 
and will display the findings on the CF Trust’s website   
 
Who is organising and funding the research? 
Great Ormond Street Hospital Special Trustees/ Children’s Charity is funding this research, 
which also has approval from the UK Cystic Fibrosis Trust 
 
Who has reviewed this Study?  
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity.  
 
This study has been reviewed and given favourable opinion by  the Research Ethics Committee 
at UCL, Institute of Child Health and GOS Hospital for Children who consider that it is 
addressing an important question regarding treatment  of infants with CF and that there will be 
minimal risk to you or your child if you participate. 
 
What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak to your Specialist 
CF consultant, CF nurse or one of the researchers who will do their best to answer your 
questions. Their contact numbers are at the end of this information sheet. If you remain unhappy 
and wish to complain formally, you can do this through the NHS Complaints Procedure. Details 
can be obtained from the hospital (contact number). 
 
In the extremely unlikely event that something does go wrong and you or your baby are harmed 
during the research and this is due to someone’s negligence then you may have grounds for a 
legal action for compensation against (add details)  but you may have to pay your legal costs. 
The normal National Health Service complaints mechanisms will still be available to you (if 
appropriate).  
 
Who can I talk to about this study?  
Your Specialist CF consultant or any of the research team will be more than happy to talk to you 
about this study. Their contact details are below:   
 
If you would like further information before this time, you can either telephone or email  
 
a)  Dr XXX (Responsible clinician @ CF centre) 
 
b)  Xxx (Responsible research nurse) 
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c) Xxx (one of the principle investigators) 
 
You can also contact the CF Trust, with whom we keep in close touch  
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Parent Information Sheet 
 
Early detection of lung disease in infants with CF diagnosed by newborn screening 
NREC Number: _09H071314  
 
 
Thank you for taking the time to read this information document. 
 
PART 1: Essential elements of the study 
 
We would like to invite you to take part in a research study to find out the best ways of detecting 
early lung disease in babies who have been diagnosed with cystic fibrosis (CF) through the 
national UK newborn screening programme.  We are approaching you as a parent of a healthy 
baby. 
 
Before you decide whether to take part, you need to understand why the research is being done 
and what it would involve for you and your baby. Please take time to read the information in this 
document. Ask us if there is anything that is not clear or if you would like more information. Once 
you have decided whether you would like your child to take part you will be given a copy of this 
information and a signed consent form to keep. 
 
What is the purpose of this study? 
Newborn screening for CF is now undertaken routinely the UK. This means that we can identify 
babies who have CF very early, often while they are still healthy. However, there will be no 
benefits to newborn screening unless we develop suitable treatments to minimise lung damage 
during the critical first years of life when the lungs are growing and developing very quickly.  
 
In order to detect changes in babies with lung disease, we need to understand how the lung 
grows and develops in healthy babies. That is why we are asking for your help as we would like 
to measure breathing patterns in your baby at around 3 months of age and again at around one 
year of age. The information we obtain will help improve the treatment of children born with CF.  
 
Do we have to take part in this study? 
You do not have to take part in this research project if you don’t want to. It is up to you to decide. 
If you decide not to take part, this will not affect your child’s care in any way. We are sending you 
this information sheet to read so you think about whether you would like to be involved. We will 
then phone you to discuss this further and answer any questions you may have. You will have 
further opportunities to ask questions if you bring your baby for the breathing tests.  We will then 
ask you to sign a consent form to show you have agreed to take part.  You are free to withdraw 
from this study at any time, without giving a reason.  
 
If we take part, what will this involve? 
We will invite you to Great Ormond St Hospital when your baby is around 3 months and one 
year of age to measure his/her lung function. Each visit will take about 3 hours in total. You can 
take your child home as soon as he/she is fully awake. 
 
A) Breathing Tests: 
The breathing tests are described below but we are also sending you a separate leaflet which 
shows some photos of the tests.  Breathing tests in babies are very safe and painless, but are 
only available at a few centres round Britain. We therefore need you to come to Great Ormond 
Street Hospital for Children (GOSH) for these tests. We will arrange the timing of these visits to 
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suit your family and all travel expenses will be refunded. You can stay with your child all the time 
that they are being tested. 
 
Older children and adults do breathing tests by taking deep breaths and blowing through special 
equipment. Babies are unable to co-operate in this way and therefore need to be asleep for the 
tests to be done. Babies do not always sleep for long during the day, so we give them a mild 
sleeping syrup called chloral hydrate to help them fall asleep. This medicine is often used in 
children and has been used for breathing tests in babies for over 25 years. Your baby will be 
able to feed before the tests and eat/drink normally as soon as they wake up. The tests do not 
upset the babies, who usually sleep through the whole process. It usually only takes about an 
hour to do all the tests but it is difficult to predict how quickly the baby will fall asleep, so it is best 
to allow about three hours for the visit. During the visit a research doctor will examine the baby 
and ask a few health questions.  
 
We use four tests to see how the lungs are developing and growing: 
 
a) Breathing Patterns using Electrical impedance tomography (EIT) and Structured Light 
Plethysmography (SLP) 
Most of the lung function tests we make require babies to be fast asleep, which is why we need 
to give some sedative syrup before we start. However, some new approaches are now being 
developed that could make it easier to obtain similar results without sedation. This would mean 
we could offer these assessments to far more babies with breathing problems and in hospitals 
without the special facilities available at GOS. The first technique simply involves placing small 
sticky pads around the baby’s chest. This allows us to record tiny changes which occur as the 
baby breathes in and out and tells us whether the air breathed in is being spread evenly over the 
lungs, or whether there are some parts of the lung which are getting less air (for example due to 
some obstruction of the airway). The pads will remain on the baby’s chest throughout the testing 
session. 
 
The second approach (SLP) is even more straightforward and simply involves projecting a light 
grid onto the baby’s chest and recording the movements of this grid with two overhead cameras 
as they breathe.  Several sets of measurements will be taken, each lasting approximately 1 
minute. The technique is entirely painless and non-invasive and does not require anything to be 
connected to your child.  There is no radiation involved. 
 
b) Multiple breath washout test 
This test is designed to find out how evenly your child breathes. The baby breathes in a special 
air mixture through a face mask which contains a small amount of a gas called Sulphur 
Hexafluoride (or SF6). SF6 is ‘inert’ which means that it does not cross from your child’s lungs 
into the blood stream, and has no taste or smell. The gas has been used safely at GOSH in 
babies and young children for the past 10 years and is used at many other specialist hospitals 
throughout the world. The baby breathes this mixture for a few minutes so that it mixes through 
the lungs. After a few minutes the gas mixture is swapped for normal air and we measure how 
quickly the baby breathes (or “washes”) out the SF6 from the lungs. Babies with normal lungs 
quickly wash out SF6 whereas babies with early lung disease take longer to clear the gas from 
their lungs.  
 
c) Lung volumes 
The third test measures how big the lungs are (lung volume). In order to do this the baby lies in 
a special cot (which looks a bit like a large incubator) and breathes air through a face mask. The 
cot has a transparent hood which is closed for 2-3 minutes so that we can record the tiny 
pressure changes that occur while your baby is breathing quietly.  
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d) Forced expiration 
This last breathing test measures how quickly your baby can breathe out. An inflatable jacket (like 
a small life jacket) is placed around the baby’s chest and tummy. Once the baby has taken a 
breath in we inflate the jacket. This gives a gentle squeeze to the chest and encourages air to be 
breathed out quickly. Babies with lung disease cannot blow out as much air or as quickly as babies 
with normal lungs.  
 
B) Other investigations:  
While you are at the laboratory, we will also weigh and measure your baby, and ask you a few 
questions about your family and your baby’s health.  We would also like to know about your 
views and experiences of being a part of this study. We will ask you to fill out a questionnaire 
once at the beginning and once at the end of the study.  
 
While the measurements are being made we will collect a urine sample from your baby. This 
will be sent to the laboratory to examine it for a substance which is produced when inflammation 
is broken down in the lungs and also for a substance which indicates passive exposure to 
tobacco smoke. This urine sample will be stored securely for six years and then destroyed. The 
reason for storing the extra urine is in case we need to look at the sample again in the future. 
You can be informed of any extended analysis if you wish.  
 
Are there any risks or discomfort for my baby? 
Breathing tests:  Since we can only perform the breathing tests while babies are sleeping quietly, 
we make sure that they remain comfortable at all times. The only time when they might object is 
while they are being given the spoonful of syrup (which has a slightly bitter taste), and when we 
are measuring them to see how tall they are. While the medicine is wearing off, which may take 
a few hours, you baby may remain a little sleepy and need to be watched carefully to ensure 
they do not tumble if they have already started to walk 
 
PART 2: Additional Information to be read before you decide whether to participate or not. 
 
Why is this study important? 
Children with Cystic Fibrosis are more prone to chest infections and repeated infections lead to 
lung damage. These infections may occur very early in life and some can go unnoticed (because 
the baby does not have an obvious cough or other symptoms). It is very important that these 
infections are detected and treated rapidly, using tests like those described for this study, to 
prevent irreversible damage to the lungs which may limit the child’s physical ability and lifestyle.  
 
Who will this study help? 
As a parent of a healthy child, participating in this study will not be of any direct benefit to your 
baby, but the information we obtain will help improve the treatment of children born with CF. It 
will help us to understand more about CF lung disease in the first few years of life, and which 
test, or combination of tests, is likely to be most useful in detecting early changes in the lungs. 
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and any information about you or your child will be 
handled in strictest confidence and only used in a way that will not allow you or your baby to be 
identified. 
 
Who has reviewed this Study?  
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed 
and given favourable opinion by the Research Ethics Committee at UCL, Institute of Child Health 
and GOS Hospital for Children who consider that it is addressing an important question 
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regarding treatment  of infants with CF and that there will be minimal risk to you or your child if 
you participate. 
 
What if there is a problem?  
In the extremely unlikely event that something does go wrong and you or your baby are harmed 
during the research and this is due to someone’s negligence then you may have grounds for a 
legal action for compensation  but you may have to pay your legal costs. The normal National 
Health Service complaints mechanisms will still be available to you.  
 
 All members of the infant lung function team will be happy to explain the tests and answer your 
questions. You may phone us at Great Ormond Street Hospital on 020 7405 9200 (ext. 5454), or if 
you cannot get through on this line, then contact our secretary, Jana Varma (Portex Unit) on 020 
7905 2382. 
 Dr Ah-Fong Hoo and Dr Jane Chudleigh, who will be organising the tests can also contacted via 
the above telephone numbers.  
 
Thank you for your time. 
 
Great Ormond Street Hospital for Children
NHS Trust and the Institute of Child Health
Breathing tests
for babies
Information for families
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Why do we need to measure babies’
lungs and breathing?
Breathing problems are very common in babies
and young children, for example:
• Some babies and young children are prone to
chest infections or wheezy episodes which
may continue through infancy and into adult
life.
• Premature and other small babies sometimes
have under-developed lungs and they may
need to be given oxygen or assisted
ventilation. Occasionally, they continue to
have breathing problems when they are older. 
• Very rarely, babies are born with serious lung
problems such as diaphragmatic hernia or
cystic fibrosis.
Breathing tests done soon after birth can help us
to understand more about how these problems
arise and how we can treat them.
We need your help 
in this work
To find out more about breathing
problems in sick babies, we need
to measure breathing patterns in
as many healthy infants as
possible. This is why we have a
special baby testing room at GOS
Hospital.
A member of our research team
may contact you to ask if you
would like to be involved in this
work.
What do breathing 
tests involve?
Breathing tests are carried out
while your baby sleeps and are
not at all painful or upsetting.
Young babies usually fall asleep
after a feed, but we usually need
to give older babies a spoonful of
sedative syrup that helps them to
sleep for about an hour. We then
gently place a small mask over
their mouth and nose. This is
attached to a meter (or sensor)
which monitors your baby’s
breathing, and the results are
displayed on a computer screen. 
For many years, a research team of doctors and nurses from
this hospital have been measuring breathing patterns in babies
in order to help prevent and treat chest problems in infants and
young children.
This leaflet is designed to explain simply and clearly the work
that we do – assessing the way babies’ lungs work.
A sleeping baby breathing
through a flow sensor
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We measure the amount of air
that your baby breathes, how fast
the air goes in and out, and how
much effort your baby is making.
One of the important pieces of
information that we need is how
much air the lung holds at the
end of each breath, and how
rapidly your baby can remove
waste gases that the body
produces (e.g. carbon dioxide)
from his/her lungs. We can do
this by giving your baby a special
air mixture to breathe for 1-2
minutes. This mixture has the
same amount of oxygen that your
baby normally breathes and is
completely harmless.
You may know that breathing
tests in older children and adults
involve taking a deep breath in,
and then breathing out as fast as
possible.
We obviously cannot ask a baby
to do this, but we are able to do
the same test by giving him/her
some help. We encourage your
baby to take a deep breath in by
providing extra air through the
facemask.
In order to help him/her to
breathe out quickly, a small jacket
(rather like a miniature life
jacket) is secured around the
chest and inflated when your
baby has taken a breath in.
This test has been performed many
times by the research team, and at
other centres around the world with
no problems. Babies usually stay
sound asleep.
For some tests, we may place your
baby in a special cot with a Perspex
hood, which looks rather like an
incubator so that we can measure
how big your baby’s lungs are.
What do we find out 
from these tests?
The infant lung function tests are
used to measure how much effort
your baby needs to make to breathe,
and how big their lungs and
breathing tubes (airways) are.
The lungs contain a huge network of
branching tubes, which look rather
like two upside-down trees. The air
can get in and out easily if the
airways are wide and the lung tissue is
stretchy.
When a baby has narrow airways or
stiff lungs, they have to work much
harder to breathe.
Babies usually sleep
through all these
measurements and
begin to wake towards
the end of the test or as
soon as it has finished.
A baby wearing the jacket
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Will the test hurt my baby?
No! The test does not involve any needles or painful procedures.
We need your baby to be sleeping quietly before we can make any
measurement, and so we try to make him/her as comfortable and
relaxed as possible.
How long will the test take?
The time of the test can be rather variable, depending upon when your
baby falls asleep. We try to fit in around your normal routine as far as
possible. If your baby wakes during the test, they can be fed or changed,
which can take a little time. Most tests are completed within two hours.
Can I come and watch?
Yes. We like parents to be actively involved in the tests and to ask
questions. You know your baby best, and so your help is very useful.
What happens afterward?
After the test, we measure your baby’s length and weight, and ask a few
questions that are relevant to the tests (e.g. family history of asthma).
We then take you and your baby back to the ward, or offer transport if
you have come from home.
Does my baby have to take part?
No. Taking part is your decision whether your baby has breathing
problems or is a ‘healthy control’. Your baby will receive all the care
they need whether or not you take part.
Questions  you may have
Where can I get more information?
Members of the Infant Lung Function Team will
be happy to answer any questions you may have.
You can contact us at the Lab on 
020 7405 9200 ext 5454, or our secretary
(Portex Unit) on 020 7905 2382.
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Great Ormond Street Hospital for Children NHS Trust and Institute of Child 
Health Research Ethics Committee REC Number: _09H071314 
 
 Consent Form for PARENTS OR GUARDIANS 
 of Children Participating in Research Studies 
 
 Early detection of lung disease in infants with CF diagnosed 
by newborn screening:  
 
 
NOTES FOR PARENTS OR GUARDIANS 
 
1. Your child has been asked to take part in a research study. The person organising that 
study is responsible for explaining the project to you before you give consent. 
 
2. Please ask the researcher any questions you may have about this project, before you 
decide whether you wish to participate. 
 
3. If you decide, now or at any other stage, that you do not wish your child to participate in 
the research project, that is entirely your right, and if your child is a patient it will not in any 
way prejudice any present or future treatment. 
 
4. You will be given an information sheet which describes the research project.  This 
information sheet is for you to keep and refer to.  Please read it carefully. 
 
5. If you have any complaints about the way in which this research project has been or is 
being conducted, please, in the first instance, discuss them with the researcher.  If the 
problems are not resolved, or you wish to comment in any other way, please contact the 
Head of the Research and Development Unit, Institute of Child Health, 30 Guilford Street, 
London WC1N 1EH or if urgent, by telephone on 0207 905 2179. 
 
 
Please initial boxes 
1. I confirm that I have read and understand the information sheet dated 18/03/2009 
(version 2) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily 
 
2. I understand that my participation is voluntary and that I am free to withdraw my 
child at any time without giving any reason, without his/her medical care or legal 
rights being affected 
 
3. I understand that relevant sections of my child’s medical notes and data collected 
during the study, may be looked at by individuals from regulatory authorities or from 
the NHS Trust, where it is relevant to taking part in this research. I give permission 
for these individuals to have access to my child’s records, and to use relevant 
information in subsequent scientific publications in a way that ensures neither I nor 
my child can be identified. 
 
4. I agree to my GP being informed of my child’s participation in the study.  
5. I agree for my child to take part in the above study.  
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________________________________  _______________ ___________________ 
Name of Parent/Guardian                          Date   Signature  
 
Relationship to child 
 
 
 
 
 
________________________________ ________________ ___________________  
Name of Person taking consent           Date                         Signature 
   
 
When completed, 1 copy for family; 1 copy for researcher site file; 1 (original copy) to be kept in 
medical notes 
 
 
 
NOTES FOR THE RESEARCHER 
 
 It is your responsibility to ensure that the parents/guardians and child (if mature 
enough) understand what the research project involves, both theoretically and 
practically.  You must allow sufficient time to do this.  You must make the 
judgement of whether or not the child can understand the project.  Age alone is 
not important.  Make sure that the relatives or child can contact you if they have 
additional questions. 
 
 A copy of this completed form must be placed in the patient's clinical records and 
a copy must be kept by you with the research records. 
 
 If there are any unforeseen ethical problems with this study you must inform [a 
representative of the sponsor] and follow this up in writing.  
 
A5 Test Study Questionnaires 
 
 Initial and subsequent test study questionnaires for CF Infants 
 
 Initial and subsequent test study questionnaires for Healthy Control Infants 
 
 
 
A6 Lung Function Test Record Form for Infants 
 
 
Subject No: 5 3    Hospital Number:__________________ 
Subject ID:     NHS number:___________________________ 
Date        
 
CF_GOSH  1 
 
Questionnaire for GOSH CF referral 
 
Background Information 
 
Baby's surname: Date of Birth        
        First name:        
 Birth weight       kg 
 EDD       
 Gestational age    w +  d 
 
Sex Male    Female Date of test 1        
 Date of test 2        
         
Mother’s first name  Mother’s last name  
Mother’s DOB  Mother’s email  
Father's first name  Father’s last name  
Father’s DOB  Father’s email  
  Child’s address 
 
 
 
 
 
 
 
 
Telephone number            Home 
or            Mum work 
or            Mum mobile 
or            Dad work 
or            Dad mobile 
or            Other 
 
Social History: 
 
Does the child’s natural mother have parental responsibility? Yes No Not sure 
 
Mother's most recent job (title/description, state if self-employed): 
 
 
Father's current job (title/description, state if self-
employed): 
(For later coding)    
Subject No: 5 3    Hospital Number:__________________ 
Subject ID:     NHS number:___________________________ 
Date        
 
CF_GOSH  2 
 
 
 
 
 
 
Mother's ethnic origin   Father's ethnic origin  
White/British   White/British  
White/Irish   White/Irish  
Other White   Other White  
Black-Caribbean   Black-Caribbean  
Black-African   Black-African  
Black-other   Black-other  
White-Black-Caribbean   White-Black-Caribbean  
White-Black-African   White-Black-African  
White-Asian   White-Asian  
Other mixed   Other mixed  
Pakistani   Pakistani  
Bangladeshi   Bangladeshi  
Indian   Indian  
Chinese   Chinese  
Other Asian   Other Asian  
Other   Other  
 
Number of siblings:  
Number of older siblings:  
Day care: No Yes, Nursery Yes, Child Minder Age when started (months)  
 
Recruitment centre  Date of recruitment       
Referring LCFC 
Consultant 
  
Date of referral 
      
GOSH Consultant  
 
Local Paediatrican Name: GP's name: 
Address: Practice address: 
  
  
  
Telephone no: Practice tel no: 
 
 
(For later coding)    
Years mother spent in full time education after the age of 16:  
Subject No: 5 3    Hospital Number:__________________ 
Subject ID:     NHS number:___________________________ 
Date        
 
CF_GOSH  3 
Date of Diagnosis       
 
Genotype 
(if and when 
known) 
Mutation one Mutation two 
  
 
Presentation 
 
Mode(s) of Presentation   Sweat Test 
Result 
 
 Repeat 
Sweat Test Result 
 
 
Asymptomatic   Positive  Positive  
Meconium ileus   Negative  Negative  
Failure to thrive/malabsorption   Borderline  Borderline  
Recurrent chest infections   Not Done  Not Done  
Recurrent wheezy episodes       
Prolonged jaundice       
Biochemical abnormalities   Cl
- 
 Cl
- 
 
Rectal Prolapse   Na
2+ 
 Na
2+ 
 
Antenatal bowel pathology   Osmol  Osmol  
Family history       
Screening       
 
 
Recorded Diagnosis/Diagnoses, 
including CF and any Congenital 
Abnormalities: 
 
 
Significant neonatal history (if admitted for special care, document reason) 
 
 
 
Duration Exclusively breastfed (weeks)  
 
Number of respiratory admissions before diagnosis:  
Number of respiratory admissions between diagnosis and before first RFTs:  
URTI  LRI  
 
Has a doctor diagnosed upper airway 
obstruction in your child? 
Yes No Not 
sure 
 
Subject No: 5 3    Hospital Number:__________________ 
Subject ID:     NHS number:___________________________ 
Date        
 
CF_GOSH  4 
Family medical History: 
 
Does anyone in your family have cystic fibrosis? 
 
None  Mother  Brother  Grandfather  Niece  
  Father  Half-sibling  Aunt  Nephew  
  Sister  Grandmother  Uncle  Cousin  
 
Family history of atopy: Have any of the people below been diagnosed with the 
following by a doctor? 
 
 Mother Father Sister Brother Half-sibling 
Asthma      
Wheezing      
Eczema      
Hay Fever      
 
Additional 
information: 
 
 
 
Source of information:   
 
Are there any reasons for exclusion from study? 
 
History of apnoeic episode  Neonatal lung disease  
Upper airway pathology  Heart, lung, renal disease  
Failure to thrive  Parental psycho-social reasons  
Lack of Understanding   
 
 
Does your child have any other disease congenital or acquired? Yes No 
 
If so, what is the other 
problem? 
 
 
 
Study number 5 3    Test occasion: 01                    Date       
 
CF_GOSH  1 
Questionnaire for GOSH CF Referral 
 
Information From Parent at First Visit Only 
 
Baby's name: Date of Birth        
 
Time of arrival at test site      
(oral) chloral sedation:  Yes / No   Dose of sedation given:                    mg/ kg             
Time of administration of sedation      
Time of sleep      
Time of test commencement      
Time of leaving test site      
Number of sleep epochs required to complete test:  
 
Barometric Pressure           mbar  Face mask: type /size  
Temperature        C  PNT Size (MBW)  
Humidity        %  PNT Size (Jaeger)  
     
Operators    
 
Test MBW Tidal Pleth Crs RTC RVRTC EIT Other 
Order         
Data acceptable?         
 
Physical examination at time of test: Performed by: 
 
Wheezes Yes / No                    Crackles Yes / No 
Pre sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
Post sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
 
Remainder of clinical examination normal: Yes No – comment: 
  
 
Anthropometry: Weight      kg 
 
Crown-heel length     cm   OFC     Cm 
 
Whether the child has any atopic disorder? Yes No Not known 
Whether the child has developed eczema? Yes No Not known 
Respiratory problems other than CF? No Not known Yes (details?) 
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CF_GOSH  2 
Non-respiratory medical problems? No  Not known 
If Yes, please give details: 
 
Note: all symptoms of cough or wheeze should be considered CF related and should not be 
recorded here. 
 
Hospital admissions since birth, the following information is required for each: 
Date of admission; reason for admission; hospital name; date of discharge; whether in-patient treatment for a 
respiratory infection included I/V antibiotics; Duration and type of any ventilation. 
 
Date Admitted 
/ Discharged 
Reason and hospital name 
 
Ventilation 
(Date/duration) 
(Mode/Modes used) 
IV/Inhaled 
Antibiotics 
(for chest) 
     
     
     
     
     
 
Intermittent antibiotic therapy 
 
For each parameter record number of courses and name of drug (if applicable) received since diagnosis: 
Date Reason for course 
(respiratory/nonrespiratory) 
Location 
(Home/Hosp/Both) 
Route 
(Oral/IV/Inhaled) 
Total 
(Number) 
     
     
     
 
Whether the child has had bronchiolitis? Yes No Not known 
Number of admissions for bronchiolitis since birth?  
 
Number of admissions for respiratory illnesses (excl above) since birth?  
 
 
Any operations since birth: 
 
 
 
  
Whether the child has ever needed mechanical ventilation since 
birth? 
Yes No Not known 
Date ventilation started:   No. of days ventilated  
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Medications Occasion 1: Tick all current medications 
 
Pulmonary Yes No 
Antibiotics – oral (not quinolones)   
Antibiotics – inhaled   
Corticosteroids   
Bronchodilators (specify):    
Mucolytics   
Oxygen   
   
 
Nutritional Yes No 
Pancreatic enzymes   
H2 Blockers   
Proton Pump Inhibitors   
Motility agents   
Vitamin supplements   
 
Has your child ever been prescribed a bronchodilator ? Yes No 
 
Has your child had a bronchodilator in the last 12 hours? Yes No 
 
Hours since bronchodilator given               hrs 
  
Has your child had a cold in the last 3 weeks?   Yes  / No 
   
URTI in last 3 weeks  No   
  Yes but asymptomatic for  days 
  Yes and still symptomatic   
 
How often has your child coughed and has he/she wheezed in the last 7 days? 
Cough None With physio only Not just with physio, but not daily Daily 
 
Wheeze Yes No Don’t Know 
 
Physiotherapy given?  not at all  Once a day  times a day 
 
No. of hours since last physio session:   hrs 
 
Smoking History 
 
Mother's smoking habit: How many cigarettes a day did you smoke during your pregnancy?  
Not at all     
Yes  Number of cigarettes per day    
Unknown  If gave up, when? (Weeks)   
 
Does mother smoke now?                   No   Yes    cigarettes a day 
Does mother’s partner smoke now?                  No   Yes    cigarettes a day 
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Number of smokers living in the same house as the infant (including mother)   smoker(s) 
 
Child Regularly exposed to non-household smoking?  No  Yes 
Exposure to any other cigarette smoke in the past 24hrs?  No  Yes 
If yes - Who?   
 
Has urine been collected? Yes  No 
Has saliva been collected? Yes No 
 
Cough Swab taken?  Yes No Date       
 
Microbiology from cough swabs (note all cultures identified) 
Pseudomonas aeruginosa NMuc E. coli Burkholderia cepacia 
Pseudomonas aeruginosa  Muc Aspergillus Streptococcus pneumoniae 
Staphylococcus aureus S. maltophilia Grp A Strep 
Enterobacter Serratia Marescens  
Haemophilus influenzae MRSA No growth / Normal flora 
Candida Klebsiella 
 
 
 
Specimen  
(BAL/Cough Swab/Sputum) 
Date 
 
Recorded Cultures 
(See list – include no growth)  
        
        
        
 
Date and result of 
CXR: 
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Questionnaire for GOSH CF Referral 
 
Information From Parent at Subsequent Visit Only 
 
Baby's name: Date of Birth        
 
Time of arrival at test site      
(oral) chloral sedation:  Yes / No   Dose of sedation given:                    mg/ kg             
Time of administration of sedation      
Time of sleep      
Time of test commencement      
Time of leaving test site      
Number of sleep epochs required to complete test:  
 
Barometric Pressure           mbar  Face mask: type /size RB /  1,  2   (circle) 
Temperature        C  PNT Size (MBW) Fleisch  0 
Humidity        %  PNT Size (Jaeger) S 
     
Operators    
 
Test MBW Tidal Pleth Crs RTC RVRTC EIT CT Bronch Other 
Order           
Data acceptable?           
 
Physical examination at time of test: Performed by: 
 
Wheezes Yes / No                    Crackles Yes / No 
Pre sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
Post sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
 
Remainder of clinical examination normal: Yes No – comment: 
  
 
Anthropometry: Weight      kg 
 
Crown-heel length     cm   OFC     Cm 
 
 
pH study performed 
since previous visit 
Yes   No 
If Yes – date & result       
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BAL performed 
since previous visit 
Yes   No 
If Yes – date & result       
 
Date and result of CXR: Yes No If Yes – date & result       
Yes No If Yes – date & result       
If CT/BAL booked state date Yes No If Yes – date & result       
          
 
Whether the child has any atopic disorder? Yes No Not known 
Whether a doctor has ever diagnosed asthma? Yes No Not known 
Whether the child has developed eczema? Yes No Not known 
Whether the child has developed hay fever? Yes No Not known 
 
Respiratory problems 
other than CF? 
No  Not known Yes (Details):  
Non-respiratory medical problems? No  Not known 
If Yes, please give details: 
 
Note: all symptoms of cough or wheeze should be considered CF related and should not be 
recorded here. 
 
Hospital admissions since birth, the following information is required for each: 
Date of admission; reason for admission; hospital name; date of discharge; whether in-patient treatment for a 
respiratory infection included I/V antibiotics; Duration and type of any ventilation. 
 
Admitted / 
Discharged 
 
Reason and hospital name 
 
Ventilation 
(Date/duration) 
(Mode/Modes used) 
IV/Inhaled 
Antibiotics 
(for chest) 
     
     
     
     
     
 
Intermittent antibiotic therapy 
 
For each parameter record number of courses and name of drug (if applicable) received since diagnosis: 
Date Reason for course 
(respiratory/nonrespiratory) 
Location 
(Home/Hosp/Both) 
Route 
(Oral/IV/Inhaled) 
Total 
(Number) 
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Whether the child has had bronchiolitis since last LFT? Yes No Not known 
Number of admissions for bronchiolitis since last LFT?  
 
Number of admissions for respiratory illnesses (excl above) since last LFT?  
 
 
Any operations since last LFT: 
 
 
 
 
Whether the child has needed mechanical ventilation since last 
LFT? 
Yes No Not 
known 
Date ventilation started:   No. of days ventilated  
 
Medications Occasion 1: Tick all current medications 
 
Pulmonary Yes No 
Antibiotics – oral (not quinolones)   
Antibiotics – inhaled   
Corticosteroids   
Bronchodilators (specify):    
Mucolytics   
Oxygen   
   
 
Nutritional Yes No 
Pancreatic enzymes   
H2 Blockers   
Proton Pump Inhibitors   
Motility agents   
Vitamin supplements   
 
Has your child been prescribed a bronchodilator since last 
LFT ? 
Yes No 
 
Has your child had a bronchodilator in the last 12 hours? Yes No 
 
Hours since bronchodilator given                 hrs 
 
Has your child had a cold in the last 3 weeks? 
 
URTI in last 3 weeks  No   
  Yes but asymptomatic for  days 
  Yes and still symptomatic   
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How often has your child coughed and has he/she wheezed in the last 7 days? 
 
Cough None With physio only Not just with physio, but not daily Daily 
 
Wheeze Yes No Don’t Know 
 
 
Physiotherapy given?  not at all  once a day  times a day 
 
No. of hours since last physio session:   hrs 
 
Smoking History 
 
Does mother smoke now?                   No   Yes    cigarettes a day 
Does mother’s partner smoke now?                  No   Yes    cigarettes a day 
 
Number of smokers living in the same house as the infant (including mother)   smoker(s) 
 
Child Regularly exposed to non-household smoking?  No  Yes 
Exposure to any other cigarette smoke in the past 24hrs?  No  Yes 
If yes - Who?   
 
Has urine been collected? Yes  No 
Has saliva been collected? Yes No 
 
Cough Swab taken?  Yes No Date      
 
Microbiology from cough swabs (note all cultures identified) 
Pseudomonas aeruginosa NMuc E. coli Burkholderia cepacia 
Pseudomonas aeruginosa  Muc Aspergillus Streptococcus pneumoniae 
Staphylococcus aureus S. maltophilia Grp A Strep 
Enterobacter Serratia Marescens  
Haemophilus influenzae MRSA  
Candida Klebsiella No growth / Normal flora 
 
Specimen  
(BAL/Cough Swab/Sputum) 
Date 
 
Recorded Cultures 
(See list – include no growth)  
        
        
        
 
 
 
Subject No: 5 3    Hospital Number:__________________ 
Subject ID:     NHS number:___________________________ 
Date        
 
CF_GOSH  1 
 
Questionnaire for GOSH Healthy Control 
 
Background Information 
 
Baby's surname: Date of Birth        
        First name:        
 Birth weight       kg 
 EDD       
 Gestational age    w +  d 
 
Sex Male    Female Date of test 1        
 Test 1 ID        
 Date of test 2        
         
Mother’s first name  Mother’s last name  
Mother’s DOB  Mother’s email  
Father's first name  Father’s last name  
Father’s DOB  Father’s email  
  Child’s address 
 
 
 
 
 
 
 
 
Telephone number            Home 
or            Mum work 
or            Mum mobile 
or            Dad work 
or            Dad mobile 
 
Social History: 
 
Does the child’s natural mother have parental responsbility? Yes No Not sure 
 
Mother's most recent job (title/description- state if self-employed): 
 
 
Father's current job (title/description- state if self-
employed): 
(For later coding)    
Subject No: 5 3    Hospital Number:__________________ 
Subject ID:     NHS number:___________________________ 
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Mother's ethnic origin   Father's ethnic origin  
White/British   White/British  
White/Irish   White/Irish  
Other White   Other White  
Black-Caribbean   Black-Caribbean  
Black-African   Black-African  
Black-other   Black-other  
White-Black-Caribbean   White-Black-Caribbean  
White-Black-African   White-Black-African  
White-Asian   White-Asian  
Other mixed   Other mixed  
Pakistani   Pakistani  
Bangladeshi   Bangladeshi  
Indian   Indian  
Chinese   Chinese  
Other Asian   Other Asian  
Other   Other  
 
Number of siblings:  
Number of older siblings:  
Day care: No Yes, Creche Yes, Child Minder Age when started (months)  
 
 
GP's name: 
Practice address: 
 
 
 
Practice tel no: 
 
 
 
 
 
 
(For later coding)    
Years mother spent in full time education after the age of 16:  
Subject No: 5 3    Hospital Number:__________________ 
Subject ID:     NHS number:___________________________ 
Date        
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Significant neonatal history (if admitted for special care document reason) 
 
 
 
Duration Exclusively breastfed  
 
Family medical History: 
 
Does anyone in your family have cystic fibrosis? 
 
None  Mother  Brother  Grandfather  Niece  
  Father  Half-sibling  Aunt  Nephew  
  Sister  Grandmother  Uncle  Cousin  
 
Family history of atopy: Have any of the people below been diagnosed with the 
following by a doctor? 
 
 Mother Father Sister Brother Half-sibling 
Asthma      
Wheezing      
Eczema      
Hay Fever      
 
 
Additional 
information: 
 
 
 
Source of information:   
 
 
Are there any reasons for exclusion from study? 
 
History of apnoeic episode  Neonatal lung disease  
Upper airway pathology  Heart, lung, renal disease  
Failure to thrive  Parental psycho-social reasons  
Lack of Understanding  History of bronchiolitis  
 
Does your child have any other disease congenital or acquired? Yes No 
 
If so, what is the other 
problem? 
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Study No 5 3    Test occasion: 01                    Date       
Hospital No   
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Questionnaire for GOSH Healthy Controls 
 
Information From Parent at First Visit Only 
 
Baby's surname: Date of Birth        
        First name:        
 
Time of arrival at test site      
Sedation preparation used  
Dose of sedation given                            mg/kg 
Time of administration of sedation      
Time of sleep      
Time of test commencement      
Time of leaving test site      
Number of sleep epochs required to complete test:  
 
Barometric Pressure           mbar  Face mask: type /size  
Temperature        C  PNT Size (MBW)  
Humidity        %  PNT Size (Jaeger)  
     
Operators    
 
Test MBW Tidal Pleth Crs RTC RV-RTC EIT Other 
Order         
Data 
acceptable? 
        
 
Physical examination at time of test: Performed by: 
 
Wheezes Yes / No                    Crackles Yes / No 
Pre sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
Post sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
 
Remainder of clinical examination normal: Yes No – comment: 
  
 
Anthropometry 
 
Weight      kg  Crown-heel length     cm 
Study No 5 3    Test occasion: 01                    Date       
Hospital No   
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OFC     Cm 
 
Whether the child has any atopic disorder? Yes No Not known 
Whether the child has developed eczema? Yes No Not known 
 
 
 
Any operations since birth: 
 
 
 
Whether the child has needed mechanical ventilation? Yes No Not 
known 
Date ventilation started:   No. of days ventilated  
 
Has your child had a cold in the last 3 weeks? 
 
URTI in last 3 weeks  No   
  Yes but asymptomatic for  days 
  Yes and still symptomatic   
 
How often has your child coughed and has he/she wheezed in the last 7 days? 
 
Occasion 1 
Cough None With physio only Not just with physio, but not daily Daily 
 
Wheeze Yes No Don’t Know 
 
Smoking History 
 
Mother's smoking during pregnancy: How many cigarettes a day did you smoke 
during your pregnancy?  
Not at all     
Yes  Number of cigarettes per day    
Unknown  If gave up, when? (Weeks)   
 
Does mother smoke now?                   No   Yes    cigarettes a day 
Does mother’s partner smoke now?                  No   Yes    cigarettes a day 
 
Number of smokers living in the same house as the infant (including mother)   smoker(s) 
 
Child Regularly exposed to non-household smoking?  No  Yes 
Exposure to any other cigarette smoke in the past 24hrs?  No  Yes 
Study No 5 3    Test occasion: 01                    Date       
Hospital No   
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If yes - Who?   
 
Has urine been collected? Yes  No 
Has saliva been collected? Yes No 
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Questionnaire for GOSH Healthy Control 
 
Information From Parent at visit 2 and subsequent visits  
 
 
Baby's surname: Date of Birth        
        First name:        
 
Time of arrival at test site      
Sedation preparation used  
Dose of sedation given                            mg/kg 
Time of administration of sedation      
Time of sleep      
Time of test commencement      
Time of leaving test site      
Number of sleep epochs required to complete test:  
 
Barometric Pressure           mbar  Face mask: type /size  
Temperature        C  PNT Size (MBW)  
Humidity        %  PNT Size (Jaeger)  
     
Operators    
 
Test MBW Tidal Pleth Crs RTC RV-
RTC 
EIT Other 
Data 
acceptable? 
        
Order         
 
Physical examination at time of test: Performed by: 
 
Wheezes Yes / No                    Crackles Yes / No 
Pre sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
Post sedation 
Respiratory rate   bpm SaO2   %          Mean HR    
 
Remainder of clinical examination normal: Yes No – comment: 
  
 
Anthropometry 
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Weight      kg  Crown-heel length     cm 
OFC     Cm 
 
Whether the child has any atopic disorder? Yes No Not known 
Whether a doctor has ever diagnosed asthma? Yes No Not known 
Whether the child has developed eczema? Yes No Not known 
Whether the child has developed hay fever? Yes No Not known 
 
Respiratory problems 
developed since last test? 
No  Not known Yes:  
Non-respiratory medical problems? No  Not known 
If yes, please give details:  
 
Hospital admissions since last LFT, the following information is required for each: 
Date of admission; reason for admission; hospital name; date of discharge; whether in-patient treatment for a 
respiratory infection included I/V antibiotics; Duration and type of any ventilation. 
 
Date admitted / 
Discharged 
Reason and hospital name 
 
Ventilation 
(Date/duration) 
(Mode/Modes used) 
    
    
    
    
    
 
Whether the child has had bronchiolitis? Yes No Not known 
Number of admissions for bronchiolitis since last test?  
 
Number of admissions for respiratory illnesses (excl above) since last test?  
 
 
Any operations since last 
test: 
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Whether the child has needed mechanical ventilation? Yes No Not 
known 
Date ventilation started:   No. of days ventilated  
 
Medications Occasion 1: Tick all current medications 
 
Pulmonary Yes No 
Antibiotics – oral    
Corticosteroids   
Bronchodilators (specify):    
   
 
 
Has your child ever been prescribed a bronchodilator ? Yes No 
 
Has your child had a bronchodilator in the last 12 hours? Yes No 
 
Hours since bronchodilator given Occ 1 
 
 
Has your child had a cold in the last 3 weeks? 
 
URTI in last 3 weeks  No   
  Yes but asymptomatic for  days 
  Yes and still symptomatic   
 
How often has your child coughed and has he/she wheezed in the last 7 days? 
 
 
 
Smoking History 
 
Does mother smoke now?                   No   Yes    cigarettes a day 
Does mother’s partner smoke now?                  No   Yes    cigarettes a day 
 
Number of smokers living in the same house as the infant (including mother)   smoker(s) 
 
Child Regularly exposed to non-household smoking?  No  Yes 
Exposure to any other cigarette smoke in the past 24hrs?  No  Yes 
If yes - Who?   
 
Has urine been collected? Yes  No 
Has saliva been collected? Yes No 
 
 Lung Function Lab, Level 6, Cardiac Wing  
Tel: 020 7405 9200 extension 5454 / 0404 
Direct Line: 020 7905 2382 (Secretary) 
 
LUNG FUNCTION TESTS FOR INFANTS 
 
  
 
 
Copies to: a) GOSH medical notes;  b) GOSH Lung Function Lab;  c) referring consultant;  d) local consultant       v.13May2009 
 
 
GOS Hospital No:    Referring Consultant: Dr. 
      Referring Hospital: 
Child’s name:     Referring Hospital number: 
DOB:   male / female   
 
Test date:    Study no:       (test:          )        Time of arrival:                hrs 
 
Weight (kg)                       Crown-Heel length 
(cm) 
    
 
Physical Examination 
Clinician name: ………………………..……… Signature:………………………… 
 
Wheeze:   Yes   No Crackles:  Yes   No 
Was overall physical examination normal?  Yes  No  
__  Comments: 
 
 
Cough swab taken?   Yes   No Comments: 
 
Sedation: Chloral Hydrate ……………….. mg given orally at ……………….. hrs 
Any observed adverse effects from sedation  No        Yes   
 
Comments: 
 
Pre-sedation: oxygen saturation: ………….. %  RR: …….… bpm Heart rate: ……….. bpm 
Post sedation: oxygen saturation: ………….. %  RR: ….…… bpm Heart rate: ……….. bpm 
 
On Completion of Lung Function Test 
(a) Is infant fully arousable / responsive?       Yes        No         
 
 
 
(b) Taken a Feed / Drink?  Yes        No         
Comments: 
 
Time of departure: ……………. hrs  
Lung function tests performed by:  ………………………  /  ……………………… 
Present at tests:  Yes      No      parents / relative  
 
Post test phone call made by:                                               Date & Time:                       
Comments: 
Comments: 
A7 Standardised Treatment Protocol for CF Infants 
 
 
 
 
A8 Clinical Record Form for CF Infants 
 
 
A9 Infection Control and Cleaning Protocol for Equipment 
 
 
 
 
 
June 2009 
   1 
APPENDIX 2: ANTIBIOTIC PROTOCOL:   
EARLY DETECTION OF LUNG DISEASE IN NEWBORN SCREENED INFANTS WITH CF 
 
A. Definition of chest exacerbation 
 
Background: Many studies have followed the definition of an exacerbation first used in the 
Genentech DNase study [1]. Their protocol-defined exacerbation was confirmed when the 
patient had 4 or more of the following 11 criteria: 
1. adverse change in sputum production (volume, colour, consistency);  
2. new or increased haemoptysis;  
3. increased cough; 
4. increased dyspnoea;  
5. malaise, fatigue and lethargy;  
6. fever > 38ºC;  
7. anorexia or weight loss;  
8. sinus pain,  
9. tenderness or discharge;  
10. FEV1 or forced vital capacity (FVC) drop of 10% or more from previous recording;  
11. adverse changes in chest sounds on auscultation (crackles, wheeze); chest radiographic 
changes.  
 
However, many clinicians and investigators feel that in practice this definition of an exacerbation 
is too strict, as most clinicians would not wait for 4 criteria to be satisfied before instituting 
therapy. For example, an increase in purulent sputum accompanied by a fall in FEV1 of over 
10% would almost always lead to a course of antibiotics on the assumption the patient had a 
chest exacerbation (even though only two criteria were satisfied for the study definition). 
Furthermore, many patients would be treated with intravenous antibiotics if they felt ‘not quite 
right’ and had a big event like an exam coming up for which they really needed to be well. 
 
A newer definition has been derived from North American ESCF data, which for patients 6 years 
or older has suggested 3 out of 4 of  
1. decreased FEV1, 
2. increased cough frequency,  
3. new crackles and  
4. haemoptysis [2].  
 
This is, however, still unsuitable for the infants in our study as lung function will only be 
measured intermittently (3 and 12 months when the child is clinically stable) and haemoptysis 
almost never occurs in this age group. Indeed defining an exacerbation is far more difficult in 0-2 
year olds as we have no access to spontaneously expectorated sputum or regular lung function, 
which form the main clinical criteria in older children, and there is in any case no validated 
definition in this age group even from centres where regular infant lung function is available.  
 
Rather than come up with yet another definition, for the purposes of this collaborative study, it 
has been decided to use the pragmatic definition of new courses of antibiotics determined by 
the treating clinician, as a substitute, as used in CF WISE [3]. The actual reasons for the 
antibiotic course will be recorded prospectively. Any new course (oral or intravenous) of either 
hospital or home-administered antibiotic will be recorded as a single event, and a change of 
drug once antibiotic sensitivities are known does not count as a new antibiotic event [3]. Routine 
3-monthly intravenous antibiotics will not count as a new course and in any case are unlikely to 
be implemented in under two year olds (currently, no participating centre has an infant this 
young on this regime).  
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Conclusion: New courses of antibiotics rather than a protocol-defined exacerbation will 
be used as an outcome (excluding those given prophylactically for increased home infection 
exposure etc). For primary care prescribing of antibiotics, the data extracted from the primary 
care databases will enable matching of antibiotic prescription to corresponding event read code, 
i.e. LRTI, thereby enabling identification of new courses of antibiotics from those prescribed as 
prophylaxis. For hospital prescribed courses, this would be captured in the study CRF.  
 
1. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein 
BJ, Smith AL, Wohl ME for the Pulmozyme Study Group. Effect of aerosolized recombinant 
human DNase on exacerbations of respiratory symptoms and on pulmonary function in 
patients with cystic fibrosis. N Engl J Med 1994 331:637–42. 
2. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan 
MW, Regelmann WE; Epidemiologic Study of Cystic Fibrosis. Pulmonary exacerbations in 
cystic fibrosis. Pediatr Pulmonol 2004;37:400–6.  
3. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, Elborn JS, on behalf of the CF 
WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators. Multicenter randomized 
controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Resp Crit Care 
Med 2006;173:1356-62. 
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B. Treatment protocol for infants with CF diagnosed by NBS 
 
1. Cough swabs 
 
All infants in the study to have cough swabs done at all clinic visits, and as a minimum of 2-3 
monthly using a standard protocol for collection, storage and analysis of samples.1  
 
 
2. Oral flucloxacillin prophylaxis dose  
 
3 to < 5 kg  125 mg bd     
5 to < 9 kg   175 mg bd    
9-15 kg (~1-2 y) 250 mg bd     
 
Based on therapeutic dose given twice daily to achieve MIC for Staphylococcus Aureus with 
each dose. 
 
 
3. Pseudomonas aeruginosa (PsA) 
 
a. First growth 
 
Cough swabs to be done at monthly intervals while on treatment. 
 
Well child (clinical judgment), home therapy:2 
  
 Oral Ciprofloxacin 15mg/kg bd for 3 weeks, PLUS  
 Nebulised Colistin 1 mu bd for 3 months 
 
Unwell child (clinical judgment), hospital therapy - 
The choice of the initial IV antibiotics will be independent of sensitivities and if necessary tailored 
once sensitivities are known3;4 
 
 IV tobramycin 10 mg/kg once daily for 2 weeks (trough level 23 hours after 2nd dose, 
must be < 1 mg/l), PLUS 
 IV ceftazidime 50 mg/kg three times a day  
 
 Also start nebulised Colistin 1 mu bd for 3 months, (initiated in hospital as appropriate). 
 
 
b. Re-growth during the initial 3 month treatment period (whilst still on colistin) 
 
Well child  
 
 Give a further 3 weeks Ciprofloxacin 15mg/kg bd for 3 weeks 
 
Unwell child  
 
 IV Tobramycin and Ceftazidime for 2 weeks then further 3 months nebulised colistin 
(doses as above). 
 
 OR If IV antibiotics already given at 1st isolation, can give 3 weeks ciprofloxacin and further 
3 months nebulised colistin (if 2nd IVAB  course inappropriate). 
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c. Regrowth at end of 3 months nebulised colistin course 
 
 Admit for 2 weeks of IV antibiotics (tobramycin and ceftazidime) and 3 further months 
nebulised Colistin (1 mu bd) or TOBI (300mg bd). 
 
 
d. Regrowth after IVs and at least 6 months of nebulised colistin 
 
 Try 28 days nebulised TOBI ™ 5 and then continuous nebulised colistin 1 mu bd for a 
further six months. In practice this is unlikely to arise during the study  
 
 
e. Regrowth > 6 months from first growth 
 
 Treat as for 3a ie first growth. 
 
 
f. Chronic Pseudomonas Infection 
 
Defined for analysis purposes by the Leeds criteria:6 
 Never  never cultured 
 Free  cultured previously but not in last year 
 Intermittent cultured in < 50% of samples in past year  
Chronic cultured in > 50% of samples in past year 
 
 
4. Staphylococcus aureus 
 
a. First growth 
 
Well child (clinical judgment), home therapy: 
 
 Oral augmentin duo (400/57) 0.3 mls/kg bd for 2 (minimum) to 4 weeks (clinical judgment) 
 
 or equivalent dose of co-amoxiclav syrup tds  
<1 year 0.25ml/kg TDS Augmentin 250/62; >1 - 2 yrs 5ml TDS Augmentin 250/62 
 for 2 (minimum) to 4 weeks (clinical judgment) 
 
Unwell child (clinical judgement), hospital therapy:   
  
 Tobramycin 10 mg/kg once daily (trough level 23 hours after 2nd dose, must be < 1 mg/l), 
for 2 weeks, PLUS 
 Teicoplanin 10 mg/kg 12 hrly for 3 doses then 6mg/kg once daily for 2 weeks total 
 
 
b. Re-growth after more than 6 months from first growth 
 
 Treat as for 4a ie first growth. 
 
 
c. Re-growth less than 6 months from first growth 
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 Oral flucloxacillin 50mg/kg bd for 28 days   
 
 
d. Further re-growth within 6 months 
 
 Two oral anti-staphylococcal antibiotics (clinical judgment) for 28 days. 
 
 
5. Haemophilus influenzae 
 
a. First growth 
 
Well child (clinical judgement), home therapy: 
 
 Oral augmentin duo (400/57) 0.3 mls/kg bd for 2 (minimum) to 4 weeks (clinical judgment) 
 
 or equivalent dose of co-amoxiclav syrup tds  
<1 year 0.25ml/kg TDS Augmentin 250/62; >1 - 2 yrs 5ml TDS Augmentin 250/62 
 for 2 (minimum) to 4 weeks (clinical judgment) 
 
Unwell child (clinical judgement), hospital therapy: 
 
 IV tobramycin 10 mg/kg once daily for 2 weeks (trough level 23 hours after 2nd dose, 
must be < 1 mg/l), PLUS 
 IV ceftazidime 50 mg/kg three times a day  
 
  
b. Re-growth after more than 6 months from first growth 
 
 Treat as for 5a ie first growth 
 
 
c. Re-growth less than 6 months from first growth 
 
 Oral augmentin duo (400/57) 0.3 mls/kg bd for 2 (minimum) to 4 weeks (clinical judgment) 
 
 or equivalent dose of co-amoxiclav syrup tds  
<1 year 0.25ml/kg TDS Augmentin 250/62; >1 - 2 yrs 5ml TDS Augmentin 250/62 
 for 2 (minimum) to 4 weeks (clinical judgment) 
d. Further re-growth within 6 months 
 
 Clarithromycin 62.5-125mg daily for 14-28 days. In practice this is unlikely to arise during 
the study  
 
 
6. Other growths 
 
 Well child (clinical judgment), home therapy: Oral antibiotic (clinical judgment) for 2 
(minimum) to 4 weeks  
 
 Unwell child (clinical judgment), hospital therapy: 2 IV antibiotics (clinical judgment) for 2 
weeks  
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7. Viral URTI (otherwise well child) 
 
 Oral augmentin duo (400/57) 0.3 mls/kg bd for 2 (minimum) to 4 weeks (clinical judgment) 
 
 or equivalent dose of co-amoxiclav syrup tds  
<1 year 0.25ml/kg TDS Augmentin 250/62; >1 - 2 yrs 5ml TDS Augmentin 250/62 
 for 2 (minimum) to 4 weeks (clinical judgment) 
 
Cough swab, treat as per protocol for any organism cultured. 
 
 
8. Respiratory exacerbation with unknown organism, unwell child (clinical judgment) 
 
Depending on severity of exacerbation: 
 
 Oral augmentin duo (400/57) 0.3 mls/kg bd for 2 (minimum) to 4 weeks (clinical judgment) 
 
 or equivalent dose of co-amoxiclav syrup tds  
<1 year 0.25ml/kg TDS Augmentin 250/62; >1 - 2 yrs 5ml TDS Augmentin 250/62 
 for 2 (minimum) to 4 weeks (clinical judgment) 
 
 
OR  
 
 IV tobramycin 10 mg/kg once daily for 2 weeks (trough level 23 hours after 2nd dose, 
must be < 1 mg/l), PLUS 
 IV ceftazidime 50 mg/kg three times a day  
 
NOTE: choice of antibiotic may vary from the protocol depending on culture sensitivities 
 
Data recording must pick up use of all additional drugs.   
 
June 2009 
   7 
References 
 
 (1)  Equi AC, Pike SE, Davies J, Bush A. Use of cough swabs in a cystic fibrosis clinic. Arch 
Dis Child 2001; 85(5):438-439. 
 (2)  Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with 
Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of 
pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23(5):330-335. 
 (3)  Davies G, McShane D, Davies JC, Bush A. Multiresistant Pseudomonas aeruginosa in a 
pediatric cystic fibrosis center: natural history and implications for segregation. Pediatr 
Pulmonol 2003; 35(4):253-256. 
 (4)  Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of 
Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic 
administration: lack of association in cystic fibrosis. Chest 2003; 123(5):1495-1502. 
 (5)  Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A et al. Significant 
microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J 
Respir Crit Care Med 2003; 167(6):841-849. 
 (6)  Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new 
definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst 
Fibros 2003; 2:29-34. 
 
 
 
 
Early Detection of lung disease in newborn 
screened infants with cystic fibrosis 
 
 
 
 
Case Record Form 
 
 
 
   
Patient Initials: 
  
___  ___ 
 
 
  
Research ID: 
  
 
 
 
  
CF Centre: 
  
 
 
   
 
 
 
The London Collaborative Cystic Fibrosis Group: 
Barts & the Royal London Hospitals, Great Ormond Street Hospital for Children,  
Lewisham Hospital, Kings College Hospital, St Helier Hosptal & The Royal Brompton & Harefield NHS 
Trust 
 
 
 
For any queries regarding the study please contact: 
Lena Thia 
The Portex Respiratory Unit 
Guilford Street, London WC1N 1EH 
Tel: 020 7905 2226  
Fax: 020 7829 8634 
j.chudleigh@ich.ucl.ac.uk 
  
  
 
 
 
CLINICAL DETAILS 
 
 
Date of birth           Sex:  M       F 
 
 
Date of sweat test:   
 
 
Sweat chloride results:  
 
 
Genotype:       Date:  
 
 
Pancreatic function:  Sufficient  Insufficient               
 
 
Mode of presentation:  Antenatal         Newborn screening          Meconium Ileus          
 
Other (specify)_______________________________________ 
 
 
 
 
 
RECRUITMENT CHECK LIST 
Prior to recruiting a patient to the study please check the following: 
 
Does the patient fulfil the eligibility criteria for the study? 
 
Have the child’s parent(s) / legal guardian given written informed  
consent for their child to participate in the study? 
 
 
 
 
 
 
  
    Early Detection of lung disease in newborn screened infants with cystic fibrosis 
 
    SUBJECT INITIALS  RESEARCH ID         
       
  
 YES     NO 
/ 
  
 
 
 
VISIT DATE: 
 
    
   Height:                   cm         Weight:                           kg           OFC:                  cm 
   
RECENT HISTORY (Since previous visit to Specialist Centre) 
 
Hospital attendance / admissions 
 
Date     Reason 
 
 
 
  Yes  No 
 
Viral URTI since last visit         dates (approx): ______________   ______________ 
    
Cough since last visit:            
 
Wheeze since last visit     (Parental report / Clinician diagnosed) Please circle 
   
 
Please ensure that any new and or short term courses of medications taken since the last visit are entered on concurrent medication form.  
       
 
INVESTIGATIONS: Cough swabs since last visit    Cough swab today:  Y  /  N 
 
DATE:   GROWTH:     
 
1.      None / Normal flora / Ps A  / StaphA /  Haemoph /  Other  _____________________ 
           
2.      None / Normal flora / Ps A  / StaphA /  Haemoph /  Other  _____________________ 
 
3.      None / Normal flora / Ps A  / StaphA /  Haemoph /  Other  _____________________ 
 
CURRENT STATUS     Cough details: dry  /  wet  
YES       NO       
Chest:  Cough       daytime / nocturnal  /  with physiotherapy 
           
Wheeze        
 
CLINICAL EXAMINATION  Non respiratory complications: (specify)  
YES       NO            
    Chest:  Wheeze    Suspected GOR  
   
Crackles    Confirmed GOR      
 
  Tachypnoea    GA since last visit     reason: _________________ 
   Comments:       Other: _________________________________ 
 
CURRENT TREATMENT /TREATMENT CHANGES 
Please ensure that ALL medications are correct on the concurrent medication form and enter any changes / new medications.  
Current:   YES       NO       Other Current:   Changes:  
Creon   
  Multivitamins 
  Vitamin E    
COMPLETED BY:                                   SIGNATURE:                                  DATE: 
    Early Detection of lung disease in newborn screened infants with cystic fibrosis – Clinic visit 
     
   SUBJECT INITIALS       RESEARCH ID       
Following completion please fax to 
Jane Chudleigh: 020 7829 8634 
  
 
 
 
           
 
 
 
 
 
 
 
Drug 
(Generic name) 
    Date 
Started 
Date Stopped Indication 
(CF & non CF) 
Dose Units Freq Route Date 
(dd/mm/yyyy) 
Date 
(dd/mm/yyyy) 
or Cont. 
Post-
trial 
Tick 
e.g. ranitidine 150 mg bd oral 10/11/2001 27/12/2001    ulcer 
1.          
2.          
3.          
4.          
5.          
6.          
7.          
8.          
9.          
10.          
11.          
12.          
 
 
 
CONCURRENT MEDICATIONS FORM 
 
 
Please ensure that ALL medications (including short term courses between visits) and changes to medication are correctly entered on this form. 
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SUBJECT INITIALS  TRIAL NUMBER        
  
 
 
 
 
 
 
 
 
           
 
 
Drug 
(Generic name) 
    Date 
Started 
Date Stopped Indication 
(CF & non CF) 
Dose Units Freq Route Date 
(dd/mm/yyyy) 
Date 
(dd/mm/yyyy) 
or Cont. 
Post-
trial 
Tick 
e.g. ranitidine 150 mg bd oral 10/11/2001 27/12/2001    ulcer 
13.          
14.          
15.          
16.          
17.          
18.          
19          
20.          
21..          
22.          
23.          
24.          
 
CONCURRENT MEDICATIONS FORM 
 
 
Please ensure that ALL medications (including short term courses between visits) and changes to medication are correctly entered on this form. 
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SUBJECT INITIALS  TRIAL NUMBER        
      
 
 
 
 
DATE OF BRONCHOSCOPY  
 
FLUSH SAMPLE       INITIALS OF: 
  
 Growth:  -ve  / +ve (details) ___________________   Bronch Operator ________ 
          Bronch Assistant ________ 
 
RESULTS        Pooled  BAL Sample YES       NO       Cfu/L  
 
 
Bacteriology: No growth      _____ 
 
Normal flora      _____ 
 
Pseudomonas aeruginosa    _____ 
 
Staphylococcus aureus    _____ 
 
Haemophilus influenzae    _____ 
 
NTM       _____  Specify______________     
 
Other                   _____ Specify______________      
 
 
Virology:  +ve  / -ve Details of +ve culture: _________________________________ 
 
 
Fungal:  +ve  / -ve Aspergillus  /  Candida  / Other ____________________ 
 
 
Cytology: 
 Macrophages % count:   Neutrophils % count: 
  
 Eosinophils % count:   Lipid laden macrophages: Yes  / No  
 
           Mild  / Moderate  /  Severe 
 
Bronchoscopy secretion quantification: (please circle) 1       2      3      4      5      6   
(Explanation of grading overleaf)  
 
Cough swab result: 
 
    
   COMPLICATIONS 
  
 During procedure:  
 
  
Following procedure (within 24 hours):   temperature  /   cough   
 
other :_________________________________ 
 
     
 
    Early Detection of lung disease in newborn screened infants with cystic fibrosis – Bronchoscopy results 
     
   SUBJECT INITIALS       RESEARCH ID       
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chang et al Cough quality in children: a comparison of subjective vs. Bronchoscopic findings. Respir Res 2005; 6:3 
  
Secretion Quantification at bronchoscopy: 
 
BS Grade 1 = Nil secretions 
 
BS Grade 2 = Near dry = Bubbles only in < half total number of bronchi involved 
 
BS Grade 3 = Minimal = Bubbles found in > half total number of bronchi involved or 
Secretion type-I in < half total number of bronchi involved 
 
BS Grade 4 = Mild = Secretion type-I, > half total number of bronchi involved or 
Secretion type-II, < half total number of bronchi involved 
 
BS Grade 5 = Mod = Secretion type-II, > half total number of bronchi involved or 
Secretion type-III, < half total number of bronchi involved 
 
BS Grade 6 = Large = Secretion type-III, > half total number of bronchi involved  
  
 
 
     
 
 
 
 
 
 
  DATE OF CT  
 
 
 
      CT:  REFUSED  /  NOT DONE __________________________________________ 
   (please circle as appropriate and specify reason if not done) 
 
 
      
     ADVERSE EVENTS 
  
 During procedure:  
 
  
 
 
 
Following procedure:   
 
 
 
 
 
  
    Early Detection of lung disease in newborn screened infants with cystic fibrosis – CT results 
     
    SUBJECT INITIALS       RESEARCH ID  
 
      
  
 
 
 
 
 
           
 
Have all the sections of this booklet been completed? 
 
 
Did the patient complete the study? 
 
 
 
If NO, please tick the primary reason for withdrawal (tick one box only). 
  
   Non-attendance 
 
   Patient withdrew, give reason _________________________ 
 
   Other, please specify: ________________________________ 
 
   __________________________________________________ 
 
 
  
  Date of withdrawal:  
             Day      Month  Year 
 
   
Investigators comments: ________________________________________ 
 
  ____________________________________________________________ 
   
  ____________________________________________________________ 
 
 
  
 
 Investigator’s signature _________________________  Date ____________ 
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    SUBJECT INITIAL TRIAL NUMBER       
 
STUDY SUMMARY 
  
 YES     NO 
CLEANING POLICY 
1. Remove PNT from its housing and support arm/or connecting tubings. 
2. Disassemble the PNT into its individual components. 
 
 Jaeger (J) PNT 
o Affix a ‘nipple’ onto the metal balloon control inlet of the Jaeger 
shutter to prevent moisture from getting inside the balloon during the 
cleaning/disinfectant process. 
 
3. If urgently required for subsequent use (i.e. within 1 hr) 
o Clean PNT components with hot soapy water 
o Soft brush wire mesh/screens 
o Rinse under tap water, and then 
o Soak ALL PNT components in alcohol for 10 minutes 
o Wipe over the transducer housing and support arm (Jaeger) with 
alcowipes. 
 
If there are no further studies for the day requiring use of these PNTs, then cleaning strategy 
may follow the protocol as given for the Fleisch PNT (see below). 
Please note changes to cleaning of Fleisch PNTs 
 
 Fleisch PNT (NOT to be soaked in alcohol) plus white connectors 
 
o Rinse the flow tube and connectors with water 
o Soak PNT and connectors in Terralin solution 0.5% (disinfectant) for 1 
hr* (effective for MRSA) 
*  If  Tuberculosis is suspected, equipment will need to be soaked for 4 
hrs 
o Rinse the flow tube and connectors under tap water, then 
o Rinse the flow tube with distilled/sterile water 
o Remove water from the interior of flow tube using compressed air at a 
pressure up to 3 bar 
o Dry flow tube in the compressed air jet or in normal room air 
 
Note: Terralin (0.5%) and Milton (1/80; i.e. 125 ppm) solution when diluted for 
use is active for 24 hrs. 
 
 
Other Equipment Cleaning Strategy 
Putty Disposable 
Face mask  Heat treated decontamination 
by HSDU 
Inflatable bladders Washed in hot soapy water 
Squeeze jackets Washed in hot soapy water 
Large-bore 3-way tap of barrel Wipe down with alcohol 
 
Tubing: PNT to transducers  
CF study: 
 Dispose and replace after each study 
 
Non-CF study:   
 Rinse/syringe through with soapy water 
 soak in Milton (1:80) for 30 min 
 Dry tubing using compressed air (immediately) 
 
Mouth pieces, connectors for Spirometry  Wash in hot soapy water and 
soak in Milton 
Y-piece or T-piece connector (green)  Dispose and replace after each 
test 
Corrugated tubing for bias flow  Dispose and replace after each 
test 
Plethysmograph  Clean surfaces with hot soapy 
water and dry 
Mattress  As above 
Sheets and Linen  Send to laundry. Fresh linen for 
each subject 
Toys  Wash in hot soapy water 
 
 
A10 Chest CT Scanning and General Anaesthesia Protocols 
 
 Old Guidelines 
 
 New Amended Guidelines 
 
 
 
A11 Bronchoscopy and Broncho-alveolar Lavage Protocol 
 
 
 
A12 Brody II scoring system and scoring sheet 
 
 
 
Scanning parameters used in the study 
 Topogram Inspiratory Spiral Expiratory Spiral 
Tube voltage (kVp) 80  100 100 
Tube reference 
current (mAs) 
20 17 20 
CTDIvol (mGy)  0.57 0.67 
Detector 
collimation 
 64 x 0.6mm  
Tube rotation time  0.5 seconds 
Scan Pitch  1 1 
Coverage ~ 256 mm ~140 mm ~ 30mm less than 
inspiratory range 
Scan slice width  1mm 
Reconstructed slice 
thickness  
 1mm 
Reconstructed 
algorithm 
  1st 
reconstruction-
B60 sharp kernel  
 2nd 
reconstruction- 
mediastinum 
setting 
 lung parenchyma 
setting. 
Post processing  2mm coronal reconstruction on B60 lung 
setting 
 
Anaesthetic Guidelines CT/Bronch for CF NBS 30/04/2010 
ANAESTHETIST GUIDELINES (OLD PROTOCOL) 
Revised 30th April 2010 
 
INTRODUCTION 
 
 Unless contra-indicated, induction of anaesthesia will generally 
be gaseous using oxygen and nitrous oxide and sevoflurane.  
  
 Atracurium (0.5mg/kg) will be administered IV as a muscle 
relaxant, paralysis being maintained throughout the CT and BAL 
procedures. 
 
 The child will be intubated with an appropriately sized 
endotracheal tube to ensure minimal leak at 25 cmH2O and 
sufficient calibre to pass a 2.8mm bronchoscope. 
  
 Anaesthesia will be maintained for the CT scan with sevoflurane 
oxygen and air (FIO2 0.3) and the patient ventilated to maintain 
an appropriate end tidal CO2 (4.5-5kPa) with the addition of 
positive end expiratory pressure (5 cmH20).  
 
 Baseline ventilatory pattern via anaesthetic machine: pressure 
controlled IPPV, 
o Respiratory rate 20bpm  
o I:E ratio 1:2 
o VT 8-10ml/kg   
o PEEP: 5 cmH2O  
 
 
 
 
Anaesthetic Guidelines CT/Bronch for CF NBS 30/04/2010 
PROCEDURE 
 
 The anaesthetist will ensure patient breath-hold on full 
inspiration at 25 cmH2O (while Topogram/scout is performed) 
until instructed to release by radiographer, i.e. ‘FINISHED’.  
 
 Anaesthetist will perform ten deep slow inflations to 30 cmH2O 
with a PEEP of 5 cmH2O Anaesthetist will count down from 10 to 
1 and then say GO as he/she performs the final inflation (on the 
count of 1) to 25cmH2O prior to spiral inspiration acquisition. 
  
 During the scan, the child’s lungs will be held in inspiration for  6-
10 s at 25 cmH2O,  until radiographer instructs ‘FINISHED’.  
 
 Bag released to allow passive expiration to relaxed end 
expiratory volume (NO PEEP) 
 
 Once lung deflation complete; Anaesthetist instructs 
radiographer ‘GO’ (by which time CT settings will have been 
adjusted for expiratory scan). Nb The subsequent 6 second 
delay before scan commences should ensure completely stable 
end expiratory level attained with no subsequent volume drift 
 
 Radiographer will inform anaesthetist when complete and 
normal ventilatory support can resume. 
Anaesthetic Guidelines CT/Bronch for CF NBS 11/11/2010 
Research Project: Structural Changes in infants diagnosed with Cystic 
Fibrosis by Newborn Screening 
ANAESTHETIST’S_RADIOGRAPHER’S GUIDELINES  
(Read in conjunction with CT Scan protocol) Revised 11th Nov 2010 (NEW) 
 
INTRODUCTION 
 Unless contra-indicated, induction of anaesthesia will generally 
be gaseous using oxygen and nitrous oxide and sevoflurane.  
  
 Atracurium (0.5mg/kg) administered IV as a muscle relaxant, 
paralysis being maintained throughout the CT and BAL. 
 
 The child will be intubated with an appropriately sized 
endotracheal tube to ensure minimal leak at 35 cmH2O and 
sufficient calibre to pass a 2.8mm bronchoscope. 
  
 Anaesthesia will be maintained for the CT scan with sevoflurane 
oxygen and air (FiO2 0.3) and patient ventilated to maintain 
appropriate end tidal CO2 (4.5-5kPa) with 5 cmH20 PEEP, using 
handheld pressure gauge/manometer. (essential equipment to take 
to CT– do not rely on ventilator settings) 
 
 During initial mask bagging, there is a tendency for air to enter 
stomach which may distort images. Pass NG tube and apply 
suction to reduce any gastric distension PRIOR to initial 
topogram. 
 
 Baseline ventilatory pattern via anaesthetic machine: pressure 
controlled IPPV, 
o Respiratory rate 20 bpm  
o I:E ratio 1:2 
o VT 8-10ml/kg   
o PEEP: 5 cmH2O  
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PROCEDURE 
 Radiographer will adjust scan parameters and once ready for 
topogram will say ‘READY FOR TOPOGRAM’.  
 
 The anaesthetist will then ensure patient breath-hold on full 
inspiration at 25 cmH2O and say ‘GO FOR TOPOGRAM’  until 
instructed to release by radiographer who will say ‘FINISHED’.  
 
 Radiographer will adjust scan parameters for inspiratory and 
expiratory acquisitions. Once ready, radiographer will say 
‘START INFLATIONS for INSPIRATORY SCAN’.   
 
 Anaesthetist will then perform  
- 6 deep slow inflations to 35 cmH2O with a PEEP of 6 
cmH2O to reverse any anaesthetic related atelectasis 
(anaesthetist will count up from 1 to 6), followed by  
- 4 deep slow inflations to 25cmH2O with a PEEP of 5 
cmH2O to provide standard lung volume history 
(anaesthetist will count down from 4 to 1 and then say GO 
at the final inflation (on the count of 1) to 25cmH2O.  
  
 During the inspiratory scan, the child’s lungs will be held in 
inspiration for ~6s at 25 cmH2O, until radiographer instructs 
‘FINISHED INSPIRATORY SCAN’.  
 
 Anaesthetist will then release BAG completely to allow passive 
expiration to relaxed end expiratory volume (ZERO PEEP). 
 
 Once lung deflation complete; Anaesthetist instructs 
radiographer by saying ‘GO FOR EXPIRATION’ (In-built 6s delay 
before scan commences ensures stable end expiratory level) 
 Radiographer will inform anaesthetist when complete and 
normal ventilatory support can resume. 
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Research Project: Structural Changes in infants diagnosed 
with Cystic Fibrosis by Newborn Screening 
CT Scan under General Anaesthetics Protocol  
To be read in conjunction with Anaesthetist_Radiographer 
guidelines v.11th  November 2010 (NEW) 
 
Amendment to volume history prior to CT, 11th November 2010 
Rationale for amendment:  
Following the first 22 CT scans that were performed, there were concerns about anaesthetic 
related atelectasis in dependent lung regions in some scans. In order to minimise this, both 
the Americans and Australians have found it necessary to perform the initial lung inflations to 
35-40cmH2O with 5-6 cmH2O PEEP, to preclude/reverse any atelectasis rather than the 30 
cmH2O that we have used to date.  
Hence for subsequent CT scans, we will use higher inflation pressures for the first 6 inflations 
(35-40cm H20), followed by the remaining 4 inflations to 25cm H20. This will not however 
influence the procedure during the actual CT scans in any way  
 
The DAY before CT scan 
 Senior LCFC representative at each centre to ensure that anaesthetist, ODP, and 
radiographer responsible for the procedure realise that this is a RESEARCH CT with 
special protocol that must be adhered to from the point of anaesthetics, ventilatory 
pattern and scanning parameters. 
 To read the respective research protocols (anaesthetics and scanning protocols) prior 
to the day of the procedure. 
 Ensure that intercom fully functional in CT suite 
Preparation before patient’s arrival ( At least 15 minutes before patient’s arrival) 
 Anaesthetist, radiographer, ODP and senior member of the LCFC meet to discuss 
execution of the research protocol and to clarify instructions/ communication about 
acquiring topogram, inspiratory spiral and expiratory scans.  
 Ensure that handheld manometer gauge and anaesthetic circuit set up as per 
research protocol and working. (fresh circuit per subject)  
 Ensure that intercom between CT scan and control room is working and at adequate 
volume. It is VITAL that anaesthetist and radiographer can hear each other clearly, as 
communication MUST be verbally expressed and not through automated CT 
machine. 
Topogram/Scout (Planning)  
Anaesthetist will ensure patient breath-hold on full inspiration 25cmH2O until 
instructed to release by radiographer to mimic circumstances during 
inspiratory scan 
Include from top of apices to costo-phrenic angle. 
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kVp  80 
mAs  20 
coverage  256 mm 
nb Expiration Topogram/Scout not carried out to avoid increase in radiation dose. 
Plan both Inspiration and Expiration ranges so that they follow each other. 
Inspiration – Spiral Acquisition 
Anaesthetist will ensure patient breath-hold on full inspiration at 25 cmH2O for 
up to 10s and until instructed to release by radiographer (see accompanying 
Guidelines for precise wording) 
kVp    100 
Ref mAs   17 
CTDIvol   0.57mGy 
Collimation   32 x 0.6mm (64 with flying focal spot technology) 
Tube rotation time  0.5 seconds 
Coverage   140mm (should not be necessary to exceed this length) 
Pitch (table feed)  1 (19.2mm)  
Dose modulation  Care dose 4D used 
Scan slice width  1mm 
Recon slice thickness  1mm 
Recon algorithm  B30 medium-soft kernel on mediastinum setting,  
    B60 sharp kernel on lung parenchyma setting 
Post processing  2mm coronal reconstruction on B60 lung setting 
 
 Radiographer will notify Anaesthetist on completion of scan.  
 Do not reconstruct scan data at this stage.  
 Anaesthetist will cease ventilation and expiratory acquisition will occur 
immediately following passive deflation to stable end expiratory plateau.  
 Anaesthetist will notify Radiographer when to start scanning for expiration at 
ZERO PEEP. 
 A 6-second scan start delay is factored in to ensure full deflation.  
 
Expiration - Spiral Acquisition 
Scan Start delay  6 second 
kVp    100 
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Ref mAs   20 
CTDIvol   0.67mGy 
Collimation   32 x 0.6mm (64 with flying focal spot technology) 
Tube rotation time  0.5 seconds 
Coverage   Around 30mm less than Inspiration range 
Pitch (table feed)  1 (19.2mm)  
Dose modulation  Care dose 4D used 
Scan slice width  1mm 
Recon slice thickness  1mm 
Recon algorithm  B60 sharp kernel on lung parenchyma setting   
Post processing  2mm coronal reconstruction on B60 lung setting 
 
Once CT completed, resume normal ventilation via hand bagging/ventilator, before 
proceeding to BAL.  
 
Clinical CT Reports:  Each centre will prepare a standard clinical report to be forwarded 
asap to the child’s referring consultant.  
GOSH will send reports together with the anonymised CT data on a CD to Lewisham, Kings 
College Hospital and Epsom St Helier’s where appropriate  
CT scoring for research study:  
 For the purposes of the study, all CT images will be viewed and scored on a 
Leonardo Console (Siemens Erlangen) at GOSH by two experienced paediatric 
radiologists, masked to the patient’s clinical details.  
 These radiologists will assess, modify and score the CT scans according to a 
validated CT scoring system adapted for CF lung disease.(Brody 2006, Brody 2007). 
Additional scoring using approach adopted by the Australian  AREST CF group may 
also be undertaken, still under discussion 
 Post processing will include high resolution algorithm reconstruction on lung 
parenchymal windows for the presence and extent of bronchiectasis, bronchial wall 
thickening, and air trapping using the modified BRODY score (Brody 2006, Brody 
2007 – see below)  
 
Funding: 
Funding has been made available for CT and bronchoscopy under GA by the London 
Collaboration of Research Networks (LCRN) or CF Trust and each department will be 
reimbursed individually following the satisfactory completion of tests.   
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Protocol for samples collected at bronchoscopy - GOSH 
  
i) INFLAMMATORY MARKERS – SAMPLES TO Somers Clinical Research Facility (CRF)  
CRF lab assistant (extn 6934) must be informed beforehand so that they are expecting 
the samples (research team member). Also please inform them when the child is called 
to theatre for the bronchoscopy. 
 
BAL 
 Research BAL sample should be divided into 2 universal samples and handed to Research 
Team member.  
 The BAL samples for inflammatory marker assessment will be labelled with the child’s study 
number, date and time of the sample, type of sample [one labelled WHOLE BAL and the 
other labelled SPUN BAL]. 
 They will be placed in a specimen bag with additional labels, stating child’s study number 
and date of sample. 
 They will be taken to the CRF by Research Team member. 
 WHOLE BAL is stored in a freezer at –80C at the CRF.  
 SPUN BAL sample will be centrifuged for 10 minutes at 3500rpm at 4C. 
 The supernatant will be aspirated into aliquots of 0.5ml and will be stored at –80C at the 
CRF.  
 The following week, Research Team member will collect all the samples. Check that all 
samples are appropriately labelled (study number; date; type of sample i.e. whole BAL, 
Spun BAL [supernatant]) and take it to the Portex freezer (–80C) for long-term storage.  
 
Blood 
 Three mLs of blood in a large brown or white top bottle will be obtained when the child is 
anaesthesized for the CT/ bronchoscopy for inflammatory marker assessment. 
 The sample will need to be mixed by inversion 8–10 times in theatre. 
 The sample will be labelled with the child’s study number, date and time of the sample, type 
of sample. 
 It will be then be taken to the CRF by Research Team member and allowed to stand for at 
least 30 minutes to clot. 
 Within 1 hour of sampling, the sample will be centrifuged for 10 minutes at 2,000g at 4C.  
 The serum will then by aspirated into two bottles and labelled with the child’s study number 
and date the sample was taken.  
 The sample will be stored in a freezer at –80C at the CRF.  
 The following week, Research Team member will place the sample in a specimen bag with 
an additional label, stating child’s study number, date and type of sample, and take it to the 
Portex freezer (–80C) for long-term storage.  
 
*   *   *   *   *   *   *   *   *   *   *   *   *   * 
 
ii) SAMPLES TO MICROBIOLOGY 
 
 The microbiology lab (Garth Dixon and Peter Watson) must be informed about the 
bronchoscopy and BAL beforehand so that they are expecting the sample. Will need to 
reach the lab before 3pm. 
 
BAL 
 This sample will also need to be assessed for respiratory viruses and a portion will need to 
be sent to the virology department for respiratory viral immunoflurescence (adenovirus, 
influenza, parainfluenza and RSV). 
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 The BAL sample sent to the microbiology department will be assessed for microscopy and 
culture. On the form it is important to clearly state: Infant CF BAL Sample – For Colony 
Counts.  
 
 The BAL sample for microbiology will be taken to the microbiology reception in the Camelia 
Botnar Lab by Research Team member. 
 
 
 
 
 
Useful contacts at GOSH Somers Clinical Research Facility 
 
 
Beth Towlson (CNS)  Tel ext: 6893        bleep 0161 
email: towlse@gosh.nhs.uk 
 
 
 
 
Jignasha Gajera (Lab tech) tel ext: 6934 
    email: GajerJ@gosh.nhs.uk  
 
Catherine Irvine (Lab tech) tel. ext: 6934 
    email: IrvinC@gosh.nhs.uk  
 
 
 
Reception desk   tel ext: 6872 
 Sample Guidelines CT/Bronch for CF NBS 15/11/10 
 
LCFC Infant CF Bronchoscopy Samples 
 
CONTROL sample 
 5ml saline sucked through bronch prior to insertion into patient 
 Send to microbiology for MC&S [PIMS form test code = MCS] 
  State on form: 
  “CONTROL SAMPLE, Infant CF BAL sample for colony 
counts” 
 
1
st
 BAL sample from patient pooled with 4
th
 BAL sample for patient 
SPLIT into 2 aliquots 
 1. Smallest aliquot, send to virology for Routine Respiratory screen  
[PIMS form test code = V047] 
 2. Biggest aliquot, send to microbiology as 1 sample for 
   MC&S [PIMS form test code = BAL] 
   TB culture [PIMS form test code = B027] 
   Fungal culture [PIMS form test code = FUNG] 
  State on form: 
  “Infant CF BAL sample for colony counts” 
 
2nd BAL sample from patient 
 SPLIT into 2 aliquots 
 1. Smallest aliquot, send to haematology for 
   Fluid cell count [PIMS form test code = H059] 
2. Biggest aliquot, send to histology for cytology [PIMS form test code = 
T100] 
  State on form: 
 “Any inflammatory cells, if so which and are they raised 
mild/mod/severe and % count. Any fat laden macrophages, 
are they raised mild/mod/severe” 
  
3
rd
 BAL sample from patient 
  SPLIT into 2 aliquots (in 2 universal bottles) 
 Give both samples to Research team member for freezing & storage. 
Research samples 
 
4
th
 BAL sample from patient pooled with 1
st
 BAL sample from patient – see 
above 
Brody II Scoring analysis 
 
Figure E1: CFCT Scoring Sheet 
  ID no:      Lobe: RUL/RML/RLL/LUL/Ling/LLL  
 
Bronchiectasis                  None   SP(spurious) 
Size*     Largest     2x           3x 
 
 
  Average     2x       3x 
 
 
 
Appearance cylindrical varicose saccular 
 
Extent            Central    1/3           2/3 
0 
 
      Peripheral             1/3                          2/3 
0 
 
Mucous Plugging                 None   SP 
Extent          Central     1/3      2/3 
0 
 
 Peripheral                     1/3                            2/3 
0 
 
Peribronchial thickening                None                               SP 
 
Severity  mild moderate  severe 
 
Extent          Central    1/3               2/3 
0 
 
Peripheral 1/3                       2/3 
0 
 
Opacity† SP     1/3           2/3 
0 
 
Ground Glass SP    1/3           2/3 
0 
 
Cysts/Bullae SP    1/3              2/3 
0 
 
 
Hyperinflation 
Extent SP     1/3           2/3 
0 
 
Appearance subsegmental segmental or larger 
 
 
 
